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Medication adherence is vital to ensuring optimal patient outcomes, particularly amongst 
older adults prescribed polypharmacy. However, complex interventions aimed at improving 
adherence have shown only limited effectiveness. To maximise effectiveness, the Medical 
Research Council (MRC) supports the use of both evidence and theory in developing 
interventions. Feasibility and pilot testing is then recommended to optimise interventions in 
advance of definitive trials. The aim of this research was to develop a novel complex 
intervention (using evidence and theory) to improve adherence in older adults (prescribed 
polypharmacy) and to test the feasibility of delivering this in community pharmacies.    
Methods 
The presented research models the MRC complex intervention framework and focuses on 
development and feasibility testing phases. Firstly, a systematic review was conducted to 
address an identified evidence gap in relation to theory-based adherence interventions 
previously delivered to older adults prescribed polypharmacy. Qualitative research was then 
conducted to explore older patients’ adherence behaviour and identify determinants 
(barriers, facilitators) to target for change. Using the Theoretical Domains Framework (TDF) 
as a lens, key domains were selected for targeting and mapped to behaviour change 
techniques (BCTs) using established methods. These BCTs formed the basis of a complex 
intervention that was delivered to older patients by community pharmacists (CPs) as part of 
a small-scale feasibility study. In addition to exploring older patients’ adherence behaviours, 
further research focused on CPs’ clinical behaviour in relation to providing medication 
adherence support (MAS). The qualitative TDF-based methods used in the patient study were 
extended and a mixed methods (qualitative, quantitative) approach was used to identify 
determinants influencing CPs’ behaviour. Key target domains were identified and mapped to 
BCTs that could be directed at CPs (e.g. in a training package) to improve future 
implementation of the patient intervention.  
Results 
The systematic review found that adherence interventions delivered to older patients 
prescribed polypharmacy were rarely based on theory, supporting the need for further 
research. The qualitative research conducted with older patients identified eight key domains 
(e.g. ‘Beliefs about consequences’, Memory, attention and decision process’) that could be 
targeted and these domains were mapped to 11 BCTs (e.g. ‘Prompts/cues’, ‘Self-monitoring’) 
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vi 
 
which formed the basis of a complex intervention. The feasibility study demonstrated that 
the intervention was highly acceptable to both patients and CPs but some modifications were 
suggested. It also highlighted the need for additional research that focuses on CPs’ behaviour 
(i.e. MAS provision). Findings from the mixed methods study on CPs’ behaviour led to the 
identification of seven key domains that could be targeted for change (e.g. ‘Skills’, 
‘Motivation and goals’). Eighteen BCTs were then selected for inclusion in a training package 
(e.g. ‘Demonstration of the behaviour’) or for delivery alongside the patient intervention in 
future research (e.g. ‘Rewards/incentives’) to improve implementation. 
Discussion/Conclusion 
The MRC framework served as a useful guide for developing a complex intervention to 
improve adherence in older patients prescribed polypharmacy. This systematic theory-based 
approach that involved explicitly linking theoretical domains to intervention components 
(BCTs) will aid future replication and understanding of how the intervention aims to bring 
about behaviour change. Aside from targeting patients’ adherence behaviours, this research 
emphasised the importance of exploring the behaviours of intervention providers (i.e. CPs) 
to enhance implementation. Future research will involve pilot testing a refined version of the 
patient intervention and CP training package to establish if a definitive trial of effectiveness 
(e.g. randomised controlled trial) is warranted. 
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1.1 Medicines use in older adults 
1.1.1 The ageing population 
With declining birth rates and increasing life expectancy, the global population is undergoing 
a major demographic shift (United Nations, 2015). Over the coming years the largest rate of 
growth is expected in older adults, a population group commonly defined as those aged 65 
years and over. By 2050, the number of older people worldwide is expected to increase two-
fold (United Nations, 2015). In Northern Ireland (NI), the number of older people is predicted 
to rise from approximately 286,000 to almost half a million, between 2014 and 2039 







Figure 1.1: Northern Ireland’s (NI) projected population figures by age category from 2014 to 2039 
(Adapted from: Northern Ireland Statistics and Research Agency, 2015)  
1.1.2 Chronic conditions and multimorbidity 
With increasing economic pressures, healthcare services worldwide will have to adapt to 
meet the complex care needs of an ageing population. During the ageing process, the human 
body undergoes a number of physiological changes, for example, cardiac output is reduced, 
blood pressure (BP) is raised and lung function is impaired (Dillin et al. 2014). Examples of 
the most common causes of death in older adults globally include stroke, heart disease and 
chronic lung disease. These types of conditions are described as chronic or long-term 
conditions (LTCs) as they last longer than 12 months and cannot be cured, but can often be 
controlled with medication as part of a management plan (Scottish Government, 2015). A 
recent United Kingdom (UK) Government report, ‘Future of an Ageing population’, has 
emphasised that a shift in focus from acute conditions towards LTCs is a high priority if the 
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(Government Office for Science, 2016). To make optimal use of limited resources, there is a 
need for better management of LTCs and optimisation of drug treatments.  
The term comorbidity describes the presence of other conditions in addition to an index 
condition, with the latter generally deemed to be of greatest importance (Valderas, 2015). 
Multimorbidity is a more useful term that is used to describe patients who suffer from two 
or more LTCs as it does not place greater emphasis on any one condition (Chew-Graham et 
al. 2016). Although multimorbidity is seen in all age groups it is most prevalent in older adults 
(Salive, 2013; Tinetti et al. 2012), with approximately 65% of older patients suffering from 
multimorbidity (Barnett et al. 2012). The treatment of multiple LTCs often follows single 
disease treatment guidelines, such as those published by the National Institute for Health 
and Care Excellence (NICE), and commonly leads to the prescribing of several medications. 
Recent NICE guidance on multimorbidity has recognised the limitations of single disease 
guidelines as these have generally been developed based on evidence from younger patients 
suffering from single conditions and taking comparatively fewer medications (National 
Institute for Health and Care Excellence, 2016). The guidance recommends that healthcare 
professionals (HCPs) should adopt a tailored approach to caring for multimorbid patients. 
The risks and benefits of treatments, as well as patient preferences, should be carefully taken 
into consideration when making decisions about treatment regimens. Nonetheless, the 
prescribing of multiple medications to treat LTCs in older adults is a very common practice in 
modern medicine and one that is likely to continue. 
1.1.3 Polypharmacy 
Where several medicines are concomitantly prescribed, this is often referred to as 
polypharmacy. Although the concept of polypharmacy was first discussed in the literature 
over 150 years ago, there is still no standard and agreed definition (Wise, 2013). Common 
definitions include numerical thresholds such as the consumption of at least four or five 
regular medications or more (Rollason and Vogt, 2003; Duerden et al. 2013; Patterson et al. 
2014). The term polypharmacy has previously carried a negative connation and has been 
seen as a major evil in geriatric medicine (Aronson, 2004; Cadogan et al. 2016b). However, 
recent research conducted with large population datasets challenges the viewpoint that 
polypharmacy is always negative and should be avoided (Appleton et al. 2014; Payne et al. 
2014). These cohort studies highlight the important role that polypharmacy can play in 
treating multimorbid older patients, provided that prescribing is evidence-based and takes 
into consideration the clinical context and relevant drug interactions. It is therefore 
increasingly being recognised that polypharmacy can be entirely appropriate in treating older 
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multimorbid patients and has been described more recently as a ‘necessary evil’ (Wise, 2013; 
Duerden et al. 2013). To take into account this changing viewpoint, there has been a 
suggestion to go beyond simple counts of medicines when defining polypharmacy and 
introduce the possibility of it being either appropriate (‘many’ drugs) or inappropriate (‘too 
many’ drugs) (Aronson, 2004; Hughes et al. 2016). However, as a new definition is yet to be 
agreed, the most common definition of ‘four or more medications’ has been used throughout 
this thesis to denote polypharmacy (Patterson et al. 2014).  
The increasing incidence and prevalence of polypharmacy in recent years, particularly in 
older adults, has been illustrated by a study that analysed prescribing and dispensing data 
for over 300,000 patients in Scotland (Guthrie et al. 2015). The authors reported that in 2010, 
20.8% of patients (in all age groups) were dispensed five or more medicines, an increase of 
almost 10% since 1995 (11.4%). They also reported that in 2010, 17.2% of patients aged over 
65 years old were dispensed 10 or more medicines compared to just 4.9% in 1995. Similar 
findings have been reported in other countries such as Sweden, the United States of America 
(USA) and Italy (Haider et al. 2007; Bourgeois et al. 2010; Franchi et al. 2014). Whilst the 
consequences of inappropriate polypharmacy are important to consider (e.g. safety, drug 
interactions, adverse events), the potential benefits to be gained should not be overlooked 
(Kaur, 2013). Where polypharmacy has been appropriately prescribed using the best 
available evidence, in order to achieve potential benefits (e.g. improved condition control, 
increased functional capacity, improved quality of life and longevity), it is important that 
patients adhere to the prescribed directions (Elliott, 2013). 
1.2 Adherence to long-term treatments 
1.2.1 Terminology and concepts 
Over 2000 years ago, Hippocrates first recognised that patients do not always take medicines 
as prescribed (Vrijens et al. 2012). In 1985, a high profile US Surgeon-General (C. Everett 
Koop) famously stated that ‘Drugs don't work in patients who don't take them’ (Osterberg 
and Blaschke, 2005). Adherence to medicines has been an area of great interest for 
practitioners, academics and policy makers around the world for over four decades (Dunbar-
Jacob and Mortimer-Stephens, 2001). Adherence is a complex behaviour defined by the 
World Health Organisation (WHO) as: 
“The extent to which a person’s behaviour-taking medication, following a diet, and/or 
executing lifestyle changes, corresponds with agreed recommendations from a health 
care provider.” (Sabate, 2003)  
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The term ‘adherence’ is often used interchangeably with the terms ‘compliance’ and 
‘concordance’, despite there being some subtle, and indeed notable differences between 
these terms (Horne et al. 2005; De las Cuevas, 2011). ‘Compliance’ is an older term that has 
been defined by Haynes et al. (1979) as ‘the extent to which the patient’s behaviour matches 
the prescriber’s recommendations’. It has fallen out of favour in recent years as it implies 
that the patient has a passive role in the decision-making process, whereas adherence 
involves an agreement between the prescriber and patient about how the medicines should 
be taken or used (Banning, 2008). ‘Concordance’, a term that focuses on the relationship 
between the patient and prescriber as opposed to the medication-taking behaviour itself, is 
sometimes used incorrectly as a synonym for adherence (Horne et al. 2005).  
As ‘adherence’ is currently the preferred term, it will subsequently be used throughout this 
thesis to describe the medication-taking (or medication-use) process (Nieuwlaat et al. 2014). 
Although the term of choice, there has been much debate in the literature as to what exactly 
‘adherence’ encompasses. In an attempt to clarify this, Vrijens et al. (2012) undertook a 
group consensus exercise with 40 participants including researchers and HCPs from across 
13 different countries. They agreed that adherence involves three key stages: ‘initiation’ 
(taking the first dose of a medication), ‘implementation’ (the extent to which dosing 
corresponds with the prescriber’s directions) and ‘discontinuation’ (where a medication is 
stopped without instruction from a prescriber). ‘Persistence’ is used to describe the time 
between the ‘initiation’ and ‘discontinuation’ stages.   
Non-adherence has also been separated into primary and secondary non-adherence (Fischer 
et al. 2011; Tamblyn et al. 2014). Primary non-adherence indicates instances where patients 
do not obtain the medication from the pharmacy in the first place, whereas secondary non-
adherence involves the patient obtaining the medication but not taking it as prescribed. The 
latter encompasses the three stages outlined by Vrijens et al. (2012) (i.e. initiation, 
implementation and discontinuation). The focus of the research presented in this thesis is on 
secondary non-adherence, and in particular the ‘implementation’ phase. 
In 2005, the National Coordinating Centre for the NHS also made the distinction between 
‘intentional’ and ‘un-intentional’ medication non-adherence—this has proved useful for 
understanding the complexity of this behaviour. Intentional non-adherence involves a 
conscious decision-making process where decisions are made based on the individual’s 
beliefs; this decision-making process can be seen as either rational or irrational (Horne et al. 
2005). In contrast, un-intentional non-adherence involves an unconscious act that can be 
affected, for example, by orientation in time, prospective memory and physical difficulties 
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(e.g. forgetting to take medications, misunderstanding instructions, difficulty swallowing 
medications) (Lehane and McCarthy, 2007). These types of adherence behaviours can vary 
both within and between individuals. It is possible that an individual patient can be both 
intentionally and unintentionally non-adherent, for example, the chance of forgetting a 
medication (unintentional) is likely to be increased when the patient deems the medication 
to be of limited importance (intentional) (Clifford et al. 2008).  
1.2.2 Measuring medication adherence  
There are a variety of ways in which adherence can be measured, although there is no gold 
standard method of measurement currently available (Williams et al. 2013). Direct measures 
are seen as evidence that the medication has been consumed by the patient but these 
methods are very time-consuming and expensive. Some examples of direct measures 
include: drug (or metabolite) level monitoring, measurement of biological markers which are 
added to the formulation and directly observing patients. Indirect measures involve some 
degree of assumption that the patient has consumed the medication, for example: pill 
counts, measures calculated from prescription dispensing databases (refill measures), 
electronic monitoring devices and self-report measures (Farmer, 1999; Horne et al. 2005; 
Garfield et al. 2011). Each method has known limitations, for example, self-report 
questionnaires are commonly used in randomised controlled trials (RCTs) due to their low 
cost but they can be affected by social desirability bias (i.e. where false information is 
provided based on what the individual thinks that others would like to hear) (Horne et al. 
2005). The ideal adherence measure should be low cost, practical to use in research/clinical 
practice, objective, user-friendly and reliable (Lam and Fresco, 2015). As no such adherence 
measure currently meets all of the desired criteria, combining methods has been suggested 
as a way of overcoming some of the limitations of individual methods (Sabate, 2003). 
Based on direct or indirect measurements, patients’ adherence rates can range from taking 
0% to beyond 100% of the prescribed doses, with those taking more than the number of 
prescribed doses (>100%) considered to be over-adherent. Although there is no consensus 
on what the optimal level of adherence should be, researchers commonly use an arbitrary 
cut-off point of consuming less than 80% of the recommended doses to categorise patients 
as non-adherent. This cut-off point has been supported by research that examined the 
association between adherence levels (calculated using prescription dispensing data) and 
hospitalisations (all-cause and disease-specific) for a range of common chronic conditions 
such as diabetes, hypertension and congestive heart failure (CHF) (Karve et al. 2009). 
Research conducted by Hansen et al. (2009) also demonstrated that this cut-off point 
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provides sufficient balance between specificity (i.e. ability to correctly detect non-adherent 
patients) and sensitivity (i.e. ability to correctly detect adherent patients) for three commonly 
used adherence measures (self-report, electronic monitoring and prescription dispensing 
data-based measures). In reality, the optimal level of adherence for each patient is unlikely 
to be as clear-cut as this. Instead it is likely to differ from patient-to-patient due to 
heterogeneity in conditions and prescribed medications. However, due to the difficulty 
associated with determining such optimal levels for each individual patient and limited 
research in this area, a cut-off point of 80% was deemed sufficient for medications that are 
used to treat LTCs (Hansen et al. 2009; Karve et al. 2009).  
1.2.3 Incidence of medication non-adherence in older adults 
Non-adherence exists in all patient groups irrespective of age, education or socioeconomic 
status. Although age is not a strong predictor of medication adherence, older patients often 
have more risk factors for non-adherence. Older patients are also more commonly prescribed 
several medications (i.e. polypharmacy) which is correlated with lower adherence (Kardas et 
al. 2013). In addition, older multimorbid patients may be prescribed highly complex regimens 
which can include a mixture of formulations (e.g. tablets, inhalers, patches), multiple daily 
doses (e.g. three times daily) or special administration instructions (e.g. take half an hour 
before food). Regimen complexity has been reported to have a negative impact on 
medication adherence (Barat et al. 2001; Kardas et al. 2013).  
On average, half of all patients in developed countries do not take their medications for 
chronic conditions as prescribed. For older adults, estimates of non-adherence in the 
literature range from 26% to 60% (van Eijken et al. 2003; McGraw and Drennan, 2004; Jimmy 
and Jose, 2011; Lee et al. 2013a). Due to the methodological difficulties associated with 
measuring adherence as discussed in Section 1.2.2, it is likely that the true extent of the 
problem is underestimated.  
1.2.4 Consequences of non-adherence  
Despite over 40 years of research into medication adherence, many patients still do not take 
medications as recommended by the prescriber (Sabate, 2003; Brown and Bussell, 2011). 
Consequences of non-adherence include poor disease control and reduced quality of life 
(Sabate, 2003). Non-adherent patients are also more likely to visit their general practitioner 
(GP) in the primary care setting and accident and emergency departments in the secondary 
care setting (Malhotra et al. 2001; DiMatteo et al. 2002; Sabate, 2003). In the USA, it has 
been estimated that between 33% to 69% of hospital admissions and 125,000 deaths per 
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year are the result of mediation non-adherence (McCarthy, 1998; Osterberg and Blaschke, 
2005; Benjamin, 2012). 
Increasing healthcare costs and wastage of medications resulting from non-adherence has 
major financial implications for healthcare systems (Malhotra et al. 2001; DiMatteo et al. 
2002; Sabate, 2003). A recent report from the Institute for Healthcare informatics estimated 
that total avoidable costs from suboptimal medicine use (which included non-adherence, 
antibiotic misuse, medication errors, untimely medicine use, mismanaged polypharmacy, 
suboptimal use of generics) globally amounted to an annual total cost of US$475 billion 
(Aitken and Gorokhovich, 2012). Of this, non-adherence represented the largest avoidable 
cost at 57% of the total cost (approximately US$270 billion per year). In England, it is 
estimated that an improvement in adherence across five key chronic diseases (type 2 
diabetes, asthma, cardiovascular disease/hypercholesterolemia, hypertension and 
schizophrenia) could save the NHS £500 million per year (Trueman et al. 2011). The clinical 
impact and associated cost of non-adherence varies from patient to patient and so these 
figures only estimate the extent of the problem. Nonetheless, the global scale of non-
adherence is considered to be equivalent to a major disease epidemic. The WHO has 
recognised that addressing the problem of non-adherence could have a much larger impact 
on treatment effectiveness than any attempts to improve the efficacy of existing drug 
treatments (Sabate, 2003).  
A large amount of research evidence supports the efficacy of medications that are commonly 
used in the treatment of LTCs. Where medications have been appropriately prescribed as 
part of a polypharmacy regimen— with benefits outweighing the risks— adherence to the 
recommended directions is vital to treatment success (Brown and Bussell, 2011). For 
example, Sokol et al. (2005) demonstrated that higher rates of medication adherence were 
associated with reduced hospital admissions and decreased total medical costs in patients 
with a range of chronic conditions including hypertension, diabetes and CHF. Older patients 
who are appropriately prescribed multiple medications to treat several LTCs therefore have 
the most to gain from treatments and consequently the implications of non-adherence are 
greater. For that reason, improving adherence to long-term medicines continues to be a key 
priority for researchers, clinicians and policy makers across the globe (Sabate, 2003; Horne 
et al. 2005; Bosworth et al. 2011).  
                                                                                                                                       Chapter 1 
9 
 
1.2.5 Determinants of non-adherence 
A wide range of factors have been identified as potential influences on patients’ adherence 
to long-term medications (Clifford et al. 2008; Demonceau et al. 2013; Allemann et al. 2016) 









Figure 1.2: The five dimensions of non-adherence (Sabate, 2003) 
Patient-related factors include physical and psychological factors. Physical factors include 
hearing and sight impairment, cognitive impairment, impaired dexterity, reduced mobility 
and swallowing difficulties. Psychological factors include knowledge about 
conditions/medications, attitudes towards medications, motivation, confidence, fear of side 
effects and perceived benefits of treatment. Condition-related factors include severity of 
symptoms, absence of symptoms, depression and psychiatric conditions. Healthcare 
team/system-related factors include patient-HCP relationship, HCP communication skills, 
continuity of care, access to treatments and waiting times. Social/economic-related factors 
include literacy, social support levels, living conditions, and access to healthcare facilities 
(Sabate, 2003). Although this framework aids understanding of potential influences on 
adherence behaviours, the categories are too broad to guide research that seeks to change 
adherence behaviours (Allemann et al. 2016). 
Kardas et al. (2014) identified 771 individual factors (400 determinants) related to adherence 
to long-term treatments and categorised these into 40 clusters. Although having knowledge 
Dimensions 
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of all potential determinants is important, not all are amenable to change. For example, 
Allemann et al. (2016) grouped 40 identified patient determinants into modifiable (n=27 e.g. 
knowledge about therapy, forgetfulness) and unmodifiable determinants (n=13 e.g. 
chronicity of illness, prior history of medication non-adherence). However, there is also no 
single determinant that predicts adherence in all patients and the individual factors facing 
each patient are likely to differ (Marengoni et al. 2016). It is also unclear which modifiable 
determinants are the most salient in the context of older patients who are prescribed 
polypharmacy to treat a range of clinical conditions (Vik et al. 2004). 
1.3 Introduction to behaviour change and behaviour change 
interventions 
1.3.1 The challenge of behaviour change 
Medication adherence, is commonly labelled as a behaviour, a term used to describe how a 
‘person behaves in response to a particular situation or stimulus’ (Oxford English Dictionary, 
2016). Changing the behaviour of individuals (or groups of individuals) is an important part 
of health services research and one that poses a considerable challenge. Take for example, 
physical inactivity or tobacco smoking; these behaviours have gained significant attention 
over the past few decades, yet despite many years of research they continue to be difficult 
to change (Kelly and Barker, 2016). As highlighted by Michie et al. (2014a) ‘changing ingrained 
behaviour patterns can be challenging’. It requires a thorough understanding of an 
individual’s motivations, as well as any influences from others and/or the social environment. 
Understanding these factors can help to identify how to change and maintain the desired 
behaviour (Kelly and Barker, 2016).  
For a given behaviour to be performed, Michie et al. (2011) have suggested that an individual 
must: (1) be psychologically and physically capable of performing the desired behaviour; (2) 
have social and physical opportunities to do so; (3) be motivated to carry out the behaviour. 
This has been described as the COM-B (capability, opportunity, motivation—behaviour) 
model (see Figure 1.3). The COM-B model has been derived from a larger, more complex, 
framework for understanding behaviour change known as the Theoretical Domains 














Figure 1.3: COM-B model [adapted from Michie et al. (2011)] 
In the context of medication adherence, the main behaviour is of those required to take or 
use the medications (i.e. patients), however, the behaviours required of others who engage 
with patients in the clinical context (e.g. HCPs) should also be considered. The behaviour of 
HCPs in the context of providing adherence support to patients is discussed in more detail in 
Section 1.4.3.  
1.3.2 Behaviour change interventions (BCIs) 
One way of changing an individual’s (or groups of individuals’) behaviour (e.g. patients, HCPs) 
is through the delivery of an intervention. An intervention can be described as a single action 
or set of actions delivered to the target recipient(s) at a specific time and place (Conn et al. 
2016a). When the intervention aims to change a specific behaviour and includes multiple 
components, it is described as a behaviour change intervention (BCI). BCIs are defined by 
NICE as ‘sets of techniques, used together, which aim to change the health behaviours of 
individuals, communities or whole populations’ (National Institute for Health and Clinical 
Excellence, 2007). 
1.4 Interventions to improve medication adherence in older adults 
1.4.1 Single verses multi-component adherence interventions 
A plethora of adherence interventions have been tested over the last four decades to change 
patients’ adherence behaviours, with the earliest interventions first reported in the early 70’s 
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individual component interventions such as simple reminders through to multi-component 
intervention packages. Interventions have been educational-based (e.g. improving patients’ 
knowledge of medications and conditions), cognitive/behavioural-based (e.g. daily 
reminders, modifications to packaging, counselling) or a mixture of both (Nieuwlaat et al. 
2014). The majority of adherence interventions have been directed at patients’ adherence 
behaviours, as opposed to HCPs’ behaviours, although the latter should not be overlooked 
(see Section 1.4.3). 
Where ‘multiple interacting components’ are delivered as part of an intervention package, 
these interventions can be described as BCIs or complex interventions (Craig et al. 2008). 
Aside from the number of intervention components, complexity can also arise from the 
number and difficulty of behaviours required either by intervention recipients or providers 
and the amount of individualisation or tailoring of intervention content to individual 
circumstances that is permitted. Thus, due to the complexity of the behaviour itself, 
adherence interventions are rarely ever truly simple in nature.  
A range of single component interventions (e.g. regimen simplification, provision of pill 
reminder boxes) have been tested in an attempt to improve medication adherence but these 
have shown mixed effects (Nieuwlaat et al. 2014). Based on the knowledge that medication 
adherence is a complex behaviour with a range of potential determinants, it seems highly 
unlikely that a single component intervention will be the answer for all non-adherent 
patients. This view is supported by a Cochrane review that assessed the effectiveness of 182 
RCTs in terms of improving both medicine adherence and clinical outcomes in all age groups 
(Nieuwlaat et al. 2014). The review authors concluded that out of the 17 studies with the 
lowest risk of bias, only five showed improvements in both adherence and clinical outcomes. 
Those demonstrating effectiveness were complex in nature but improvements were 
generally limited. The interventions delivered were heterogeneous in design, ranging from 
daily support through to educational and behavioural-based interventions. Although the 
authors highlighted some concerns around the use of complex interventions (such as 
difficulty in identifying the most effective components and difficulty with replication due to 
poor reporting), they indicated that it is rational to adopt them for targeting a complex 
behaviour such as medication adherence. 
1.4.2 Adherence interventions targeting older adults 
A small number of systematic reviews have focused more specifically on adherence 
interventions that target older adults, patients with multimorbidity and/or patients 
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prescribed multiple medications (van Eijken et al. 2003; Banning, 2008; George et al. 2008; 
Ruppar et al. 2008; Williams et al. 2008). A systematic review conducted by George et al. 
(2008) identified only a limited number of interventions (n=8) that targeted older patients 
who were prescribed polypharmacy. Out of the eight interventions identified, only four 
showed improvements in adherence. Strategies included Monitored Dosage Systems (MDS; 
plastic containers with slots for each day and time of the week), group education, individual 
medication lists and medication reviews but there was no common effective component 
identified.  
Williams et al. (2008) conducted a systematic review of adherence interventions targeting 
multimorbid patients, with five out of the eight studies they identified targeted at older 
adults aged 70 years or older. They found that adherence was commonly addressed as part 
of larger interventions to manage polypharmacy and reduce healthcare costs, with 
pharmacists as the most prominent intervention provider. The authors indicated that the 
current evidence base for such interventions was weak and interventions often lacked a 
psycho-social focus (i.e. they did not focus on the influence of the social environment on 
adherence behaviours).  
More recently, a systematic review conducted by Marcum et al. (2017) explored 
interventions that aimed to improve medication adherence and health outcomes (e.g. 
mortality, morbidity, healthcare costs) in older adults. This review reported mixed findings, 
with only five out of the 12 identified studies showing improvements in both adherence and 
health outcomes; two combined educational and behavioural strategies and three were 
pharmacist-led counselling interventions. The authors indicated that interventions delivered 
by pharmacists produced promising findings but that such interventions need to be more 
carefully designed and evaluated in future research.  
Adherence interventions have commonly focused on improving older patients’ knowledge of 
medications/medical conditions through education (Nieuwlaat et al. 2014; Conn and Ruppar, 
2017). Although knowledge is an important pre-requisite and necessary for adherence, it has 
been recognised that education alone is insufficient for changing adherence behaviours, 
particularly with regards to unintentional non-adherence such as forgetfulness (Conn et al. 
2009; Conn et al. 2016b; Kahwati et al. 2016). A review by Schlenk et al. (2008) found that 
educational-based interventions were not consistent in improving older patients’ medication 
adherence. Instead they found tailored interventions with ongoing contact with HCPs (e.g. 
pharmacists, health mentors) were more effective than brief interactions or mailed 
education, but further research in this area is required.  
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1.4.3 Healthcare professionals’ role in improving medication adherence  
As alluded to previously, whilst most interventions have focused on patients’ behaviour, 
research has recognised that adherence is not solely the result of an individual’s actions but 
can be influenced by both the healthcare setting and HCPs’ behaviours. For example, actions 
undertaken by HCPs and their relationships with patients have been reported as 
determinants of adherence (Kardas et al. 2013; Conn et al. 2015; Allemann et al. 2016). 
Consequently, the role that HCPs can play in tackling non-adherence is of growing interest in 
the field of adherence research (Huston, 2015).  
The WHO report on medication adherence recognised that HCPs have an important role to 
play in identifying non-adherence and in the delivery of interventions to improve it (Sabate, 
2003). The report also indicated that HCPs require access to training on how to manage non-
adherence and healthcare systems need to be designed in such a way to facilitate this. 
Guidance produced by NICE in 2009 on medicines adherence (CG76) has also discussed HCPs’ 
clinical role in both assessing adherence (e.g. asking about adherence when 
prescribing,dispensing or reviewing medicines) and delivering interventions to improve it 
(e.g. information provision, practical changes, encouragement/support) (National Institute 
for Health and Clinical Excellence, 2009). Despite this guidance, recent research has shown 
that HCPs do not frequently ask patients about their medication adherence behaviours and 
they are unable to accurately predict non-adherence in their patients (Zeller et al. 2008; Conn 
et al. 2015).   
A survey, conducted in Switzerland and nine other European Union (EU) countries (e.g. 
England, France, The Netherlands), explored the role of primary care and community-based 
HCPs’ (doctors, nurses and pharmacists) in managing medication adherence. This cross-
sectional study found that only half of all HCPs routinely questioned patients about missed 
doses (Clyne et al. 2016). Out of the three groups of HCPs who were surveyed, pharmacists 
intervened the least. However, pharmacists from England, the Netherlands and Portugal 
reported slightly more frequent assessment of non-adherence and information provision 
than pharmacists in other countries. Pharmacists in England and the Netherlands also 
reported more frequent recommendation of practical strategies to improve adherence in 
comparison with pharmacists from other countries. In the primary care setting, community 
pharmacists (CPs) are seen as the most accessible HCP who have frequent contact with 
patients (e.g. every time medication is dispensed) (Kocurek, 2009). Therefore, CPs are being 
presented with an opportunity to support patients with medication adherence and help them 
obtain maximum benefit from treatments.  
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A small number of qualitative studies have recently been conducted to explore CPs’ 
perceived barriers to providing medication adherence support (MAS) in the USA (Bacci et al. 
2014), Scotland (Lowrie et al. 2014) and Switzerland (Marquis et al. 2014). Initial findings 
indicate that time pressures, lack of remuneration, CPs’ confidence and concerns around 
discussing multiple medical conditions may be contributory factors that influence CPs’ 
behaviour (i.e. the provision of MAS). However, it appears that barriers to providing MAS 
may vary both within and between countries. For example, a lack of confidence was 
identified as a barrier in qualitative interviews with CPs in Switzerland (Marquis et al. 2014), 
whereas, a Scottish study (Lowrie et al. 2014) showed that CPs appeared to be confident, 
although the latter study focused solely on the provision of adherence support to heart 
failure patients. With contrasting findings in the current (somewhat limited) evidence base, 
there is a need for additional research into the most influential barriers and facilitators to the 
provision of MAS by CPs (Huston, 2015). Due to the influence of HCPs on patients’ adherence 
behaviours, it may be necessary to target HCPs’ behaviour directly (e.g. through a training 
package, changes to policy) to have an impact on patients’ behaviour.  
A recent systematic review by Conn et al. (2015) explored HCP-targeted interventions that 
ultimately aimed to improve patients’ medication adherence. This review identified 218 
interventions which, overall, produced a small overall effect size (Cohen’s d) of 0.233 in 
comparison with usual/standard care (effect sizes ranged from 0.088 to 0.301 for individual 
interventions, where 0.2 indicates a small effect size, 0.5 a moderate effect size and 0.8 a 
large effect size). Interventions that contained multiple components (i.e. complex 
interventions) directed at HCPs were more effective but there was a lack of evidence to 
support any particular strategy. Interventions ranged from educating HCPs on adherence and 
skills training (e.g. communication skills, barrier identification skills, Motivational 
Interviewing skills) through to reminder systems to prompt HCPs to ask patients about 
adherence. It is unclear how such multi-component interventions (e.g. training packages) 
directed at HCPs have been developed and their anticipated mechanisms of actions. Thus, 
there is a need for more research in this area. 
1.4.4 Pitfalls with adherence intervention research 
Although there has been a substantial amount of work in the field of adherence research, it 
is clear that no individual intervention component or package of components has led to 
substantial improvements in medication adherence in older patients (Brown and Bussell, 
2011). Those interventions that have led to improvements in adherence have shown only 
modest improvements. For example, meta-analyses have shown improvements in adherence 
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measures in the range of 4-11% (Peterson et al. 2003; Kripalani et al. 2007; Bosworth et al. 
2011). 
There are a number of major issues with previous adherence research. Firstly, adherence 
interventions have commonly targeted individual (or groups of) medications for a single 
clinical condition, yet over two-thirds of older patients are multimorbid and require 
treatment with several medications (Barnett et al. 2012). Boyd and Fortin (2011) have 
emphasised the importance of taking ‘…care of people with multimorbidity, not the 
individual conditions that add up to multimorbidity’. As stated in the latest Cochrane review 
on medication adherence interventions, the clinical condition is not deemed to be a major 
determinant of behaviour (Nieuwlaat et al. 2014). Therefore to be relevant for future clinical 
practice, adherence research needs to shift its focus away from single conditions. Instead, 
interventions need to be designed to account for the presence of multiple medications and 
clinical conditions, which will likely vary from patient-to-patient (Salisbury, 2012). There is a 
need for more research that explores the effectiveness of novel complex interventions that 
can be tailored to each older patient’s individual medications/conditions and readily 
integrated into clinical practice. Previous interventions have also failed to focus on the 
patient perspective to medication-taking and are described as being only ‘loosely patient-
centric’ (Bosworth et al. 2011). 
Another issue is that adherence is often addressed as part of a complex disease management 
programme instead of being the sole focus of interventions (Nieuwlaat et al. 2014). Details 
of exactly what has been delivered as part of complex intervention packages and their 
proposed mechanism of action for changing patients’ adherence behaviours are often 
unclear, missing or not fully described in published reports. Researchers need to carefully 
report the components of complex interventions to allow for replication or adaption by 
others.  
1.5 Developing and evaluating complex behaviour change interventions  
1.5.1 Challenges associated with complex interventions 
As discussed in Section 1.4, complex interventions are often employed in an attempt to 
improve medication adherence and these are usually directed at patients (although they can 
also be directed at HCPs). However, challenges have been identified around the design, 
standardisation and delivery of such interventions (Craig et al. 2008). Research into methods 
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used in clinical trials suggests that there is often a lack of initial preparatory work, which may 
impact on the outcomes and overall success of complex interventions (Eldridge et al. 2004).  
What appears to be lacking from the current evidence base is clear justified reasons for 
selecting particular intervention components and a detailing understanding and report of 
their proposed mechanism of action for eliciting behaviour change (e.g. a change in patients’ 
adherence behaviours) (Nieuwlaat et al. 2014). Conventionally, components of complex 
interventions have been selected based on what researchers think might be effective, rather 
than on established theory and patient views. A better understanding of how adherence 
interventions work through the use of theory could help to advance this field of research 
(Michie et al. 2015).    
1.5.2 The potential role of theory in adherence research 
A theory has been defined as: 
“(…) a systematic way of understanding events or situations. It is a set of concepts, 
definitions, and propositions that explain or predict these events or situations by 
illustrating the relationship between variables.” (Glanz and Rimer, 2005, p.4) 
Theories (also termed models) consist of building blocks called ‘theoretical constructs’ which 
are labels given to complex sets of observations of human behaviour (Binning, 2016). 
Theories can stem from a range of disciplines including psychology, sociology, anthropology 
and economics. Psychological theories are the most common type of theory used in the field 
of health behaviour change and are therefore the focus of this research (Michie et al. 2014a). 
These can facilitate researchers’ understanding of health behaviours by: (1) explaining and 
predicting the behaviour (when, how and why it occurs); (2) helping to identify key influences 
on behaviour that could be targeted to bring about behaviour change.  Incorporating theory 
into the design of adherence interventions could prove to be effective but further research 
is required. 
A range of psychological theories have been used to explain and predict health behaviours. 
Social Cognitive Theory (SCT), the Health Belief Model (HBM) and the Theory of Planned 
Behaviour (TPB) are examples of commonly used theories; these are briefly explained below 
in Table 1.1 as illustrative examples (Munro et al. 2007; Holmes et al. 2014).  





Table 1.1: Examples of psychological theories including brief descriptions and illustrative diagrams 





SCT focuses on how individuals learn from past 
experiences and the actions of others, as well 
as the impact from the environment. Three 
key factors (environment, personal, 
behavioural) continuously influence each 















TPB explains that a combination of beliefs 
(attitudes towards the behaviour, subjective 
norm, perceived behavioural control) predict 
an individual’s intention (motivation) to 













and social) (E.g. 
access to services, 
social influences) 
Behavioural factors  
(E.g. skills, self-control) 
 







Attitudes towards behaviour (e.g. 
extent to which they see the outcomes 
as favourable/unfavourable) 
Subjective norm (i.e. an individual’s 
perceptions of how important other 
people think the behaviour is) 
Perceived behavioural control (i.e. 
how able the person feels in 



















Table 1.1 (cont’d): Examples of psychological theories including brief descriptions and illustrative diagrams 




1974; Glanz et 
al. 2008) 
A health behaviour can be predicted by core 
theoretical constructs including perceived 
susceptibility and severity of the illness and 
perceived barriers and benefits. Behaviour can 
also be influenced by internal or external cues 
to action and a person’s self-efficacy (i.e. an 
individual's belief in their ability to carry out 









Cues to action (e.g. 






Modifying variables (e.g. 
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Although a wide range of psychological theories have been used to help explain and predict 
patients’ non-adherence behaviours, it seems that only a limited number of interventions to 
improve adherence have been explicitly based on theory (Nieuwlaat et al. 2014). 
Consequently, there is a need to explore exactly how researchers have used psychological 
theory to develop complex interventions to improve medication adherence in older adults 
who are prescribed polypharmacy. 
Although theory cannot guarantee intervention effectiveness, there are a range of reasons 
why it is thought that its use could advance scientific research. Theory can provide 
intervention developers with a lens through which to view the behaviour of interest and 
identify exactly what factors need to be targeted for change. It can also be used to explore 
the intervention’s underlying mechanisms of action and contribute to the knowledge base 
on how interventions work (Rothman, 2004; Michie et al. 2014a). It can be difficult to identify 
the most effective individual active components within complex interventions (Campbell et 
al. 2000). Psychological theories offer a potential way of addressing this complexity. As a 
result, theory can increase research efficiency by ensuring researchers undertake a 
systematic and methodological approach to generating new knowledge (Michie et al. 2014a).  
Recommendations to have a coherent theoretical underpinning for complex interventions 
(including guidance from the UK Medical Research Council; see Section 1.5.4) have led to 
researchers selecting commonly cited theories (e.g. HBM, SCT) to develop BCIs without fully 
exploring the target behaviour in their target audience (Moore and Evans, 2016). Moore and 
Evans (2016) argue that this approach acts as a distraction from identifying the true 
mechanism of action through which behaviour change could be achieved. Citing such 
theories without exploring their true fit to the target audience is also unlikely to lead to 
improved intervention effects. It is therefore important to explore the behaviour in detail 
when establishing the theoretical basis of a complex intervention. 
Holmes et al. (2014) conducted a review that looked at the ability of psychological theories 
to predict medication adherence in adults (>18 years). The majority of studies were cross-
sectional in nature (49 out of 67) and the most common condition under investigation was 
HIV (n=22). The authors concluded that individual theories or models only explained a small 
amount of the variability in adherence across adult patients. This may be because individual 
theories do not cover all of the possible influences on a person’s behaviour, for example, SCT 
does not take into account the role that habits have to play in adherence (Bandura, 1998). 
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Benefits of using theory are likely to be limited if researchers limit their selection to individual 
theories rather than taking into consideration a broad range of theories (Munro et al. 2007; 
Holmes et al. 2014; Michie et al. 2014a). Psychological theories, often with overlapping 
constructs, are abundant in the literature; this makes it difficult to select the most 
appropriate one to inform intervention development (Michie et al. 2014a).  
1.5.3 The Theoretical Domains Framework (TDF)  
To overcome problems associated with theory selection, a group of psychologists and health 
service researchers designed the Theoretical Domains Framework (TDF) of behaviour change.  
The original 12 domain framework (TDF1), developed in 2005, incorporates theoretical 
constructs from 33 psychological theories of behaviour change (Michie et al. 2005). 
Definitions of each domain in TDF1 and descriptions in the context of medication adherence 
are presented in Table 1.2. Theoretical constructs assigned to each theoretical domain are 
also provided. The TDF can be used by intervention developers to inform the design of 
complex interventions and incorporate a theoretical underpinning in their development 






Table 1.2: Domains in TDF1 (Michie et al. 2005), definitions, descriptions of the domain in the context of medication adherence behaviour and theoretical constructs 
assigned to each domain [adapted from Francis et al. (2014)] 
Domain in TDF1 Definition of domain (Michie et al. 
2005) 
Description of domain in the context of 
medication adherence behaviour 
Theoretical constructs represented within each domain (Michie 
et al. 2005) 
Knowledge ‘An awareness of the existence of 
something’ 
Knowledge related to medications, 
regimens and clinical conditions  
Knowledge (including knowledge of condition/scientific 
rationale); Procedural knowledge; Schemas+ mindsets+ illness 
representations 
Skills ‘An ability or proficiency acquired 
through practice’ 
Abilities (i.e. physical skills) required to take 
several medications as prescribed   
Skills; competence/ability/skill assessment; Practice/skills 
development; Interpersonal skills; Coping strategies 
Social/ 
professional 
role and identity 
‘A coherent set of behaviours and 
displayed personal qualities of an 
individual in a social or work 
setting’ 
Whether patients see the behaviour as 
their own responsibility or as someone 
else’s 
Identity; Professional identity/boundaries/role; group/social 
identify; Social/group norms  
Beliefs about 
capabilities1 
‘Acceptance of the truth, reality, or 
validity about an ability, talent, or 
facility that a person can put to 
constructive use’ 
How confident the patient feels about 
being able to adhere to a multiple 
medication regimen (i.e. ease or difficulty 
of the behaviour) 
Self-efficacy; Control—of behaviour and material and social 
environment; Perceived competence; Self-
confidence/professional confidence; Empowerment; Self-
esteem; Perceived behavioural control; Optimism/pessimism 
Beliefs about 
consequences2 
‘Acceptance of the truth, reality, or 
validity about outcomes of a 
behaviour in a given situation’ 
Perceptions about the outcomes of taking 
(or not taking) several medications as 
prescribed (benefits and unwanted side 
effects) 
Outcome expectancies; Anticipated regret; 
Appraisal/evaluation/review; Consequents; Attitudes; 
Contingencies; Reinforcement/punishment/consequences; 
Incentives/rewards; Beliefs; Unrealistic optimism; Salient 
events/sensitisation/critical incidents;  Characteristics of 
outcome expectancies–physical, social, emotional; 
Sanctions/rewards, proximal/distal; Valued/not valued, 




‘Mental representations of 
outcomes or end states that an 
individual wants to achieve and 
their intentions to perform the 
target behaviour’ 
Strength of intention to adhere to the 
medication regimen 
Priorities, perceived importance and 
commitment to taking several medications 
as prescribed 
Intention; Stability of intention/certainty of intention; Goals 
(autonomous, controlled); Goal target/setting; Goal priority; 
Intrinsic motivation; Commitment; Distal and proximal goals; 












Table 1.2 (cont’d): Domains in TDF1 (Michie et al. 2005), definitions, descriptions of the domain in the context of medication adherence behaviour and theoretical 
constructs assigned to each domain [adapted from Francis et al. (2014)]] 
Domain in TDF1 Definition of domain (Michie et al. 
2005) 
Description of domain in the context of 
medication adherence behaviour 
Theoretical constructs represented within each domain (Michie 





‘The ability to retain information, 
focus selectively on aspects of the 
environment and choose between 
two or more alternatives’ 
Memory—whether adherence to 
polypharmacy is problematic because 
patients simply forget 
Decision-making – whether patients choose 
to take certain medicines over others; 
whether they decide to have occasional 
breaks from taking medications; 




‘Any circumstances of a person’s 
situation or environment that 
discourages or encourages the 
development of skills and abilities, 
independence, social competence, 
and adaptive behaviour’ 
Physical factors (e.g. difficulty swallowing 
large tablets) 
Financial and healthcare system factors (e.g.  
difficulty accessing a repeat prescription 
service) 
Circumstances (e.g. location, time) under 
which the behaviour is occurring (e.g. 
whether adherence is more difficult when 
the patient is away from home) 
Resources/material resources (availability and management); 
Environmental stressors; Person X environment interaction; 
Knowledge of the task environment 
Social 
influences 
‘Those interpersonal processes that 
can cause individuals to change 
their thoughts, feelings, or 
behaviours’ 
External pressure/influence from others 
(e.g. HCPs, carers, family, other patients)  
Whether patients take several medications 
as prescribed simply because they are told 
to 
 
Social support; Organisational development; Leadership; Team 
working; Group conformity; Organisational climate/culture; 
Social pressure; Power/hierarchy; Professional boundaries/roles; 
Management commitment; Supervision; Inter-group conflict; 
Champions; Social comparisons; Identity; Group/social identity; 
Organisational commitment/alienation; Feedback; Conflict—
competing demands, conflicting roles; Change management; 
Crew resource management; Negotiation; Social support: 
personal/professional/organisational, intra/interpersonal, 
society/community; Social/group norms: subjective, descriptive, 





Table 1.2 (cont’d): Domains in TDF1 (Michie et al. 2005), definitions, descriptions of the domain in the context of medication adherence behaviour and theoretical constructs 
assigned to each domain [adapted from Francis et al. (2014)] 
Domain in 
TDF1 
Definition of domain (Michie et 
al. 2005) 
Description of domain in the context of 
medication adherence behaviour 
Theoretical constructs represented within each domain (Michie et 
al. 2005) 
Emotion ‘A complex reaction pattern, 
involving experiential, 
behavioural, and physiological 
elements, by which the 
individual attempts to deal with 
a personally significant matter 
or event’ 
Affect (positive or negative) 
Feelings towards taking (or not taking) several 
medications as prescribed  
Affect; Stress; Anticipated regret; Fear; Burn out; Cognitive 




‘Anything aimed at managing or 
changing objectively observed 
or measured actions’ 
Whether patients have ways of monitoring 
their medication adherence/non-adherence 
and outcomes 
Whether patients have difficulty translating 
intentions to take several medications as 
prescribed into action  
Goal/target setting; Action planning; Self-monitoring; Goal priority; 
Generating alternatives; Feedback; Moderators of intention-
behaviour gap; Project management; Barriers and facilitators 
Nature of the 
behaviours4 
‘Essential characteristics of the 
behaviour’ 
Past experiences of adherence/non-adherence 
to polypharmacy 
Whether medication adherence is a 
routine/automatic behaviour for the patient 
Routine/automatic/habit; Breaking habit; Direct experience/past 
behaviour; Representation of tasks; Stages of change model. 
1 Split into two domains in TDF2 (14 domains): ‘Optimism’ and one retaining the original name; 2Split into two domains in TDF2 (14 domains): ‘Reinforcement’ and one retaining the original 














This framework has recently been updated to a 14 domain version (TDF2) (Cane et al. 2012), 
however, both versions of the TDF are useful frameworks for developing complex 
interventions such as BCIs (Huijg et al. 2014b; Atkins et al. 2017).  
As discussed previously in Section 1.3.1, three key factors need to be taken into consideration 
in the context of behaviour change: capability, opportunity and motivation; these form the 
COM-B model (Michie et al. 2011). Jackson et al. (2014) have recommended the use of the 
COM-B model in exploring medication adherence as it offers ‘a more complex explanation of 
adherence than existing models’. The TDF1 is a more comprehensive framework that can be 
mapped onto the COM-B model. The links between the TDF1 and the COM-B model are 
shown below in Figure 1.4. The COM-B was developed to simplify the framework for use by 
a wider audience, such as policy makers. As the TDF is more detailed than the COM-B model, 









Figure 1.4: Links between the COM-B model (central pie chart) and the TDF1 (outer boxes) 
NB: The domain ‘Nature of the behaviours’ is considered to be slightly different to the other 11 domains 
in the TDF1 as it is not deemed a source of the behaviour (i.e. independent variable); instead it is 
described as a dependent variable (Cane et al. 2012; Michie et al. 2014b).  
 
In order to bring about behaviour change it is important to fully understand the target 
behaviour in the target audience. The TDF can be used as a ‘theoretical lens’ to identify key 
determinants of target behaviours (Stewart and Klein, 2016; Atkins et al. 2017). These key 
determinants are seen as barriers and/or facilitators, where a barrier is anything that 
prevents the behaviour being carried out and a facilitator helps in carrying out the behaviour. 
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a behavioural analysis via qualitative and/or quantitative methods. Key theoretical domains 
can then be selected for targeting and linked to the most appropriate intervention 
components (Michie et al. 2008; Michie et al. 2013; Cane et al. 2015). In the field of behaviour 
change, the components of complex BCIs are termed behaviour change techniques (BCTs). 
BCTs are defined as…. 
“…the smallest components of behaviour change interventions that on their own in 
favourable circumstances can bring about change.” (Michie et al. 2014b) 
BCTs can be described as ‘theory-based’ as they originate from social science and behavioural 
theories (Kok et al. 2016). A change in key determinants (barriers, facilitators) through 
targeting key domains (from the TDF) with appropriate BCTs will, in theory, lead to behaviour 
change (Michie et al. 2014a). 
To date, TDF-based intervention development studies have primarily focused on HCPs’ 
clinical behaviours, particularly in relation to the implementation of evidence-based 
guidelines (Francis et al. 2012). More recently, the TDF has been used to explore patients’ 
behaviours. For example, Cahir et al. (2015), McCullough et al. (2015) and Easthall et al. 
(2014) have used the TDF to explore medication adherence, albeit in different patient 
populations (in patients with breast cancer, bronchiectasis and cardiovascular disease, 
respectively). However, no studies have explored older patients’ adherence to multiple 
medications (i.e. polypharmacy) using the TDF as a ‘theoretical lens’. 
1.5.4 Guidance from the Medical Research Council 
The Medical Research Council (MRC) has produced guidelines for those undertaking complex 
intervention studies to help overcome the difficulties associated with their design and testing 
(Craig et al. 2008). The most recent MRC framework was published in 2008 and advises that 
intervention development should consist of a number of non-linear stages including: 























Figure 1.5. The key stages involved in ‘developing and evaluating complex interventions’ (Adapted 
from: Medical Research Council, 2008) 
The MRC recommends that the initial development stage should include establishing the 
intervention’s evidence and theoretical base and triangulating these findings to develop an 
intervention. Previous complex interventions have been developed using the acronym as 
‘ISLAGIATT’: ‘It Seemed Like A Good Idea At The Time’ (acronym created by Martin Eccles; 
Emeritus Professor of Clinical Effectiveness, and implementation researcher) rather than 
using a systematic development approach (Michie et al. 2014a). Using the MRC approach to 
development, may involve conducting a systematic review (evidence base), in addition to 
conducting primary research such as interviews or focus groups (qualitative methodology) or 
questionnaire studies (quantitative methodology) to explore the behaviour in detail and 
develop the interventions’ theoretical base. 
By developing an understanding of the behaviour that needs changed through the use of 
theory (or a theoretical framework such as TDF), the most appropriate intervention 
components (i.e. BCTs) can be chosen to facilitate the behaviour change process (Glanz and 
Rimer, 2005; Michie and Prestwich, 2010). It is also thought that interventions based on 
theory are more likely to be effective than those with unknown mechanisms of actions 
(Holmes et al. 2014).  
Following the systematic development of an intervention, the MRC recommends that such 
interventions should undergo feasibility and pilot testing. The terms feasibility and piloting 
are commonly used interchangeably in the literature, but some authorities claim that there 
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are subtle difference between the two (Arain et al. 2010). The National Institute for Health 
Research (NIHR) describes feasibility studies as research studies that are conducted in 
advance of a main trial to answer the key question ‘Can this study be done?’ (definitions of 
‘Feasibility studies’ and ‘Pilot studies’ can be found at http://www.nets.nihr.ac.uk/glossary). 
Based on the NIHR’s definition, the aim of a feasibility study can also be to address key study 
parameters required to inform future evaluations such as the willingness of HCPs to recruit 
patients and willingness of patients to be recruited, time needed to collect data etc. Eldridge 
et al. (2016) have provided the following definition for feasibility and pilot studies:  
“A feasibility study asks whether something can be done, should we proceed with it, 
and if so, how. A pilot study asks the same questions but also has a specific design 
feature: in a pilot study, a future study, or part of a future study, is conducted on a 
smaller scale.” 
The definition of a feasibility study proposed by the NIHR was adopted for the research 
presented in this thesis due to it being the most up-to-date definition available at the time 
that the research was conducted. Irrespective of the definition used, it is clear that feasibility 
studies do not aim to evaluate the effect of the intervention on any outcomes of interest; 
rather they can be used to assess whether outcomes (e.g. medication adherence outcomes, 
clinical outcomes) can be feasibly measured as part of a study in the selected setting. 
It is important to note that the stages in the MRC framework are non-linear and researchers 
can move back and forth between stages until the intervention is optimised. In addition, 
researchers may want to consider implementation issues early on in the process. As 
discussed previously in Sections 1.3 and 1.4.3, researchers may wish to consider the 
behaviour of those who will be responsible for implementing the intervention in practice 
(such as HCPs) and the context in which it will be delivered.  
1.6 Overview of research presented in this thesis  
1.6.1 Overall research aim 
The overall aim of the research outlined in this thesis was to design a complex theory-based 
intervention to improve medication adherence in older patients who are prescribed 
polypharmacy. It was intended at the outset of the project that the developed intervention 
would be delivered by CPs in the community pharmacy setting. CPs were selected as they are 
readily accessible to patients (Kocurek, 2009) and recent reviews have supported their 
involvement in interventions to improve the use of medicines by patients (Nieuwlaat et al. 
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2014; Ryan et al. 2014). Although the main focus of this research was on improving older 
patients’ adherence behaviour, the behaviour of CPs in terms of providing MAS was also 
considered important to explore and potentially target as CPs will ultimately be responsible 
for implementing the intervention into practice, if it is shown to be effective.  
The key objectives of this research project were to: 
 Identify theory-based adherence interventions, delivered to older adults prescribed 
polypharmacy, in the literature and explore which theories were selected, how they 
were used and their potential impact on effectiveness 
 Develop the theory base of a novel patient-targeted intervention to improve adherence 
to polypharmacy in older adults and select intervention components (i.e. BCTs) to target 
key behavioural determinants 
 Combine selected intervention components into an intervention package for older 
patients prescribed polypharmacy and test the feasibility of delivering this in the 
community pharmacy setting 
 Select components that could be delivered as part of a theory-based training package 
for CPs and strategies that could be used to facilitate the future implementation of the 
patient-targeted intervention in clinical practice 
1.6.2 Overview of thesis chapters 
To address the key research objectives stated above, the project was divided into four 
phases. The findings from each phase are outlined in Chapters 2-5 of this thesis: 
Chapter 2: A systematic review of theory-based adherence interventions delivered to 
older adults prescribed polypharmacy  
Chapter 3: Selection of components for a theory-based intervention to improve 
medication adherence in older adults prescribed polypharmacy 
Chapter 4: Design and feasibility testing of a theory-based intervention to improve 
medication adherence in older adults prescribed polypharmacy 
Chapter 5: Selection of components for a theory-based community pharmacist training 
package and strategies to improve the provision of medication adherence 
support: a mixed methods approach  











A systematic review of theory-
based adherence interventions 
delivered to older adults 
prescribed polypharmacy 
  




This chapter focuses on a systematic review, conducted in line with the development stage 
of the UK MRC framework for complex interventions (Medical Research Council, 2008). The 
study reported here sought to address gaps in the current evidence base and inform the 
development of a novel complex intervention to improve medication adherence in older 
adults prescribed polypharmacy. 
2.1.1 Overview of the current evidence base 
As discussed in Chapter 1, a wide range of systematic reviews (and meta-analyses) have 
explored the effectiveness of medication adherence interventions across different clinical 
conditions, settings and population groups (Nieuwlaat et al. 2014; Conn et al. 2016b). A 
number of these reviews have focused specifically on older patients, multi-morbid patients 
or those prescribed multiple medications (George et al. 2008; Schlenk et al. 2008; Williams 
et al. 2008; Conn et al. 2009; Marcum et al. 2017). A common finding across previous reviews 
is the lack of strong evidence to support individual, or specific combinations of, intervention 
components. Where effectiveness has been demonstrated, improvements in adherence, 
clinical and humanistic outcomes (e.g. health-related quality of life; HRQOL) have been 
modest at best. It is evident that there is substantial room for improvement (Nieuwlaat et al. 
2014). 
It has been recognised that a ‘one-size-fits-all’ or ‘simple’ intervention approach is unlikely 
to improve medication adherence in all patients, and so the development of a complex 
intervention (with multiple interacting components) to address this problem is justified 
(Brown and Bussell, 2011; Nieuwlaat et al. 2014). However, as highlighted in Chapter 1, there 
are a number of challenges surrounding the development and evaluation of complex 
interventions. For example, the current gold standard evaluation approach (i.e. a definitive 
RCT) does not allow researchers to distinguish between active and inactive intervention 
components (Medical Research Council, 2008). Failure to understand exactly how individual 
intervention components exert their effect is a potential limiting factor in the advancement 
of this field of research.  
2.1.2 Theory and complex interventions 
An emerging concept in the development of complex interventions is the use of psychological 
theory to improve understanding of the behaviour change process (Medical Research 
Council, 2008). Psychological theories can help researchers identify:  (1) ‘What’ exactly needs 
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to change (i.e. which aspects of the behaviour should be targeted); (2) ‘How’ to bring about 
behaviour change (i.e. which intervention components should be delivered in a complex 
intervention); (3) ‘Why’ a particular effect is observed (i.e. the intervention’s underlying 
mechanism of action) (Michie and Prestwich, 2010). For example, a theory-based process 
evaluation study, conducted alongside a RCT, could help researchers disentangle the causal 
chains that link the delivery of a complex intervention with study outcomes, as shown in 




Figure 2.1: Diagrammatic representation of the linkage between complex intervention delivery and 
study outcomes 
This type of process evaluation could involve the measurement of relevant theoretical 
constructs (e.g. ‘motivation’) pre- and post-intervention delivery (Michie and Prestwich, 
2010). It is proposed that the systematic use of theory could contribute to the development 
of more effective interventions and also lead to the accumulation of evidence on what works, 
what does not work and the underlying reasons why (Medical Research Council, 2008). 
2.1.3 Theory use in previous adherence intervention research 
Little is currently known about how researchers have previously used psychological theory in 
the development of medication adherence interventions. The authors of the latest Cochrane 
review on medication adherence interventions noted whether an intervention appeared to 
be based on theory, but they did not explore this in detail (Nieuwlaat et al. 2014). Another 
recent meta-analysis of adherence interventions (delivered to adults aged over 18 years) 
examined the use of theory by identifying those that cited theory or a particular intervention 
approach commonly linked to theory (e.g. Motivational Interviewing; MI) (Conn et al. 2016a). 
This review identified 146 interventions that produced a modest overall effect size of 0.294. 
The authors indicated that this modest effect may have been influenced by poor theory 
selection, application/operationalisation, but they did not undertake a detailed examination 
of this.  
Although the UK MRC’s framework advocates the use of an underpinning theory for complex 
interventions, the guidance does not provide explicit details of exactly how theory should be 
utilised (Medical Research Council, 2008). Experts in the field of behaviour change and health 
Delivery of a complex 
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sequence of events 
/mechanism of 
action)
Study outcomes (e.g. 
adherence and 
clinical outcomes)
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psychology have recognised that the specific way in which theory is used can affect the 
outcome of the intervention. It is therefore  important to examine the exact nature of theory 
application (Michie and Prestwich, 2010). A Theory Coding Scheme (TCS) has been developed 
by Michie and Prestwich (2010) to assist researchers in systematically identifying and reliably 
describing an intervention’s theoretical base. This research tool aims to encourage 
transparency and consistency in reporting, as well as a clearer understanding of what the 
term ‘theory-based’ means when used to describe BCIs. It has been successfully utilised in a 
number of systematic reviews on behaviour change, for example, in exploring theory use in 
internet-based health interventions (Webb et al. 2010; Prestwich et al. 2014; Ayling et al. 
2015; Farmer et al. 2015). However, to date, no review has specifically investigated theory 
use in the design of adherence interventions, delivered to older adults prescribed 
polypharmacy, using the TCS. This chapter provides an overview of the methodology and 
findings from a systematic review that aimed to address this gap in the literature and inform 
the development of a novel complex intervention. 
2.2 Aims and objectives 
The overall aim of this systematic review was to determine the effectiveness of theory-based 
interventions in improving medication adherence and clinical/humanistic outcomes in older 
adults prescribed polypharmacy and explore exactly how psychological theory informed 
intervention design. The objectives were to: 
 Identify studies which explicitly referenced, applied or tested a psychological theory in 
the development of adherence interventions delivered to populations of older adults 
(aged 65 years or older) who were prescribed polypharmacy (four or more medications) 
 Determine the specific theories that underpinned these interventions  
 Examine how theory informed intervention development 
 Determine how the intervention was implemented (e.g. setting, provider)  
 Identify how the authors defined the extent of adherence (or non-adherence) and the 
method(s) used to measure it 
 Establish the effectiveness of theory-based interventions in improving medication 
adherence and clinical/humanistic outcomes in older adults prescribed polypharmacy. 
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2.3 Research design and methodology 
2.3.1 Protocol 
This systematic review followed a protocol developed using methods established by the 
Cochrane Collaboration (The Cochrane Collaboration, 2011). The review findings have been 
reported in line with the PRISMA (Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses) statement (Moher et al. 2009) (see completed PRISMA checklist in Appendix 
2.1). 
2.3.2 Eligibility criteria  
Types of studies 
All types of RCTs, including cluster trials, were considered for inclusion. Ideally, systematic 
reviews should include the highest level of primary evidence available (i.e. RCTs), but in cases 
where limited evidence is anticipated or the concepts and recommendations are relatively 
novel, the next best level of evidence should be considered to help answer the research 
question (Sackett et al. 1996; Burns et al. 2011). Based on the findings from the latest 
Cochrane review on adherence interventions and limited number of theory-based 
interventions identified, the decision was made to include quasi-experimental studies, 
providing they had a comparative control group (Nieuwlaat et al. 2014). Table 2.1 details the 
types of quasi-experimental studies that were considered to be eligible for the review, on the 
condition that they met the criteria specified in the Cochrane Effective Practice and 
Organisation of Care (EPOC) Group’s Data Collection Checklist (Bero et al. 2007). 
Table 2.1: Eligible quasi-experimental studies and criteria for inclusion (Bero et al. 2007) 
Study design Criteria for inclusion 
Non-randomised 
controlled clinical trials 
The study had a comparative control group 
Interrupted time series 
studies 
The study had a comparative control group and at least three time points 
preceded and three time points followed the intervention date  
Controlled before-and-
after studies  
Second sites were used as controls and were comparable in baseline 
characteristics. The exact times at which the intervention occurred were 
clearly stated 
Pilot RCTs were also considered for inclusion in this review as studies in the preliminary 
stages of development and testing could use theory in intervention design (Medical Research 
Council, 2008). This decision was made on the basis that preliminary findings from small-scale 
pilot studies may provide useful insights that could inform the development of future 
adherence interventions, in the absence of larger definitive trials. 
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Types of interventions 
Interventions delivered in all healthcare settings (e.g. primary care, secondary care) were 
considered for inclusion. Any type of intervention that had an underpinning psychological 
theory, theories or theoretical framework was considered for inclusion. Theories were 
included if they met the definition proposed by Glanz and Rimer (2005, p.4): 
“…a set of concepts, definitions, and propositions that explain or predict… events or 
situations by illustrating the relationship between variables.” 
Studies were excluded if they did not explicitly state that an established theory (or theoretical 
framework) underpinned the selected intervention or intervention components.  
Types of participants 
Studies were only included if the population had a mean (or median) age of 65 years or older, 
and were prescribed a mean (or median) of four or more medications (the definition of 
polypharmacy stated previously in Chapter 1). Studies focusing on patients with opioid, 
alcohol or tobacco addictions were excluded from this review as these problems are 
considerably more severe and differ in nature compared to chronic disease management 
(Sansone and Sansone, 2008; Nieuwlaat et al. 2014).  
Types of outcome measures 
To be eligible, studies had to include at least one medication adherence outcome (either 
direct or indirect measures) and one clinical or humanistic outcome (e.g. HRQOL). 
2.3.3 Search strategy 
Studies published in the English language, from inception of the database to the search date 
(March 2015), were considered for inclusion. Eight databases (Medline, EMBASE, PsycINFO, 
Scopus, CINAHL, Web of Science, International Pharmaceutical Abstracts and Cochrane 
Library) were searched using both free text terms and Medical Subject Headings (MeSH) that 
were devised in accordance with a subject librarian. Search terms focused around four key 
areas: ‘medication adherence’, ‘polypharmacy’, ‘theory’ and ‘older adults’. The MEDLINE 
search string is provided in Appendix 2.2. The search terms were adapted according to each 
database, and where applicable, variations and truncations were applied.  
Hand-searching was carried out using the reference lists of relevant papers identified through 
the electronic search above. A search of the Science Citation Index (in Web of Science) was 
also used to identify potentially relevant articles that cited studies that met the inclusion 
criteria. The ‘grey literature’ (e.g. Government reports and theses) were searched to identify 
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any other relevant studies. All other sources that were hand-searched are detailed in 
Appendix 2.3.  
2.3.4 Study selection 
After removal of duplicates, study titles and abstracts were screened independently by two 
reviewers (DP, CR) to identify studies suitable for inclusion. Following this, full-text articles 
were retrieved and assessed for eligibility. Disagreements were resolved through discussion 
and by consultation with a third reviewer (CC). 
2.3.5 Data extraction 
A data extraction form (Appendix 2.4) was developed and piloted using one of the agreed 
studies for inclusion. Refinements were made before using the data extraction form to 
extract data from the remaining studies. Any disagreement, for any component of data 
analysis, was resolved through third part discussion (CC). 
The reviewers (DP, CR) conducted independent risk of bias assessments on all included 
studies using tools developed by the Cochrane Collaboration (‘Risk of bias’ tool for 
randomised studies and ‘Suggested risk of bias criteria for EPOC reviews’ for non-randomised 
studies). Studies were assigned an overall rating of low, high or unclear risk (Bero et al. 2007; 
The Cochrane Collaboration, 2011).  
2.3.6 Data analysis 
It was anticipated a priori that a meta-analysis would not be feasible due to the wide variety 
of outcomes measures and intervention designs that are commonly reported in adherence 
interventions (Nieuwlaat et al. 2014). Therefore, an in-depth narrative analysis was selected 
to present the review findings in this instance.  
The extent of theory use in each included study was evaluated using pre-defined categories 
from the TCS (Michie and Prestwich, 2010). This coding scheme consists of 19 items, each of 
which falls into at least one of six categories. Categories 1-3 encompass the extent to which 
the intervention has been based on theory (‘Is theory mentioned?’; ‘Are relevant theoretical 
constructs targeted by the intervention?’; ‘Is theory used to select intervention recipients or 
tailor interventions?’). Categories 4-6 relate to theory testing and refinement (‘Are the 
relevant theoretical constructs measured?’; ‘Is theory tested?’; ‘Is theory refined?’). The 
items in each category in the TCS are detailed in Table 2.2. 






Table 2.2: Categories of the Theory Coding Scheme (TCS) (Michie and Prestwich, 2010)  
TCS Category Relevant items of TCS Description 





‘Theory/model of behaviour mentioned’ (TCS item 1) ‘Models/theories that specify relations among variables, in order to explain or predict behaviour 
are mentioned, even if the intervention is not based on this theory.’1 
‘Targeted construct mentioned as predictor of behaviour’ 
(TCS item 2) 
‘Evidence that the psychological construct relates to (correlates/predicts/causes) behaviour should 
be presented within the introduction or method.’1 
‘Intervention based on a single theory’ 
(TCS item 3) 
‘The intervention is based on a single theory (rather than a combination of theories or predictors).’1 




targeted by the 
intervention? 
 
‘Targeted construct mentioned as predictor of behaviour’ 
(TCS item 2) 
See above under Category 1. 
‘Theory/predictors2 used to select/develop intervention 
techniques’ (TCS item 5) 
‘The intervention is explicitly based on a theory or predictor3 or combination of theories or 
predictors.’1 
Intervention techniques(s) linked to theory-relevant 
construct(s) 
 
 ‘All intervention techniques are explicitly linked to at least 
one theory-relevant construct/predictor’ (TCS item 7) 
‘Each intervention technique is explicitly linked to at least one theory-relevant 
construct/predictor.’1 
 ‘At least one, but not all, of the intervention techniques are 
explicitly linked to at least one theory-relevant 
construct/predictor’ (TCS item 8) 
‘At least one, but not all, of the intervention techniques are explicitly linked to at least one theory-
relevant construct/predictor.’1 
 ‘Group of techniques are linked to a group of 
constructs/predictors’ (TCS item 9) 
‘A cluster of techniques is linked to a cluster of constructs/predictors.’ 1 
 
Theory-relevant construct(s) linked to intervention 
techniques(s) 
 
 ‘All theory-relevant constructs/predictors are explicitly 
linked to at least one intervention technique’ (TCS item 10) 
‘Every theoretical construct within a stated theory, or every stated predictor (see item 5), is linked 
to at least one intervention technique.’1 
 ‘At least one, but not all, of the theory relevant 
constructs/predictors are explicitly linked to at least one 
intervention technique’ (TCS item 11) 
‘At least one, but not all, of the theoretical constructs within a stated theory or at least one, but 
not all, of the stated predictors (see item 5) are linked to at least one intervention technique.’1 
Category 3: Is 






‘Theory/predictors used to select 
recipients for the intervention’ (TCS item 4) 
‘Participants were screened/selected based on achieving a particular score/level on a theory-
relevant construct/predictor.’1 
‘Theory/predictors used to tailor intervention techniques to 
recipients‘ (TCS item 6) 
‘The intervention differs for different sub-groups that vary on a psychological construct (e.g. stage 














Table 2.2 (cont’d): Categories of the Theory Coding Scheme (TCS) (Michie and Prestwich, 2010) 
TCS Category Relevant items of TCS Description 





‘Theory-relevant constructs/predictors are measured’ (TCS 
item 12) 
 
‘At least one construct of theory (or predictor) mentioned in relation to the intervention is 
measured post-intervention; At least one construct of theory (or predictor) mentioned in relation 
to the intervention is measured pre- and post-intervention.’1 
‘Quality of measures’ 
(TCS item 13) 
 
 
‘All of the measures of theory relevant constructs/predictors had some evidence for their 
reliability; At least one, but not all, of the measures of theory relevant constructs/predictors had 
some evidence for their reliability; All of the measures of theory relevant constructs/predictors 
have been previously validated; At least one, but not all, of the measures of theory relevant 
constructs/predictors have been previously validated; The behavior measure had some evidence 
for its reliability; The behavior measure has been previously validated.’1 








‘Theory relevant constructs/predictors are measured’ (TCS 
item 12) 
See above under Categeory 4. 
‘Quality of measures’ (TCS item 13) See above under Category 4. 
‘Randomization of participants to condition’ (TCS item 14) 
 
a) ‘Do the authors claim randomization? Is a method of random allocation to condition described (e.g., 
random number generator)? Was the success of randomization tested? Was the randomization 
successful (or baseline differences between intervention and control group statistically controlled)?’1 
‘Changes in measured theory-relevant constructs/predictors’ 
(TCS item 15) 
‘The intervention leads to significant change in at least one theory-relevant construct/predictor (vs. 
control group) in favour of the intervention.’1 
‘Mediational analysis of construct(s)/predictors’ (TCS item 16) Do any constructs mediate the effect of the intervention on the behaviour?3 
‘Results discussed in relation to theory’ (TCS item 17) ‘Results are discussed in terms of the theoretical basis of the intervention.’1 
Appropriate support for theory 
(TCS item 18) 
‘Support for the theory is based on appropriate mediation OR refutation of the theory is based on 
obtaining appropriate null effects (i.e. changing behaviour without changing the theory relevant 
constructs)’1 
Category 6: Is 
theory refined? 
‘Results used to refine theory’ (TCS item 19) ‘The authors attempt to refine the theory upon which the intervention was based by either: 
a) adding or removing constructs to the theory, or b) specifying that the interrelationships between 
the theoretical constructs should be changed and spelling out which relationships should be 
changed.’1 
Key: TCS= Theory Coding Scheme 
1 Explanation taken from the original TCS paper by Michie and Prestwich (2010); 2 A predictor is defined as ‘a construct that is not explicitly linked to a theory by the authors, but is targeted 
for intervention (as a means to change behavior) because it predicts behavior.’ Evidence that a predictor causes (or correlates with) the behaviour should be presented by the authors;  











The electronic searches identified 4,366 citations and hand-searching identified a further 33 
citations (total n = 3588 following duplicate removal). Following title and abstract screening, 
76 full-text articles were retrieved and reviewed for eligibility of inclusion. Five studies met 
the inclusion criteria: one RCT (Solomon et al. 2012) and four pilot RCTs (Barnason et al. 2010; 
Ruppar 2010b; Williams et al. 2012; O’Carroll et al. 2013). A PRISMA flow diagram of the 



















Figure 2.2: PRISMA flow diagram of the literature searching process 
 
As expected, the included studies were heterogeneous in terms of outcome measures, 
targeted clinical conditions and psychological theories underpinning intervention design. In 
addition, four out of the five included studies were pilot RCTs with small sample sizes. 
Therefore, a descriptive overview of the included studies is presented in the next section 
along with a narrative summary outlining how each study reported the use of theory during 
                  1Authors were contacted in both instances with no response 
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intervention development. Outcome data have been summarised to give an indication of 
preliminary findings (Lancaster, 2015).  
2.4.1 Description of included studies 
A total of 2,294 participants were recruited across all five studies (range: 15- 2097). The mean 
age of participants ranged from 67-78 years and the mean number of regularly prescribed 
medications ranged from 5.5-11.25 medications. Four studies targeted individual clinical 
conditions [hypertension (Ruppar, 2010a), osteoporosis (Solomon et al. 2012), heart failure 
(Barnason et al. 2010), stroke (O’Carroll et al. 2013)] and one study focused on co-existing 
conditions [diabetes and chronic kidney disease (CKD) (Williams et al. 2012)]. Although the 
study populations were all prescribed a mean of four or more medications, only two studies 
measured adherence to all prescribed medications (Barnason et al. 2010; Williams et al. 
2012); the other three studies measured adherence to a group of medications used to treat 
the particular condition that was the intervention target (Ruppar, 2010a; Solomon et al. 
2012; O’Carroll et al. 2013). Four studies used a cut-off point to classify patients as adherent, 
using  self-report scores, pill counts or electronic monitoring (Barnason et al. 2010; Ruppar, 
2010a; Williams et al. 2012; O’Carroll et al. 2013). Two studies specifically recruited patients 
who were classified as non-adherent using electronic monitoring (Ruppar, 2010a) and a self-
reported measure (O’Carroll et al. 2013).  
All of the interventions were complex in nature (i.e. multiple interacting components) and 
included a range of educational and behavioural techniques, such as self-monitoring, 
prompts, feedback and MI. Intervention participants received between 1-8 sessions, ranging 
from 2-89 minutes in duration. Participants were followed up for various time periods, from 
3-12 months. Adherence measures varied across studies, with three studies relying on a 
single measure (Barnason et al. 2010; Ruppar, 2010a; Solomon et al. 2012). Measures 
included self-report, Medication Possession Ratios (MPR) calculated using pharmacy 
dispensing records, pill counts, and electronic monitoring using Medication Event Monitoring 
Systems (MEMS). The clinical outcomes measured depended on the clinical condition 
targeted, for example, a change in BP for patients with hypertension and self-reported falls 
and fractures for patients with osteoporosis. Only two studies measured generic humanistic 
outcomes (e.g. HRQOL) (Barnason et al. 2010; Solomon et al. 2012). A summary of the 
characteristics of included studies is provided in Table 2.3.  






Table 2.3: Descriptive summary of included studies 













1. Mean age (SD): years 
2. Mean number of 
medications (SD) 
3. % of males 
Intervention 
Provider 






Adherence outcome(s)  
 
Clinical outcomes(s)  
Barnason 
(2010, USA)  
Pilot RCT  
(N=40) 
[Heart failure] 
1. 76.9  
        (+ 6.5) 
2. 11.3 (+3.8) 
3. 65% 
Nurse Hospital transition 
intervention 
Telephone counselling and 
three education modules 





education program.  
>88% Effect shown 
(statistically significant) 
Self-reported adherence, 
measured via BMQ, was 
higher in the intervention 
group than control group 
[F(1,35)= 13.4, p< 0.001]1 
(Svarstad et al. 1999) 
Effect shown (statistically 
significant) HRQOL measured via 
KCCQ (Green et al. 2000). The 
intervention group had 
significantly fewer heart failure-
related symptoms that impaired 
HRQOL [F(1,35)= 9.1, p<0.05]1 
and fewer social limitations 
[F(1,35)= 8.6, p<0.05]1 when 
compared to control.  
O’Carroll 
(2012, UK) 
Pilot RCT  
(N= 62) 
[Stroke] 
1. Not stated for 
total sample. 











Two brief sessions 
consisting of: (1) 
Modification of incorrect 
illness/medication beliefs; 
(2) Action planning. 
Control 
Same number of visits as 
intervention group but 
sessions focused on non-
medication related 





they scored less 
than maximum 





et al. 2000). 
Effect shown (statistically 
significant) 
Electronic monitoring:  
Intervention group had 
higher adherence on all three 
MEMS outcome measures2 
than control group, but only 
significant for % doses taken 
on schedule (mean difference 
9.8% CI (0.2, 16.2) p=0.048).1  
Self-report: Adherence, 
measured by MARS, 
improved in both groups at 
follow-up but a significantly 
greater improvement was 
observed in the intervention 
group (mean difference, 0.61; 
95% CI (0.1, 1.2); p=0.0027).1 
 
No effect shown 
BP: both groups showed a 
reduction in systolic and 
diastolic BP but there was no 














Table 2.3 (cont’d): Descriptive summary of included studies 













1. Mean age (SD): years 
2. Mean number of 
medications (SD) 
3. % of males 
Intervention 
Provider 






Adherence outcome(s)  
 
Clinical outcomes(s)  
Ruppar 








       (+ 8.5) 












delivering: feedback, skills 
training, education and 
habit adjustment. Delivered 
biweekly over 8 weeks. 
Usual care (control) 
Varied according to usual 







Electronic monitoring: Timing 
adherence (measured via 
MEMS). Treatment group 
adherence was higher than 
the control group at the end 
of the intervention (week 8) 
(Median MA: 96.45% vs. 
16.4%3, U=5.00, P=0.013).1 
Intervention group had a 
median improvement of 
+15.4%, control had a change 
of -5.6% (U=2.00, P=0.003).1 
Effect shown 
(statistically significant) 
Systolic BP: slightly improved in 
intervention group. 
Statistically significant when 
compared with control group at 
week 12 (intervention group 
median= 130mmHg; control 
group median= 152mmHg, 
U=4.50, P=0.008)1 but not at 
week 20. 
No significant impact on diastolic 
BP. 
Solomon 





1. 78.0 (SD not 
stated) 








sessions on specific 
education topics and 
attitudes/barriers to 
adherence (average: 8 
sessions). Also received 
educational mailings. 
Education only (control) 
Seven educational mailings 
on various topics (e.g. falls). 
Not stated No effect shown 
Pharmacy dispensing records 
(used to calculate MPR): 
No statistically significant 
differences in intervention 
versus control groups.   
Intervention group median 
MPR= 49% (IQR 7-86%);   
Control group median MPR= 
41% (IQR 1-88%)  
(P=0.074).4 
No effect shown 
Self-reported fractures: No 
statistically significant 
differences noted (intervention 
group= 11%, control group= 
11%). 
Self-reported falls: No 
statistically significant difference 
in groups found (intervention 
group=38%; control group= 
36%). 
General health: No difference 
between groups in either poor or 
fair general health categories 
(intervention group=40%; 












Table 2.3 (cont’d): Descriptive summary of included studies 













1. Mean age (SD): years 
2. Mean number of 
medications (SD) 
3. % of males 
Intervention 
Provider 






Adherence outcome(s)  
 








1.  67.0  
       (+  9.6) 
2. Not stated for 
total sample 
       Intervention 
mean:  7.6 (+ 
2.6); Control 








DVD and fortnightly MI-
based telephone calls for 
12 weeks.  
Standard care (control) 
Dependent on individual 
circumstances. BP control 
was a key component.  
>  80% No effect shown 




control= 66.0% (SD: 22%) 
intervention= 58.4% (SD: 
24.3%) 
Self-report (Morisky’s 4 item 
questionnaire) (Morisky et al. 
1986): No difference 
between intervention and 
control groups. 65.3% had no 
change in adherence in terms 
of forgetting to take the 
medication. 
Effect shown 
(not statistically significant) 
BP: Mean Systolic BP reduction 
was greater in intervention 
group but not statistically 
significant.  
Intervention= -6.9 (95% CI -13.8, 
0.02); Control= -3.0 (95% CI -8.4, 
2.4) (P=0.371); 
Average Diastolic BP reduction: 
Intervention= -2.3 (95% CI -5.2, 













KEY: BMQ= Brief Medication Questionnaire; BP= Blood pressure; CI= Confidence Interval; CKD= Chronic kidney disease;  F(1,35)= F statistic from ANCOVA (analysis of covariance) test 
(degrees of freedom); HCP: Healthcare professional; HRQOL= Health-related quality of life; IQR= Interquartile range; KCCQ= Kansas City Cardiomyopathy Questionnaire; MA=Medication 
adherence; MARS= Medication Adherence Reporting Scale; MEMS= Medication Event Monitoring System; MI= Motivational Interviewing; MPR= Medication Possession Ratio; P= p value 
(probability associated with selected test statistic); RCT= Randomised controlled trial; SD= Standard deviation; U= U statistic from Mann-Whitney U test 
1 Significance level p< .05; 2 Percentage of doses taken, percentage of days that the correct dosage was taken, percentage of doses taken on time; 3 Non-significant baseline differences noted; 
4 Significance level not stated 
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2.4.2 Theoretical underpinning of included studies 
All of the included studies were originally based on a single theory, although O’Carroll et al. 
(2013) also made reference to a separate related theory in a linked publication regarding a 
process evaluation; this is discussed below in more detail (O’Carroll et al. 2010; O’Carroll et 
al. 2014). The majority of included studies (n=4) in this review were small-scale pilot studies 
and only one study reported testing the underpinning theory (O’Carroll et al. 2013). None of 
the authors reported theory refinement based on the study results. Consequently, the 
decision was made to focus solely on Categories 1-3 of the TCS for the purposes of this in-
depth narrative review, as these categories explore how the researchers have directly used 
theory in developing their interventions. TCS categories 4-6 focus more on theory testing and 
refinement, which are processes often carried out by researchers during the later stages of 
intervention testing (i.e. evaluations). An overall judgement of ‘Yes’, ‘No’ or ‘Partially’ has 
been made for TCS Categories 1-3 based on whether the study met all, none or some of the 
relevant TCS items (see Table 2.2 in Section 2.3.6 for descriptions of items). A summary of 
the overall judgement for TCS Categories 1-3 is presented below in Table 2.4.  
 
Table 2.4: Summary of overall judgement for TCS Categories 1-3 for each included study 
Study Category 1 Category 2 Category 3 
Barnason et al. (2010) Yes Yes Partially 
O’Carroll et al. (2013) Yes Yes No 
Ruppar (2010a) Yes Partially No 
Solomon et al. (2012) Partially No No 
Williams et al. (2012) Yes Partially No 
 
Further explanations for judgements on whether relevant TCS items in each category were 
met or not met are presented in Table 2.5 (Category 1), Table 2.6 (Category 2), and Table 2.7 
(Category 3).  





Table 2.5: Explanations for judgements of TCS items in Category 1 (Is theory mentioned?) 
Study  Overall 
judgement 
for category1 
TCS item 1: Theory/model of behaviour 
mentioned  
TCS item 2: Targeted construct mentioned as 
predictor of behaviour 





Yes Based on Bandura’s Social cognition theory 
(SCT) 
Targeted constructs of SCT (e.g. self-
regulation) were mentioned as predictors of 
adherence 




Yes Based on Leventhal’s Self-regulation Model 
(SRM)2  
Targeted construct of SRM (‘illness 
perceptions’) was mentioned as a predictor 
of adherence 
Based on Leventhal’s SRM2 
Ruppar 
(2010a) 
Yes Based on Leventhal’s SRM2 Targeted construct (‘illness perceptions’) was 
mentioned as a predictor of adherence 
behaviour 




Partially Based on Prochaska’s Transtheoretical 
Model of behaviour change (TTM) 
Not met: The authors did not explicitly 
indicate that the constructs of TTM (e.g. 
stage of change, process of change, self-
efficacy) were predictors of adherence 




Yes Based on Health Belief Model (HBM) 
(Modified) 
Targeted constructs of the modified HBM 
were mentioned as predictors of adherence 
(e.g. self-efficacy) 
Based on HBM (Modified) 
 
  
1Judgement of ‘Yes’ if study met TCS items 1 and 2 and 3 in Category 1. Judgement of ‘Partially’ if study met any of the TCS items in Category 1. Judgement of ‘No’ if study did not meet 












Table 2.6: Explanations for judgements of TCS items in Category 2 (Are relevant theoretical constructs targeted by the intervention?) 




TCS item 2: Targeted construct 
mentioned as predictor of 
behaviour 
TCS item 5: Theory/predictors 
used to select/develop 
intervention techniques   
TCS items 7 or 8 or 9: 
Intervention techniques(s) linked 
to theory-relevant construct(s) 
TCS items 10 or 11: 
Theory-relevant construct(s) 





Yes Targeted constructs of SCT (e.g. 
self-regulation) were mentioned 
as predictors of adherence 
Theory was used to select 
intervention techniques (e.g. 
self-monitoring selected based 
on self-regulation construct of 
SCT) 
All intervention techniques were 
linked to theoretical constructs 
or predictors (e.g. verbal 
persuasion technique linked to 
self-efficacy) 
Targeted constructs were linked 





Yes Targeted construct of SRM 
(‘illness perceptions’) was 
mentioned as a predictor of 
adherence 
Theory was used to select 
intervention techniques (e.g. 
health consequences was 
selected based on theory)  
All intervention techniques were 
linked to theoretical 
constructs/predictors (e.g. health 
consequences was linked to 
illness perceptions) 
Targeted constructs/predictors 
were linked explicitly to at least 
one intervention technique 
Ruppar 
(2010a) 
Partially Targeted construct (‘illness 
perceptions’) was mentioned as 
a predictor of adherence 
behaviour 
Not met: Theory was not used to 
select all intervention techniques 
(e.g. prompts) 
At least one, but not all 
intervention techniques were 
explicitly linked to theoretical 
constructs (e.g. habit 
modification not linked) 
Key theoretical constructs (e.g. 





No Not met: The authors did not 
explicitly indicate that the 
constructs of TTM (e.g. stage of 
change, process of change, self-
efficacy) were predictors of 
adherence 
Not met: Theory did not appear 
to guide the selection of MI 
techniques. MI techniques 
appear to have been selected 
based on similar interventions 
and then linked back to theory 
Not met: MI techniques were 
not directly linked back to 
constructs within the model 
Not met: Key constructs of TTM 





Partially Targeted constructs of the 
modified HBM were mentioned 
as predictors of adherence (e.g. 
self-efficacy) 
Not met: Theory was not used to 
select all intervention techniques 
(e.g. self-monitoring) 
At least one, but not all 
intervention techniques were 
explicitly linked to theoretical 
constructs (e.g. goal setting 
wasn’t linked to constructs) 
Not met: Theoretical constructs 
were not explicitly linked to 
intervention techniques 
 1 Judgement of ‘Yes’ if study met TCS items 2 and 5 and 7, 8 or 9 and 10 or 11 in Category 2. Judgement of ‘Partially’ if study met any of the TCS items in Category 2.  Judgement of ‘No’ if 













Table 2.7: Explanations for judgements of TCS items in Category 3 (Is theory used to select intervention recipients or tailor interventions?) 
 




TCS item 4: Theory/predictors used to select 
recipients for the intervention 





Partially Not met: Intervention recipients were not selected using theory 
(e.g. based on ‘self-efficacy’ levels) 
Met: Predictors (e.g. motivation) were examined via questionnaires 




No Not met: Intervention recipients were selected based on a self-
report questionnaire score but not specifically using theory (e.g. 
based on ‘illness perceptions’) 
Not met: Intervention was not tailored based on theory 
Ruppar 
(2010a) 
No Not met: Intervention recipients were not selected using theory 
(e.g. based on their ‘illness perceptions’) 





No Not met: Intervention recipients were not selected using theory 
(e.g. based on their ‘stage of change’) 
Not met: The authors did report that MI is based on an ‘individual’s 




No Not met: Intervention recipients were not selected using theory 
(e.g. based on their level of ‘self-efficacy’) 
Not met: MI was tailored but this was not linked to theory. Other 








1 Judgement of ‘Yes’ if study met TCS items 4 and 6 in Category 3. Judgement of ‘Partially’ if study met any of the TCS items in Category 3. Judgement of ‘No’ if study did not met any TCS 
items in Category 3. 
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Bandura’s Social Cognition Theory (SCT)   
Barnason et al. (2010) based their counselling and education intervention on SCT (TCS 
Category 1: Yes) (Bandura, 1986). The intervention was delivered to patients with heart 
failure on transition from secondary to primary care. SCT helps to understand human thought 
and behaviour and includes a core reciprocal model whereby personal, behavioural and 
environmental factors influence each other. The authors indicated that personal factors (e.g. 
motivation) and environmental factors (e.g. assistance from others) impacted on adherence 
behaviour. Key constructs in this model are ‘self-efficacy’ and ‘self-regulation’ and these were 
linked to intervention techniques, such as verbal persuasion and self-monitoring, 
respectively (TCS Category 2: Yes). Techniques were also linked to a Medication Adherence 
Conceptual Framework which was used alongside the theoretical basis to guide intervention 
design. This conceptual framework, developed through a literature review, links closely with 
SCT and focuses on ‘the relationship between environmental factors, patient characteristics, 
and medication adherence as a process that ultimately affects patient outcomes’ in older 
adults with HF (Murray et al. 2004).  
SCT was not used to select patients for inclusion in the trial but it was used to tailor the 
intervention based on an initial assessment of personal factors (e.g. participants with low 
motivation were given tailored information on the benefits of adherence) (TCS Category 3: 
Partially). This intervention was tested in a randomised pilot study and led to statistically 
significant differences in both self-reported adherence and HRQOL (see Table 2.3).  
Leventhal’s Self-regulation Model (SRM) 
Leventhal’s SRM was cited as the basis for intervention development in two of the included 
studies (Ruppar, 2010a; O’Carroll et al. 2013). Firstly, SRM was cited by Ruppar (2010a) as 
the basis of an intervention that aimed to improve adherence to medicines prescribed for 
hypertension (TCS Category 1: Yes) (Leventhal et al. 1984). SRM consists of three constructs: 
(1) ‘illness perceptions’ (i.e. the beliefs a person holds about their illness); (2) ‘coping 
responses’/action planning; (3) ‘appraisal’/monitoring of responses. The key construct in this 
model, ‘illness perceptions’, consists of both cognitive perceptions (e.g. identity/illness label 
and symptoms, cause, time-line, consequences and curability/controllability) and emotional 
perceptions (e.g. anxiety, depression, fear).  
In Ruppar’s study, SRM was discussed in terms of how it related to hypertension as these 
patients are commonly asymptomatic. This is in contrast to other conditions, where 
symptoms act as feedback that medication doses have been missed (e.g. Parkinson’s 
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disease). The author proposed that a lack of feedback from ‘perceived symptoms’ (i.e. the 
identity dimension’ of the ‘illness perceptions’ construct) was a possible predictor of non-
adherence. To account for the lack of symptom feedback, Ruppar’s intervention was based 
on feedback gained from BP monitoring and medication-taking behaviour. Education on 
health consequences of poorly controlled hypertension was also linked to the ‘illness 
perceptions’ construct (i.e. ‘consequences’ dimension). However, other techniques, such as 
habit analysis and prompts, were not explicitly linked to theory/predictors (TCS Category 2: 
Partially).  
Ruppar (2010a) discussed the difficulty encountered when attempting to link the study 
outcomes back to the theoretical basis and suggested that researchers should measure 
changes in relevant theoretical constructs (e.g. changes in ‘illness perceptions’) to allow them 
to relate theory to outcomes (e.g. changes in adherence). Participants were not selected 
based on theory, nor was theory used to tailor the intervention (TCS Category 3: No). This 
randomised pilot study reported a statistically significant difference in medication adherence 
between intervention and control groups at the end of the intervention period (week 8). A 
significant decrease in systolic BP was noted at week 12 for the intervention group but this 
increased slightly again at week 20 (see Table 2.3).  
O’Carroll et al. (2013) also cited Leventhal’s SRM as the underpinning theory for an 
intervention that aimed to improve adherence in stroke survivors, a group of patients who 
are commonly prescribed multiple medications (TCS Category 1: Yes). The authors indicated 
that the two main intervention components [(1) modification of incorrect medication/illness 
beliefs and (2) implementation planning i.e. action plans of when and where to take 
medications], would target intentional non-adherence and unintentional non-adherence, 
respectively. The first intervention component was linked to the ‘illness perceptions’ 
construct of SRM. The second component was linked to a predictor of medication adherence 
that had been demonstrated in previous research (i.e. forgetfulness due to cognitive 
impairment) (O’Carroll et al. 2010).  
In a process evaluation paper, O’carroll et al. (2014) also made reference to a newer self-
regulation theory posed by Hall and Fong (Temporal Self-regulation Theory; TST) (Hall and 
Fong, 2007). TST incorporates a theoretical construct termed ‘behavioural pre-potency’ 
[‘…reflecting frequency of past performance and/or the presence of cues to action in the 
environment’ (Hall and Fong, 2007)] which the authors also linked to the implementation 
planning component of this intervention (TCS Category 2: Yes). Theory was not used to select 
intervention recipients, nor used to tailor this intervention (TCS Category 3: No). This study 
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led to improvements in objectively measured adherence via MEMs but this finding was only 
statistically significant for the percentage of doses taken on schedule. Both groups reported 
higher self-reported adherence at follow-up and this was significantly greater in the 
intervention group. There were no statistically significant differences in changes to diastolic 
or systolic BP between groups (see Table 2.3). 
Transtheoretical model of behaviour change (TTM) 
Solomon et al. (2012) used MI as the basis of their telephone intervention to improve 
adherence to medications prescribed for osteoporosis. The TTM (also known as the Stages 
of Change Model) was cited as the underpinning theory for MI (Prochaska and DiClemente, 
1982). TTM consists of multiple constructs: ‘stages of change’; ‘process of change’; ‘self-
efficacy’; ‘temptation’ and ‘decisional balance’. The ‘stages of change’ construct consists of 
five sequential stages: pre-contemplation, contemplation, preparation, action and 
maintenance (Michie et al. 2014). It appears that the authors selected MI based on success 
in previous adherence studies and then linked the approach to the TTM (TCS Category 1: 
Partially) (Heather et al. 1996; Miller, 1996; Prochaska and DiClemente, 1982).  
Solomon et al. (2012) discussed MI in general, indicating that it makes use of active listening 
and relationship-building to allow participants to evaluate risks and treatment options, but 
they did not make explicit links between their intervention and relevant theoretical 
constructs in TTM (TCS Category 2: No). The authors did not appear to use theory to select 
participants or report whether the intervention was tailored based on theory (TCS Category 
3: No). Statistically significant improvements in medication adherence, changes in self-
reported falls, fractures or general health were not demonstrated in this RCT (see Table 2.3). 
Health Belief Model (HBM) 
A modified version of the HBM was cited by Williams et al. (2012) as the basis for a multi-
component behavioural and educational intervention, delivered to patients with co-existing 
diabetes and CKD (TCS Category 1: Yes). The original HBM consists of four key constructs: 
‘perceived barriers’; ‘perceived benefits’; ‘perceived severity’ and ‘perceived susceptibility’ 
(Rosenstock, 1974; Glanz et al. 2008) . This model suggests that an individual’s thoughts and 
actions are mainly rational and the behaviour will be carried out if the perceived threat 
(severity and susceptibility) is high and perceived benefits outweigh barriers. The modified 
version incorporates the additional construct ‘self-efficacy’ (Rosenstock et al. 1988). 
In the intervention developed by Williams et al. (2012), a psychosocial DVD (i.e. focusing on 
the interactions between thoughts, feelings and the social environment) was proposed to 
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exert its effect by ‘motivating people to take their medications, appealing to knowledge, 
thoughts and feelings’. It included information on the consequences of hypertension and 
benefits of medications, as well as examples of patients sharing their experiences of taking 
multiple medications and tips to help patients take medications as prescribed. The authors 
indicated that individuals who were confident in self-managing their health would be more 
adherent. Confidence (i.e. ‘self-efficacy’) was linked to aspects of the DVD but other 
techniques that formed part of this complex intervention, such as MI, self-monitoring and 
goal-setting, were not clearly linked to theory (TCS Category 2: Partially). Theory was not 
used to select participants or tailor the intervention in any way (TCS Category 3: No). This 
pilot study reported no statistically significant improvements in adherence or BP control (see 
Table 2.3). However, the authors noted that a larger study might demonstrate significant 
differences. 
2.4.3 Risk of bias of included studies 
The risk of bias summary, displayed in Figure 2.3, gives an overview of the quality of included 
studies. An overall assessment of low risk of bias was judged for four studies (Ruppar, 2010a; 
Solomon et al. 2012; Williams et al. 2012; O’Carroll et al. 2013) and an unclear risk for the 
fifth (Barnason et al. 2010). 
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O’Carroll et al. 
(2013)          
 
Ruppar 
(2010a)          
 
Solomon et al. 
(2012)          
 
Williams et al. 
(2012)          
 
 
Figure 2.3: Risk of bias summary for the five included studies 
Key: = High risk = Low risk = Unclear risk 
1Other potential sources of bias included bias relating specifically to adherence studies, for example, 
self-report bias. 
2.5 Discussion  
This systematic review adds to the existing evidence base by providing an in-depth 
examination of theory-based adherence interventions delivered to older adults prescribed 
polypharmacy. It differs from other reviews in the literature as it has examined, in detail, the 
extent to which psychological theory was used in intervention development (van Dulmen et 
al. 2007; Conn et al. 2009; Holmes et al. 2014; Nieuwlaat et al. 2014; Conn et al. 2016a). This 
review also explored the methods used to measure adherence and the types of clinical 
outcomes investigated as these are important to consider when developing an intervention 
for older patients prescribed polypharmacy with a range of potential clinical conditions. 
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2.5.1 Adherence and clinical/humanistic outcomes 
Both adherence and clinical/humanistic outcomes were considered to be important as an 
improvement in adherence alone does not prove that this has led to positive 
clinical/humanistic outcomes for patients. Conversely, solely demonstrating an improvement 
in clinical/humanistic outcomes cannot guarantee that this has been the direct result of 
improved medication adherence (Nieuwlaat et al. 2014). The type of adherence measures 
varied across studies and only two studies followed recommendations to employ multiple 
measures (O’Carroll et al. 2013; Williams et al. 2012). Self-report, which potentially 
overestimates adherence, was the only measure used by Barnason et al. (2010). This 
introduced potential bias, particularly as it was unclear whether this pilot study was 
effectively blinded. Electronic monitoring via MEMS, was used in two studies and provided a 
more objective adherence measure (Ruppar, 2010a; O’Carroll et al. 2013). However, this 
form of assessment is costly and has the potential to act as an intervention component in 
both intervention and control groups, because it prompts monitoring of the behaviour.  
Pill counts were employed alongside self-report by Williams et al. (2012) but the authors 
indicated that this approach ‘was confounded by the participants’ multiple medications’ as 
patients had difficulty recalling prescription start dates. Solomon et al. (2012) used pharmacy 
dispensing data to calculate MPRs (‘Number of days’ supply obtained during observation 
period’ divided by ‘number of days in observation period’), however this was only calculated 
for participants’ osteoporosis medication. Calculating an average MPR for multiple 
medications confers several potential challenges, for example, this could potentially under 
or over-estimate adherence (Arnet et al. 2014). Another similar measure that is widely used 
in adherence research is the Proportion of Days Covered (PDC) (Nau, 2006). This has been 
adapted for calculating adherence to multiple related medications, by identifying the 
proportion of days that have been covered by all regular long-term medications (Choudhry 
et al. 2009; Basak et al. 2014). At present, there is no consensus or guidance on how best to 
measure adherence to multiple medications using pharmacy dispensing data. Validated 
measures that are currently available (e.g. MPR, PDC) require further testing with multiple 
medications to determine their suitability. To allow adherence research to advance, it is 
essential that robust methods of measuring adherence to polypharmacy are developed, 
tested and consensus reached.  
Only two studies considered the impact of polypharmacy on medication adherence and 
discussed the associated challenges (Williams et al. 20012; O’Carroll et al. 2013). For patients 
prescribed polypharmacy, reasons for non-adherence can vary both across and within 
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individuals, depending on the prescribed regimens, clinical conditions and their associated 
beliefs. Nonetheless, as highlighted by Nieulwaat et al. (2014), the ‘clinical condition is not a 
major determinant of medication adherence’ and the types of adherence problems reported 
across conditions are generally comparable. This has important implications for adherence 
research and psychological theory has a potentially important role to play in allowing 
complex interventions to be tailored to the individual needs of older patients, prescribed 
polypharmacy to treat a range of clinical conditions.  
The methods employed for measuring adherence can impact on study outcomes, as can the 
types of participants selected for inclusion (Conn et al. 2016b). Studies that include 
participants who are classified as highly adherent, may find it difficult to demonstrate a 
significant effect as there is limited scope for improvement, a phenomenon referred to as 
the ‘ceiling effect’ (Ruppar, 2010a). To avoid this, future interventions need to specifically 
target patients who are non-adherent at baseline, as these patients are likely to benefit most. 
Exact cut-off points were used for classifying patients as adherent or non-adherent in four of 
the studies, but only two studies reported using this classification to recruit non-adherent 
patients  (Ruppar, 2010a; O’Carroll et al. 2013).  
In adherence research, it is important that clinical outcomes are carefully selected based on 
the target population. The variety of clinical outcomes measured by included studies reflects 
the range of clinical conditions targeted. Although general humanistic outcomes (e.g. 
HRQOL) were measured in two studies, no studies measured healthcare utilisation (e.g. GP 
visits, hospitalisations) or mortality rates. This is likely due to study design, most of which 
were pilot studies (n=4) of short duration and lacked sufficient power to demonstrate a 
significant effect. For future adherence studies that include multi-morbid patients, generic 
humanistic outcomes such as HRQOL or healthcare utilisation measures, may be more 
appropriate as opposed to condition-specific outcomes (Nieuwlaat et al. 2014).  
2.5.2 Intervention effectiveness 
Pilot studies, which the MRC recommends should be part of the preliminary evaluation of 
complex interventions, are described as ‘a version of the main study that is run in miniature 
to test whether the components of the main study can all work together’ (Arain et al. 2010). 
Although not powered to test for significance, all four pilot studies identified in this review 
used some form of hypothesis testing, with three describing the positive effects shown as 
significant (Barnason et al. 2010; Ruppar, 2010a; O’Carroll et al. 2013). Results from pilot 
studies are not always reported and many fail to advance to definitive trials. On the one hand, 
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it is possible that a significant effect may be missed in an underpowered pilot study, but 
conversely, there is also the chance of observing the opposite effect in a larger definitive trial 
(Thabane et al. 2010). Consequently, the results of pilot studies should be interpreted with 
caution. This limitation was recognised by Williams et al. (2012) whose pilot study failed to 
show significant effects. The authors indicated that the intervention appeared to be 
acceptable and feasible and that statistically significant differences may be seen in a larger 
trial. Although conclusions on the overall effectiveness of theory-based studies cannot be 
drawn from this review, the findings from the included pilot studies are a stepping stone in 
the advancement of the application of theory in designing adherence interventions (Arain et 
al. 2010; Lancaster, 2015).  
2.5.3 Theoretical basis 
Overall, very few studies cited theory as a basis for their intervention and only one reported 
theory testing based on study outcomes (O’Carroll et al. 2013). An in-depth analysis, using 
Categories 1-3 of the TCS, indicated that the selection of intervention components was not 
always guided by theory, or was not reported as such. Both studies that included MI did not 
outline exactly how the key constructs of the cited theory explicitly linked to MI techniques 
(Miller, 1996; Miller and Rollnick, 2012). MI was not originally developed from a single theory, 
and although some researchers have attempted to link it to various theories (e.g. TTM, SCT), 
the mechanisms through which it facilitates behaviour change remain unclear (Burke et al. 
2003). Solomon et al. (2012) described MI as a method that was ‘built upon Prochaska’s 
trantheoretical model of behaviour change’ but did not make explicit links between 
theoretical constructs and their own adherence intervention. This lack of theoretical 
understanding may be reflected in the design of this MI-based intervention and the 
subsequent outcome.  
The other four studies employed a more theory-driven approach whereby theory guided the 
selection of intervention techniques (Barnason et al. 2010; Ruppar, 2010a; Williams et al. 
2012; O’Carroll et al. 2013). However, in two of these studies all techniques were not linked 
to theory (Ruppar 2010a; Williams et al. 2012). It is evident from the analysis that theory 
could be utilised further, either in recruiting participants or in tailoring the intervention to 
their needs based on theoretical constructs. For example, Barnason et al. (2010) measured 
relevant theoretical constructs/predictors (e.g. motivation) and used these to tailor the 
intervention to participants; this approach may have influenced the positive effect seen.  
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As discussed previously, an in-depth analysis of TCS Categories 4-6 was not undertaken in 
this review due to the pilot nature of the majority of studies (n=4) and the lack of theory 
testing and refinement. However, O’Carroll et al. (2014) have provided a useful example of 
how theory can be utilised to explore the intervention’s mechanism of action via the 
measurement of theoretical constructs in a theory-based process evaluation.  
All five interventions targeted the same behaviour (adherence) but were based on a range of 
different psychological theories. As discussed previously in Chapter 1, with such a wide range 
of theories available in the literature, selecting just one to guide intervention development 
can be a difficult task. As a result, theory selection is commonly based on experience, 
personal preference or what is ‘in fashion’ (Michie et al. 2014a). When selecting theory it is 
important to provide a clear rationale, however, none of the study authors clearly outlined 
their choice. It is, however, possible that the authors gave theory selection due consideration 
but did not report this. Selecting the most appropriate theory can also be challenging in 
instances where individual theories do not cover all potential influences on the target 
behaviour. For example, the role that habits play in medication-taking are often overlooked. 
Failure to consider all potentially relevant psychological processes, such as non-reflective 
processes, can place limitations on the types of techniques developed. A comprehensive 
theoretical framework such as the TDF (discussed in Chapter 1) has the potential to overcome 
these limitations.  
This systematic review presents preliminary findings from pilot work and demonstrates that 
even when cited, theory appears to be under-utilised when designing interventions. Further 
research needs to be conducted in order to draw definitive conclusions regarding the 
effectiveness of theory-based interventions that aim to improve adherence in older adults 
prescribed polypharmacy. Other reviews of theory-based interventions targeting health-
related behaviours (e.g. physical activity, diabetes self-management) have shown some 
marginally positive effects, but in common with this review, they identified an overall under-
utilisation of theory (Lopez et al. 2011; Ayling et al. 2015; Gourlan et al. 2015). A recent review 
that looked specifically at text messaging and medication-use monitoring interventions to 
promote adherence in Type 2 diabetics (in all age groups), showed that only four out of 
eleven trials stated an underlying theory (Farmer et al. 2015). The review authors also used 
the TCS but they did not go beyond identifying the number of studies that met each TCS item 
and the specific theory that each intervention was based on. In contrast, the current review 
provides an additional in-depth narrative discussion of each intervention which will inform 
the development of future theory-based adherence interventions. 
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As Michie et al. (2014a) highlight, using an explicit theory does not guarantee the 
intervention will be effective. It has been proposed that in order for theory to influence 
intervention effectiveness, it must form a key component of rigorous and systematic 
intervention development (Michie and Prestwich, 2010; Ayling et al. 2015). It is important to 
note that the use of theory in intervention design is based primarily on principle and 
therefore more empirical research is required to determine whether appropriate use of 
theory does, in fact, lead to more effective interventions (Colquhoun et al. 2013). A review 
by George et al. (2008) has presented findings from non-theory based adherence 
interventions (n=8) delivered to older adults prescribed polypharmacy. Effective 
interventions in this review (n=4) were resource-intensive and had no common components. 
Without a theoretical understanding of the interventions’ mechanism of action, it is 
impossible to decipher the essential ingredients that led to behaviour change. Even if theory-
based interventions fail to produce a positive effect, they can still be used to develop an 
understanding of what does and does not work and, more importantly, provide better 
insights into the underlying reasons for the observed outcomes. Where no effect is observed, 
theory could help researchers avoid re-testing ineffective approaches and strengthen any 
weak links in the proposed causal chain. A theory-based approach therefore has the potential 
to advance the field of adherence research (Michie et al. 2014a).  
The TCS was used in this systematic review to guide a detailed and systematic evaluation of 
how theory was reportedly used during intervention development. Another useful 
application of this tool is as a guide for researchers who are developing theory-based 
adherence interventions and reporting their findings in publications. Its use in this manner 
would be in line with WIDER (Workgroup for Intervention Development and Evaluation 
Research) guideline recommendations which advocate that researchers include detailed 
descriptions of the underpinning design and proposed mechanism of change, including any 
psychological theory (Albrecht et al. 2013). 
2.5.4 Limitations 
This review was limited to studies published in the English language and delivered to older 
adults that were prescribed a mean of four or more medications. Given the paucity of 
adherence research that targets older adults, studies were deemed eligible if the sample 
population had a mean/median age of 65 years or older. As study inclusion/exclusion age 
was not part of the eligibility criteria for this review, studies may have included a small 
proportion of patients who were younger than 65 years old. However, as noted in Section 
2.3.6, the pooling of outcome data in a meta-analysis was not undertaken and so this was 
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not considered to have any significant implications on the findings of the review. Although 
extensive electronic and hand-searching strategies were conducted for this review, studies 
which met the inclusion criteria but were not adequately indexed in the literature may have 
been missed. The TCS which was used to guide the narrative summary relies solely on details 
reported by authors in published articles. Studies that made use of theory but failed to report 
this in published reports may also have been overlooked.  
2.6 Conclusion  
There is a lack of robust evidence on theory-based adherence interventions delivered to 
older adults who are prescribed polypharmacy and, therefore, no overall conclusion on 
intervention effectiveness can be drawn at this stage. Four key findings from this review are 
pertinent to the development of future interventions in this area: (1) the importance of 
having theory as core component of the design process as opposed to a loosely applied 
framework to allow the intervention’s underlying mechanism of action to be understood and 
tested; (2) the potential usefulness of theory in tailoring the components of complex 
interventions to individual patients’ needs; (3) the need to identify and target non-adherent 
patients as these patients are most likely to benefit; (4) the importance of carefully selecting 
adherence and clinical outcomes that are relevant to patients with multi-morbidities and 
prescribed polypharmacy.  
The findings from this review support the need for the development of the intervention 
outlined in this thesis. At present there is insufficient evidence to support the use of any 
individual theory in developing an intervention to improve medication adherence in older 
adults prescribed polypharmacy. Therefore, to ensure all relevant psychological processes 
are considered, the use of a comprehensive theoretical framework, such as the TDF, to guide 
intervention development is justified. Chapter 3 outlines how the TDF has been used to 
develop the theoretical basis of a novel complex intervention that aims to improve 
medication adherence in older adults (prescribed polypharmacy).  













Selection of components for a 
theory-based intervention to 
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3.1 Introduction  
The MRC framework for ‘developing and evaluating complex interventions’ recommends 
that they should be developed based on relevant theory such as psychological theory 
(Medical Research Council, 2008). As highlighted in Chapter 2 of this thesis, there are a lack 
of adherence interventions targeting older adults (prescribed polypharmacy) with a robust 
theoretical underpinning. The objective of the study outlined in this chapter was therefore 
to develop the theoretical basis and components of a novel intervention to improve 
adherence to polypharmacy in older adults in the primary care setting, using the TDF as the 
underpinning theoretical model of behavioural determinants (Michie et al. 2005). 
3.1.1 Theoretical Domains Framework (TDF) 
As discussed in the preceding chapters (Chapters 1 and 2), the TDF is a comprehensive 
theoretical framework that incorporates a wide range of theoretical constructs (Allemann et 
al. 2016). There are currently two versions in existence: TDF1 (original 12 domain version 
developed in 2005) and TDF2 (updated 14 domain version developed in 2012) (Michie et al. 
2005; Cane et al. 2012). Both versions of the TDF can act as a ‘theoretical lens’ through which 
determinants (i.e. barriers and facilitators) of the behaviour can be identified for targeting 
with an intervention (Michie et al. 2014a). Previous studies employing the TDF as an 
underpinning theoretical model have utilised a range of research designs to explore 
behavioural determinants. This has included qualitative designs (e.g. interviews, focus 
groups), quantitative designs (e.g. cross-sectional surveys) and systematic reviews of the 
literature (Francis et al. 2012). The most commonly selected approach to date has been 
qualitative research designs (Atkins et al. 2017). For example, Duncan et al. (2012) used 
qualitative interviews to explore prescribing errors made by trainee doctors, whereas 
Bussières et al. (2012) used qualitative focus groups to identify barriers and facilitators to 
implementing guideline recommendations for patients with spinal disorders. 
To date, TDF-based studies have mostly targeted HCPs’ clinical behaviours, particularly in 
relation to the implementation of evidence-based guidelines (Dyson et al. 2011; French et al. 
2013). More recently, the TDF has been used to explore patients’ behaviours such as dietary 
intake (Edwards et al. 2010; Guillaumie et al. 2010). Cahir et al. (2015), McCullough et al. 
(2015) and Easthall et al. (2014) have used the TDF to explore medication adherence, albeit 
in different patient populations (breast cancer, bronchiectasis and cardiovascular disease 
patients, respectively).  
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3.1.2 Selection of key theoretical domains to target for behaviour change 
Methods for selecting key TDF domains to target with an intervention have varied according 
to the selected research methodology (e.g. interviews, focus groups etc.). The first 
consideration in selecting key domains to target is the relevance/importance of each domain 
in relation to the behaviour of interest. Previous researchers have employed pre-defined 
decision criteria (e.g. frequency counts in interviews) and group consensus techniques to 
assess domain relevance (Francis et al. 2009; Bussières et al. 2012; Cadogan et al. 2015). For 
example, in a TDF-based interview study that explored clinicians’ blood transfusion 
behaviours, a domain was considered to be ‘…relevant if frequently mentioned responses 
indicated that it might affect performance of the clinical behaviour’ (Francis et al. 2009). 
Domains that are considered relevant/important in the context of the behaviour of interest 
are then assessed to determine whether they contain barriers and facilitators that could 
feasibly be targeted for change with an intervention. Factors that need to be taken into 
consideration are the available project resources and any contextual factors such as 
limitations of the proposed research setting (Cadogan et al. 2015).  
3.1.3 Mapping key domains to behaviour change techniques (BCTs) 
Selected key TDF domains can then be mapped to BCTs using established methods reported 
in the literature (Michie et al. 2008; Cane et al. 2015). As discussed in Chapter 1, BCTs are the 
active ingredients of behaviour change interventions that aim to bring about change (Michie 
et al. 2013). Michie et al. (2008) have produced a mapping matrix which indicates links 
between 35 BCTs and theoretical domains in TDF1 (see Appendix 3.1). The 35 BCTs in this 
preliminary work were identified from two systematic reviews and links were agreed by four 
experts in behaviour change. Cane et al. (2015) have updated this TDF to BCT linking process 
by mapping BCTs in BCT Taxonomy version 1 (BCTTv1) to domains in TDF2 (see Appendix 3.2) 
(Michie et al. 2013). BCTTv1 consists of 93 BCTs, along with definitions and illustrative 
examples. It is important to note that a number of the BCTs from the preliminary 35 BCTs 
identified by Michie et al. (2008) have overlapping characteristics with BCTs in BCTTv1. For 
example, ‘Information regarding behaviour, outcome’ overlaps with ‘Information about 
health consequences’ and can therefore be considered equivalent. 
BCTs selected using this mapping approach can then form the ‘active ingredients’ of a theory-
based intervention, whereby they are used to bring about the required changes in the target 
behaviour (Michie et al. 2009). For example, Cadogan et al. (2015) employed both mapping 
resources mentioned above in identifying BCTs to include in an intervention to improve the 
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appropriate prescribing of polypharmacy by GPs. Eight key TDF domains (e.g. ‘Skills’) were 
identified to target for behaviour change and these mapped these across to four BCTs (e.g. 
‘Modelling/demonstration of behaviour by others’). This offers a robust and systematic 
approach to developing theory-based behaviour change interventions and understanding of 
the proposed theoretical mechanism of action (Francis et al. 2012).  
The research presented in this chapter focuses on the identification of determinants (i.e. 
barriers and facilitators) of adherence to multiple medications (i.e. polypharmacy) in older 
adults using the TDF as the underpinning theoretical model. It also outlines the process of 
mapping from key TDF domains to BCTs for inclusion as components in a community 
pharmacist-led adherence intervention. As mentioned in Chapter 1, CPs were selected as the 
intervention provider from the outset of the project due to their accessibility in the primary 
care setting and evidence from two recent Cochrane reviews that supported pharmacists’ 
involvement in adherence interventions (Nieuwlaat et al. 2014; Ryan et al. 2014). 
3.2 Aims and objectives 
The overall aim of the current study was to develop the theoretical basis and components of 
an intervention to improve adherence to polypharmacy in older adults using the TDF as the 
underpinning theoretical framework of behavioural determinants. The objectives were to: 
 Identify determinants (barriers and/or facilitators) of adherence to polypharmacy from 
the viewpoint of older adults using the TDF as a ‘theoretical lens’ (Stage 1) 
 Select key TDF domains to target in an intervention to bring about change in the target 
behaviour (adherence to polypharmacy) (Stage 2)  
 Map key TDF domains to appropriate BCTs for inclusion in an intervention that could 
feasibly be delivered by community pharmacists (Stage 3) 
3.3 Research design and methodology 
3.3.1. Rationale for choice of research design 
As discussed in Section 3.1 there are a range of research designs available to explore the 
target behaviour using the TDF. The choice of research design (e.g. quantitative, qualitative) 
and methodology (e.g. cross-sectional survey, interviews) in any project is influenced by a 
range of factors including the research objectives and nature of the research question, the 
target audience, project resources and timelines (Bryman, 2013). Qualitative approaches, 
which focus on words and language, allow researchers to gain in-depth information on the 
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behaviour of interest and explore ‘why?’, ‘what?’ and ‘how?’ type research questions. In 
comparison, quantitative approaches focus more on numbers in an attempt to quantify the 
behaviour and answer research questions such as ‘how many?’ or ‘how much?’ (Pope and 
Mays, 2006). A number of studies have previously explored medication adherence in older 
adults using both qualitative and quantitative research designs (Tordoff et al. 2010a; Tordoff 
et al. 2010b; Ben-Natan and Noselozich, 2011; Henriques et al. 2012; Lee et al. 2013b). 
However, no studies have explored, in detail, the barriers and facilitators that influence 
adherence to polypharmacy in older adults using the TDF as a ‘theoretical lens’.   
For the study outlined in the current chapter, a qualitative approach was selected to facilitate 
a detailed examination and theoretical understanding of the target behaviour (adherence to 
polypharmacy). An overview of qualitative research design is provided in the following 
section.  
3.3.2. Overview of qualitative research design 
Data collection methods 
A range of research methods are available for studies that adopt a qualitative research 
design, including interviews, focus groups and participant observation (Bryman, 2013). There 
are three types of interviews available: structured, semi-structured, and unstructured 
interviews. In a structured interview, there is little flexibility and questions are posed in the 
same order and phrased in the same way for all participants. Semi-structured interviews have 
more flexibility and additional questions can be posed based on the respondent’s answers, 
but the researcher generally follows a pre-prepared topic guide (i.e. a list of questions) to 
ensure consistency. With unstructured interviews, although the researcher will have an idea 
of the main themes for the interview (e.g. a list of topics), the participant is encouraged to 
talk freely about the topic under study (Edwards and Holland, 2013).   
Focus groups are group-based interviews (with approximately 4-10 participants per group) 
that are facilitated by a moderator. The ideal number of participants per group is 6-8 
participants and the suggested maximum number of participants is 10. Beyond this size, the 
group becomes too difficult to manage and some participants may not get the opportunity 
to contribute (Krueger and Casey, 2009). A semi-structured topic guide is developed to guide 
the group discussion but conversation is not restricted to set questions (Bryman, 2012). Focus 
groups encourage group interaction and help to explore decision-making processes and 
uncover how participants think and feel (Barbour, 2008).  
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Participant observation involves the immersion of the researcher in a social setting in which 
they observe behaviours, listen to conversations and ask questions (Bryman, 2013). This 
research method is more applicable for research into group-based behaviours (e.g. school 
classroom activities, community pharmacy teams) and so will not be discussed in great detail 
in the following sections. The key considerations, in terms of advantages and disadvantages 
of interviews, focus groups and participant observation are presented below in Table 3.1.  
Table 3.1. Advantages and disadvantages of qualitative data collection methods (Pope and Mays, 
2006; Krueger and Casey, 2009; Bryman, 2013) 
 Pros Cons 
Interviews  Ability to collect in-depth 
information 
 Can probe/clarify meaning  
 Can be tailored to individuals 
 
 Time-consuming 
 Smaller sample sizes (than focus 
groups) 
 Can be expensive (e.g. if travelling 
to conduct interviews, payment for 
participation) 




 Ability to collect in-depth 
information 
 Can probe/clarify meaning  
 Efficient approach for collecting 
information from a larger number 
of participants than interviews 
 Group setting can stimulate others 
and help generate new ideas 
 Participants from mixed 
backgrounds can encourage 
alternative ways of thinking 
 Time-consuming 
 Can be expensive (e.g. payment for 
participation) 
 Confidentiality concerns 
 Dominant group members may 
affect input from other participants  
 Some participants may be more 
comfortable on a one-to-one basis 




 More natural setting 
 Observer can be passive 
(observation only) or active 
(involvement in activities, asking 
questions etc.) 
 Observation skills required 
 More applicable to group-based 
behaviours 
 Time consuming 
 ‘Hawthorne effect’ (i.e. changes in 
behaviour that arise from being 
observed)  
 Active involvement may reduce 
objectivity of researcher 
 
Sampling and sample size 
Another key consideration when conducting qualitative research is the approach by which 
individuals are selected to participate in the study (i.e. the sampling strategy) (Pope and 
Mays, 2006). Sampling strategies are commonly categorised into random/probability or non-
random/non-probability approaches. Quantitative research, which seeks to produce 
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statistically representative findings, often employs random sampling strategies, whereas for 
qualitative research, non-random sampling strategies are generally sufficient for answering 
the research question (Bryman, 2013). There is no general rule for selecting the sampling 
approach, however, sampling decisions should be systematically determined at the outset of 
a research study and reported in subsequent publications (Holloway and Wheeler, 2013).  
Two common types of non-random sampling are convenience sampling and purposive 
sampling. With convenience sampling, participants are selected because they are readily 
available to the researcher (Bryman, 2013). In comparison, purposive sampling is a strategic 
approach commonly employed by qualitative researchers to identify ‘information-rich’ 
individuals using pre-defined eligibility criteria (Patton, 2015). Maximum variation sampling 
is a sub-set of purposive sampling whereby researchers seek heterogeneity in a sample and 
aim to identify a diverse range of participants (e.g. participants from different settings). 
Another subset of purposive sampling is snowball sampling i.e. ‘…the researcher makes initial 
contact with a small group of people… and then uses these to establish contacts with others’ 
(Bryman, 2013).  
In relation to the size of the sample in qualitative research, there are no set rules and an 
upper limit is generally not imposed at the outset of the study (Pope and Mays, 2006). 
Instead, sample size is determined by the quality of information obtained from participants. 
The point at which no new relevant themes are emerging from participants is referred to as 
‘data saturation’ and data collection will cease once this stage has been reached (Fusch and 
Ness, 2015). Guest et al. (2006) have indicated that sample sizes as small as 6 may be 
sufficient for obtaining data saturation in qualitative interviews. Sample sizes between n=12 
and n=58 have been reported in TDF-based interview studies in the literature (Pitt et al. 2008; 
Helms et al. 2011; Francis et al. 2012). In comparison with interview studies, fewer TDF-based 
studies have employed focus groups as part of their methodology (Francis et al. 2012). 
Krueger and Casey (2009) have recommended that three or four focus groups should be 
conducted as a minimum. Dyson et al. (2011) conducted three focus groups as part of a mixed 
methods TDF-based study (n=21 participants) and Bussières et al. (2012) held six focus groups 
(n=21 participants) with TDF as the underpinning theoretical framework.  
Topic guides and questions 
To ensure that there is a degree of consistency across qualitative interviews and focus 
groups, a topic guide is often prepared prior to commencing data collection (Tracy, 2012). 
Topic guides can be structured, semi-structured or unstructured, with the latter two being 
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more common in qualitative research (Bryman, 2013). Standard topic guides consist of 
opening questions, main questions and closing questions. Opening questions are 
introductory in nature, easy to answer and help to establish rapport between the interviewer 
and interviewee. These introductory questions are followed by the main questions which 
explore the topic of interest in detail. For TDF-based interviews or focus groups, the main 
questions explore each of the theoretical domains in the framework (e.g. ‘Skills’, 
‘Knowledge’). Both open-style questions (e.g. ‘What do you think of X?’) and closed-style 
questions (e.g. yes or no responses) can be included, but open-style questions are generally 
preferred to allow rich, in-depth information to be obtained (Tracy, 2012; Bryman, 2013). 
Probing questions can be included to encourage elaboration of views or opinions, reassure 
participants that the researcher is actively listening, clarify ambitious responses and to avoid 
misinterpreting the meaning. Closing questions usually allow participants to add in anything 
else they feel is relevant to the topic but has not already been covered (Bryman, 2013). 
Data collection and management 
Data can be managed by audio-recording, video-recording and/or by taking notes during or 
following sessions. Where possible, recordings are preferred as these help to ensure that key 
information is not overlooked. Audio-recordings are often selected for qualitative research 
as they are seen as less intrusive for participants than video-recordings. It is recommended 
that researchers test their recording devices in advance of sessions and are prepared (e.g. 
back-up device, note taking) for equipment malfunctions. Audio-recordings are then 
transcribed verbatim and identifiable information (e.g. names, locations) removed for 
confidentiality purposes. Software programs (e.g. NVivo®) can assist in organising large 
volumes of qualitative data, however, they do not replace the need for the researcher to 
interpret the data (Bryman, 2013).  
Data analysis 
There are a wide range of approaches available for analysing and interpreting qualitative 
data. Four approaches that have been widely used in the field of health research are 
grounded theory, thematic analysis, content analysis and the framework method (Bryman, 
2013; Green and Thorogood, 2014). Although there are a number of differences in these 
approaches, what they all share in common is a process known as data coding (i.e. the 
assignment of descriptive labels to short phrases or words) (Saldana, 2009).  
Grounded theory, first introduced by Glaser and Strauss (1967) focuses on developing theory 
using an inductive bottom-up style approach. A key strength of this approach is its cyclical 
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nature which includes data collection, analysis, provisional coding, further data collection 
and so forth. This process continues until no new theoretical constructs are emerging from 
the data (i.e. theoretical data saturation is reached). Another important feature of grounded 
theory is a concept called ‘constant comparison’ whereby codes are compared and 
contrasted across cases (e.g. individual interviews). Grounded theory, when carried out 
correctly, is a lengthy process and one that is often not feasible in healthcare research due 
to time constraints. It is also a method that is often confused with thematic analysis and 
content analysis (Green and Thorogood, 2014).  
Thematic analysis is the most commonly cited method in qualitative healthcare research 
(Green and Thorogood, 2014). However, it has been described as a ‘poorly branded’ method 
that is broadly defined as ‘a method for identifying, analysing and reporting patterns 
(themes) within data’ (Braun and Clarke, 2006). As a result, the boundaries between thematic 
analysis and content analysis are often blurred. Arguably, thematic analysis differs from other 
approaches (such as content analysis and grounded theory) in that it does not outline a 
distinct set of activities to be undertaken by researchers (Bryman, 2013).  
In contrast to thematic analysis, content analysis has been well-defined as: 
 “…a systematic coding and categorizing approach used for exploring large amounts 
of textual information unobtrusively to determine trends and patterns of words used, 
their frequency, their relationships, and the structures and discourses of 
communication.” (Vaismoradi et al. 2013) 
In more recent years it has been recognised that there are two distinct forms of content 
analysis; quantitative and qualitative. Quantitative content analysis has received criticism in 
its attempts to reduce text into small ‘quantifiable units’ (i.e. frequency counts) (Cho and Lee, 
2014). Pyett (2003) argues that strict reliance on ‘counting responses [misses] the point of 
qualitative research’ as frequency does not always equate to importance. Consequently, 
qualitative content analysis has emerged as a more holistic approach to exploring insights 
and meanings from the data without the need for strict frequency counts (Kracauer, 1952; 
Schreier, 2014). Qualitative content analysis can be either inductive (codes/categories are 
derived solely from the data) or deductive (codes/categories are predefined from previous 
research or theories) (Cho and Lee, 2014).  
The framework method is another approach that was first introduced by the National Centre 
for Social Research in the 1980s as a structured method for organising data (Ritchie and 
Lewis, 2003; Gale et al. 2013; Green and Thorogood, 2014). The framework method outlines 
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distinct steps to undertake to analyse data including ‘familiarisation’ (repeated listening to 
audio-recordings, re-reading transcripts), ‘indexing’ (application of codes to the entire data 
set) and ‘charting’. ‘Charting’ is a unique feature of the framework method that includes the 
production of a summary matrix (e.g. a Microsoft Excel spreadsheet) whereby rows represent 
cases (e.g. individual participants in interviews) and columns represent codes. This is a useful 
method to employ if a pre-defined theory or framework (e.g. TDF) is guiding data analysis. 
Using the framework method allows researchers to organise, compare/contrast and reduce 
large volumes of data. Other methods can be used alongside the framework method such as 
quantitative content analysis (i.e. rigid frequency counting techniques) or qualitative content 
analysis (i.e. less-rigid but with pre-defined analytical rules). Irrespective of the selected data 
analysis approach for qualitative research, it is important that the steps undertaken are 
reported transparently in publications to maintain scientific rigour.  
Rigour in qualitative research 
Rigour and trustworthiness of qualitative research is of upmost importance given the 
criticism that it commonly receives in comparison with quantitative research (Pope and 
Mays, 2006). Quantitative research strives for internal validity (i.e. confidence placed in the 
cause-effect relationship), external validity (i.e. generalisability beyond the study settings) 
and reliability (i.e. repeatability of study findings) (Bryman, 2013; Heale and Twycross, 2015). 
In comparison, qualitative research strives for credibility, transferability, and dependability, 
respectively (Shenton, 2004). Credibility (also referred to as the truth value) relates to the 
extent to which the results are believable from the point of view of the research participants. 
Credibility can be improved by having findings validated by participants where possible and 
through transparent reporting. Transferability (also referred to as applicability) is a concept 
whereby study findings can be transferred from one context, setting or group to another if 
there is a good fit (Guba, 1981). Transferability can be facilitated by providing accurate 
descriptions of the sampling strategy, data analysis procedures and any assumptions made. 
This will allow researchers to interpret whether the findings are transferable to their own 
proposed setting.  
Dependability (also referred to as consistency or neutrality) is equivalent to reliability in 
quantitative research, a concept whereby the same results would be obtained if the study 
were to be repeated. This concept focuses on the trustworthiness of the methods used and 
can be influenced by the researchers own perspectives. Dependability can be improved in 
qualitative research by having multiple independent data coders and a clear audit trail of all 
decisions made, for example using computer-assisted packages such as NVivo® (Shenton, 
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2004; Elo et al. 2014). Reflexivity is an important part of ensuring dependability in qualitative 
research as it involves the researcher reflecting on their own personal assumptions and 
preconceptions and how this could impact on the findings (Bryman, 2013). Reflexivity is also 
about transparency and self-awareness, which can be facilitated by the use of reporting 
checklists such as the ‘Consolidated criteria for reporting qualitative studies’ (COREQ) 
checklist (Tong et al. 2007). 
3.3.3 Rationale for the use of focus groups 
The study outlined in this chapter formed part of a larger polypharmacy research project 
which explored the prescribing and dispensing of appropriate polypharmacy to older adults 
(Cadogan et al. 2015). The polypharmacy project involved the conduct of qualitative 
interviews with both GPs and pharmacists and also sought to gain older adults’ perceptions 
of the roles of HCPs in providing services to them (i.e. prescribing and dispensing of 
polypharmacy). Focus groups, which were selected to explore older patients’ views on HCPs’ 
roles as part of this larger polypharmacy project, were also used to explore barriers and 
facilitators to adherence using the TDF. This latter phase of the larger polypharmacy project 
formed part of the study outlined in the current chapter.  
Focus groups were selected for this study for three main reasons. Firstly, focus groups are a 
more efficient method for collecting data from a larger number of individuals than 
interviews. Secondly, group interaction in this setting can help stimulate ideas and remind 
participants of similar situations they have encountered with regards to medication-taking. 
Thirdly, as argued by Krueger and Casey (2009) people are more likely to disclose information 
with others that they perceive to be similar to them. Therefore, focus groups comprised of 
patients of a similar age (who were all prescribed several medications) were selected over 
one-to-one interviews with a researcher. 
3.3.4 Sampling and recruitment strategy 
General practices that had participated in a previous linked study (described in Section 3.3.3) 
were approached and asked if they would facilitate patient recruitment for the focus groups. 
This included general practices from across the five Health and Social Care Trusts in NI (two 
per Trust area). A purposive sampling strategy was adopted for this study to identify 
‘information-rich’ participants. Pre-defined eligibility criteria were: patients aged 65 years or 
older, living in their own homes, prescribed four or more medicines (the definition of 
polypharmacy adopted for this study) and not cognitively impaired. Patient recruitment 
within each practice was overseen by primary care research nurses from the Northern Ireland 
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Clinical Research Network (NICRN). NICRN nurses screened practice records and identified 
patients who met the eligibility criteria. Judgements of cognitive impairment were made by 
NICRN nurses based on patients’ medical notes and confirmed by their GP. Written invitation 
letters from the practices were issued to patients who met the inclusion criteria. A reply slip 
and pre-paid return envelope was included with the invitation letter (Appendix 3.3). Patients 
interested in taking part in the study were instructed to return the reply slip to a member of 
the research team (CC), who then made follow-up contact with patients. Each patient was 
provided a study information sheet (Appendix 3.4). Participants were offered an honorarium 
of £50 for taking part in the study. 
One focus group was scheduled per practice (7 practices in total) after an adequate number 
of patients (five patients minimum; 10 patients maximum) confirmed that they could attend. 
Written informed consent was obtained from all participants before each focus group was 
convened (Appendix 3.5). Ethical approval was granted by the Office of Research Ethics 
Committees for Northern Ireland (ORECNI) (Research Ethics Committee reference: 
13/NI/0114) (Appendix 3.6). 
3.3.5 Topic guide development 
A semi-structured topic guide (Appendix 3.7) was developed by the research team which 
included a health psychologist (JF) with expert knowledge of the TDF (Francis et al. 2012). In 
developing the topic guide, the research team made the decision to use the original 12-
domain version of the framework (TDF1) rather than the more recent 14-domain version 
(TDF2) (Michie et al. 2005; Cane et al. 2012). This decision was based on the research team’s 
discussion of the importance of the ‘Nature of the behaviours’ domain in the context of older 
adults’ adherence behaviour, as previous research has described this behaviour as ‘routine’ 
(Tordoff et al. 2010a). As the ‘Nature of the behaviours’ domain was thus deemed likely to 
be important to the target behaviour (i.e. adherence to polypharmacy), and is absent from 
TDF2, TDF1 was selected as the underpinning theoretical model for the current study.  
Key interview questions (Appendix 3.7) were developed based on each of the 12 theoretical 
domains in TDF1 (Michie et al. 2005). Example questions are provided below: 
 How important is it to you to take all of your different medicines as the GP has 
instructed/directed/prescribed? [Motivation and goals domain] 
 What do you think the disadvantages are to taking all your medicines as prescribed? 
[Beliefs about consequences domain] 
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Prompts were also included to elicit further information from participants where necessary. 
The topic guide was piloted before use by a group of Pharmacy PhD students and Post-
doctoral Research Fellows who acted as participants aged over 65 taking four or more 
medicines. Refinements were made to the topic guide with ambiguous questions being re-
phrased and more examples of prompts included. 
3.3.6 Conduct of focus groups                                                                                                
Focus groups were convened by two members of the research team who acted as moderator 
(CC: BSc, PhD, Post-Doctoral Research Fellow at time of study, qualified pharmacist) and 
note-taker (DP: MPharm, MPSNI, PhD Research Student/practising community pharmacist), 
respectively. Both researchers had undergone training (CC, DP) and/or had experience (CC) 
in qualitative research methods prior to conducting the focus groups. Participants were 
contacted via telephone to arrange a suitable time and location for each focus group. 
Participants were not informed of the researchers’ backgrounds but were made aware that 
the study was being conducted by the School of Pharmacy at Queen’s University Belfast 
(QUB). Focus groups were held between October 2014 and January 2015, either at the 
patients’ general practice or another convenient location (e.g. local community centre). 
Refreshments were provided and an oral summary of the key questions and answers 
provided by participants was given by the note taker (DP) at the end of each focus group. 
With participants’ consent, each focus group was digitally recorded, transcribed verbatim 
and checked for accuracy. Patient identifiers were removed and an anonymous code was 
assigned to each participant (e.g. FG01PT01). The code denoted the specific focus group (i.e. 
FG01, FG02, etc.) and the individual participant (i.e. PT01, PT02, etc.). Following transcription, 
data were transferred to NVivo QSR 10. All recordings, consent forms etc. were stored either 
in a locked fire-resistant filing cabinet or on a password protected laptop, to which only the 
research team had access. The qualitative aspect of this study has been reported in 
accordance with the 32 item COREQ checklist (see completed checklist in Appendix 3.8), 
which seeks to ensure the comprehensive and explicit reporting of qualitative research such 
as focus group studies. 
3.3.7 Data analysis 
Data analysis consisted of three stages: (1) Identification of determinants of adherence; (2) 
Identification of key TDF domains; (3) Mapping of key TDF domains to BCTs. Figure 3.1 
provides an overview of these three stages with further details provided in the subsequent 
text.  
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Figure 3.1 An overview of the three stages involved in data analysis  
1A domain was considered to be important/relevant if it met the criterion ‘evidence of verbal agreement or strong beliefs expressed by an individual’; 2Selection was based on 
expected feasibility of BCT delivery in the proposed setting and applicability to target group; 3No BCTs were mapped to ‘Memory, attention and decision processes’ and 
‘Social/professional role and identity’ domains in the primary reference source 
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Stage 1: Identification of determinants of adherence 
The framework method was used to systematically index and chart data into a framework 
matrix (Gale et al. 2013). TDF1 was used as the analytical framework whereby each of the 12 
domains served as the coding categories (Michie et al. 2005). Following transcription of focus 
group recordings, an in-depth familiarisation process was undertaken through repeated 
reading of focus group transcripts, as well as listening to audio recordings (‘familiarisation’ 
phase of framework method). Each transcript was coded independently by at least two 
members of the research team (DP, CR, CH) (‘indexing’ phase of framework method). Coding 
was compared and agreed between the coders and any discrepancies were resolved by 
discussion. The data were managed using NVivo QSR 10 before being imported into a 
Microsoft Excel spreadsheet to generate a framework matrix (‘charting’ phase of framework 
method).  
Qualitative content analysis was then performed inductively on the framework matrix to 
identify emerging themes relating to determinants (i.e. barriers and/or facilitators) of 
adherence within each TDF domain. A summary of the qualitative content analysis was 
reviewed by three members of the research team (DP, CR, CH) and content themes were 
agreed upon. 
Stage 2: Identification of key TDF domains 
The second stage of data analysis involved identifying key domains to target as part of an 
intervention. As discussed in Section 3.3.2, qualitative TDF-based studies have often involved 
the use of semi-structured interviews and comparatively fewer studies have used focus 
groups (Francis et al. 2012). The study by Bussières et al. (2012) was the only focus group 
study identified by the research team that outlined the methods used to assess the 
importance/relevance of domains with respect to the target behaviour. This involved the use 
of frequency counts (i.e. the number of times that beliefs/statements were mentioned per 
domain) as one of the assessment criteria.  
Although frequency counts have commonly been used as a criterion to assess the relevance 
of domains in TDF-based interview studies, there are challenges involved in applying this type 
of quantitative content analysis approach to focus group data (Atkins et al. 2017). For 
example, in a focus group context, there are many verbal and non-verbal ways that 
participants can indicate their agreement with other participants (e.g. short verbal 
responses, head nodding) which can be difficult to capture accurately from audio recordings 
(Krueger and Casey, 2009). Hence, relying solely on strict frequency counts from the analysed 
  Chapter 3 
74 
 
transcripts of the audio-recordings of focus groups may underestimate the relevance of a 
theoretical domain. To overcome these challenges, the research team also took into 
consideration the expression of strong beliefs (whereby an individual emphasised or re-
iterated a belief) as an indicator of a domain’s relevance/importance, in addition to the 
verbal agreement amongst participants in each group or similarities across focus groups. This 
adapted criterion (i.e. ‘evidence of verbal agreement or strong beliefs expressed by an 
individual’) guided decisions regarding the relevance/importance of each domain to the 
target behaviour (i.e. adherence to multiple medications).  
Although a domain could be deemed as relevant/important to the behaviour it may not be 
feasible to target identified barriers (or necessary to enhance facilitators) with an 
intervention in the proposed setting. For example, in the study by Cadogan et al. (2015) 
(described previously in Section 3.1) it was not considered possible to overcome barriers 
identified under the ‘Knowledge’ domain, such as the lack of evidence available to support 
prescribing and dispensing decisions for multimorbid older adults by GPs and CPs, 
respectively. In the current study, key domains to target in an intervention were selected 
based on the feasibility of overcoming barriers (or enhancing facilitators further) in the 
proposed setting of community pharmacies and using the wider project’s resources. All 
decisions involved a consensus-based approach.  
Stage 3: Mapping of key TDF domains to BCTs  
The process for mapping theoretical domains to BCTs was guided by methods reported by 
Cadogan et al. (2015) which involved the use of a two reference sources (Michie et al. 2008; 
Cane et al. 2015). A mapping table (Appendix 3.2) published by Cane et al. (2015) was used 
as the primary reference source as it provided the most up-to-date guidance on BCT mapping 
using the current available BCT taxonomy (BCTTv1) (Michie et al. 2013). During group 
discussions a number of limitations were noted with the primary reference source (Cane et 
al. 2015). Firstly, BCTs had not been mapped to two domains (‘Memory, attention and 
decision processes’ or ‘Social/professional role and identity’), and secondly the mapping 
process was carried out with TDF2, whereas the current study was based on TDF1. To 
overcome these limitations, the original mapping matrix developed by Michie et al. (2008) 
was consulted as a secondary reference source. This matrix linked 35 BCTs (from a provisional 
list of BCTs established prior to BCTTv1) to domains in TDF1 as agreed by four experts. 
The BCT selection process involved a consensus-based approach and was informed by the 
summary of findings from the qualitative content analysis of focus group data. In selecting 
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BCTs to target key domains, the research team considered two main factors: (1) the 
applicability of particular BCTs to the target group (i.e. older adults prescribed 
polypharmacy), (2) the expected feasibility of BCT delivery with regards to contextual 
constraints of the community pharmacy setting (e.g. time-limited interactions with HCPs). 
Potential implementation issues (such as likely BCT preparation and delivery time) were also 
taken into consideration at this early stage of intervention development to help exclude BCTs 
that were unlikely to be feasible for delivery in primary care by CPs.  Using this approach, the 
study outlined in this Chapter follows the latest WIDER guidelines which recommend 
reporting on: ‘1) The intervention development; 2) The change techniques used in the 
intervention; 3) The causal processes targeted by these change techniques’ (Albrecht et al. 
2013). 
3.4 Results 
3.4.1 Participant characteristics  
Seven of the ten general practices that participated in the previous linked study (Section 
3.3.3) agreed to facilitate patient recruitment and seven focus groups were convened (one 
at each practice) (Cadogan et al. 2015). In total, 382 letters were sent out to patients by 
NICRN nurses from the seven general practices and 50 participants (60% female) were 
recruited into the study. Numbers of non-responders or those declining to participate were 
not recorded. Each focus group consisted of between five and 10 participants (see Table 3.2) 
and all those in attendance were active participants. The duration of each focus group ranged 
from 65 to 123 minutes (618 minutes in total). Data saturation was reached by the seventh 
focus group as no new relevant themes were emerging at this point.  



















Health and Social 
Care Trust area 
(urban/rural)1 
1 10 3:7 102 1 (urban) 
2 9 5:4 123 2 (urban) 
3 7 2:5 88 3 (rural) 
4 6 2:4 87 4 (rural) 
5 6 2:4 65 2 (urban) 
6 7 3:4 84 4 (urban) 
7 5 3:2 69 3 (rural) 
1 In NI ‘...the divide between urban and rural lies among settlements whose populations are between 3,000 and 
5,000’ (Northern Ireland Statistics and Research Agency, 2005) 
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3.4.2 Summary of findings from Stage 1 (Identification of determinants of 
adherence) 
The main determinants (i.e. barriers, facilitators) of older patients’ adherence to 
polypharmacy that were identified within each theoretical domain are listed in Table 3.3 





Table 3.3: Determinants (barriers, facilitators) of older patients’ adherence behaviour identified within each TDF domain and illustrative quotes 
TDF domain Determinants (barriers, facilitators) of adherence to polypharmacy Illustrative quotes 
Knowledge  Lack of/incorrect knowledge of clinical indication, treatment 
duration or administration timing (barrier) 
 Lack of/incorrect knowledge of the consequences of adherence 
or non-adherence (barrier) 
 Extent of knowledge on medication side effects (barrier or 
facilitator)1 
“I wasn’t aware, and I’ll have to read the boxes again. I wasn’t aware of, of 
the time of the day or night…” (FG07PT02)  
“You know, a build-up of this, that and the other, you just sort of wonder can 
that be good or would you be better off taking a break…” (FG05PT02) 
“Sometimes the less you know the better, just take it.” (FG05PT01) 
Beliefs about 
consequences  
 Concerns about medication side effects/long term consequences 
of adherence or non-adherence (barrier) 
 Beliefs that missed doses cause no harm (barrier) 
 Beliefs that medications are unnecessary and/or lack benefit 
(barrier) 
 Beliefs that non-adherence has negative outcomes (e.g. 
hospitalisation, mortality) (facilitator) 
 Beliefs that medications are necessary and/or beneficial (e.g. 
improves quality of life, prolongs survival) (facilitator) 
 Return of symptoms (facilitator) 
“Well, blood pressure is very serious, I would take my blood pressure tablet 
every day. I’m on aspirin, I take that every day. See this is why I laughed when 
I got the letter and it said, you know, ‘Four tablets plus’. I am officially down 
as four tablets plus but I don’t take four tablets plus…” (FG03PT06) 
“I remember at one stage thinking I don't think them tablets are doing me any 
good, I would say to the wife, ‘You wouldn't be taking them no more’. I said, ‘I 
want to stop, I don't think they're doing me a lot of good…’” (FG02PT04) 
“…I’ve never stopped taking them but I sort of wondered if I stopped taking 
these what would happen but I tried it for a wee while but my blood pressure 
went away up. And then it takes a wee while for the tablets to be effective 
again.” (FG04PT01) 
Emotion  Anxiety about side effects/long term consequences of adherence 
or non-adherence (barrier) 
 Anxiety about potential consequences of non-adherence 
(facilitator) 
“Well, I would worry about the side effects but I know I have no choice but 
take them.” (FG01PT04) 
“I’d be afraid of not taking them, I don’t know what the effect would be but 
I’d be afraid if I didn’t take them that it would affect me badly.” (FG07PT02)  
Skills   Lack of physical skills to take medicines as prescribed (e.g. ability 
to swallow medications, poor manual dexterity) (barrier) 
“But I couldn’t, I couldn’t actually physically get them out, [Out of the thing, 
yeah] trying to get the back open.” (FG01PT09) 










Table 3.3 (cont’d): Determinants (barriers, facilitators) of older patients’ adherence behaviour identified within each TDF domain and illustrative quotes 
TDF domain Determinants (barriers, facilitators) of adherence to polypharmacy Illustrative quotes 
Beliefs about 
capabilities 
 Belief about lack of physical capability (see ‘Skills’ domain) 
(barrier) 
 Belief that medication use is not difficult (facilitator) 
“And I would say, ‘Excuse me, I can't take those, [Can’t swallow] no, can you 
give me those ones that's in the water?’…” (FG01PT01) 
“But it’s the top, if you've one of those tops they’re impossible if you’ve 
arthritic hands.” (FG01PT06) 
“I've no difficulty there with anything… there, as long as I'm able to take the 




 Access to medications (e.g. at weekends) (barrier) 
 Changing environment (e.g. on holidays, day trips) (barrier) 
 Physical resources (e.g. MDS, medication lists) (barrier) 
 “…you have to make sure you have everything with you and sometimes you’d 
be in meetings or something like here and the time you’re supposed to take it 
is gone by.” (FG03PT03)  
“I get it in a bubble pack [MDS] for the week and he leaves it out morning and 
evening, it’s just so easy in case you forget them….” (FG05PT04) 
Motivations and 
goals 
 Goals to reduce the total number of prescribed medications 
(barrier) 
 Relative priority placed on medications that patients deem to be 
of greater importance (barrier/facilitator)2 
 High intrinsic motivation to take medicines as prescribed 
(facilitator) 
 Health goals such as goals to avoid hospital admission, maintain 
driving license, clinical goals (e.g. symptom control) (facilitator) 
“You decide what’s the serious ones and if you run out of a lesser tablet, well 
it’s not as dangerous, you can wait till you get to the pharmacist, you know. 
There's a couple of my tablets that, well I need to take them but they’re not 
as important if you know what I mean as the blood pressure tablets…” 
(FG03PT03) 
“Well I think it’s very important for me too because I would have…kidney 
failure or kidney disease and I think if I didn’t do me things right I might end 




 Systems that alert patients to missed doses (e.g. MDS) 
(facilitator) 
 Practical and reminder strategies (e.g. placement of medication 
in a visually prominent place) (facilitator) 
 Action planning (e.g. planning administration times) (facilitator) 
 Self-monitoring of medication use and outcomes (e.g. blood 
glucose, symptom control) (facilitator) 
“And I put it [MDS] down beside the kettle because I know I'm going to the 
kettle in the mornings, the tablets are there for me.” (FG07PT03) 
 “I have a wee weekly box and I take so many tablets in the morning they're 
divided between two compartments but I do all my week’s drugs on a Sunday 










Table 3.3 (cont’d):  Determinants (barriers, facilitators) of older patients’ adherence behaviour identified within each TDF domain and illustrative quotes 





 Forgetting to take medicines as prescribed (barrier) 
 Paying attention to medications deemed to be of greater 
importance (barrier/facilitator)2 
 Paying attention to medications when out of normal context (e.g. on 
holidays, at meetings) (facilitator) 
 Making decisions regarding medication use without consulting a 
HCP (e.g. reducing doses, non-persistence) (barrier) 
 Involving HCPs in decisions regarding medications (facilitator) 
“So obviously I've forgotten, not that I'm that fond of statins anyway 
because they keep giving me pains, they’re desperate.” (FG06PT07) 
 “I have at several times… with different medications cut down to see how I 
can go, I've never actually stopped… that I cut it out altogether, no I 
haven’t done that.” (FG04PT02) 
“Sometimes when I go on holiday I don’t take my fluid one. I just– but it’s 
combined with my blood pressure tablet… so I’m cutting both of them out 
but I do, for a few days anyway.” (FG01PT06) 
Social 
influences 
 Social support/pressure from family (facilitator) 
 Social support/pressure from HCPs (facilitator) 
 Lack of (or withdrawal of) social support from family (e.g. death 
of spouse) (barrier) 
“’You’re not taking your tablet, I know by the look on your face’… that sort 
of reacts to you because the girl [Diabetic nurse] knows you and you know 
the girl, it’s not as if she's a stranger.” (FG01PT01) 
“My wife passed away last Christmas and I, I find it difficult to manage [my] 
tablets. She remembered every time I had to take a tablet and sometimes I 





 Patient autonomy (i.e. viewing medication use as their own 
responsibility) (facilitator) 
“Everyone would be responsible for themselves.” (FG04PT06) 
“… I'm the one that's been affected by it so… as far as I'm concerned… it’s 
my responsibility to do it.” (FG06PT01) 
Nature of the 
behaviours 
 Having a personalised routine (e.g. linked to meal times) 
(facilitator) 
 Lack of routine or ineffective routine (barrier) 
 Return of symptoms (direct experience) (facilitator) 
“Well, I used to worry about, as I say, taking the tablets and so I developed 
a wee routine, you know. Here's me, I'll take them this way. So I take the, 
the wee one in the morning and then start eating my porridge…” 
(FG02PT06) 
“It’s no difficulty for me because as soon as I have my breakfast into the 
kitchen, into the cupboard, get them out, that’s it. It’s just routine.” 
(FG01PT08) 
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Many of the focus group participants did not perceive their knowledge of the medications 
they were prescribed to be a barrier to adherence. However, some participants did not know 
the expected length of treatment duration or the appropriate time to take their medication 
and this posed barriers to adherence. There was a lack of consensus amongst participants in 
relation to the desired amount of knowledge on medication side effects (domain: 
‘Knowledge’). Based on their level of knowledge of the outcome of taking medications as 
prescribed, participants reported various beliefs about the consequences of adherence or 
non-adherence (domain: ‘Beliefs about consequences’) which in turn influenced their 
decisions to take their medications in accordance with the prescribed directions (domain: 
‘Memory, attention and decision processes’). For some participants, beliefs about potential 
harms of non-adherence led to feelings of anxiety (domain: ’Emotion’). 
A number of participants placed higher priority on medicines that they believed to be of 
greater importance (e.g. warfarin) often to the detriment of other medicines. This acted as a 
barrier to their overall adherence to polypharmacy. For example, some patients were less 
concerned about having a supply of other medications that they deemed to be less important 
(domains: ‘Motivation and goals’, ‘Memory, attention and decision processes’). Participants 
also noted that setting goals (e.g. to avoid hospital admission), either with or without a HCP, 
facilitated adherence to polypharmacy. However, this was conditional on an appropriate goal 
being set as some participants aimed to decrease the overall number of prescribed 
medications and this acted as a barrier to adherence (domain: ‘Motivation and goals’).  
For most participants, taking several medications was not seen as a difficult task (domain: 
‘Beliefs about capabilities’). However, some participants indicated that this would likely 
change if they became cognitively impaired. The only physical difficulties reported by 
participants in taking their medication as prescribed were in relation to the opening of 
medication packaging and swallowing oral dosage formulations. These problems were often 
attributed to poor manual dexterity skills, medication formulation and packaging (domains: 
‘Skills’, ‘Environmental context and resources’).   
Participants cited a number of resources and practical strategies that facilitated adherence, 
including MDS, medication lists prepared in secondary care (including details of 
administration times) and routine medication reviews by GPs  (domains: ‘Environmental 
context and resources’, ‘Behavioural regulation’). A lack of access to medication supplies 
outside of normal general practice hours (e.g. over the weekend) was perceived as a barrier 
to adherence (domain: ‘Environmental context and resources’).  
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In discussing their decisions to take their medicines as prescribed, participants commonly 
stated that they felt they had no choice but to follow their GPs’ directions (domains: 
‘Memory, attention and decision processes’, ‘Social influences’). For some participants, these 
decisions were not as clear-cut and were based on their ‘knowledge’ of the clinical outcome 
of medication use and personal ‘beliefs about consequences’ of taking medications as 
directed. Decisions were also informed by the patients’ direct experience which included 
return of symptoms following trial periods of stopping their medication without consulting 
their GP (domains: ‘Nature of behaviours’, ‘Beliefs about consequences’). Participants’ 
adherence behaviour was influenced by their interactions with HCPs and good relationships 
with HCPs, such as GPs and CPs, were perceived as a facilitator of adherence. The social 
support provided by family members was also perceived as a facilitator of adherence (e.g. 
reminders, encouragement) (domain: ‘Social influences’). Irrespective of the level of 
available social support, participants reported that it was their own personal responsibility 
to take their medicines as prescribed and this facilitated adherence (domain: 
‘Social/professional role and identity’).  
Participants in all seven focus groups discussed how taking several medications formed part 
of their normal ‘routine’ and everyday life (domain: ‘Nature of the behaviours’). These 
routines which were often highly individualised and generally linked to meal times facilitated 
adherence to polypharmacy (domain: ‘Behavioural regulation’). However, difficulties with 
adherence were encountered by participants when they had to take medications at 
particular times of the day (e.g. evening doses) or where their normal routine was disrupted 
(e.g. holidays) and this often led to participants forgetting to take their medicines as 
prescribed (domains: ‘Environmental context and resources’, ‘Memory, attention and 
decision processes’, Behavioural regulation).  
3.4.3 Summary of findings from Stage 2 (Identification of key domains) 
Based on the research team’s review of the summary findings from data analysis Stage 1 
(Section 3.4.2), all 12 domains met the criterion ‘evidence of verbal agreement or strong 
beliefs expressed by an individual’ and were therefore considered to be relevant/important 
to the target behaviour (adherence to multiple medications). Through group consensus, eight 
of the 12 domains were selected as key domains to target as part of an intervention 
(‘Knowledge’, ‘Beliefs about consequences’, ‘Motivation and goals’, ‘Environmental context 
and resources’, ‘Social influences’, ‘Memory, attention and decision processes’, Behavioural 
regulation’ and ‘Nature of the behaviours’). Four domains were not selected as key domains 
  Chapter 3 
82 
 
to target (‘Social/professional role and identity’; ‘Beliefs about capabilities’; ‘Skills’; 
‘Emotion’). The reasons for this are discussed in Section 3.5.1.  
3.4.4 Summary of findings from Stage 3 (Mapping of key domains to BCTs) 
The eight key domains identified in Stage 2 (Section 3.4.3) were mapped across to BCTs using 
the two reference sources discussed previously (Section 3.1) (Michie et al. 2008; Cane et al. 
2015). Forty-one potential BCTs were identified using this method and subsequently 
considered for inclusion in an intervention to improve adherence to polypharmacy in older 
adults (See Table 3.4). Based on discussion among the research team eleven BCTs were 
subsequently selected for inclusion in an intervention: ‘Information about health 
consequences’, ‘Feedback on behaviour’, ‘Goal-setting (outcome)’, ‘Goal-setting 
(behaviour)’, ‘Review of outcome goal’, ‘Review of behaviour goal’, ‘Action planning’, 
‘Prompts and cues’, ‘Self-monitoring (of the behaviour)’, ‘Restructuring the physical 
environment’, ‘Social support (unspecified)’ (see Table 3.4). BCTs that were not selected and 
the reasons for this are outlined in Table 3.4. 










a=Primary reference source (Cane et al. 2015)  
b=Secondary reference source (Michie et al. 2008)  
BCT 
selected 
 = YES 
X = NO 
Rationale for selection (or non-selection) of BCT(s) to include in the patient-targeted 
intervention 
Knowledge  Information about health 
consequencesa /Information regarding 
behaviour, outcomeb  
 Verbal information could be provided by outlining positive consequences of adhering to 
medications and negative consequences of non-adherence. This BCT also mapped to ‘Beliefs 
about consequences’ and ‘Motivation and goals’—see below. Note: The BCT ‘Information 
regarding behaviour, outcome’ encapsulates the BCT ‘Information about health consequences’. 
 Feedback on behavioura  Patients could be provided with verbal feedback on their adherence behaviours. This BCT also 
mapped to ‘Beliefs about consequences’—see below. 
 Antecedents (e.g. distraction, adding 
objects)a 
X Due the restricted time environment in the proposed setting of primary care, BCTs in this 
grouping were not deemed to be necessary in addition to previously selected BCTs–see above.  
 Biofeedbacka X Providing feedback on the outcomes of behaviour (e.g. improvements in clinical parameters) 
would be difficult to achieve in the context of community pharmacy and with the current 










 Comparative imagining of future 
outcomesa 
 Pros and consa 
 Covert conditioninga 
X Due the restricted time environment in the proposed setting of primary care, these BCTs were 
not deemed to be necessary in addition to BCTs previously selected to target the ‘Knowledge’ 
domain (‘Feedback on behaviour’, ‘Information about health consequences’) which also map to 
the ‘Beliefs about consequences’ domain—see below. 
 Emotional consequencesa X It is beyond the scope of the current study to target patients’ emotions directly and this BCT 
would likely require extensive delivery over a long period of time. 
 Salience of consequencesa X This BCT would likely require significant and detailed preparation which would be difficult to 
achieve in the context of the current intervention which targets a heterogeneous patient group. 
 Covert sensitizationa 
 Anticipated regreta 
X These BCTs were not considered to be appropriate for inclusion, as the current intervention will 
focus on improving medication adherence (i.e. a wanted behaviour) rather than an unwanted 
behaviour 
 Social and environmental 
consequencesa 
X This BCT is not applicable to the target audience as participants in the focus groups focused 


















a=Primary reference source (Cane et al. 2015)  
b=Secondary reference source (Michie et al. 2008)   
BCT 
selected 
 = YES 
X = NO 





 Vicarious reinforcementa X This BCT is not applicable to the target audience as the behaviour is highly individualised based 
on the patients’ own medications and medical conditions. 
 Threata X Threats were not considered to be appropriate for attempting to change patient’s adherence 
behaviour as they could evoke negative emotions and harm the patient-HCP relationship.  
 Self-monitoringa  Patients could self-monitor their medication use via a personalised daily medication diary. This 
BCT also mapped to ‘Behavioural regulation’ and ‘Memory, attention and decision processes’–
see below. 
 Persuasive communicationb X This BCT would likely require delivery over an extended time period which was not seen as 
feasible in the proposed setting of community pharmacies. 
 Information regarding 
behaviour/outcomeb  
 Equivalent to ‘Information about health consequences’. See ‘Knowledge’ domain above. 





 Restructuring the physical 
environmenta/ Environmental 
changesb 
 Changes to the physical environment, such as non-child resistant bottles, re-packaging 
medications in MDS, could be made to facilitate adherence. Note: These BCTs were deemed 
equivalent. 
 Discriminative (learned) cuea X It is beyond the scope of this project to offer rewards or incentives. 
 Prompts and cuesa  Patients could use reminder stickers or strategic placement of medications in a visually 
prominent place to prompt medication use (e.g. kitchen bench). This BCT also mapped to 
‘Behavioural regulation’ and ‘Memory, attention and decision processes’  
 Restructuring the social environmenta X It is beyond the scope of this project to restructure patients’ social environment. 
 Avoidance/changing exposure to cues 
for the behavioura 
X This BCT was not considered to be appropriate for inclusion, as the current intervention will 


















a=Primary reference source (Cane et al. 2015)  
b=Secondary reference source (Michie et al. 2008) 
BCT 
selected 
 = YES 
X = NO 


















 Goal setting (outcome)a 
 Goal setting (behaviour)a   
 Review of outcome goala 
 Review of behaviour goala 








Patients could be prompted to set goals related to positive outcomes of medication use (e.g. 
fewer symptoms, avoiding hospital admissions) and/or medicine use (i.e. behaviour) goals 
tailored to their own medications. These goals could be reviewed at follow-up appointments. 
These BCTs also mapped to the ‘Behavioural regulation’ domain. Note: ‘Goal/target specified: 
behaviour or outcome’ encompasses the following four BCTs: ‘Goal setting (outcome)’, ‘Goal 
setting (behaviour)’, ‘Review of outcome goal’ and ‘Review of behaviour goal’. 
 Action planninga   Patients could make explicit plans with their HCPs as to how to use their medication. This BCT 
also mapped to ‘Memory, attention and decision processes’ and ‘Behavioural regulation’.  
 Contracta,b 
 Graded tasks, starting with easy tasksb 
 Behavioural commitmenta 
X Due to the limited available time in the proposed setting of primary care, these BCTs were not 
deemed to be necessary in addition to previously selected BCTs (e.g. ‘Goal-setting’, ‘Action 
planning’). 
 Rewards; incentivesb X It is beyond the scope of this project to offer rewards or incentives. 
 Increasing skills: problem solving, 
decision making, goal settingb 
X This BCT encapsulates some aspects of previously selected BCTs (e.g. ‘Goal setting (behaviour)’. 




Patients could be advised to seek additional support from family or friends or HCPs could 
encourage adherence. This BCT also mapped to ‘Social influences’—see below. 
 Persuasive communicationb 
 Motivational interviewingb 
X These BCTs would likely require delivery over an extended time period which was not seen as 
feasible in the proposed setting of community pharmacies. 
 Information regarding behaviour, 
outcomeb 




 Self-monitoring (of behaviour)a 
 
 Refer to ‘Beliefs about consequences’ domain above. 
 Goal/target specified: behaviour or 
outcomeb 


















a=Primary reference source (Cane et al. 2015)  
b=Secondary reference source (Michie et al. 2008)   
BCT 
selected 
 = YES 
X = NO 






 Use of imageryb 
X Due to the restricted time environment in the proposed setting of community pharmacies, 
these BCTs were not deemed to be necessary in addition to previously selected BCTs. 
 Planning, implementationb  Equivalent to ‘Action planning’. Refer to ‘Motivation and goals’ domain above. 






 Self-monitoringb  Equivalent to ‘Self-monitoring (of behaviour)’. Refer to ‘Beliefs about consequences’ domain 
above. 
 Planning, implementationb  Equivalent to ‘Action planning’. Refer to ‘Motivation and goals’ domain above. 





 Social support (unspecified)a/ Social 
processes of encouragement, 
pressure, supportb 
 Refer to ‘Motivation and goals’ domain above. Note: these BCTs were deemed equivalent. 
 Social comparisona 
 Vicarious reinforcementa 
 Identification of self as role modela 
X These BCTs are not applicable to the target audience as the behaviour is highly individualised 
based on the patients’ own medications and medical conditions (Brown and Bussell, 2011). 
 Information about others approvala 
 Social rewarda 
X Due the restricted time environment in the proposed setting of primary care, these BCTs were 
not deemed to be necessary in addition to the previously selected BCT—see above. 
 Social support (emotional)a 
 Social support (practical)a 
X 
 
These BCTs encapsulate aspects that are already covered by the previously selected BCT ‘Social 
support (unspecified)’. 
 Restructuring the social environmenta X It is beyond the scope of this project to restructure the social environment. 
 Modelling or demonstrating the 
behaviourb 
X This BCT would require significant and detailed preparation which would be difficult to achieve 
in the context of the current intervention which targets a heterogeneous patient group. 
Nature of the 
behaviours 
 None identified N/A This domain was not included in either reference source, therefore, no BCTs were mapped to 
this domain. This domain will be targeted indirectly using BCTs that were mapped to the other 
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3.5 Discussion  
This chapter describes the findings from the systematic process that was undertaken to select 
components of a theory-based intervention to improve medication adherence in older adults 
prescribed polypharmacy. This study involved a detailed exploration of determinants of older 
adults’ adherence behaviour as part of a focus group study, using TDF as the underpinning 
theoretical model of behaviour (Michie et al. 2005). Key theoretical domains that could be 
targeted in a CP-led intervention were then mapped to BCTs from an established taxonomy 
(BCTTv1) (Michie et al. 2008; Michie et al. 2013; Cane et al. 2015). The selected BCTs will form 
the proposed active components of an intervention. 
3.5.1 Behavioural determinants and selection of key TDF domains to target 
The focus group findings highlight the wide range of determinants perceived to be influencing 
older patients’ adherence behaviour, as well as the challenge for researchers in selecting key 
domains to target as part of an intervention. Participants across all seven focus groups 
described their adherence behaviour as ‘routine’ and emphasised the importance of their 
own bespoke routines in facilitating adherence to multiple medications. Participants who 
lacked a routine, or encountered disruptions to their normal routine (e.g. during holidays), 
reported difficulties in taking their medication as prescribed. The importance of routine to 
patients’ adherence behaviour is consistent with previous qualitative studies which, in 
contrast to the current study, were not underpinned by a theoretical framework of behaviour 
change (Tordoff et al. 2010a; Tordoff et al. 2010b; Sanders and Van Oss, 2013). As ‘routine’ 
was coded under the ‘Nature of the behaviours’ domain which has since been removed from 
the framework in TDF2, the focus group findings support our rationale for the selection of 
TDF1 as the underpinning model for the study (Michie et al. 2005). Based on the focus group 
findings, it was evident that the ‘Nature of the behaviours’ domain would need to be 
targeted, albeit indirectly, in an intervention to improve adherence to polypharmacy. 
Both ‘Environmental context and resources’ and ‘Social influences’ were identified as key 
target domains for an intervention. Despite recommendations in the WHO’s 2003 report that 
those attempting to change adherence behaviour should consider the impact of 
environmental and social factors on adherence, such factors are not always taken into 
consideration when designing adherence interventions (Sabate, 2003; Nieuwlaat et al. 2014). 
Although it is beyond the scope of this project to directly target some of the barriers 
identified under these domains, it is possible to provide alternative solutions to the issues 
identified. For example, to address a lack of access to medications at weekends when GP 
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surgeries are closed (domain: Environmental Context and resources) CPs could recommend 
strategies to remind patients to re-order medications in a timely manner (BCT: 
‘Prompts/cues’). 
Previous interventions targeting adherence have also rarely focused on setting goals that are 
important to patients (Bosworth et al. 2011; Allemann et al. 2016). This study identified a 
number of barriers and facilitators under the ‘Motivation and goals’ domain that are relevant 
to patients prescribed multiple medications (e.g. some patients placed higher importance on 
medicines they deemed more important, often to the detriment of other medications). It is 
important that appropriate treatment goals, relevant to patients, are discussed and jointly 
agreed between patients and HCPs. This will be achieved in the intervention by delivering 
goal-based BCTs [e.g. goal-setting (outcome), goal-setting (behaviour)].  
Domains not selected for targeting 
Four domains were not selected to target in an intervention because they did not contain 
barriers and facilitators that were considered as feasible to target within the available project 
resources and selected setting of community pharmacies (‘Social/professional role and 
identity’; ‘Emotion’;  ‘Skills’; ‘Beliefs about capabilities’).  
Although the ‘Social/professional role and identity’ domain was considered to be 
relevant/important to the behaviour, participants reported awareness that the responsibility 
of medication use was their own and so this facilitator did not need to be enhanced further. 
Participants did indicate that this might change in the future should they become cognitively 
impaired. However, as this research did not seek to focus on patients with cognitive 
impairment, this domain was not selected as a key target for behaviour change. Non-
adherent patients with cognitive impairment (e.g. with a diagnosis of dementia) would likely 
require an intervention of a different nature (e.g. enhanced practical support from carers).  
In terms of the ‘Beliefs about capabilities’ domain the majority of patients believed that, 
provided they had no cognitive impairment, they had the psychological capability required 
to manage and take their medicines. Physical capability was discussed rarely by only a few 
participants in the context of medication packaging, and this linked to the ‘Skills’ and 
‘Environmental context and resources’ domains. Patients discussed the physical skills 
involved in opening mediation packaging (manual dexterity) and swallowing oral dosage 
formulations, and this influenced participants’ beliefs about their physical capabilities 
(‘Beliefs about capabilities’). The findings in this study correlate with findings in the literature, 
for example, a study by Philbert et al. (2014) demonstrated that over a quarter (28.4%) of 
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older adults experienced difficulties opening packaging (e.g. removing tablets from blister 
packs). These are recognised issues that are important to consider in ensuring the 
appropriate use of polypharmacy in older adults (Hughes et al. 2016) but it was beyond the 
scope of the current project to improve patients’ physical skills relating to manual dexterity 
or swallowing ability. Hence, the ‘Skills’ domain was not considered for intervention 
targeting. Instead, it was intended that the barriers identified under both the ‘Skills’ and 
‘Beliefs about capabilities’ domains would be addressed indirectly by ensuring that 
appropriate types of formulations (e.g. liquids) and medication packaging (e.g. non-child 
resistant medication caps) were issued to patients where required (‘Environmental context 
and resources’). Patients’ cognitive ability, which could be seen as a psychological skill, was 
coded under the domain ‘Memory, attention and decision processes’ and patients’ ability to 
organise their medications was coded under the domain ‘Behavioural regulation’ (i.e. action 
planning). Both of these domains were identified as key target domains for behaviour 
change.  
In relation to the domain ‘Emotion’, participants’ emotion (e.g. fear) generally stemmed from 
their’ beliefs about the consequences of medication adherence or non-adherence. Targeting 
patients’ emotions directly was considered to be beyond the scope of the current project as 
it would likely require extensive training of CPs and delivery of BCTs over a long period of 
time. It was also considered inappropriate to directly illicit negative emotions (e.g. 
anxiety/fear) in an attempt to improve adherence. By targeting the ‘Beliefs about 
consequences’ domain (e.g. using the BCT ‘information on health consequences’), it is 
proposed that patients’ emotions would be indirectly altered.  
3.5.2 Selection of BCTs to include in an intervention 
As outlined previously (Section 3.1), this study formed part of the development phase of the 
MRC framework in that it endeavoured to establish the theoretical underpinning for a novel 
complex intervention. In operationalising the MRC framework, practical implementation 
issues were also considered during initial BCT selection. As noted in the MRC framework, 
failure to consider these practicalities at an early stage can result in ‘weaker interventions 
that are harder to evaluate, less likely to be implemented and less likely to be worth 
implementing’ (Medical Research Council, 2008). Hence, the research team’s decisions about 
whether or not to select a BCT for inclusion in the intervention were based on the 
applicability to the target group (i.e. older adults) and the expected feasibility of BCT delivery 
by CPs. 
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Throughout the decision-making process regarding BCT selection, the research team was also 
conscious of the time constraints in the primary care setting which have been well-publicised 
(George et al. 2010; Smith et al. 2010; Wallace et al. 2015). Drawing on knowledge of relevant 
literature that argues multifaceted interventions are not necessarily more effective in 
changing target behaviours than single component interventions, we aimed to keep the 
intervention as simple as possible (Squires et al. 2014). It was clear that inclusion of all 41 
BCTs would make the intervention too complex and impossible to implement in the 
community pharmacy setting. Hence, it was beneficial if BCTs targeted multiple key domains 
and this was taken into consideration during the selection process. For example, the BCT 
‘Action planning’ was selected instead of the BCT ‘Graded tasks, starting with easy tasks’, as 
the former targets three key domains (‘Motivation and goals’, ‘Behavioural regulation’ and 
‘Memory, attention and decision processes’), whereas the latter targets only one key domain 
(‘Motivation and goals’). The BCT ‘Threats’ was considered to be an inappropriate and 
unethical method for attempting to change older adults’ ‘Beliefs about consequences’ of 
adherence/non-adherence and was therefore excluded. This is because threats can evoke 
negative emotions which could be detrimental to the patient-HCP relationship. Conversely, 
the BCT ‘Information about health consequences’ was considered more appropriate for the 
target intervention recipients. 
As discussed previously in Section 3.1, a number of BCTs in the two reference sources have 
similar names and overlapping characteristics (Michie et al. 2008; Cane et al. 2015). 
Therefore, to avoid potential duplication in the intervention, the research team considered 
these BCTs to be equivalent and opted for the most up-to-date terminology, as reported by 
Cane et al. (2015), thereby retaining the BCT labels proposed in BCTTv1 (Michie et al. 2013).  
The ‘Nature of the behaviours’ domain was the only domain that did not map directly to any 
BCTs in either reference source (Michie et al. 2008; Cane et al. 2015). This is because this 
domain is considered to be distinct from the other domains, in that it represents the 
‘essential characteristics of the behaviour’ (dependent variable), rather than a predictor of 
the behaviour (independent variable) (Cane et al. 2012). However, it is proposed that BCTs 
(e.g. ‘Prompts/cues’) selected to target other key domains (e.g. ‘Memory, attention and 
decision processes’) will influence the routine/habitual nature of patients’ adherence 
behaviours and, hence, target the ‘Nature of the behaviours’ domain indirectly. Habits are 
defined in psychology as ‘actions that are triggered automatically in response to contextual 
cues that have been associated with their performance’ (Gardner et al. 2012). For example, 
getting into a car (cue), triggers the action of putting on the seatbelt. In the case of 
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medication-taking, other common routines, such as teeth brushing, morning coffee, may be 
recommended as cues to trigger medication-taking. Through associative learning, the 
repetition of this action over time will become habitual and part of the patient’s daily routine 
(Lally et al. 2010).  
3.5.3 Methodological advancements  
While the TDF was originally developed to investigate the implementation of evidence-based 
practices by HCPs, it is increasingly being used to explore patient behaviours (Cahir et al. 
2015; McCullough et al. 2015). This study contributes to the growing body of literature that 
is extending the application of the TDF in the development of patient-targeted behaviour 
change interventions. It also highlights the usability of the TDF as the underpinning 
theoretical model in focus group studies examining patient behaviours.  
To date, only one study has documented the process of mapping from TDF domains to BCTs 
to include in patient-targeted interventions. McCullough et al. (2015) employed the original 
mapping matrix developed by Michie et al. (2008) to map TDF domains to BCTs in designing 
an intervention to improve adherence to treatments in bronchiectasis patients. The 
approach undertaken in the current study updates this process by using the most recent work 
by Cane et al. (2015) as the primary reference source (supplemented with the original 
mapping matrix to overcome identified limitations with the primary reference source). The 
current approach represents an advancement of the application of the TDF and BCTTv1 in 
the development of patient-targeted behaviour change interventions. 
3.5.4 Study strengths and limitations  
This study follows the latest WIDER guidelines by reporting on the BCTs that will be included 
in the intervention and the domains targeted by these (i.e. ‘proposed causal processes’) 
(Albrecht et al. 2013). The qualitative component of this study has also been reported in 
accordance with the COREQ checklist (see completed checklist in Appendix 3.8). 
As a limitation of the study, it must be noted that focus group participants were self-selected 
and their level of adherence was not formally measured. Nonetheless, variation in the sample 
of participants was evident, ranging from those who reported no issues with adherence to 
those who reported frequent non-adherence behaviours. The inclusion of both adherent and 
non-adherent patients strengthens the findings by enabling the exploration of both 
facilitators and barriers to the target behaviour. 
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It must also be noted that the intervention development work is underpinned by a qualitative 
study. The qualitative findings were not validated in this study by conducting further 
quantitative research (e.g. a cross-sectional survey). At the time of this study, the majority of 
TDF-based studies had employed qualitative research methodologies (e.g. interviews) to 
explore the target behaviour and develop theory-based interventions (French et al. 2012; 
Cadogan et al. 2015). However, more recently, researchers have adopted a mixed methods 
approach (qualitative and quantitative) using the TDF, to overcome known limitations of 
qualitative methods (such as the limited generalisability of study findings) (Alqubaisi et al. 
2016). Although the selected qualitative approach allowed for an in-depth exploration of the 
target behaviour, the findings are not readily generalisable to the wider population of older 
adults in primary care. However, the sampling strategy incorporated participants from both 
urban and rural areas from across the regions of NI which helps to increase the transferability 
of the focus group findings. Credibility of the qualitative findings was enhanced by giving a 
short oral summary of the key discussions to participants at the end of each focus group, 
which gave participants the opportunity to correct any misinterpretations. Dependability (i.e. 
qualitative equivalent of reliability in quantitative research) of the findings was increased by 
having the focus group transcripts independently coded by two researchers.  
3.6 Conclusion 
This chapter has outlined the systematic process that was undertaken to identify key 
domains (n=8) to target as part of an intervention to improve adherence to polypharmacy in 
older adults and to map these domains to BCTs (n=11) for inclusion in an intervention as the 
active ingredients. By making explicit links between the intervention components and key 
determinants of behaviour change, this will facilitate our understanding of how the 
intervention will exert its effect (Michie and Abraham, 2004). Specifying the intervention 
content in terms of BCTs from an established taxonomy will facilitate implementation of the 
intervention in future evaluations and, ultimately, into clinical practice, if the intervention is 
shown to be effective (Michie et al. 2013). Chapter 4 outlines how the selected BCTs have 
been incorporated into an intervention and delivered by CPs to older adults as part of a small-
scale feasibility study at two community pharmacy sites.














Design and feasibility testing of 
a theory-based intervention to 
improve medication adherence 
in older adults prescribed 
polypharmacy 
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4.1 Introduction  
Following the systematic selection of intervention components (i.e. BCTs) using theory, the 
next stage is to operationalise each of these and combine them into an intervention package. 
Following this, the feasibility of delivering the intervention in clinical practice should be 
explored (Medical Research Council, 2008). Accordingly, the focus of the current chapter is 
on how the 11 BCTs identified in Chapter 3 were combined into a complex intervention 
package and tested in a small-scale feasibility study in the community pharmacy setting. As 
discussed in previous chapters, it was decided at the outset of the current project that any 
developed intervention would be delivered to older adults prescribed polypharmacy in the 
community pharmacy setting on an individual (i.e. one-to-one) basis. Individual delivery was 
deemed most suitable due to the heterogeneity of the target audience. A brief introduction 
to intervention design (including operationalising BCTs) and feasibility testing is provided 
below.  
4.1.1 Intervention design 
Once the overall mode of delivery for the intervention package has been decided (in this case 
face-to-face, on an individual basis), the next step is to consider the mode and/or format of 
delivery of each individual BCT. Potential modes of BCT delivery for an overall face-to-face 
intervention can include: verbal face-to-face delivery, printed materials (e.g. leaflets) 
delivered in-person or digital delivery (e.g. via a smartphone or wearable device) delivered 
initially in-person (by providing digital devices). Formats of BCT delivery can include: 
text/written information, images/pictures, videos or audio. Definitions for each BCT have 
been provided in BCTTv1 to assist in the selection of the most suitable mode(s)/format(s) of 
delivery (Michie et al. 2013). For example, the BCT ‘Self-monitoring of the behaviour’ is 
defined in BCTTv1 as, ‘Establish a method for the person to monitor and record their 
behavior(s) as part of a behavior change strategy’.  
Based on each BCT definition provided, potential modes/formats of delivery can be 
considered. For example, the BCT ‘Self-monitoring of the behaviour’ could be delivered via 
two modes: (1) using printed materials (e.g. providing patients with a written medication 
diary) or (2) providing patients with digital technology to use [e.g. a mobile telephone 
application (app) to record medication use each day]. Final decisions should be made based 
on the suitability of each mode/format to the selected setting, target audience and target 
behaviour (Michie et al. 2014a). The APEASE criteria has been introduced by Michie et al. 
(2014a) to help researchers decide on the overall mode of intervention delivery (e.g. face-to-
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face on an individual or group basis; distance-based such as media broadcast) and also the 
mode/format of delivering each individual BCT. The six criteria in APEASE are outlined in 
Table 4.1 below.  
Table 4.1: APEASE criteria for deciding on the most suitable mode/format for delivery of behaviour 
change techniques (BCTs) (Adapted from: Michie et al. 2014a) 
APEASE criterion Description 
Affordability Intervention designers should take into consideration any costs associated 
with designing and delivering the BCT using each proposed BCT delivery 
format/mode  
Practicability Intervention designers should take into consideration whether it is practical to 
design and deliver the BCT using each proposed format/mode 
Effectiveness/cost
-effectiveness 
Where evidence is available, intervention designers should consider the 
effectiveness/cost-effectiveness of delivering the BCT using each proposed 
format/mode 
Acceptability Intervention designers should consider the likely acceptability of each 




Intervention designers should identify if there are likely to be any safety 
concerns or side effects from using each proposed BCT delivery format/mode 
Equity Intervention designers should consider whether the proposed modes/formats 
of BCT delivery will reach all participants or disadvantage certain groups 
 
The APEASE criteria go beyond examining the likely effectiveness/cost-effectiveness of 
proposed modes/formats of delivery, and also consider how affordable and practical each 
option is likely to be. It also takes into consideration any potential safety concerns/side 
effects and potential reach of the intervention to disadvantaged groups. These are all 
important factors to consider when selecting how to deliver individual BCTs as part of a 
complex intervention package. For example, opting to deliver the BCT ‘Self-monitoring of the 
behaviour’ via a smartphone app may disadvantage older patients who do not own a 
smartphone, and it would be very costly to supply all patients with these.  
After deciding on the most suitable modes/format(s) for BCT delivery, the next step is to 
develop any required supporting materials (e.g. paper-based record for self-monitoring of 
behaviour, leaflets etc.). An intervention manual and training package should also be 
developed to outline exactly how the intervention should be delivered; this helps to ensure 
consistency in delivery by intervention providers (Horner et al. 2006). To ensure that the 
interventions can be easily interpreted and replicated by others, the intervention content 
should be reported in detail in line with the TIDieR (Template for Intervention Description 
and Replication) guidelines (Hoffmann et al. 2014). Following the development of supporting 
intervention materials and piloting within the research group, the next stage recommended 
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in the MRC framework for complex interventions is to conduct feasibility testing with the 
target audience. 
4.1.2 Feasibility testing 
Feasibility testing is recommended by experts in trial methodology and also by funding 
bodies in advance of undertaking larger definitive trials (Medical Research Council, 2008; 
Thabane et al. 2010). As discussed in Chapter 1, feasibility studies do not seek to evaluate 
intervention effectiveness; instead their purpose is to determine whether the intervention 
can be delivered in practice or if modifications are required. A feasibility study also provides 
the opportunity to explore uncertainties with key study parameters (e.g. patient recruitment 
procedures) and optimise these in advance of future studies (Arain et al. 2010).  
A feasibility study can be used to assess the following: usability/acceptability of the 
intervention; need for refinements to the mode/format or intervention materials; feasibility 
of study screening, recruitment and data collection procedures (a definition for ‘Feasibility 
studies’ can be found at http://www.nets.nihr.ac.uk/glossary).  
Usability and acceptability of intervention 
Gaining feedback from feasibility study participants (e.g. via questionnaires or qualitative 
interviews) can help researchers understand which intervention components are most useful 
and acceptable to providers and recipients and identify where improvements could be made. 
This information can then be used to refine the intervention mode/format of delivery and 
content prior to future testing (Arain et al. 2010).  
Fidelity of intervention delivery 
Feasibility studies also provide the opportunity to explore fidelity of intervention delivery (i.e. 
whether the intervention can be delivered as outlined in the intervention manual) (Michie et 
al. 2014a). Larger effect sizes have been reported where interventions have been 
implemented with high fidelity (Durlak and DuPre, 2008). Consequently, it is important that 
researchers attempt to improve fidelity at all stages of intervention development and testing. 
During the design phase, fidelity can be maximised by producing a detailed intervention 
training manual and intervention record (e.g. a booklet that guides each intervention 
appointment and includes space for recording notes) which can act as ‘blueprints’ for the 
intervention (Knittle, 2014). Although measuring fidelity is most useful in the latter stages of 
intervention testing (e.g. to help interpret the study outcomes in a large-scale RCT), 
measuring fidelity as part of early feasibility testing can help researchers optimise the 
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intervention design (Horner et al. 2006). Fidelity (of intervention delivery) can be measured 
via self-report, in-person observations or video or audio-recordings (Bellg et al. 2004; 
Breitenstein et al. 2010; Walton et al. 2017). Self-report methods (e.g. feedback interviews, 
provider-completed checklists) are less costly, less time-consuming and less intrusive than 
other methods, however, they are potentially limited by social desirability and recall bias 
(Breitenstein et al. 2010; Borrelli, 2011).  
Feasibility of screening and recruitment procedures 
Another key aspect of feasibility testing is in exploring important study procedures such as 
patient screening and recruitment. These procedures are critical to the success of a trial 
because a study that fails to recruit the required number of participants may not be 
adequately powered to detect differences between intervention and control groups 
(Treweek et al. 2013). As a result, clinically significant differences may be reported as non-
significant, resulting in potential abandonment of an effective intervention. 
Feasibility of data collection procedures 
Feasibility testing also offers the opportunity to test important data collection procedures, 
such as proposed outcomes for a future RCT. A wide range of outcomes have been measured 
by studies that aim to examine the effectiveness of medication adherence interventions; 
these can be broadly divided into adherence outcomes and clinical/humanistic outcomes 
(Nieuwlaat et al. 2014). 
As discussed previously (Chapter 1), direct measures of medication adherence (e.g. 
measurement of drug levels in blood) are expensive and not practical for research purposes. 
Consequently, indirect measures are often selected, such as self-report questionnaires, pill 
counts, electronic monitoring and measures calculated from dispensing data. It is 
recommended that at least two non-direct adherence measures are selected due to known 
limitations reported with individual approaches (Sabate, 2003).  
Most adherence measures have been developed with a view towards measuring adherence 
to individual medications. Despite being of clinical importance, measurement of adherence 
to multiple medications (i.e. polypharmacy) has not been extensively studied and there is no 
guidance or consensus as to the best approach (Basak et al. 2014). Pednekar et al. (2016) 
sought to compare measures used to measure adherence to multiple medications. From the 
151 articles that they identified, the main adherence measures employed included self-
report questionnaires (most commonly the Morisky Medication Adherence Scale; MMAS) 
(n=81) and the use of dispensing data to calculate the MPR (n=25) and PDC (n=29).  
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In addition to adherence outcomes, it has been recommended that researchers should 
measure clinical/humanistic outcomes (Nieuwlaat et al. 2014). Examples of clinical outcomes 
commonly measured in adherence research include disease-specific outcomes (e.g. BP, 
blood glucose and cholesterol levels). HRQOL is an example of a humanistic outcome. As 
discussed previously (Chapter 2), generic clinical/humanistic outcome measures are more 
appropriate for the current study which focuses on patients prescribed polypharmacy to 
treat a range of potential medical conditions. Examples of generic outcomes include: HRQOL, 
GP visits, hospitalisations, mortality. Although HRQOL is deemed an important outcome for 
patients, it is not commonly measured when testing the effectiveness of adherence 
interventions (Nieuwlaat et al. 2014). There are a range of tools available to measure HRQOL, 
such as the EuroQol (EQ-5D-5L) and Short-Form (SF-36) surveys (McHorney et al. 1993; Ware 
et al. 1996; Herdman et al. 2011). The latest guidance from the UK body NICE indicates that 
the EQ-5D-5L is the preferred measurement tool for HRQOL (National Institute for Health 
and Care Excellence, 2013). 
This current chapter outlines how the 11 BCTs identified from previous research (Chapter 3) 
were combined into an intervention package. This package was given the acronym: ID-MAP 
(IDentification of Medication Adherence Problems) intervention. The chapter also outlines 
the findings from a small-scale feasibility study that explored the feasibility of delivering the 
ID-MAP intervention in the community pharmacy setting, and the utility of key study 
parameters to inform future evaluations. 
4.2 Aims and objectives 
The overall aim of the study presented in this chapter was to design the ID-MAP intervention 
using the 11 BCTs identified in previous research (Chapter 3) and test the feasibility of 
delivering this intervention in the community pharmacy setting. The specific objectives were 
to: 
 Operationalise each of the previously selected BCTs (n=11) and combine these into an 
intervention package 
 Recruit and train community pharmacists at two sites to deliver the intervention to 
older patients prescribed polypharmacy (five patients per site) 
 Test the usability and acceptability of the intervention from the viewpoint of both CPs 
and older patients 
 Conduct a self-report assessment of fidelity to intervention delivery to help optimise 
the intervention 
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 Investigate the need for refinements to the content and mode of delivery of the 
intervention package 
 Assess the feasibility of selected patient screening and recruitment procedures 
 Assess the feasibility of collecting outcome data on medication adherence and HRQOL 
from older patients 
To address these study objectives two sequential phases were undertaken: Phase 1-
Intervention design, followed by Phase 2- feasibility testing. Both of these phases are 
outlined in the current chapter with the methodology and results from Phase 1 presented 
first (Sections 4.3 and 4.4), followed by the methodology and results from Phase 2 (Sections 
4.5 and 4.6).  
4.3 Phase 1-Intervention Design: Research methodology 
4.3.1 Selection of format for the delivery of each BCT 
The research team identified all potential modes/formats available for delivering the 
selected 11 BCTs as part of a face-to-face intervention delivered by CPs to patients (on a one-
to-one basis) in the community pharmacy setting (e.g. verbal, written). The research team 
agreed on the most suitable mode/format(s) for each BCT using a consensus-based approach. 
Decisions were informed by considering whether each proposed mode/format for delivery 
of BCTs met the following APEASE criteria: ‘Affordability’, ‘Practicability’, ‘Acceptability’ and 
‘Equity’ (see descriptions in Table 4.1 in Section 4.1). The ‘effectiveness/cost-effectiveness’ 
and ‘safety/side effects’ criteria from APEASE were not applied in this project due to the lack 
of strong evidence currently available on the effectiveness and safety of individual BCTs in 
relation to improving medication adherence in older adults. The ‘Equity’ criterion mostly 
relates to population-based interventions (e.g. the reach of media campaigns). However, 
where possible, ‘Equity’ considerations were identified and considered, for example, an 
electronic medication diary delivered via a mobile app may not reach those who lack access 
to a smartphone.  
4.3.2 Tailoring BCTs: selection of ‘Core’ and ‘Optional’ BCTs  
Findings from the previous chapter highlighted that older patients’ reasons for non-
adherence (to polypharmacy) were often individual and it would therefore be unnecessary 
and inappropriate to deliver all 11 BCTs to each patient. Hence the research team recognised 
the need for tailoring BCT delivery to each individual patients’ needs. As there is currently no 
guidance on how to undertake this process, three members of the research team used a 
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group consensus approach to select BCTs that could be potentially useful for all patients 
(classified as ‘Core’ BCTs e.g. ‘Self-monitoring of the behaviour’) and BCTs that could be 
delivered based on an assessment of individual patients’ needs (classified as ‘Optional’ BCTs 
e.g. ‘Prompts and cues’ for patients who reported forgetfulness). To be considered a ‘Core’ 
BCT, the BCT had to be potentially relevant to all patients irrespective of their underlying 
reasons for non-adherence (e.g. intentional and/or unintentional reasons). BCTs that were 
not considered to be relevant for all patients were classified as ‘Optional’ BCTs and delivered 
based on patients’ needs. Decisions about the potential relevance of BCTs to all patients or 
only some patients were informed by findings from the qualitative focus groups with older 
patients (as outlined in Chapter 3). For example, a patient who reported non-adherence due 
to forgetfulness (unintentional non-adherence) would likely require different types of BCTs 
in comparison with a patient who reported non-adherence due to misinformed beliefs about 
medication side effects (intentional non-adherence).  
4.3.3 Number and structure of intervention appointments 
Following classification of BCTs as ‘Core’ or ‘Optional’, the next stage was to combine these 
into an intervention package for delivery in the community pharmacy setting. It was 
recognised that it would not be possible to deliver all of the required BCTs at one face-to-
face appointment in this setting. For example, it would not be possible to deliver all goal-
based BCTs at one appointment (e.g. the ‘Core’ BCT ‘Review of behaviour goal’ could only be 
delivered after a period of time from delivering the BCT ‘Goal setting-behaviour’). The 
number of appointments was therefore decided based on: the minimum anticipated number 
of appointments required to deliver BCTs included in the intervention (minimum of 2), 
knowledge of the proposed setting and research team members’ experience of developing 
similar interventions.  
The structure of appointments, including the time period between appointments, was also 
determined, based on knowledge of the proposed setting and research team members’ 
experience of developing similar interventions and working in this environment. For 
example, it was estimated that a maximum of 1-2 weeks would be sufficient to allow for any 
communication between CPs and GPs prior to delivering BCTs. It was deemed likely that CPs 
would be unfamiliar with the terms ‘behaviour change technique’ or ‘BCT’. Consequently, to 
avoid confusion the 11 BCTs were grouped into four categories; these categories were 
termed ‘adherence solution categories’ (see Section 4.4.3 for further details of categories). 
This also helped to structure the delivery of the intervention. 
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4.3.4 Intervention materials 
To support the delivery of BCTs, a range of intervention materials were developed. This 
included: an intervention record to record notes on the delivery of BCTs (adherence 
solutions), an adherence assessment tool to assist tailoring of ‘Optional’ BCTs (adherence 
solutions), supporting materials (e.g. leaflets to provide to patients), a paper-based 
intervention manual and a training package. 
All intervention materials were developed based on: findings from the systematic review 
(Chapter 2) and other relevant literature, findings from the qualitative focus groups 
conducted with older patients (Chapter 3), research team members’ experience of 
developing interventions for the target audience and knowledge of the selected setting. All 
intervention materials were reviewed extensively within the research team and piloted with 
three pharmacists (two of which were practising in the community setting at the time of the 
study) from within the Primary Care Research Group (QUB).  
The training package was developed based on relevant literature and research team 
members’ previous experience of providing similar intervention training for HCPs. The 
training consisted of a didactic presentation using Microsoft PowerPoint. To start the training 
session the following information was covered in the presentation: background information 
on the problem of non-adherence in older patients, the different types of non-adherence 
(e.g. intentional, unintentional) including examples, potential consequences of non-
adherence, importance of the intervention and a summary of findings from the patient focus 
groups including illustrative quotes. Part of the training session focused on feasibility study 
procedures, such as screening and recruitment of patients and data collection (see Section 
4.5). The remainder of the training session focused on delivery of the intervention and 
outlined how to deliver this in the context of the community pharmacy setting. This focussed 
on three main aspects: (1) How to identify adherence problems in older adults prescribed 
polypharmacy; (2) How to deliver tailored adherence solutions; (2) How to review adherence 
solutions. Step-by-step information was provided for each of these aspects and where 
possible, pictures of intervention materials were used to engage CPs. All of the information 
provided in the training package was covered in the paper-based intervention manual.  CPs 
were encouraged to ask questions throughout the presentation to clarify and discuss any 
potential queries. The training session was piloted with the three pharmacists mentioned 
previously and estimated to take approximately 1.5 hours to deliver. Example patient 
scenarios were also developed by the researcher (DP) and reviewed among the research 
team. These examples were based on similar scenarios discussed by older patients who 
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participated in the patient focus groups (Chapter 3). The purpose of these examples was to 
illustrate the processes involved in delivering the intervention. 
4.4 Phase 1-Intervention Design: Results 
4.4.1 Selection of format for the delivery of each BCT 
Based on the definition of each BCT provided in BCTTv1 and application of the subset of 
APEASE criteria (‘Affordability’, ‘Practicability’, ‘Acceptability’, and ‘Equity’), an agreement on 
the final format for delivering each of the 11 BCTs was reached. The findings from this process 
are summarised in Table 4.2. 
 
  
  Chapter 4 
103 
 
Table 4.2: Selected mode/format(s) for the delivery of each behaviour change technique (BCT) 
(including reasons for selection) 
BCT Definition from BCT 
Taxonomy Version 1 




Selected mode/format(s) for 




‘Provide information (e.g. 
written, verbal, visual) about 
health consequences of 
performing the behaviour’ 
 
Option 1: Verbal 
information provided 
by the pharmacist  
Option 2: Printed 
written information 
provided by the 
pharmacist 
Options 1 and 2 were both 
selected as these were 
considered practical to deliver 
in a time-restricted 
environment and also likely to 
be acceptable to patients. 
Generic written information 
could be pre-prepared (e.g. 
leaflets about importance of 
taking medications as 
prescribed). Both options were 
identified as low-cost. Selection 
of both options would also help 




‘Monitor and provide 
information or evaluative 
feedback on performance of 
the behaviour (e.g. form, 
frequency, duration, 
intensity)’ 
Option 1: Verbal 
information provided 
by pharmacist 





Option 1 was selected as this 
was deemed most practical to 
deliver in a time-restricted 
environment and likely to be 
acceptable to 
providers/patients. It was 
identified as a low-cost format 
of delivery. Option 2 was not 
selected as it would be time-
consuming to prepare written 
patient-specific information 
during the appointments. The 
selected option would also 




‘Introduce or define 
environmental or social 
stimulus with the purpose of 
prompting or cueing the 
behaviour. The prompt or cue 
would normally occur at the 




prompts already in 
place (e.g. time, 
location)  
Option 2: Reminder 
stickers 





Options 1 and 2 were selected 
as these were deemed low-cost, 
practical to provide/recommend 
in the proposed setting and 
likely to be acceptable to 
participants. Option 3 was not 
selected due to the higher cost 
associated with providing such 
devices to patients and 
concerns over equity for, and 




‘Establish a method for the 
person to monitor and record 
their behaviour(s) as part of a 




Option 2 Electronic 
record (e.g. a mobile 
app) 
 
Option 1 was selected as it was 
low-cost, practical to 
provide/recommend and likely 
to be accepted by older 
patients.  
Option 2 was not selected due 
to the high cost (app design, 
provision of smartphones), user-
training required, and concerns 
over equity.  
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Table 4.2 (cont’d): Selected mode/format(s) for the delivery of each behaviour change technique 
(BCT) (including reasons for selection) 
BCT Definition from BCT  
Taxonomy Version 1  




Selected mode/format(s) for 





‘Change or advise to change 
the physical environment in 
order to facilitate 
performance or create 
barriers to the unwanted 
behaviours (other than 
prompts/cues, rewards and 
punishment)’ 
Option 1: Verbal 
instructions outlining 
change to be made by 
patient/pharmacist/ 
GP 
Option 2: Written 
instructions outlining 
change to be made 
Options 1 and 2 were selected 
to deliver each of these BCTs as 
both may be required, 
depending on the individual’s 
circumstances. Both options 
were deemed to be low-cost 
(i.e. affordable), likely to be 
accepted by participants and 
practical to deliver in the 
community pharmacy setting. 
Selection of both options 
would also help avoid equity 
issues (e.g. low literacy levels). 
Social support 
(unspecified) 
‘Advise on, arrange or provide 
social support (e.g. from 
friends, relatives, colleagues, 
’buddies’ or staff) or non-
contingent praise or reward 
for performance of the 
behaviour. It includes 
encouragement and 
counselling but only when it is 
directed at the behaviour’ 
Option 1: Verbal 
instructions detailing 
social support plan  
Option 2: Written 
instructions detailing 
social support plan 
Goal setting-
behaviour 
‘Set or agree a goal defined in 
terms of the behaviour to be 
achieved’ 
 
Option 1: Verbal 
discussion/agreement 
of behavioural goal(s) 
Option 2: Written 
record of agreed 
behavioural goal(s)  
Options 1 and 2 were selected 
to deliver all of these BCTs as a 
written record would aid their 
delivery. Both options were 
deemed to be low-cost, 
practical to deliver in the 
community setting and likely to 
be accepted by providers and 
recipients. Selection of both 
options would also help avoid 




‘Review behaviour goal(s) 
jointly with the person and 
consider modifying goal(s) or 
behaviour change strategy in 
light of achievement. This may 
lead to re-setting the same 
goal, a small change in that 
goal or setting a new goal 
instead of (or in addition to) 
the first, or no change.’ 
Option 1: Verbal 
discussion/review of 
behavioural goal(s) 
Option 2: Written 
record of review of 





‘Set or agree a goal defined in 
terms of a positive outcome 
of wanted behaviour’ 
 
Option 1: Verbal 
discussion/agreement 
of outcome goal(s) 
Option 2: Written 




‘Review outcome goal(s) 
jointly with the person and 
consider modifying goal(s) in 
light of achievement. This may 
lead to re-setting the same 
goal, a small change in that 
goal or setting a new goal 
instead of, on in addition to 
the first’ 
Option 1: Verbal 
discussion and review 
of the outcome 
goal(s) 
Option 2: Written 
record of review of 
outcome goal(s) 
Action planning ‘Prompt detailed planning of 
performance of the behaviour 
(must include at least one of 
context, frequency, duration 
and intensity). Context may be 
environmental (physical or 
social) or internal (physical, 
emotional or cognitive’ 
Option 1: Verbal 
discussion and 
agreement of action 
plan 
Option 2: Written 
record of action plan 
provided to patient 
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4.4.2. Tailoring BCTs: selection of ‘Core’ and ‘Optional’ BCTs  
Five out of the 11 BCTs were selected as ‘Core’ BCTs as these were deemed relevant for all 
patients, irrespective of their underlying reason for non-adherence (see Table 4.3). The 
remaining six BCTs were classified as ‘Optional’ as they would not be relevant for all patients 
i.e. they could be delivered if required based on an assessment of each patient’s underlying 
reasons for non-adherence (e.g. intentional non-adherence or unintentional forgetfulness) 
(See Table 4.4). 
Table 4.3: ‘Core’ BCTs that were recommended for delivery to all patients 
 
Table 4.4: ‘Optional’ BCTs that were recommended for delivery only when deemed necessary by CPs 
based on an adherence assessment of underlying reasons for non-adherence 
‘Core’ BCT Brief description  
Self-monitoring of 
the behaviour 
A paper-based medication diary could be used by all patients to monitor 
and record their medication-taking behaviour.  
Goal-setting 
(behaviour) 
A goal that focuses on the behaviour to be achieved could be jointly set 




The ‘behaviour goal’ could be jointly reviewed by each patient and 
pharmacist.   
Action planning A detailed plan of how to perform the behaviour could be developed (e.g. 
including time and location). 
Feedback on 
behaviour 
Feedback on performance could be given to each patient based on a review 
of their medication diary. 
‘Optional’ BCT Brief description 
Health 
consequences 
This BCT would be most beneficial for patients who are intentionally non-
adherent. Information on the health consequences of adherence/non-
adherence could be given to these patients.  
Social support 
(unspecified) 
Not all patients require additional social support and so this BCT could be 
delivered based on each patient’s needs. A verbal (and/or written) plan for 
obtaining support from relevant individuals (e.g. family, HCPs) could be 
developed.  
Prompts and cues This BCT would be most beneficial for patients who are forgetful. An 
environmental or social stimulus that acts as a prompt or cue to the 




This BCT would be most beneficial for patients who are non-adherent for 
practical reasons (e.g. related to medication packaging). A change in the 
physical environment could be recommended in these circumstances.  
Goal setting 
(outcome) 
These BCTs would be most beneficial for patients with low motivation. A 
goal that focuses on the positive outcome of performing the behaviour (e.g. 
reduction in symptoms) could be set jointly between the patient and 
pharmacist to try and improve motivation. 
Review of 
behaviour goal 
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4.4.3 Number and structure of intervention appointments 
The intervention was separated into three face-to-face appointments that would be 
delivered in the community pharmacy by CPs. Most services currently offered in the 
community setting in NI are delivered over one or two appointments, such as the Medicine 
Use Review (MUR) service (Business Services Organisation, 2014) and the Managing Your 
Medicines (MYM) service (Business Services Organisation, 2010). These services are 
discussed in more detail in Chapter 5. A two appointment model was initially considered by 
the research team, because a number of the BCTs could only be delivered after a period of 
implementing another BCT. For example, the core BCT ‘Feedback on behaviour’ could only 
be delivered to all patients following a period of ‘Self-monitoring of the behaviour’ using a 
medication diary. However, following further discussions among the research team, an 
additional appointment was added to allow time to prepare any resources required to deliver 
BCTs (e.g. prepare the medication diary) and also time for communication between the CP 
and the patients’ GP. Further details of the content of each of the three appointments are 
provided below.  
The purpose of Appointment 1 was to identify the underlying nature of each patient’s 
adherence problems using an adherence assessment tool (see Section 4.4.4 for further 
details). BCTs would then be delivered over Appointments 2 and 3 based on findings from 
the initial adherence assessment. Table 4.5 outlines the BCTs that were proposed for delivery 
at each of the three appointments. 




‘Core’ BCTs delivered during 
appointment to all patients 
‘Optional’ BCTs delivered during 
appointment if deemed necessary 
based on adherence assessment 
Appointment 1 Not applicable: assessment of underlying reasons for non-adherence using 
adherence assessment tool (ID-MAP Tool; see Section 4.4.4 for details) 
Appointment 2  Self-monitoring of the behaviour  
 Goal-setting (behaviour) 
 Action planning 
 
 Restructuring the physical environment  
 Prompt/cues  
 Social support (unspecified) 
 Health consequences  
 Goal setting (outcome) 
Appointment 3  Feedback on behaviour  
 Review of behaviour goal  
 Review of outcome goal 
 
It was proposed that the three appointments would take place over a five to eight week 
period. CPs were advised to schedule Appointment 2 one to two weeks after Appointment 1 
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to allow sufficient time to prepare any necessary resources and contact the patients GP if 
necessary. A final review appointment (Appointment 3) was then recommended after a 
period of at least four weeks to allow the patient time to implement any suggested changes 
(i.e. BCTs). At Appointment 3, CPs were asked to review suggested changes provided at the 
previous appointment (e.g. the medication diary). Figure 4.1 illustrates the recommended 





Figure 4.1: Timeline of appointments proposed for the ID-MAP intervention  
As discussed in Section 4.3.3, to provide structure to the intervention and avoid the use of 
the term ‘BCT’, the 11 BCTs were separated into four adherence solution categories (A, B, C, 
D). The BCTs assigned to each category are outlined below in Figure 4.2. Solutions (and BCTs) 










Figure 4.2: Structuring of ‘Core’ and ‘Optional’ BCTs into adherence solution categories 
1The BCT ‘Health consequences’ was placed into two solution categories 
Solution A
Self-monitoring 









































Findings from the previous study (Chapter 3) provided important contextual information that 
informed exactly how each of the selected BCTs was operationalised as part of the 
intervention package. For example, a number of patients reported receiving medication lists 
from secondary care which they found useful. Due to the large numbers of medications 
commonly prescribed to this group of patients, inclusion of a similar list as part of the 
medication diary (BCT ‘Self-monitoring of the behaviour’) was deemed important. Focus 
group participants also indicated places that they stored their medications as reminders 
which they found helpful. This informed the types of reminder strategies (BCT: prompts and 
cues) suggested, for example, placing medications in a visually prominent place such as on 
the kitchen bench. 
4.4.4 Intervention materials  
Intervention record (ID-MAP Booklet) 
An intervention record (Image 4.1) for guiding each intervention appointment and making 
brief notes was developed by the research team (see Appendix 4.1 for full contents). The 












Adherence Assessment Tool (ID-MAP Tool) 
An adherence assessment tool (ID-MAP Tool) was developed by the research team to assist 
CPs in selecting which ‘Optional’ BCTs should be delivered to each patient in addition to 
‘Core’ BCTs. This tool was included in the intervention record (ID-MAP Booklet; see full 
contents in Appendix 4.1) and consisted of seven open style questions to identify the nature 
of adherence problems (i.e. underlying reasons for non-adherence). The questions were 
developed based on the findings from the previous qualitative research (Chapter 3). These 
Image 4.1: Picture of Intervention 
record (ID-MAP Booklet) 
Section 1: Space to record the patient’s medication 
history in advance of Appointment 1 
Section 2: Adherence assessment Tool (ID-MAP Tool; 
see below) for use at Appointment 1 
Section 3: Space to record notes of adherence solutions 
(i.e. BCTs) delivered at Appointment 2 
Section 4: Space to record notes following review of 
adherence solutions (i.e. BCTs) at Appointment 3 
 
Box 4.1: Sections of ID-MAP Booklet 
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questions were designed to aid identification of adherence problems related to the following: 
knowledge of medications (Q1), routine or organisational barriers (Q2), practical barriers 
(Q3), level of social support (Q4), forgetfulness (Q5), intentional non-adherence (Q6) and 
level of motivation (Q7). CPs were advised to tick any relevant problems identified during 
discussions with the patient and then map these to potential adherence solutions. An 







Figure 4.3: Example of a completed question from the adherence assessment tool (ID-MAP Tool) 
Supporting materials 
Other resources that were developed to assist CPs in delivering the BCTs are shown below in 











Image 4.2: Supporting materials for intervention delivery  
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Table 4.6: Materials developed by the research team to assist delivery of BCTs 
BCT Materials developed by research team to assist CPs in 
delivering the BCT(s) 
Self-monitoring of the 
behaviour 
Paper-based medication diary which included space for 
documenting a list of the patients’ regular medications 
(Appendix 4.2). 
Health consequences Leaflets on ‘voicing concerns about your medications’ and 
‘generic medications’ which could be used as discussion aids 
(Appendices 4.3 and 4.4) 
Goal setting-behaviour 
Review of behaviour goal 
Goal setting-outcome 
Review of outcome goal 
Action planning 
Goals and action plan activity sheets for CPs to document the 
patient’s personalised goals and action plans on. These were 
duplicate pages so that the patient could be provided with a 
copy to take home and a copy could be retained by the 
pharmacist (Appendix 4.5) 
Prompts and cues Reminder stickers were developed to act as visual prompts 
(Appendix 4.6).  
Restructuring the physical 
environment 
A GP communication form was developed to allow CPs to 
communicate any recommended changes to the patient’s GP 
(Appendix 4.7).  
Feedback on behaviour 
Social support (unspecified) 
Not applicable: verbal delivery only 
Intervention manual and training package  
An intervention manual (Appendix 4.8) was developed to support intervention delivery. The 
manual included content on how to: identify adherence problems, deliver/recommend 
adherence solutions (BCTs) and review adherence solutions (BCTs). The 26-page manual also 
covered training on study procedures, such as screening and recruitment procedures (see 
Section 4.5). An accompanying training package for CPs (Microsoft PowerPoint presentation 
and example patient scenarios) was also developed as discussed in Section 4.3.4 (Appendix 
4.9). 
4.5 Phase 2-Feasibility study: Research methodology 
4.5.1 Overview of study design 
CPs at two sites were recruited and trained to deliver the ID-MAP intervention to older 
patients who were prescribed polypharmacy (five patients per site). Following participation, 
both CPs and patients provided feedback on the usability and acceptability of the 
intervention during semi-structured qualitative interviews. In addition, supporting materials 
that were completed by CPs during the study period were returned to the research team for 
an assessment of fidelity to the intervention. Self-reported fidelity was also assessed by 
asking CPs (and patients) about the delivery (and receipt) of intervention components during 
the qualitative feedback interviews. Information on screening and recruitment was obtained 
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from CPs and outcome data (on medication adherence and HRQOL) were collected at 
baseline and three months follow-up to evaluate the feasibility of undertaking these key 
study procedures. Ethical approval for the study was granted by the ORECNI (Research Ethics 
Committee reference 16/NI/0028) (Appendix 4.10). 
4.5.2 Recruitment of community pharmacists 
Due to the small sample size required for this study, a convenience sampling approach was 
used to recruit CPs from two community pharmacy sites (a maximum of two CPs per site). A 
sample of CPs who were part of the undergraduate QUB Community Pharmacist Placement 
Network (used for undergraduate placement experience) were contacted with a letter of 
invitation (Appendix 4.11) and a study information sheet (Appendix 4.12). The researcher 
(DP) followed up with a telephone call, seven days after posting the invitation letter to allow 
CPs sufficient time to decide if they would be interested in participating in the study.  
To be eligible to take part, community pharmacy sites needed to have a private consultation 
room/area and printing facilities. A meeting at the community pharmacy site was arranged 
with CPs who expressed interest in taking part in the study. During this meeting, the 
researcher provided an overview of the feasibility study and answered any questions. At this 
stage CPs were provided with written consent forms (Appendix 4.13) and pre-paid return 
envelopes for posting back to the research team. CPs (n=3) from the first two community 
pharmacies who agreed to participate in the study were recruited. CPs who took part (n=3) 
were provided a certificate of participation for their Continuing Professional Development 
record (Appendix 4.14). Each community pharmacy site was provided an honorarium of £200 
as recognition of the time allocated to this study. 
4.5.3 Training of community pharmacists  
Once written informed consent was obtained from participating CPs, a date for face-to-face 
training sessions was arranged at each community pharmacy site. A short training session 
(approximately 1.5 hours) was delivered on-site using a PowerPoint presentation. As 
discussed in Section 4.3.4, the brief training session included an introduction to the research 
study, instructions on study procedures (e.g. screening and recruitment of patients), how to 
deliver the intervention (identify adherence problems, deliver adherence solutions, review 
adherence solutions) and make use of the intervention manual (Appendix 4.8). At this 
training session, CPs were given all of the documentation required to deliver the ID-MAP 
intervention, including supporting materials. CPs were also given an electronic and paper 
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version of the PowerPoint training presentation. As discussed in Section 4.3.4, two patient 
scenarios, of varying complexity (Appendix 4.9), were provided to CPs as illustrative 
examples. CPs were advised to contact the research team with any further questions about 
any aspect of the study procedures, delivery of the intervention or anything discussed during 
the training session.  
4.5.4 Screening patients for eligibility 
Upon successful completion of training, each participating CP was instructed to screen 
patients (who attended the community pharmacy in which they worked) using the inclusion 
and exclusion criteria outlined in Table 4.7.  
Table 4.7: Patient inclusion and exclusion criteria for feasibility testing of the ID-MAP intervention 
Inclusion criteria Exclusion criteria 
 65 years or older 
 Prescribed > four regular medications 
(polypharmacy)1  
 At least six months’ dispensing data available on the 
pharmacy-held patient medication record (PMR), 
from the time of screening  
 Only attended study site pharmacy for regular 
medications  
 Lived in their own home  
 Had an identified adherence problem as detected by 
eligibility screening questionnaire (MMAS-8) (see 
below) 
 Prescribed medications for the 
treatment/management of dementia2 
 Unable to provide written informed 
consent 
 High adherence identified from the 
eligibility screening questionnaire 
(MMAS-8) (see below) 
 Could not complete the eligibility 
screening questionnaire (MMAS-8) (see 
below) 
 
1Excluding medications bought over-the-counter and short-term medications (prescribed for less than eight weeks 
e.g. antibiotics); 2Acetyl cholinesterase inhibitors (donepezil, galantamine or rivastigmine) or an N-methyl-D-
aspartate (NMDA) receptor antagonist (memantine) 
CPs documented the patient’s eligibility status on the Eligibility Screening Form provided 
(Appendix 4.15). Patients who were prescribed medications for the treatment of dementia 
were excluded from this study, as the intervention was not designed to account for the 
additional challenges faced by these patients. It was, however, recognised that dementia 
could be undiagnosed in this patient population group and CPs could have identified the need 
for further testing. A Standard Operating Procedure was therefore developed to account for 
such situations (Appendix 4.16) and CPs were provided information on this during training. 
In addition, a standard operating procedure for handling the situation where a participant 
became upset or distressed during the study was developed and covered during the CP 
training session (Appendix 4.17) 
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Patients were asked to provide written informed consent (Consent Form 1; Appendix 4.18) 
before completing the eligibility screening questionnaire (MMAS-8). The MMAS-8 (Appendix 
4.19) was used as the eligibility screening questionnaire as it is a validated self-report 
measure of the patient’s medication adherence (Morisky et al. 2008; Krousel-Wood et al. 
2009; Morisky and Dimatteo, 2011). Permission for use of the MMAS-8 was granted by the 
developer (see signed licence contract in Appendix 4.20). This questionnaire contained seven 
‘yes or no’ response questions and one question with five possible response options, where 
the patient was asked to select only one option. Based on the scoring system (provided by 
the developer) the patient was assigned a level of adherence: low (scored <6 out of 8), 
medium (scored 6 to 7.75 out of 8) or high (scored 8 out of 8). Patients with low and medium 
adherence were invited to take part in the study as these patients were deemed most likely 
to benefit from the intervention. Although patients with high adherence were not deemed 
eligible for this study, they were invited to ask their CP any questions they had about their 
medications at any time. Due to the tendency for patients to over-report adherence, this cut-
off point of perfect adherence (score of 8) versus imperfect adherence (scores of less than 8) 
was used to dichotomise those who were adherent versus those who were non-adherent 
and select who to include in the intervention (Simoni et al. 2006; Stirratt et al. 2015).  
4.5.5 Recruitment of patients  
Following the initial screening process, CPs were asked to recruit patients into the study who 
met the eligibility criteria (see Table 4.7 in Section 4.5.4) (five patients per site). CPs were 
advised to briefly explain what the research study would involve and provide each patient 
with a study information sheet (Appendix 4.21) and study consent form (Consent Form 2) to 
read at home (Appendix 4.22). CPs were then advised to telephone patients one week later 
to allow the patient time to consider taking part. If a patient agreed to participate, the CP 
was required to document the date of verbal consent on the recruitment/retention form 
(Appendix 4.23). A date for Appointment 1 could then be scheduled at a time that was 
convenient for both the patient and the pharmacist. CPs were instructed to obtain written 
informed consent at the start of Appointment 1 (Consent Form 2; Appendix 4.22). CPs were 
advised to contact local GP practices to inform them that patients registered at their practice 
would be participating in the research study. A letter from the research team was prepared 
for pharmacists to provide to GPs if they wanted further information (Appendix 4.24). This 
briefly outlined the nature of the study and indicated that the CP may be in contact if any 
issues arose during the study that they deemed important to communicate. 
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4.5.6 Intervention delivery 
As outlined in Section 4.4.3, it was proposed that the intervention should be delivered over 
three (30-40 minute) appointments over a period of five to seven weeks.  
Appointment 1  
In advance of Appointment 1, CPs were advised to obtain an up-to-date list of medications 
prescribed for the patient using the PMR. This list was to be documented in the intervention 
record (ID-MAP Booklet; one per patient). If necessary, CPs were advised to contact the 
patient’s GP to confirm the definitive list of prescribed medications (e.g. where a potential 
prescribing issue was identified). When the patient arrived at the pharmacy, CPs were 
instructed to obtain consent for participating in the full research study (Consent Form 2; 
Appendix 4.22). Patients were then asked to complete a paper version of the EQ-5D-5L to 
measure their HRQOL (baseline) (Appendix 4.25). Permission for use of the EQ-5D-5L in the 
current study was granted by the EuroQol office (Appendix 4.26). The purpose of this was to 
assess the feasibility of collecting this type of data (see Section 4.5.7). The pharmacist then 
proceeded with the intervention and completed relevant sections of the ID-MAP Booklet. 
This included assessing the nature of the patient’s adherence problems using the ID-MAP 
adherence assessment Tool. CPs were then advised to conclude the appointment and 
schedule a second appointment to take place in 1-2 weeks. If any adherence problems were 
identified that required immediate attention, CPs were asked to use their professional 
judgement and contact the patient’s GP initially via telephone and then using the ‘GP 
communication form’ if required (Appendix 4.7). CPs were advised to inform the research 
team of such incidents as soon as possible.   
Appointment 2 
Identified adherence problems could then be mapped across to recommended adherence 
solutions using the ID-MAP Tool in advance of Appointment 2. As discussed previously, the 
BCTs were separated into four adherence solution categories (A, B, C and D) (see Figure 4.2 
in Section 4.4.3). CPs were advised to deliver Solution A and Solution D to all patients as these 
categories contained ‘Core’ BCTs, suitable for delivery to all patients, irrespective of their 
underlying reasons for non-adherence. Solutions B and C were optional and could be 
delivered if deemed necessary based on the adherence assessment conducted at 
Appointment 1; these solutions contained only ‘Optional’ BCTs that would not be relevant 
for all patients. Table 4.8 provides examples of BCTs delivered during Appointment 2. ‘Core’ 
BCTs are highlighted in bold text.  
  Chapter 4 
115 
 
Key:              = Solution A           = Solution B = Solution C = Solution D 
Table 4.8: Examples of adherence solutions (BCTs) delivered at Appointment 2 
Solution 
Category 
BCT (‘Core’ or 
‘Optional’) 
Example of delivery 
A Self-monitoring of 
the behaviour 
(‘Core’) 
All patients should have been provided a medication diary 
to record daily medication use. This included a list of their 
regular prescribed medications (Appendix 4.2). 
Health consequences 
(‘Optional’) 
A patient who did not know why they were taking their BP 
medicine would have been educated on the reason why they 
needed to take it.  
B Social support 
(unspecified) 
(‘Optional’) 
A patient’s spouse could have become involved in helping the 
patient order and organise their medications. 
Prompts and cues 
(‘Optional’) 
A patient who routinely forgot to take their bedtime 
medications could have been offered a reminder sticker to 
place on their bathroom mirror or advised to place their 
medication in a visually prominent place (e.g. on their 




A patient who had difficulties opening the medication 
packaging could have been provided with more appropriate 
packaging (e.g. non-child resistant bottle caps). 
C Health consequences 
(‘Optional’) 
A patient who reported not taking their medication for the 
treatment of hypertension when on holiday would have been 
informed of the consequences of uncontrolled BP. Patient 
leaflets were designed to facilitate discussions around 




A patient who routinely forgot to use their preventer 
asthma inhaler could have been prompted to set a 
medicine-related goal, such as ‘Remember to use my 
preventer inhaler every day’ (Appendix 4.5).  
Action planning 
(‘Core’) 
A patient who reported forgetting to take their cholesterol 
medication at night could have developed the following 
action plan: ‘IF I see my medication reminder sticker on the 
bathroom mirror, THEN I will take my cholesterol 




A patient who reported having low motivation for taking 
medications as prescribed could have been prompted to set a 
goal that helped them to focus on the positive outcomes of 
correct medication use, such as a goal ‘to stay out of hospital’ 
(Appendix 4.5). 
 
CPs were required to document any actions taken on the patient’s intervention record (ID-
MAP Booklet) and a final review appointment was arranged (at least 4 weeks later). Patients 
were advised to contact their CP if they experienced any difficulties with the 
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Key:      = Solution A                  = Solution D 
 
Appointment 3 
During Appointment 3, any adherence solutions that were used by the patient during the 
interim 4-5 week period (e.g. medication diary, behaviour goal) were to be reviewed by the 
pharmacist. Table 4.9 provides a summary of the BCTs delivered at Appointment 3. ‘Core’ 
BCTs are highlighted in bold text. 




CPs were asked to document brief notes from their discussions (and any further actions taken 
if required) in the ID-MAP Booklet. Patients were informed that this was the last official 
appointment of the study but they could seek advice in relation to their medications at any 
time in the future. Where completed medication diaries were returned, CPs were advised to 
retain these for the research team to examine.  
4.5.7 Data collection and analysis  
The primary outcomes that were of interest in this feasibility study were the usability and 
acceptability of the ID-MAP intervention from the view point of those delivering it (CPs) and 
those receiving it (patients). This was deemed essential to ensure the intervention would be 
practical for, and accepted by, the end-users, before moving onto larger evaluations. 
Secondary outcomes included addressing self-reported fidelity to the intervention, as well as 
testing the feasibility of key study parameters (e.g. screening procedures) that will be 





BCT (‘Core’ or 
‘Optional’) 
Example of delivery 
A Feedback on 
behaviour 
(‘Core’) 
A patient who routinely missed doses of medication on 
weekends could be given the following feedback: ‘I see from 
your diary that you missed most of your doses at weekends’. 
D Review of 
behaviour goal 
(‘Core’) 
Based on a review of the diary and discussions with the 
patient, the pharmacist should have judged if the patient met 




The pharmacist was advised to review the outcome goal set at 
Appointment 2 (e.g. ‘to stay out of hospital’) and check if this 
still motivated the patient to take medicines as prescribed. 
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Primary outcome: Usability/acceptability of the intervention from the viewpoint of 
community pharmacists 
CPs were interviewed following delivery of the intervention to their recruited patients using 
a semi-structured interview guide (Appendix 4.27). CPs were asked about their views on the 
following: training and support provided by the research team; the intervention manual and 
supporting materials; the structure and number of appointments; adherence solutions and 
general views on the intervention. The interviews were completed at the community 
pharmacy site (face-to-face), digitally recorded with the pharmacist’s consent and 
transcribed verbatim. All identifiers were removed from the transcripts and each pharmacist 
was assigned a unique identifier (e.g. S01CP01 to indicate Site 01, Community Pharmacist 
01). Data analysis consisted of reviewing transcripts for emerging themes and generating a 
descriptive overview of the feedback received.  
Primary outcome: Usability/acceptability of the intervention from the viewpoint of patients 
Patients were interviewed shortly after receiving the intervention (i.e. post-Appointment 3), 
using a semi-structured interview topic guide (Appendix 4.28). Patients were asked about 
their views on the following: structure and number of appointments; questions asked by the 
pharmacist during the adherence assessment; adherence solutions and materials provided 
by the pharmacist; support provided by the pharmacist and their overall experience of the 
intervention. The interviews were conducted via telephone, digitally recorded with the 
patient’s consent and transcribed verbatim. All patient identifiers were removed and each 
patient was assigned a unique identifier (e.g. S01PT01 to indicate Site 01, Patient 01). Data 
analysis consisted of reviewing transcripts for emerging themes and generating a descriptive 
overview of the feedback received.  
Secondary outcome: Feasibility of patient screening and recruitment procedures 
CPs were asked to record information for all patients who were approached during the study, 
including details of their eligibility status, recruitment status and reasons for drop-out (if 
appropriate). At the end of the study, CPs provided the research team with this data by 
completing a ‘Summary of patients’ form (Appendix 4.29). These data were used to calculate 
a refusal rate (i.e. number of patients who refused on initial approach out of the total number 
approached), eligibility rate (i.e. number of eligible patients out of the number of patients 
fully screened), recruitment rate (i.e. number of patients recruited out of the number of 
eligible patients) and retention rate (i.e. number of patients who completed the study out of 
the number who were recruited). Eligibility screening and recruitment/retention forms 
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(Appendices 4.15 and 4.23) were also examined for their completeness to help identify any 
problems associated with these procedures. CPs and patients provided feedback about 
screening and recruitment procedures in the qualitative interviews. This information was 
used to assess the feasibility of these procedures and identify where changes needed to 
made.  
Secondary outcome: Fidelity of intervention delivery 
The aim of the fidelity assessment at this stage in the research process was solely to help 
identify any obvious teething issues with implementing the intervention. Consequently, self-
report methods (i.e. checklists completed by intervention providers, notes made in 
intervention records and interviews with participants) were deemed sufficient. Although 
objective measures of fidelity (e.g. audio or video recordings) could have provided more in-
depth information, these were not selected at this early stage of testing as it would have 
required additional resources (audio recorders for each site) and time (e.g. transcription of 
each intervention appointment) and would have been an unnecessary burden on research 
participants.  
All intervention materials were returned to the research team upon completion of the study. 
This included intervention records (ID-MAP Booklets) that were completed for each patient. 
These booklets contained written notes on what was delivered to patients and checklists at 
the end of each appointment to indicate that adherence solutions (i.e. BCTs) had been 
delivered. All returned booklets and supporting materials were examined for completeness 
and any omissions or reporting errors were noted.  
CPs and patients were asked about the delivery and receipt of adherence solutions (i.e. BCTs) 
during the qualitative interviews (see primary outcomes above). This self-reported 
information was triangulated with information obtained from the review of completed 
intervention materials. The triangulated information was used to assess whether BCTs were 
delivered with high fidelity, low fidelity or unclear fidelity. A BCT was deemed to have been 
delivered with high fidelity if there was sufficient evidence available from written 
intervention materials and/or qualitative feedback from patients and CPs to support this. 
Where evidence (from the above sources) indicated that the BCT was not delivered as 
intended (i.e. as outlined in the intervention manual), this was deemed to have been 
delivered with low fidelity. If insufficient evidence was available (from the above resources) 
to make a judgement, then the level of fidelity was deemed to be unclear.   
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Secondary outcome: Feasibility of measuring adherence to polypharmacy using a validated 
self-report measure 
Patients were asked to complete the MMAS-8 as part of the eligibility screening process (as 
discussed in Section 4.4.5) in-person in the community pharmacy; this also acted as a baseline 
measure of self-reported medication adherence. For the three month follow-up, the MMAS-
8 was mailed to patients along with the EQ-5D-5L questionnaire (see later), a covering letter 
and a pre-paid return envelope. The feasibility of using the MMAS-8, to measure self-
reported adherence to polypharmacy in older adults was assessed as part of this study. 
Secondary outcome: Feasibility of calculating objective measures of adherence to 
polypharmacy from dispensing data 
As discussed previously, self-reported measures of medication adherence have known 
limitations and should therefore be supplemented with more objective measures of 
adherence (Horne et al. 2005). PDC and MPR measures (which can be calculated using 
dispensing data) were identified as the two most commonly used objective measures of 
adherence to multiple medications (Pednekar et al. 2016). As it was unclear in the literature 
which established method was most suitable, both measures were calculated and compared 
(Andrade et al. 2006; Choudry et al 2009; Murphy et al. 2012; Arnet et al. 2014).  
Using the pharmacy dispensing software, CPs generated printouts of all medications 
dispensed in the six months prior to intervention delivery (i.e. pre-Appointment 1) and three 
months following intervention delivery (i.e. post-Appointment 3) for each patient who 
completed the study. This included the following information: medication name, strength 
and form; directions for use; quantity of medication supplied and date of dispensing. Where 
possible, this information was used to calculate a pre- and post-intervention MPR and PDC 
for each patient using the methods described in Boxes 4.2 and 4.3 respectively. 
  
  Chapter 4 
120 
 







1Due to the short time frames in this study, a regular medication was defined as a medication that is 
commonly used in the treatment of LTCs and was prescribed (i.e. dispensed) for 8 weeks (56 days) or longer 
 








1A day was only considered covered if a supply of all medications to treat long-term conditions was 
available on that day; 2Due to the short time frames in this study, a regular medication was defined as a 
medication that is commonly used in the treatment of LTCs and was prescribed (i.e. dispensed) for 8 weeks 





The MPR was calculated using the following five steps: 
Step 1: The measurement period was defined (i.e. number of days between date of first 
and last refills in the six months pre- or three months post-intervention). 
Step 2: The number of days’ supply obtained during the measurement period (minus the 
days’ supply of the last refill in period) was calculated for a given medication.  
Step 3: The number of days’ supply of a given medication in the measurement period 
(Step 2) was divided by the total number of days in the measurement period 
(Step 1). This was multiplied by 100 to obtain a percentage MPR for a given 
medication (this value was capped at 100%). See the equation below.  
MPR (%) = Total number of days’ supply obtained during the measurement period X100 
       Number of days in measurement period 
Step 4: Steps 1-3 were repeated for each regular1 medication the patient was prescribed 
and an average MPR will be calculated.  
Step 5: Patients with an av. MPR of >80% were considered adherent to polypharmacy. 
The PDC was calculated using the following four steps: 
Step 1: The measurement period was defined (i.e. number of days between date of first 
and last refills in the six months pre- or three months post-intervention). 
Step 2: The number of days that the patient was ‘covered’1 by all regular medications in the 
measurement period was calculated. If the patient refilled  early and there was a 
period of overlap, then the prescription start date for the early refill was adjusted 
to the day after the previous refill had ended. 
Step 3: The number of days covered by all regular medications2 in the measurement period 
(Step 2) was divided by the total number of days in the measurement period (Step 
1). This was multiplied by 100 to obtain a percentage PDC for all medications. See 
the equation below. 
PDC (%) = Number of days ‘covered’ by all medications in the measurement period   X100 
     Total number of days in the measurement period   
Step 4: Patients with a PDC of >80% were considered adherent to polypharmacy. 
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The following medications were excluded from calculations: short-term medications 
(prescribed for less than 8 weeks during the six months pre-intervention and/or 3 months 
post-intervention such as antibiotic tablets, antibiotic creams), when-required medications 
(e.g. short-acting beta-agonist reliever inhalers), liquid medications and medications with 
variable dosing instructions (e.g. take one or two tablets daily). MPR and PDC calculations 
required a minimum of two refills in the study period to be calculated (i.e. in the six months 
pre-intervention or three months post-intervention). The feasibility of collecting baseline and 
three month follow-up pharmacy dispensing data, and the subsequent use of these data to 
calculate pre- and post-intervention MPR and PDC for each patient was assessed as part of 
this study. 
Secondary outcome: Feasibility of measuring health-related quality of life using a validated 
measure  
HRQOL was measured in-person at baseline using the EQ-5D-5L (beginning of Appointment 
1) and at three months follow-up (i.e. post-Appointment 3) using a postal questionnaire 
(along with the MMAS-8 questionnaire, a cover letter and freepost return envelope). The EQ-
5D-5L (Appendix 4.25) was selected because it is an internationally recognised generic self-
report measure of HRQOL that has been validated for use in the UK and Ireland across a wide 
range of patient populations (e.g. CVD, arthritis, diabetes). It has also been recommended as 
the tool of choice by NICE (National Institute for Health and Care Excellence, 2013). The 
updated EQ-5D-5L has retained the dimensions of the earlier version (EQ-5D-3L) but has 
improved sensitivity and greater reliability (Janssen et al. 2013). The questionnaire contained 
five statements about mobility, self-care, usual activities, pain/discomfort and 
anxiety/depression. Patients were instructed to select one of five options for each statement. 
These descriptive responses were then converted into an index value (van Hout et al. 2012). 
A Visual Analogue Scale (VAS) was also included in which the patient was asked to rate how 
good their own health state was on that day, on a scale of 0 to 100. The feasibility of using 
the EQ-5D-5L questionnaire to measure HRQOL, in older patients prescribed polypharmacy, 
was assessed as part of this study.  
4.6 Phase 2-Feasibility study: Results 
CPs at two community pharmacy sites were recruited into the study. Three CPs were involved 
in the study in total (one pharmacist at Site 01 and two CPs at Site 02). Both sites had several 
CPs (two or more) on duty during the working week, except on Saturdays. Characteristics of 
CP participants are presented below in Table 4.10  
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Table 4.10: Characteristics of community pharmacist participants 










S01CP01 3 years Support 
pharmacist 
2 years Independently 
owned 
S02CP01 21 years  Pharmacy 
manager 
4 years Small/medium 
chain  
(2-9 stores) 
S02CP02 20 years Support 
pharmacist 




Each pharmacy site recruited five patients into the study. One patient dropped out of the 
study (from Site 01) after attending the first intervention appointment and was not replaced. 
The CP indicated that the reason for drop out was due to concerns over confidentiality of his 
personal details, particularly in relation to the HRQOL questionnaire and his welfare 
payments (see Section 4.6.7). Table 4.11 provides further details of the numbers of patients 
who were approached, screened and recruited into the study. 
Table 4.11: Information on screening and recruitment of patient participants 
 Site 01 Site 02 Total 
Total number of patients approached 17 7 24 
Number of patients who refused on initial approach 4 0 4 
Number of patients who underwent full screening process 13 7 20 
Number of ineligible patients (high adherence)1 8 2 10 
Number of eligible patients  5 5 10 
Number of patients recruited 5 5 10 
Number of patients who dropped out 1 0 1 
Number of patients who completed the study 4 5 9 
Refusal rate2 (%) 23.5 0 16.7 
Eligibility rate3 (%) 38.5 71.4 50 
Recruitment rate4 (%) 100 100 100 
Retention rate5 (%) 80 100 90 
1Identified using eligibility screening questionnaire (MMAS-8); 2Number of patients who refused on initial 
approach out of the total number approached; 3Number of patients who were eligible out of the number of 
patients who were fully screened; 4Number of patients who were recruited out of the number of eligible patients; 
5Number of patients who completed the study out of the number who were recruited  
CPs at Site 02 delivered the content of Appointment 1 and Appointment 2 together in one 
longer appointment to their five patients (i.e. patients attended the pharmacy on two 
occasions instead of three). CPs indicated that two appointments were sufficient for the 
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patients they identified and this reduced number of appointments would help to keep 
patients engaged with the intervention. One patient at Site 02 could not attend the pharmacy 
for her final follow-up appointment and so this was conducted over the telephone. The 
pharmacist at Site 01 delivered the intervention over three appointments as intended. The 
appointments were delivered over five to eight weeks at Site 01 and over five to 12 weeks at 
Site 02. 
The CP at Site 01 recorded the exact duration of each appointment by noting the exact start 
time and finish time to the nearest minute on the intervention record (ID-MAP booklet). At 
Site 01 Appointment 1 for patients ranged from 26 to 47 minutes, Appointment 2 ranged 
from 15 to 35 minutes and Appointment 3 ranged from 10 to 33 minutes. CPs at Site 2 did 
not accurately record the duration of each appointment (start and finish times for each 
appointment were either missing from the intervention record or had been rounded up to 
the nearest 15 minutes). However, they estimated that each initial appointment (equivalent 
to Appointments 1 and 2) lasted one hour per participant and each final appointment 
(equivalent to Appointment 3) lasted less than half an hour.  
Five males and four females completed the study. Participants were aged 65 years or older 
(ranging from 66 to 88 years) and were prescribed four or more regular medications (ranging 
from 4 to 13 regular medications). Characteristics of patient participants who completed the 
study are shown below in Table 4.12. 
Table 4.12: Characteristics of patients who completed the study 






S01PT01 69 Male 9 Three 
S01PT03 68 Male 4 Three  
S01PT08 88 Male 5 Three 
S01PT13 66 Male 12 Three  
S02PT02 80 Female 8 Two2 
S02PT03 73 Female 13 Two2 
S02PT04 69 Female 9 Two2,3 
S02PT06 77 Female 9 Two2 
S02PT07 73 Male 11 Two2 
1Excluding short-term medications (prescribed for less than 8 weeks e.g. antibiotics, vitamins) and over-the-
counter medications; 2Appointment 1 and 2 combined by study CPs for these patients; 3Follow-up appointment 
conducted via telephone 
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4.6.1 Usability/acceptability of the intervention from the viewpoint of community 
pharmacists 
Overall, CPs reported that the ID-MAP intervention (and training package) was 
useful/acceptable and therefore feasible to deliver in the community pharmacy setting, 
although some modifications were proposed to enhance this. In summary, CPs indicated that 
the number of appointments should be tailored to each patient and suggested that goal-
based solutions were not necessary for all patients. CPs found the medication diary the most 
useful adherence solution and indicated that this alone was sufficient for some patients. 
Further details of feedback from CPs are provided below along with illustrative quotes. 
Training and support provided by the research team 
CPs were satisfied with the level of support and communication they received throughout 
the study from the research team. CPs found the on-site training session comprehensive and 
beneficial and particularly found the example patient scenarios useful. 
“I thought it was very good, it was very involved and it covered all the, the main parts 
and em, it was very informative…” (S02CP01) 
 “…the training material I received in terms of the em, the mock, eh, patient packs, 
em, I found really beneficial especially with my first couple of patients…” (S01CP01) 
However, CPs indicated that their confidence was low at the beginning of the study and 
thought that the opportunity to role-play the scenarios would improve this.  
“I think it’s like everything, once you do one, the second one’s a lot easier so you just 
might be a wee bit apprehensive about doing the first one.” (S02CP02) 
“I’d think I’d maybe like to maybe role play it, you know, would, would have been, 
you know, I think would have been good.” (S02CP01) 
Intervention manual and ID-MAP Booklets 
The intervention manual was described as user-friendly and CPs particularly liked the variety 
of colour, layout and use of flowcharts throughout. 
  “…the training manual, em, I thought were really good, they were very well laid out. 
And, eh, it made me– left me feeling that I had all the information I needed…” 
(S01CP01)  
 “I thought the flow charts were very good, so it was very easy to follow.” (S02CP02) 
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The ID-MAP Booklet was seen as a useful tool for guiding the appointments and recording 
notes. A few suggestions were made in relation to the format and sequencing of questions.  
“I thought was fantastic really. It really, really helped with, eh, taking notes and 
everything else and em, I knew exactly what I was meant to be doing…” (S01CP01) 
Although CPs found the paper version of the ID-MAP Booklets useful, they expressed positive 
views towards an electronic version due to the large volume of paperwork. 
“...if there was finance available for an IT sort of, em, you know, sort of thing…. I think 
that would maybe be an improvement…”  (S02CP01) 
“Yeah that [an electronic version of ID-MAP Booklet] would be fantastic actually 
that’s, that’s a good idea … ‘cause as I said there was so much paperwork… that 
would be a fantastic way to do it…” (S01CP01) 
Structure and duration of appointments 
CPs at Site 02 reduced the number of appointments from three to two indicating that three 
appointments were not necessary for the patients they identified. Although the pharmacist 
at Site 01 delivered the intervention over three appointments as intended, he also indicated 
that Appointments 1 and 2 could be combined. Nonetheless, CPs recognised that more 
appointments may be necessary in particular circumstances and so this should be tailored to 
each patient’s circumstances. 
“Oh three appointments yes aye. That, that was what we sort of, em, felt was a bit 
too much, you know, so we actually had our Appointments 1 and 2 at the same time 
and then bring people back…” (S02CP01) 
 “I thought… em, you could perhaps put, em, Appointment 1 and 2 together… ‘cause 
the… workbook is laid out so well… you can map across to the, to the intervention 
really, really easily.” (S01CP01) 
Delivery of compulsory adherence Solution A (medication diary)  
CPs expressed positive views about the medication diary and indicated that they received 
positive feedback from patients.   
“I thought the diary was absolutely fantastic. I thought it was a great idea, thought 
it was really well laid out. Em, the feedback I got from patients, from all of them was 
extremely positive.” (S01CP01) 
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“Brilliant. Loved it. I think everybody should have one. Everybody really loved the 
diary; that was the best thing… everybody wanted to keep their diaries.” (S02CP02) 
One CP reported receiving feedback from a patient suggesting modifications to improve the 
usability of the medication diary. CPs also reported using the medication diary to assist 
patients with reordering medications or monitoring their symptoms. 
“…somebody said it’s a pity, you know, if they’d something just to hook it on, just to 
the wall…”  (S02CP01) 
CPs at both sites also indicated that they provided additional medication diaries to those who 
wished to continue with this adherence solution. They thought that it should be a long-term 
solution that is recommended to all non-adherent older patients. However, one pharmacist 
thought that a list of medications may be sufficient for some patients.  
“I think longer term. Short term… it really worked but what I found people who were 
actually finished the study, when they gave back the diary were asking me if they 
could get another one because they wanted to keep one all the time.” (S01CP01) 
“I don’t think everybody needs this, sort of, format [full diary]… because it might be 
sufficient just to follow that (medication list at back of diary).” (S02CP01) 
CPs did report reviewing the medication diary when asked about this but answers provided 
were often vague.  
 “I just checked to see where they, had they adhered to whatever and had they filled 
it in and they liked it and they were very happy with it.” (S02CP02) 
 “…if there were missed doses then, then we’d have chatted maybe about it but I think 
some patients that had maybe said, ‘Oh no I did take me tablets then but I didn’t 
record it on here’.” (S02CP01) 
Delivery of optional adherence solutions (Solutions B and C) 
Optional adherence solutions (Solutions B and C) were provided less frequently to patients 
as these were deemed unnecessary using the ID-MAP tool. Reminder strategies (BCT: 
prompts/cues) were suggested most frequently (e.g. reminder stickers or visual placement 
of medications) but the effectiveness of such solutions was seen as mixed.  
“I think most of the patients, maybe it was just a case of trying to say look have their 
medication beside them at the table with their breakfast and [that] worked well” 
(S02CP01) 
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 “…the two people that took the stickers found that, em, at least for the first few 
weeks, they were useful as reminders but then they, sort of— I think they’d stopped 
paying attention to them.” (S01CP01) 
Concerns about medications were only reported by one patient in the study and the CP did 
not think it was necessary to provide the suggested leaflet on this occasion. 
 “… there was one gentleman was concerned… I didn’t have to give him a leaflet or 
anything like that but what I did do was just sat him down and talked him through it 
for about 10 or 15 minutes” (S01CP01) 
CPs indicated that the adherence solutions they did not provide (e.g. ‘generic medications’ 
leaflet) might be beneficial for other patients under different circumstances in the future and 
should not be discarded from the intervention. CPs did not recommend the addition of any 
solutions to the intervention package.  
 “…there are people who are not compliant because, you know, maybe they have 
concerns about their medication. Em, so it is good to have that but, you know, em, I 
wouldn’t remove it just in case…” (S02CP01) 
 “I think you know, everything was, sort of, covered like, em, there was nothing that, 
no there was nothing missing so there wasn’t” (S02CP01) 
Although the ID-MAP Tool acted as the main guide for choosing adherence solutions, CPs 
reported involving patients in the decision making process. 
 “…I didn’t mind really what they did but as long as they had some, sort of, system 
that worked well for them and they came up with it themselves.” (S02CP01) 
“Well I would probably have went through the options and then I think– the best 
thing, they seemed happier with the diary.” (S02CP02) 
Delivery of compulsory adherence Solution D (Goals and action plan activity) 
One pharmacist thought the ‘Goals and action plan’ activity might be more effective for 
younger patients or those with lower levels of motivation. All CPs indicated that this should 
be an optional adherence solution.  
“…for some of the elderly people or whatever I’m just not sure… if you just say ‘Look, 
this is how you go about, just take it’, they were happy enough with that so I don’t 
know whether it really… it, it helped some of the people…” (S02CP01) 
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“…I don’t know if all patients would be up for it… you could say, ‘Would you like to do 
this maybe or as part of the project? This is an option that you could do.’ and see if 
they’d be up for it.” (S02CP02) 
CPs indicated that patients expressed some reluctance in relation to the goals and action plan 
activity and suggested that patients may not have understood its purpose. One pharmacist 
suggested modifications to the written sheet to reduce the complexity of this.  
“I didn’t think they quite copped on to why I was, why I was, why we were setting a 
goal.” (S01CP01) 
“…when they saw they sheet, it’s quite, it’s quite busy and then when they were 
looking at it I think they were quite like, sort of, taken aback and okay this seems 
pretty complicated…” (S01CP01) 
Overall experience, feasibility and future implementation of intervention 
Overall, CPs reported that their experience of taking part in the study was highly positive and 
that patients obtained benefits from the delivery of the intervention. The most positive 
aspects were time spent interacting with patients and providing the medication diary.  
“I thought it was nice to help somebody and to actually make a difference and… 
actually something’s worked for somebody and even giving the diary home with them 
and they used it and they came back. I thought it was beneficial.” (S02CP02) 
CPs felt that they were the most appropriate HCP to deliver this type of intervention due to 
their accessibility and frequency of contact with patients. CPs reported that it would be 
feasible to implement the intervention in their own practice provided there was forward 
planning and funding available.  
“I definitely think there’s no reason why it shouldn’t– it couldn’t be implemented in 
everyday practice but em… I think it just would require a bit more forward, forward 
thinking from, from the pharmacy’s point of view” (S01CP01) 
One pharmacist indicated that the intervention could be an extension to existing services.  
 “… I think ideally if you could use this as part of your, your MUR [Medicines Use 
Review service], like a bigger MUR or your medicines management [Managing Your 
Medicines service]”. (S02CP02) 
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The only reported barrier to implementation was having only one pharmacist working in the 
pharmacy. If the intervention was to be rolled out as a service in the community pharmacy 
setting, advertisement was seen as a potential facilitator of implementation. 
“Obviously, every community pharmacy’s different and it depends on your level of 
cover. If you’re the only pharmacist on it isn’t going to be feasible but there’s very 
little’s going to be feasible, MURs aren’t feasible and, and everything else isn’t…” 
(S01CP01)  
“…advertising I think so that patients would know that if they need help that’s where 
they could go and there is something available there to help them…” (S02CP02) 
4.6.2 Usability and acceptability of the intervention from the view point of patients 
Overall, patients reported very high levels of satisfaction with the intervention they received 
from their CP, with all patients reporting that they would recommend the intervention to 
others. Only minor modifications were suggested to improve the acceptability of the 
intervention, such as making the goal-based adherence solution optional. Patients were 
highly satisfied with the medication diary they all received and reported that this self-
monitoring activity increased awareness of their behaviour and led to improvements in 
adherence. Further details of feedback from patients are provided below along with 
illustrative quotes. 
Patients’ views on the structure and duration of intervention 
All patients reported satisfaction with the number and structure of appointments that they 
were invited to attend in their community pharmacy.  
 “…none of the meetings were in any way too long or—… No I thought… they were all 
very useful and em, doable.” (S01PT01) 
 “You weren’t just going one week and then the same time next week and all that so 
the appointment system was very, very good so it was, to give you time.” (S02PT04) 
The majority of patients reported no issues with the length of appointments, however two 
patients (from the site which combined Appointments 1 and 2) reported that the first 
appointment they attended was quite lengthy.  
 “Well the length of it [Appointment 1 and 2 combined], you know, at the beginning 
I thought it was very, very long, you know. By the time you got to the end of it, you 
forgot the first of it.” (S02PT04) 
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A couple of patients reported feeling apprehensive about the intervention at first but this 
was alleviated when the pharmacist explained that it was for their own benefit.  
Patients’ views on compulsory Solution A (medication diary) 
Patients provided positive feedback on their experience of using the medication diary and 
reported that it acted as a reminder for medication-taking and confirmation that they had 
taken their medications as prescribed. 
“I think it’s [medication diary] a fantastic idea, a fantastic idea” (S01PT13) 
 “…I think it’s [medication diary] a good idea for elderly people. Especially if they’re a 
wee bit forgetful. It’s been a real help to me that.” (S02PT03) 
 “And I found it [medication diary] helped though…’cause some days I would have 
forgot to take my tablets.” (S02PT06) 
“And every day I filled it [medication diary] in, so it done me good, you know it really 
done me good knowing what I, what I was taking and I had taken them, you know.” 
(S02PT04) 
The majority of patients felt that long-term use of the diary would be beneficial for their 
adherence, whereas other patients indicated that short-term use was sufficient. 
”I could see me using it [medication diary] on a long term basis, yes, very much so, 
very much so. ‘Cause when I started to use it, the diary then, then I hadn’t forgot one 
day which was great.” (S02PT04) 
All patients reported receiving verbal instructions on how to use the diary but one patient 
misinterpreted these. This patient thought that additional instructions would be beneficial. 
All other patients found the diary simple and easy to use.  
 “Definitely very helpful but what I did do wrong was I only put one X at the top… of 
each day… instead of ticking each medicine (Inaudible) [on the medication diary]. I 
was bamboozled by so many squares.” (S02PT07) 
 “…it was simple… tick off each day, your morning time, your night time, whatever. I 
thought it [medication diary] was very good.” (S02PT02) 
Most patients were generally satisfied with the size and content of the diary, although a few 
patients made suggestions to improve its usability. 
“Well with a pair of glasses I’d no trouble at all. No I… I have no complaints or even 
advice to improve it [medication diary].” (S01PT08) 
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“You know it’s such a big, em, diary, you know. Maybe if it was brought down a wee 
bit better, is something you could throw into your handbag…” (S02PT04) 
All patients reported that they would recommend use of the diary to other patients who 
were taking multiple medications.  
 “…sort of taught me here you, you don’t know enough about what you’re taking and 
when to take it etcetera… so yes the diary, I would recommend the diary.”  (S01PT01) 
Patients’ views on optional adherence solutions (Solutions B and C) 
Only a limited number of solutions from solution categories B and C (optional solutions) were 
recommended to patients, such as: reminder stickers (BCT: Prompts/cues), additional 
information on dispensing labels or synchronising medication supplies (BCT: Restructuring 
the physical environment). Patients who were provided with reminder stickers did not find 
these particularly effective. 
“I put them up but they came down fairly quickly. Em… I didn’t find them— I didn’t 
find the stickers that, terribly, that terribly helpful.” (S01PT01) 
 “…they put on it [the dispensing label] what exactly it was for which was a great, 
great help to me…” (S02PT04) 
 “I felt it was better to synchronise the medications so that they all finished at the 
same time and I reordered all four…” (S01PT03) 
All patients were offered the opportunity to raise and discuss any worries or concerns they 
had in relation to their medications but only a few patients reported having concerns. 
“I definitely got the opportunity to, to discuss anything that I was worried about or 
anything, you know.” (S02PT03) 
Only one additional adherence solution, that was not part of the intervention, was suggested 
by a patient. This was in relation to having the day inscribed on the foil side of the blister 
packaging of medications.  
“Maybe there were things but I certainly didn’t miss them… I don’t think there’s 
anything else that, eh, that he could have done.” (S01PT01) 
Patients’ views on compulsory adherence solution D (Goals and action plan activity) 
Most patients reported finding the goals and action plan exercise useful but a few patients 
indicated that it was of limited benefit to them.  
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“It was, it was good because it’s like anything in life, you know, you set a goal and 
you look at it and you, you aim for that.” (S02PT04) 
“I don’t– in my case quite truthfully I don’t think it [goals and action plan activity] was 
a great deal of benefit to me.” (S01PT08) 
Patients indicated that it was helpful to have their goals and action plan documented on the 
written sheet. However, one patient reported that she never received the written sheet to 
take home. All other patients found the information on the ‘Goals and action plan sheet’ 
clear and understandable.  
 “…it was very clear… all of the language in all of the stuff that I’ve seen has been, 
em, has been pitched at a, at a very good level for understanding wise so.” (S01PT01) 
“…I read these at the very beginning and sometimes when I was sitting there in the 
evening time I would actually read over these again… it all became very clear to me, 
you know, it was well laid out actually and well written.” (S02PT04) 
One patient indicated that the general health goal (BCT: goal setting-outcome) set by the 
pharmacist was not her true goal. The same patient also indicated that she aimed to reduce 
the number of prescribed medications that she was taking. 
“…cause I was really ill that day and he put down that day (Inaudible) but that’s not—
my goal in life is to take my medication, be sure that everything is in order with me 
and enjoy my life. So the level of goal… was a wee bit, a wee bit, you know.” (S02PT02) 
A few patients reported satisfaction from achieving their goal and indicated that their 
pharmacist provided praise for this. However, one patient who incorrectly completed the 
medication diary reported that he did not think he met his goal because of this, despite 
indicating that he took all of his medication as prescribed.  
“Yes, yes and you know you do look over it and it’s satisfaction… satisfaction. It’s 
there and it, it, it encourages you…” (S02PT07) 
“Yes he did, he did and I think he was pleased by, by what he heard…I certainly (did) 
what I supposed to do and mind you I don’t often do that.“ (S01PT01) 
Patients’ experience of care from the intervention provider 
Patients generally felt comfortable discussing their medications with their CP due to 
established relationships, although one patient reported feelings of embarrassment. 
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 “Very relaxed because eh, yes I suppose, I get my medication through my pharmacist 
and you, you’re often asking information… and have a good relationship with my 
pharmacist…” (S01PT03) 
 “I get embarrassed to be quite honest… I have been a naughty boy… my better half 
was with me so I couldn’t (Inaudible) I couldn’t tell any fibs.” (S01PT03) 
Patients reported a shared decision-making approach to selecting adherence solutions. They 
also felt that all possible options were considered and discussed.  
“…he just took all that I said, he just asked me the questions and I answered them 
and we came to the conclusion that we’re both on the same, same wavelength you 
know, we had the same thoughts.” (S02PT03) 
Patients were satisfied receiving this type of intervention from their pharmacist and did not 
report a preference for receiving it from another type of HCP involved in their care (e.g. GP, 
nurse). 
“No, I was happy enough with the pharmacist doing it… I know they’re not doctors 
per se, but they’re fairly knowledgeable about a whole range of issues obviously to 
do with health and well-being.” (S01PT03) 
Impact of the intervention on adherence behaviours 
Patients discussed how the intervention increased awareness of their current adherence 
behaviour and reported that the intervention helped to improve their adherence. 
 “…it does open your eyes because you are actually… you’re actually— the medication 
you are taking… so it (makes) you a little bit more alert.” (S02PT02)  
“Well it helped me, I knew for if I had taken my medicines or if I hadn’t taken it there 
was a blank. So I knew then I hadn’t taken my medicine so I made sure I took it the 
next day.” (S02PT06) 
 “I think I missed out once—didn’t take it at the proper time. But I’ll tell you the truth 
now, I’m so pleased with myself, it encouraged me.” (S02PT07) 
Some patients felt they had high adherence prior to the intervention, although the 
intervention helped to emphasise the importance of continuing this. 
“…well I would have been quite good anyhow but I suppose it’s reinforced in me the 
importance of, you know, in making sure you do be, that I am diligent about taking 
my medication…” (S01PT03) 
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Overall experience of receiving the intervention 
Patients reported high satisfaction levels with the intervention and overall service provided. 
For some patients, the diary was described as the best part of the intervention. 
“I thought everything from start to finish was ock, 100 percent, thought everything 
was class, I really did… Nothing but praise for it, really haven’t.” (S01PT13) 
 “I would say very, very good, very, very good experience, em, (Inaudible) you know. 
It puts you into routine, I suppose that’s the word.” (S02PT04) 
 “The calendar… I must admit it was a good idea.” (S02PT07) 
All patients said that they would recommend the intervention to other patients who were 
prescribed several medications.  
“I would recommend it to everybody, that’s the truth, I really would. I would 
recommend it to everybody that’s on medication...” (S01PT13) 
4.6.3 Fidelity of intervention delivery 
Completeness of intervention records (ID-MAP Booklets) 
The majority of sections in the intervention records (ID-MAP Booklet) were completed by CPs 
as intended; however, a small number of items were omitted or incorrectly completed. For 
example: the duration of appointments was not always recorded, signatures were missing 
on medication lists, boxes were left unticked in the assessment tool and written notes were 
missing. 
Delivery of behaviour change techniques (BCTs) 
Table 4.13 provides an overview of the assigned level of fidelity (high, low or unclear) based 
on a review of completed intervention materials and/or qualitative feedback from CPs and 
patients.  
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Table 4.13: Levels of fidelity of delivery of BCTs based on self-report 
BCT (‘core’ or ‘optional’) Total number of patients 
for whom the BCT was 
recommended using the 
ID-MAP Tool  
Level of fidelity of BCT 
delivery1 
Self-monitoring of the behaviour 
(‘core’) 
9 High (n=9) 
Feedback on behaviour (‘core’) 9 High (n=3) 
Low (n=1)2 
Unclear (n=5) 
Prompts/cues (‘optional’) 8 High (n=8) 
Restructuring the environment 
(‘optional’) 
4 High (n=4) 
Social support (unspecified) 
(‘optional’) 
2 High (n=2) 
Information on health consequences 
(‘optional’) 
8 High (n=6) 
Low (n=1) 
Unclear (n=1) 
Goal-setting (behaviour) (‘core’) 9 High (n=9) 
Goal-setting (outcome) (‘optional’) 0 Low (n=5)3 
Review of behaviour goal (‘core’) 9 High (n=7) 
Low (n=2) 
Review of outcome goal (‘optional’) 0 Low (n=5)3 
Action planning (‘core’) 9 Low (n=9) 
1 Assessment was made at the individual patient level based on self-reported feedback from CPs and patients 
and evidence from completed intervention materials (including checklists); 2 It was not possible for the CP to 
provide feedback as the patient’s diary was misplaced; 3This BCT was delivered to all patients at Site 02, even 
though it was not recommended according to the ID-MAP Tool 
The BCT ‘Self-monitoring of the behaviour’ was delivered to all patients as recommended in 
the intervention manual (i.e. high fidelity). All CPs reported providing medication diaries to 
each patient and all patients reported receiving these. Eight out the nine diaries were 
returned by patients and had been completed, although one patient had misinterpreted the 
instructions and completed it incorrectly. One diary was not returned as the patient 
misplaced it.   
It is unclear in some cases whether the BCT ‘Feedback on behaviour’ was delivered to all 
patients as recommended in the intervention manual. During the qualitative interviews, CPs 
reported providing feedback to patients based on a review of their medication diary, 
however only vague descriptions were offered. There was evidence to indicate that the 
pharmacist at Site 01 provided feedback to some patients (n=3) based on written notes (i.e. 
high fidelity), but written notes were omitted in other cases (n=5) (i.e. unclear fidelity). This 
BCT could not be provided to the patient who misplaced her medication diary. 
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The BCTs ‘Prompts and cues’ (n=8), ‘Restructuring the physical environment’ (n=4), ‘Social 
support (unspecified)’ (n=2) were all delivered to patients as recommended in the 
intervention manual (i.e. high fidelity). This was evident from written notes and/or feedback 
provided from CPs and patients in the qualitative interviews. 
Delivery of the BCT ‘Health consequences’ was mainly in line with recommendations in the 
intervention manual (n=5) and evidence to support this was available in the written 
materials. However, for one patient the BCT was not delivered as intended as the 
recommended leaflet was not provided (i.e. low fidelity). For another patient it was unclear 
if this BCT was delivered due to the lack of written notes (i.e. unclear fidelity). 
The BCT ‘Goal-setting behaviour’ was delivered to all patients as intended in the manual (i.e. 
high fidelity). Each patient was set at least one medicine-related goal which was documented 
on the ‘goals and action plan sheet’ (e.g. ‘To take my simvastatin tablet at night-time instead 
of during the day’). This was evident from the written materials and feedback provided from 
CPs and patients in the qualitative interviews. However, the BCT ‘Review of behaviour goal’ 
was not always delivered as recommended in the intervention manual. For example, some 
patients’ goals were deemed to be met by the pharmacist despite their medication diary 
suggesting otherwise (i.e. low fidelity) (n=2). In other cases, the BCT was delivered as 
intended which was evident from the written materials and qualitative feedback (i.e. high 
fidelity) (n=7).   
The BCTs ‘Goal setting (outcome)’ and ‘Review of outcome goal’ were not delivered to 
patients as recommended in the intervention manual (i.e. low fidelity). All patients in this 
study reported high levels of motivation, therefore in accordance with the manual, these two 
BCTs were not required. However, CPs at Site 02 delivered these BCTs to all of their patients 
(n=5).  
The BCT ‘Action planning’ was not delivered to patients as recommended in the intervention 
manual (i.e. low fidelity). CPs did not use the suggested IF-THEN format for developing action 
plans (e.g. IF I see my medication on my bedside table, THEN I will take it). Although CPs 
reported in the feedback interview that they found the format helpful, it was evident from 
the written materials that they did not make use of this.  
In comparing fidelity of BCTs across the two pharmacy sites, it was evident that more BCTs 
were correctly delivered by the CP at Site 01 in comparison to the CPs at Site 02.  
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4.6.4 Feasibility of patient screening and recruitment procedures 
Completeness of screening and recruitment documentation 
All patients correctly completed the eligibility screening questionnaire (MMAS-8). The 
questionnaire was incorrectly scored by a pharmacist on one occasion, although this had no 
impact on the patient’s overall level of adherence and subsequent eligibility status. 
Just under three-quarters (73.7%) of eligibility screening forms and 60% of recruitment forms 
were fully completed by CPs as instructed. Examples of missing information included: missing 
dates, unticked boxes, missing dates of birth. Just over half (57.7%) of patient consent forms 
were correctly completed. Examples of missing information included: missing dates, missing 
full patient names, boxes not initialled. Only one recommendation was made to the GP 
during the study (change of formulation from capsules to liquid due to swallow difficulties) 
and a GP referral form was accurately completed for this. Another patient was advised to see 
their GP for investigations after reported nausea did not subside; a GP referral form was not 
completed on this occasion. 
Feedback on screening and recruitment procedures from qualitative interviews 
All patients found the screening procedures acceptable and reported no difficulties with 
completing the eligibility screening questionnaire (MMAS-8). Patients felt comfortable 
answering the types of questions presented in the questionnaire. One patient discussed how 
the questionnaire prompted him to think about his adherence behaviour.  
“I found that useful, eh, that I had to actually consciously start thinking about it.” 
(S01PT01) 
 “…there was no… embarrassing questions in other words, you know, or anything like 
that. It was straight forward.” (S02PT03) 
“The questionnaire was very simple… sensible... I was quite comfortable.” (S02PT07) 
The study information sheet provided was seen as comprehensible to patients and provided 
all the information required to make an informed decision about participating in the study.  
“I think it was nicely balanced. Eh, too much would have been off putting and 
obviously too little wouldn’t have been of much use. No I think it was good.” 
(S01PT01) 
 “There was, there was enough information for me. Yes, there definitely was, yes, 
definitely.” (S02PT04) 
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CPs’ views on the screening process varied across the two sites with one site experiencing 
challenges with the process. One pharmacist initially felt uncomfortable approaching 
patients, which was further exacerbated by the time-pressured environment. 
 “Yeah, the actual screening, no it was, it was fine… we’re lucky here we have a large… 
eh, a lot of elderly people would be part of our patient base so, em, you know, there 
was no problem really.” (S02CP01) 
“The screening process is probably what I found most, most difficult about the whole, 
eh, the whole study, em… initially the difficulty was actually in approaching patients 
at the counter…” (S01CP01) 
The eligibility criteria were mainly acceptable to CPs, however some suggested changes were 
proposed. For example, it was suggested that the inclusion age could be reduced to 55 years 
or 60 years.  
 “The criteria’s very good. Maybe you could go 60 years and older rather than 65, 
‘cause I do know there was a couple of people that, em, I thought could benefit but 
they were maybe 62 or 63” (S01CP01) 
“Em… yes 65 or older, four or more, yeah the four or more, that was… that was fine, 
it— four was quite low.” (S02CP02) 
CPs found the eligibility screening questionnaire (MMAS-8) useful for identifying non-
adherent patients. However, one pharmacist suspected that some patients were not entirely 
truthful when completing this. 
“Yeah, no I think it was a good starting point, you know, it was, it was user-friendly 
and it wasn’t, sort of, em, too complicated for people.” (S02CP01) 
“I still got the feeling that some people were telling me what I wanted to know 
basically… or what they thought I wanted to know I should say…” (S01CP01) 
When CPs were asked about the involvement of pharmacy support staff in the screening 
process, the views expressed were mixed. If support staff were to be involved it was 
suggested that training would be essential.  
“… if I were to have made the criteria known to everyone in the pharmacy, they could 
have turned round and told me, approach this person or this person might benefit or 
have a look at this person’s record to see would they be eligible for the study as well. 
So yes I, I really do think that they (pharmacy support staff) could be…” (S01CP01) 
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“…I think… there is maybe a role for… somebody maybe trained the counter staff or 
dispensing assistants... Em but I think that… I think probably I, I think it, it’s really, I 
think maybe a pharmacist role because… we’re the ones that’s maybe sort of dealing 
with the issues...” (S02CP01) 
The recruitment process was mainly seen as straightforward; however CPs did think that the 
consent-taking process was burdensome.  
“…the recruitment process was, was actually really smooth, em, from once we got 
over the initial screening process...” (S01CP01) 
“I think they, sort of, felt do I have to initial all these parts (of consent forms)… maybe 
in the future if they just… had an overall thing because some of them, sort of, said, 
‘Do I have to do everything?’ and kind of felt it was maybe a wee bit much for them 
to do that.” (S02CP01) 
One pharmacist received feedback from a patient who reported difficulties understanding 
the study information sheet. He indicated that more time may need to be spent with those 
types of patients. The amount of paperwork was also seen to be difficult to manage at times 
and a suggestion was made to condense information. 
“…there was just a lot of, em, paperwork and…. it was tough to keep all the… 
paperwork…” (S01CP01)  
4.6.5 Feasibility of measuring adherence to polypharmacy using a validated self-
report measure (MMAS-8) 
All returned MMAS-8 questionnaires were correctly completed by patients, however, one 
questionnaire was incorrectly scored by a pharmacist as discussed in Section 4.6.4. Five out 
of nine patients returned the three month follow-up questionnaire (containing MMAS-8 and 
also EQ-5D-5L; see later). No follow-up calls were made in this study. MMAS-8 scores and 
adherence level at baseline and three-month follow-up are presented in Table 4.14 below. 
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Table 4.14: MMAS-8 scores at baseline and three months post-intervention delivery 
Patient ID 
number 
Baseline adherence score (adherence 
level1)  (MMAS-8) 
Three-month follow up adherence 
score (adherence level1)  (MMAS-8) 
S01PT012 6.75 (Medium) — 
S01PT03 7.75 (Medium) 7 (Medium) 
S01PT082 4.5 (Low) — 
S01PT13 7 (Medium) 7 (Medium) 
S02PT02 7 (Medium) 8 (High) 
S02PT032 3.5 (Low) — 
S02PT04 5.25 (Low) 6.75 (Medium) 
S02PT06 5.75 (Low) 6.75 (Medium) 
S02PT072 5.25 (Low) — 
1 Low (score <6), medium (Score 6 to 7.75) or high (score of 8); 2 Three month follow-up questionnaire not 
returned  
Feedback on MMAS-8 questionnaire from qualitative interviews 
As discussed in Section 4.6.1, patients reported that they understood all of the questions 
posed in the MMAS-8 questionnaire (which also served as the eligibility screening 
questionnaire). Patients felt comfortable completing the MMAS-8 in the community 
pharmacy setting. CPs also indicated that patients experienced no difficulties completing the 
questionnaire, however one pharmacist did think that patients may not have been honest.  
4.6.6 Feasibility of calculating objective measures of adherence to polypharmacy 
from dispensing data 
Using dispensing data, pre-intervention MPR and PDC percentages were calculated for eight 
out of the nine patients who completed the study. One patient received medications on a 
weekly basis and as the pharmacist took responsibility for prescription ordering and 
generated labels each week, it was not deemed to be a true picture of the patient’s 
adherence. Post-intervention MPR and PDC percentages were calculated for three out of the 
nine patients who completed the study. The remaining five patients did not have at least two 
refills in the post-intervention period to allow these measures to be calculated. Short-term 
medications (prescribed for less than 8 weeks e.g. antibiotics), when required medications 
(e.g. glyceryl trinitrate spray, salbutamol inhaler) and those with unclear or variable 
instructions (e.g. take one or two tablets daily, insulin products), were excluded from all of 
the calculations. Medications that were changed during the observation period (e.g. strength 
changed, product switched) were also excluded from the calculations. The MPR and PDC 
results are presented in Table 4.15. 
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Table 4.15: Pre- and post-intervention Medication Possesion Ratio (MPR) and Proportion of Days 




Pre-intervention1 Post intervention2 Pre-intervention1 Post-intervention2 
S01PT013 89.0% — 43.1% — 
S01PT03 99.4% 100% 99.0% 100% 
S01PT083 97.9% — 96.3% — 
S01PT133 99.7% — 90.4% — 
S02PT02 96.0% 97.7% 91.1% 98.9% 
S02PT033 59.0% — 1.2% — 
S02PT063 90.5% — 29.9% — 
S02PT07 93.6% 96.0% 65.8% 91.5% 
S02PT044 — — — — 
1 Six months pre-Appointment 1; 2 Three months post-Appointment 3; 3 Did not have two refills in three months 
post intervention observation period; 4Weekly dispensing patient (not feasible to calculate MPR or PDC) 
 
4.6.7 Feasibility of measuring HRQOL using a validated measure (EQ-5D-5L) 
All returned EQ-5D-5L questionnaires were correctly completed by patients. Five out of nine 
patients returned the three-month follow-up questionnaire (containing EQ-5D-5L). Table 
4.16 below indicates each patient’s EQ-5D-5L index value and VAS scores at baseline and 
three-month follow-up. Due to non-response, these were not available for four patients. 
Table 4.16: EQ-5D-5L index value and Visual Analogue Scale (VAS) scores at baseline and three 















S01PT012 0.304 — 70 — 
S01PT03 1.000 1.000 95 90 
S01PT082 0.735 — 60 — 
S01PT13 0.683 0.778 90 80 
S02PT02 0.345 0.221 50 35 
S02PT032 0.837 — 80 — 
S02PT04 0.620 -0.081 50 50 
S02PT06 0.666 0.449 50 70 
S02PT072 0.639 — 60 — 
 
Feedback on EQ-5D-5L questionnaire from qualitative interviews 
Patients who completed the study reported no major concerns with completing the EQ-5D-
5L. All patients reported that they felt comfortable answering the types of questions posed 
by the questionnaire.  
1 Completed at the start of Appointment 1; 2Three month follow-up questionnaire not returned 
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“I had no qualms (Inaudible) a professional, the same as a doctor… you can’t, you 
can’t see your symptoms… it’s not like a—you have to tell them. So I mean it doesn’t 
annoy me.” (S02PT07) 
“I was actually glad to, to have to look at them and think about them and, you know, 
answer them...” (S01PT01) 
Some patients reported having good health which made answering the questionnaire 
straightforward. Others felt that the questionnaire provided the opportunity to discuss 
health-related issues with their pharmacist and acted as an ice-breaker. One participant 
found the pain question on the EQ-5D-5L challenging to answer due to its subjective nature 
and potential for variance on a day-to-day basis. 
“…it was a good way of opening up because you know there’s a lot of things we talk 
about and we don’t always go in to things in-depth so for somebody to sit and ask 
me those questions, eh, it was good because then I could really say how I felt.” 
(S02PT06) 
 “I think the level of pain was awkward for me. Cause I— for me personally, I couldn’t 
either tell you what my level of pain is— you know what I mean?” (S02PT02) 
Mixed views were expressed by CPs in relation to the EQ-5D-5L questionnaire. One 
pharmacist indicated that patients were sceptical about completing this. 
“…definitely the patients seemed sceptical, one or two, one especially, em, there was 
a couple of other patients were a bit like, were kind of looking at me as if to say, ‘Why 
are you asking me these questions, I thought it was about medicine, now you’re 
asking me about my health, my general health?’.(S01CP01) 
The other two CPs expressed positive views but did discuss the subjective and cross-sectional 
nature of the questionnaire and day-to-day variances in patients’ HRQOL.  
“Well I give it to the people and they were happy enough, you know… with older 
people I think… they’re quite, you know, they will tell you if they have any problems...” 
(S02CP01) 
“…they said to me, ‘Look I’m grand today but, you know, tomorrow I could be down 
or whatever’ so I suppose it’s, it’s really, em, it’s just a point in time…” (S02CP01) 
Although patients who completed the study reported no difficulties with completing the EQ-
5D-5L, the patient who dropped out of the study did so after Appointment 1. It was at the 
start of this appointment that he was asked to complete the EQ-5D-5L questionnaire to 
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measure HRQOL. Despite reassurance from his CP, the patient expressed concerns over the 
confidentiality of the collected data and impact this may have had on his welfare payments. 
The patient study information sheet (Appendix 4.21) indicated that all information collected 
would be treated with the strictest of confidence and the pharmacist confirmed this with the 
research team and reassured the patient that this was the case. However, despite this, the 
patient was unwilling to continue to participate in the study. 
4.7 Discussion  
This chapter has outlined the intervention design process and findings from preliminary 
testing of the ID-MAP intervention in a small-scale feasibility study. The ID-MAP intervention 
was designed to incorporate the 11 BCTs that were identified from previous research with 
older patients (Chapter 3). These BCTs, which were grouped into four ‘adherence solution’ 
categories, formed the proposed active ingredients of an intervention that aimed to improve 
medication adherence in older patients prescribed polypharmacy. Following intervention 
design and piloting of materials within the research team, CPs (n=3) working at two 
community pharmacy sites were successfully recruited to test the feasibility of delivering the 
intervention in their clinical practice. Ten older patients were recruited and the intervention 
was delivered fully to nine of these patients (retention rate: 90%). Following intervention 
delivery, CPs (n=3) and patients (n=9) provided feedback on the intervention and study 
procedures during qualitative interviews. 
4.7.1 Usability/acceptability of the intervention 
The primary outcome of this study was to assess the usability and acceptability of the 
intervention from the viewpoint of both intervention providers (CPs) and recipients 
(patients). Assessing usability/acceptability early on in the design and testing of a complex 
intervention is vital to the success of future evaluation studies. Gaining patients’ views on 
the intervention content also aligns with the goals of patient-centred care (Richards et al. 
2015).  
Overall, both CPs and patients reported high levels of satisfaction with the ID-MAP 
intervention package stating that they found it both useful and acceptable. CPs and patients 
provided feedback on each of the adherence solutions (i.e. BCTs) they delivered or received, 
respectively, and also commented on associated materials. Participants highlighted where 
adaptions could be made to further enhance the acceptability of the intervention. Based on 
feedback from both CPs and patients, delivery of the BCTs ‘Goal-setting-behaviour’, ‘Review 
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of behaviour goal’ and ‘Action planning’ may not be necessary and useful for all older 
patients, particularly those with relatively minor issues such as occasionally forgetting to take 
medications. These BCTs were originally deemed ‘Core BCTs’, however, they may be more 
appropriate as ‘Optional BCTs’ and delivered to patients with low levels of motivation or a 
complex range of issues (i.e. tailored to individual patients’ needs). This study has also helped 
to identify  formats for delivering BCTs that were less useful to patients, such as the reminder 
stickers that were used to deliver the BCT  ‘Prompt/cues’. Alternatively, patients found that 
placing medications in a visually prominent place (e.g. on their kitchen bench) acted as a 
more successful reminder strategy. This information will help to refine the delivery of the 
BCT ‘Prompts and cues’ and improve the acceptability of the intervention in the target 
audience. These are important findings, as we aim to deliver an optimal combination of BCTs 
to patients in the most efficient and acceptable manner. It is thought that the limited 
effectiveness of some complex adherence interventions could be a result of sub-optimal 
design and so feasibility and pilot studies offer the opportunity to optimise the intervention 
design (Levati et al. 2016). However, there is currently no guidance as to when an 
intervention design should be deemed ‘fully optimised’ and is therefore ready for testing in 
a large RCT.  
Aside from changes to the manufacturers’ packaging (which is beyond the scope of this 
project), no additional adherence solutions were suggested by patients or CPs. This highlights 
the usefulness of using the TDF-to-BCT mapping approach in ensuring the intervention 
package was comprehensive and included solutions to address all possible adherence 
problems faced by older patients prescribed polypharmacy. Future research in a larger 
number of patients is needed to confirm this finding.  
4.7.2 Fidelity of intervention delivery 
Based on self-report (from checklists, notes in intervention records, qualitative feedback), 
there was evidence to indicate that CPs were able to deliver most BCTs (n=7) with high levels 
of fidelity, such as ‘Self-monitoring of the behaviour’, ‘Prompts/cues’, ‘Restructuring the 
physical environment’. For other BCTs, the self-reported evidence suggested that CPs 
experienced some difficulties in delivering these. For example, ‘Goal setting-outcome’ and 
‘Action planning’ were not delivered as outlined in the intervention manual (low fidelity). 
This could be due to a lack of experience in delivering such techniques in the community 
pharmacy setting or due to insufficient training. In general, intervention fidelity was higher 
at Site 01, which could be due to this CP’s engagement with the intervention manual which 
he discussed extensively at the feedback interview. The extent to which the CPs at Site 02 
  Chapter 4 
145 
 
engaged with the intervention manual was unclear. CPs at Site 02 had been practising as 
pharmacists for longer and perhaps judged it unnecessary to study the manual in great detail. 
Ensuring high levels of intervention fidelity in a future RCT is essential so that if the 
intervention was deemed to be ineffective, then this outcome could be attributed to a 
genuine ineffectiveness of the intervention and not due to poor intervention delivery by 
providers (i.e. low fidelity) (Levati et al. 2016).  
Intervention training can help to improve the fidelity of intervention delivery, which in turn 
can impact on the effectiveness of an intervention. The short on-site session (1.5 hours) 
which briefly covered both study procedures and how to deliver the intervention to older 
patients may not have been sufficient in this study. CPs reported high levels of satisfaction 
with the intervention training they received, however, they indicated that additional training 
could have been beneficial. CPs thought the opportunity to practice/rehearse delivery of the 
intervention and discuss this with peers, would have improved their skills and confidence in 
this area. Due to the complex nature of providing adherence support, it is likely that CPs’ 
behaviours will also need to change to allow this type of adherence intervention to be 
successfully implemented into everyday practice. There is limited research into what factors 
help or hinder CPs in providing this type of adherence support to patients (Huston, 2015). 
This feasibility study has highlighted the need for additional research to inform the 
development of a more comprehensive training package to support the future testing and 
implementation of the ID-MAP intervention.  
4.7.3 Feasibility of patient screening and recruitment procedures 
As a secondary outcome, this study also aimed to explore key study procedures to overcome 
potential hurdles in advance of a definitive trial. One site experienced challenges in 
identifying eligible patients using the suggested screening approach. For example, due to 
time restrictions in this setting, it was not feasible for CPs to approach every patient who met 
the criteria when they were waiting on (or collecting) their prescription. Alternative 
strategies should therefore be trialled to ensure the eligibility screening process is systematic 
and avoids selection bias (Pannucci and Wilkins, 2010). For example, potentially eligible 
patients could be identified from pharmacy-held records (PMRs) and mailed letters of 
invitation. Pharmacy support staff could be involved in this screening process to reduce the 
workload for CPs but it is recognised that CPs might prefer to oversee this process, and 
training for support staff would be essential.  
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All patients who completed the screening process and were deemed eligible were 
subsequently recruited into the study (100% recruitment rate). Just over 15% (16.7%; n=4) 
of patients who were approached in the pharmacy refused to undergo screening, with the 
most commonly cited reason being lack of time to commit to the study. CPs reported that 
the MMAS-8 was a suitable screening questionnaire to identify those with adherence 
problems that could potentially benefit from the intervention. Electronic PMRs have been 
identified as an alternative means of identifying patients who are non-adherent (National 
Institute for Health and Clinical Excellence, 2009). However, this feasibility study has shown 
that adherence may appear high using the PMR, despite self-reports of non-adherence. This 
could be due to older patients stockpiling or hoarding medications, a phenomenon that has 
been discussed in the literature previously (Thompson and Stewart, 2001). Discrepancies 
between self-report and pharmacy refill-based measures have been reported elsewhere in 
the literature (Guénette et al. 2005). The limitations of self-report adherence measures have 
been recognised, including recall bias and social desirability bias (Stirratt et al. 2015). 
However, to ensure patients engaged with all aspects of the intervention, it was important 
that they were able to show some insight into their medication adherence behaviour. A 
combination of methods for identifying non-adherent patients may be a more useful 
approach.   
The informed-consent taking process undertaken as part of screening and recruitment was 
seen as burdensome for CPs. A two-stage consent process (consent to be screened and 
consent to be recruited into the full study) was adopted for this study requiring the 
completion of two separate consent forms (Appendices 4.17 and 4.21). For future 
evaluations, modifications should be considered to optimise this process. This could include 
reducing the amount of paperwork where possible and providing CPs with additional support 
and more in-depth training on informed consent to help them to understand the importance 
of this process. Monitoring of CPs’ compliance with the study protocol will be required in 
future studies to ensure the consent process is correctly implemented. Potential strategies 
have been trialled in recent years to improve the consent process and enhance patients’ 
understanding of what will be expected of them in research studies. For example, the use of 
interactive strategies (e.g. use of videos on an iPad) have shown promise in improving patient 
comprehension (Rowbotham et al. 2013; Sonne et al. 2013). 
4.7.4 Feasibility of data collection procedures (adherence and HRQOL) 
As the current study did not seek to examine the effects of the intervention in terms of the 
outcomes measured (medication adherence, HRQOL) and due to the small sample size (n=9), 
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it would be inappropriate to draw any inferences from the findings. Rather, this section 
focuses on the feasibility of collecting this type of data in the context of older patients 
prescribed polypharmacy and also in the community pharmacy setting. 
Health-related quality of life (EQ-5D-5L) 
This study has shown that it was feasible to measure HRQOL using the EQ-5D-5L survey at 
baseline in the community pharmacy setting. In relation to the follow-up measurement, this 
was not obtained for patients who did not return the postal questionnaire (n=4). Potential 
strategies to maximise the response rate could include telephone call reminders or trialling 
alternative methods of data collection (e.g. home visits to collect data).  
Patient participants who completed feedback interviews (n=9) expressed no concerns with 
completing the EQ-5D-5L questionnaire. This was in contrast to feedback from one of the CPs 
who reported that the questionnaire took patients by surprise at their first appointment and 
potentially contributed to the patient drop-out in the study. Although the patient 
information leaflet stated that patients would be asked questions about their general health, 
this may need to be clearer. For example, it could include more specific details about the 
types of questions they will be asked (e.g. questions about pain, depression etc.). As the sole 
purpose of the EQ-5D-5L questionnaire is an outcome measure, alternative methods of data 
collection could be trialled. For example, patients could complete the questionnaire and seal 
their responses in an envelope so that CPs do not have access to their responses. HRQOL is 
an important concept that is not always measured as part of adherence studies and so it is 
important to collect this information (Marcum et al. 2017). The association between 
medication adherence and quality of life is unclear with some studies reporting a positive 
correlation and others reporting a negative or no correlation (Saleem et al. 2012; Hanus et 
al. 2015; Harlow et al. 2017). It is therefore important to assess the impact of interventions 
that seek to improve medication adherence on older patients’ HRQOL. 
Self-reported medication adherence (MMAS-8) 
The MMAS-8 had a dual purpose in this study in that it served as an eligibility screening 
questionnaire and as an outcome measure of self-reported adherence. This study has shown 
that it was feasible to measure self-reported adherence using MMAS-8 at baseline. However, 
as discussed for the EQ-5D-5L, four patients did not return their three-month follow-up 
questionnaire and so strategies to improve this need to be considered.  
The MMAS-8 was originally designed to encourage patients to think about medications 
prescribed for a particular condition (e.g. hypertension) as opposed to medications for all of 
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their chronic conditions. Although the change of wording to account for this was approved 
by the developer (Morisky), the impact of this on the validity of the measure is unknown. As 
previously discussed, the limitations of self-report are well-known (e.g. social desirability 
bias, recall bias). Nonetheless, research has shown that validated self-report questionnaires 
(e.g. MMAS) have moderate to high levels of correlation with other measures (e.g. electronic 
monitoring) (Garber et al. 2004; Stirratt et al. 2015). Stirratt et al. (2015), recommend that 
validated self-report scales should be used where possible and attempts made to improve 
the quality of such measures (e.g. attempting to reduce social desirability bias). Self-report 
measures have high specificity (i.e. good ability to correctly identify those with poor 
adherence) and low sensitivity (i.e. poor ability to correctly predict those without poor 
adherence). In other words, if a patient indicates that they are non-adherent, then this is 
likely to be reliable (Stirratt et al. 2015). In the current study, one pharmacist recognised the 
potential for social desirability bias and indicated that he could have benefited from training 
on how to avoid this. Despite the known limitations, MMAS-8 served as an efficient, low-cost 
method for both identifying non-adherent patients and measuring adherence (as an 
outcome) in a time-restricted environment. 
Pharmacy dispensing data to calculate objective measures of adherence (MPR, PDC)  
In addition to self-report, measures calculated using pharmacy dispensing data were selected 
as more objective measures of adherence. The collected information was used to calculate 
two commonly employed measures: MPR and PDC. Although both measures attempt to 
examine the amount of medication that the patient has available over the defined period (as 
a surrogate for consumption), they differ in how their values are calculated. It was evident 
from reviewing the MPR and PDC percentages obtained for each patient that there could be 
variability in how the findings are interpreted. For example, a patient who was deemed 
adherent (cut-off of 80%) in the six months pre-intervention delivery using the MPR measure 
(90.5%), was deemed non-adherent when employing the PDC measure (29.9%). If adherence 
was assessed solely using MPR, only one out of the nine included patients would have been 
deemed non-adherent pre-intervention (MPR < 80%), whereas using PDC, four out of nine 
patients would be deemed non-adherent pre-intervention (PDC <80%).  
Measuring adherence is a recognised challenge in this field of research and further 
complicated when attempting to measure adherence to multiple medications (i.e. 
polypharmacy). The Multiple Medication Adherence Measurement Working Group of ISPOR 
(International Society For Pharmacoeconomics and Outcomes Research) have recently 
undertaken research to explore the accuracy of measures commonly used to measure 
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adherence to multiple medications (Malmenäs et al. 2016). Using simulated patient data, 
they estimated that an MPR (average) had an estimated sensitivity of 100% and specificity of 
30%. In comparison, PDC (for all medications) has an estimated sensitivity of 97% and 
specificity of 96%. These findings illustrate that the PDC measure is better at identifying 
patients with poor adherence than the MPR measure in the context of polypharmacy (i.e. 
higher specificity) which aligns with the findings in this study.  
The PDC measure could, however, be seen as too strict in this context as a patient is only 
deemed ‘covered’ on a given day when he/she has all medications in the polypharmacy 
regimen available. So, for example, if Patient A had only one out of ten medications available 
and Patient B had nine out of ten medications available on a given day, that day would be 
classified as ‘not covered’ for both patients, despite there being a notable difference in the 
level of availability of medications (proxy for medication adherence). A newer objective 
measure, termed the ‘Daily Polypharmacy Possession Ratio’ (DPPR) that has been proposed 
could provide a more conservative estimate of a patient’s adherence to a polypharmacy 
regimen (Arnet et al. 2014). This method has been successfully utilised in a RCT which 
assessed the effectiveness of a ‘Polymedicine Check’ service in Switzerland using community 
pharmacy dispensing records (Messerli et al. 2016). The DPPR measure is similar to the PDC 
measure in that it also looks at every day in the measurement period, but the DPPR measure 
differs in that it takes into consideration the ratio of medications available on a given day. So 
in the example above, Patient A would be deemed to have a ratio of 0.1 coverage and Patient 
B a ratio of 0.9 coverage for that day. However, it should be noted that calculating DPPR and 
PDC values are much more time-consuming than calculating the MPR. This is because a 
‘supply diary’ for each day has to be produced to account for early refills and assess the level 
of adherence on each given day in the observation period (Arnet et al. 2014). 
There is a need for guidance in this area to ensure that studies measuring adherence to 
multiple medications can be easily compared and contrasted. There is currently ongoing 
work into the development of a ‘Core Outcome Set’ which seeks to identify a minimum set 
of outcomes that should be reported in clinical trials with patients prescribed polypharmacy 
(http://www.comet-initiative.org/studies/details/933). In addition to identifying ‘what’ 
should be to measured (e.g. adherence, hospitalisations), it will be important to identify 
exactly ‘how’ each outcome should be measured to ensure consistency across research 
studies.   
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4.7.5 Intervention tailoring 
Due to the wide range of potential barriers and facilitators experienced by older patients in 
relation to taking multiple medications, the intervention was designed so that the content 
could be tailored to each individual patient’s needs. Delivery of all components to all patients 
would have been a time-consuming and inefficient approach. This is one of the first studies 
to report tailoring of BCT delivery to patients’ needs. CPs reported that the adherence 
assessment tool (ID-MAP tool) aided the selection of BCTs to deliver to each patient (i.e. 
tailoring of intervention components). The questions in the tool were also reported to be 
acceptable to patients and patients reported that a shared decision-making approach was 
used to select the most appropriate adherence solutions. However, it should be noted that 
CPs at one site incorrectly delivered two additional BCTs (‘Goal setting-outcome’, ‘Review of 
outcome goal’) to all of their patients despite the tool recommending that these were 
unnecessary. The development of an electronic version of the adherence assessment tool 
could help to avoid this in future studies. Based on a patient’s response to each question (e.g. 
using a similar tick box selection style approach), an electronic tool could automatically 
generate options for an individualised adherence support plan. All CPs expressed positive 
opinions about the use of information technology (IT) in delivering the intervention (e.g. 
using an iPad) and so this warrants further investigation. This approach would also serve to 
reduce the volume of paperwork for CPs which was perceived as being potentially 
burdensome and also help ensure that all relevant sections are completed before advancing 
to the next stage.  
This feasibility study has demonstrated that a rigid approach to appointments in this patient 
group may not be optimal. Adherence problems can range in severity and so patients require 
differing levels of contact and support. For the patients identified in this study, CPs at both 
sites thought it was unnecessary to leave a gap between Appointments 1 and 2 for 
preparation of adherence solutions as suggested in the manual and accordingly, CPs at one 
of the sites combined these appointments reducing the number of intervention 
appointments from three to two. Nevertheless, CPs did recognise that some patients may 
require more than two appointments and suggested that the number of appointments 
should be decided on a case-by-case basis (i.e. tailored). Telephone calls were also suggested 
as a useful method for following up with patients to check on the effectiveness of adherence 
solutions. These are important findings that reflect recent guidance published by NICE on 
managing multimorbidity in primary care (National Institute for Health and Care Excellence, 
2016). This guidance recognises the heterogeneity of patients taking several medications for 
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multiple medical conditions and the need to adopt a tailored approach to providing 
healthcare. 
Previous adherence interventions, have generally focused on delivering the same 
intervention components to all patients, despite research showing that there are a wide 
range of reasons for patients’ non-adherence. Adopting a tailored approach to intervention 
design and delivery may improve the effectiveness of adherence interventions and so future 
research should focus on how best to tailor both intervention content (i.e. BCTs) and the 
number of appointments to each patients’ needs in a consistent manner.   
4.7.6 Study strengths and limitations 
The intervention has been designed and tested in line with the MRC complex intervention 
development framework. The intervention content has also been reported in line with the 
TIDieR guidelines which aim to ensure that the interventions can be easily interpreted and 
replicated by others (see completed checklist in Appendix 4.30). The qualitative nature of the 
feedback interviews gave participants the opportunity to express their views on the 
intervention in-depth so that components of the intervention that worked well or less well 
could be identified. This will help to ensure that the intervention is refined so that it is most 
relevant to those that it seeks to help (older patients) and those responsible for 
implementing it (CPs).  
A potential limitation of this study is that the pharmacist training and feedback interview 
sessions were conducted by the same researcher which may have led to social desirability. 
There were, however, changes suggested by all pharmacist participants to improve the 
intervention content and study procedures and so this level of bias is thought to be minimal. 
Patient participants had no prior contact with the researcher and were informed that any 
information provided during feedback telephone interviews would be confidential and not 
relayed back to their pharmacist. Although all feedback interviews were conducted as soon 
as possible after intervention delivery, slight delays in reaching participants and scheduling 
suitable interview dates/times, may have resulted in recall bias. 
The sampling strategy for identifying community pharmacies for this study was based on 
pragmatism (i.e. convenience sampling of personal contacts) and was limited to one 
geographical area. To improve the transferability of findings, future research should test 
sampling and recruitment of community pharmacies on a larger scale. 
The findings from the fidelity assessment are limited due to the self-reported nature of data 
which could have impacted on their validity (i.e. accuracy) (Breitenstein et al. 2010). Future 
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research should incorporate objective measures of fidelity (e.g. video or audio recordings, 
observations) to objectively measure if a modified version of the intervention package can 
be delivered by CPs as intended and ultimately link this with study outcomes (Borrelli, 2011).  
4.8 Conclusion 
This feasibility study has demonstrated the usability and acceptability of the ID-MAP 
intervention from the viewpoint of both older patients (intervention recipients) and CPs 
(intervention providers) and warrants further testing in a future pilot study. Although many 
of the findings from the feasibility study were positive, in order to optimise the intervention 
design/delivery, some modifications will be required. An important finding from this study 
was the need for additional training for CPs to enhance intervention fidelity. Chapter 5 
presents findings from a mixed methods study that aimed to further explore CPs’ training 
needs in relation to providing this type of adherence support intervention to older patients. 
The purpose of this is to guide the selection of components to include in a modified training 
package and to support the future delivery of the ID-MAP intervention.












Selection of components for a 
theory-based community pharmacist 
training package and strategies to 
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adherence support: a mixed 
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The previous chapters of this thesis (Chapters 2 to 4) reported on the development and 
feasibility testing of the ID-MAP intervention, an intervention designed for the target audience 
of older patients prescribed polypharmacy (≥4 medicines) to improve the target behaviour of 
medication adherence. As highlighted in Chapter 4, findings from the feasibility study indicated 
that modifications are required to the training package that accompanies the ID-MAP 
intervention. This is necessary to ensure the intervention can be delivered by CPs as intended 
(i.e. with high fidelity) in future research studies and ultimately in clinical practice if the 
intervention is effective.   
5.1.1. Targeting community pharmacists’ behaviour to improve the provision of 
medication adherence support 
As discussed in Chapter 1, there is growing recognition that in addition to targeting patients’ 
adherence behaviour directly, it is important to consider the behaviours required of those who 
are responsible for delivering interventions to improve adherence (Sabate, 2003; National 
Institute for Health and Clinical Excellence, 2009; Huston, 2015). The 2003 WHO report 
recognised that HCPs require specific training in both assessing patients who are at potential 
risk of non-adherence, and in the delivery of interventions to improve it (Sabate, 2003). 
Supporting the WHO report, the latest guidance on medication adherence from NICE describes 
the provision of medication adherence support (MAS) as a complex clinical behaviour, consisting 
of both identifying non-adherent patients and providing tailored adherence support 
interventions (National Institute for Health and Clinical Excellence, 2009). 
As alluded to previously, there has been limited research into exactly what helps and hinders 
CPs in providing MAS to patients (Huston, 2015). Preliminary qualitative and quantitative 
research has shown that potential barriers to the provision of MAS include a lack of time, 
perceived resistance from patients and CPs’ lack of confidence, although the latter has varied 
across studies (Bacci et al. 2014; Lowrie et al. 2014; Mansoor et al. 2014; Marquis et al. 2014; 
Mansoor et al. 2015). The training package for CPs that will accompany the patient-targeted (ID-
MAP) intervention provides a unique opportunity to overcome modifiable barriers to the 
provision of MAS such as CPs’ lack of knowledge, skills and/or confidence. In addition, it is 
important to explore other perceived barriers and facilitators that need to be considered such 
as availability of resources, time and reimbursement as these are all factors that could impact 
on the future implementation of the ID-MAP intervention. 
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5.1.2 Current provision of medication adherence support by community pharmacists 
in Northern Ireland 
In the context of NI, the extent to which CPs identify non-adherent older patients and provide 
adherence support is currently unclear. Despite non-adherence being a widespread problem 
(Bosworth et al. 2011), there is currently no commissioned service in NI that specifically focuses 
on improving medication adherence in older adults prescribed polypharmacy. Two currently 
funded services offer potential opportunities for CPs to identify non-adherence and provide 
adherence support. These include firstly, the MUR service, which in NI is targeted at patients 
who have a clinical diagnosis of asthma or diabetes (Business Services Organisation, 2014). 
Secondly, the MYM service is a medication review service available to support patients who are 
deemed to be at high risk or vulnerable (including patients taking four or more medications or 
taking high risk medications e.g. digoxin or warfarin) (Business Services Organisation, 2010). To 
be eligible for MYM, the service guidance indicates that patients should have either an identified 
lack of support for managing their medications, poor adherence or a significant change to their 
medication following recent hospital discharge. However, it is unclear exactly how poor 
adherence is defined, measured and addressed by CPs as part of either service. For example, 
MUR guidance indicates that CPs can provide ‘advice on medicines usage (prescribed and OTC), 
aiming to develop improved adherence’ (Business Services Organisation, 2014) and MYM 
guidance indicates that: ‘The service should assist in achieving safe and cost-effective use of 
medication, improve adherence and ensure that all measures are implemented to achieve the 
best possible quality of life for the individual patient’ (Business Services Organisation, 2010). 
One common component of both the MUR and MYM services is the provision of education to 
improve patients’ knowledge. Although appropriate medication knowledge is an important 
prerequisite for adherence, recent evidence has shown that education alone is insufficient in 
changing patients’ non-adherent behaviours (Nieuwlaat et al. 2014; Allemann et al. 2016). Both 
services currently offered in NI lack a clear structure with regards to improving medication 
adherence, and their effectiveness (in terms of adherence and clinical/humanistic outcomes e.g. 
HRQOL), and cost-effectiveness currently remains unknown (Wright, 2016).   
CPs’ current involvement in supporting medication adherence is likely to impact on future 
evaluations and implementation of the ID-MAP intervention (an intervention which focuses 
specifically on adherence). It is therefore important to explore exactly what CPs in NI are doing 
to support older patients with medication adherence in greater detail. It is also important to 
explore perceived barriers and facilitators faced by CPs in providing MAS to identify how these 
could be addressed as part of a future training package and/or to help identify strategies to 
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improve implementation (e.g. as part of future research studies). The target behaviour in this 
chapter is therefore the ‘provision of MAS to older adults prescribed polypharmacy’ and the 
target audience is CPs.   
5.1.3. Using the Theoretical Domains Framework to explore community pharmacists’ 
behaviour  
Training packages for HCPs often contain multiple interacting components and can therefore be 
seen as a form of complex intervention. Thus, in line with recommendations from the MRC, 
theory could be useful in enhancing the content of this training package. The TDF, which was 
used previously to develop the patient-targeted (ID-MAP) intervention as outlined in previous 
chapters, was originally developed to act as a ‘theoretical lens’ to explore HCPs’ clinical 
behaviours (Michie et al. 2005). The TDF can be used to gain a more comprehensive 
understanding of the key influences (barriers, facilitators) on the target behaviour and identify 
exactly what aspects should be targeted to bring about behaviour change.  
As discussed previously, the vast majority of TDF-based studies have adopted qualitative 
research designs such as interviews or focus groups (Francis et al. 2012). More recently 
researchers have recognised the potential usefulness of quantitative research designs, such as 
surveys, in TDF-based research studies (Brotherton et al. 2010; Amemori et al. 2011; Gnich et al. 
2015). For instance, Amemori et al. (2011) developed a 35-item questionnaire using the TDF to 
explore barriers and facilitators to the provision of smoking cessation counselling by dentists. As 
noted in Chapter 3, qualitative methods are limited by their generalisability (although the 
findings can often be transferred to other contexts i.e. transferability). Quantitative designs, 
such as surveys, offer an opportunity to increase the generalisability of findings, but one 
disadvantage is that they are restricted by the depth of information that can be obtained. This 
is of particular importance when little is known about the target behaviour, as is the case for the 
behaviour under investigation in the current study. 
5.1.4 Mixed methods studies using the Theoretical Domains Framework 
To overcome known limitations of both qualitative and quantitative research designs, a number 
of TDF-based studies have combined these two approaches (Brotherton et al. 2010; Clarkson et 
al. 2010; Dyson et al. 2011). For example, Brotherton et al. (2010) conducted TDF-based 
qualitative interviews initially to explore, in detail, the delivery of a Human Papillomavirus 
Vaccination programme by GPs, followed by a TDF-based quantitative survey to explore the 
views of a larger sample of GPs. The preliminary qualitative findings also helped to inform the 
content of the quantitative survey.  
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Upon identification of barriers and facilitators using both qualitative and quantitative 
approaches (with the former informing the content of the later), the findings can be 
triangulated. Triangulation has been defined as the process of combining different approaches 
or methods within a research study with the use of qualitative and quantitative approaches 
described as a ‘mixed methods’ study (Erzberger and Prein, 1997; Lingard et al. 2008; O’Cathain 
et al. 2010). The process of triangulation involves looking for convergence (i.e. similar 
information) and/or discrepancies (i.e. contradictory information) between findings of multiple 
approaches. This can help gain a more complete picture of the topic under question (O’Cathain 
et al. 2010) which can then inform the selection of theoretical domains to target for behaviour 
change. Key domains can subsequently be mapped across to BCTs for inclusion as the active 
ingredients of an intervention, such as a training package for CPs (Michie et al. 2008; Cane et al. 
2015; Michie et al. 2015). 
The current chapter outlines findings from a mixed methods study that focused on the 
identification of determinants (barriers, facilitators) perceived to be influencing the provision of 
MAS by CPs (specifically to older patients prescribed polypharmacy). In-depth qualitative 
interviews informed the content of a quantitative survey that aimed to gain a broader overview 
from a larger sample of CPs from across NI. Qualitative and quantitative findings were 
triangulated and informed the selection of key TDF domains to target for behaviour change. This 
chapter also outlines the process of mapping from key TDF domains to BCTs for inclusion in a 
training package for CPs and/or to deliver as part of a future research study to improve the 
provision of MAS and subsequent implementation of the ID-MAP intervention.  
5.2 Aims and objectives 
The overall aim of the current study was to select components (i.e. BCTs) to include in a theory-
based training package for CPs (and/or to deliver as part of a future research study) to improve 
the provision of MAS (specifically to older adults prescribed polypharmacy). The key purpose of 
this was to improve the future implementation of the patient-targeted (ID-MAP) intervention. 
The TDF was selected as the underpinning theoretical framework of behavioural determinants 
for this mixed methods study. The main objectives were to: 
 Identify determinants (barriers, facilitators) perceived to influence the provision of MAS 
from the viewpoint of CPs using TDF-based qualitative interviews  
 Explore CPs’ experiences of providing MAS (target behaviour) to older adults prescribed 
polypharmacy using a cross-sectional survey 
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 Identify determinants (barriers, facilitators) perceived to be influencing the provision of 
MAS by CPs using a TDF-based cross-sectional survey  
 Triangulate data from qualitative and quantitative approaches to inform the selection of 
key TDF domains that could be targeted for behaviour change 
 Map key TDF domains across to BCTs that could be included in a theory-based CP training 
package and/or delivered as part of a future research study to improve the implementation 
of the patient-targeted (ID-MAP) intervention 
5.3 Research design and methodology 
5.3.1. Rationale for choice of research design 
As discussed previously, qualitative research designs have been the most commonly used 
approach in TDF-based research studies. However, it is recognised that this approach is limited 
by the lack of generalisability beyond the study sample. To explore the views of a larger number 
of CPs in order to increase the generalisability of findings, a mixed methods research design 
using both qualitative and quantitative approaches was adopted for the current study. 
Qualitative research design has been discussed in detail in Chapter 3 (Section 3.3.2). An overview 
of quantitative research design is provided below (Section 5.3.2). 
5.3.2 Overview of quantitative research design 
Quantitative research involves the collection and analysis of numerical data (Sukamolson, 2007). 
This encompasses experimental, cross-sectional and longitudinal research (Bryman, 2013). 
Experimental research includes clinical trials, such as RCTs, which compare findings between 
intervention and control groups. Cross-sectional studies collect data from a group of participants 
at a single point in time, whereas longitudinal studies collect data at multiple points in time 
(Neuman, 2013). Examples of cross-sectional studies include structured observations and 
surveys. Structured observations involve the researcher observing the phenomenon of interest 
(e.g. a specific behaviour) in the original setting, whereas surveys can be used to collect data on 
characteristics, attitudes and behaviours of individuals (Bryman, 2013). Surveys are the most 
commonly used cross-sectional research method in pharmacy practice research due to their 
efficiency and relatively low cost. Surveys will therefore be the focus of the following sections 
(Aparasu, 2011). 
Administration of surveys 
Questionnaires (i.e. a structured list of questions) are the measurement tool used to collect data 
in survey research; these can be administered by the researcher or self-administered (Bryman, 
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2013). Self-administered questionnaires are less time-consuming and negate the interviewer 
effect seen with researcher-administered questionnaires. However, self-administered 
questionnaires often achieve lower response rates than researcher-administered 
questionnaires. It is also not possible to prompt for additional information with self-
administered questionnaires and they are restricted by the number of questions that can be 
asked (Bryman, 2013; Bresee, 2014). Self-administered questionnaires can be either electronic 
(participants are emailed a link to the questionnaire) or paper-based (a paper copy of the 
questionnaire is sent via post to participants) (Neuman, 2013). Electronic questionnaires 
generally achieve lower response rates than paper-based questionnaires, but the latter can be 
more expensive and time-consuming to prepare and analyse. It is necessary to have access to 
participants’ email addresses for electronic questionnaires and postal addresses for postal 
questionnaires; thus the type of information available to the researcher may dictate the method 
that is adopted (Bresee, 2014). 
Sampling and generalisability of surveys 
One of the key advantages of quantitative survey research is the potential ability to generalise 
the research findings beyond the study sample, a concept referred to as external validity 
(Lavrakas, 2008). As it is generally not feasible to survey all of the population, a sample of the 
population is generally surveyed (Neuman, 2013). The preferred method of sampling is random 
(probability) sampling as this ensures that all individuals in the population have an equal chance 
of being selected, therefore generating a more representative sample. Non-random (non-
probability) sampling strategies, such as convenience or purposive sampling are used in 
circumstances where the researcher does not have access to details of, or access to, every 
individual in the population (Bryman, 2013).  
Survey response rates 
The survey response rate is defined as the number of returned and completed questionnaires 
divided by the number of questionnaires that were distributed. A response rate of 60% or higher 
is desirable (Bryman, 2013) but this is often difficult to achieve in the context of health services 
research. As mentioned previously, the method of questionnaire administration (e.g. postal, 
electronic) has been shown to have an impact on the response rate. This has been illustrated in 
a US study by Hardigan et al. (2016) that explored differences in survey response rates from 
pharmacists (predominantly community-based) across three different methods: postal survey 
(21.0%), email link to online survey (6.8%), mailed postcard link to online survey (3.2%). The 
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postal method achieved the highest response rate in this study and was also deemed to be the 
most cost effective method.  
Postal survey response rates reported from research studies involving healthcare professionals 
(HCPs) in the literature have ranged from as low as 20% up to as high as 90% (Smith, 1997; Paul, 
2005; Barry et al. 2013; Cottrell et al. 2015; Millar et al. 2016). Smith (1997) indicated that postal 
survey response rates from CPs have ranged from around 30% to over 90%, although the cause 
of this wide variation is unknown. Cook et al. (2009) discussed how ‘response rates to postal 
surveys of healthcare professionals are low and probably declining’ which is likely due to survey 
fatigue. A recent Australian survey, similar to the one presented in this chapter, aimed to explore 
CPs’ ‘attitudes and perceived barriers to [the] provision of adherence support’. The study 
investigators distributed a postal questionnaire to 500 randomly selected community 
pharmacies in New South Wales (Australia) and obtained a response rate of 27.6% (Mansoor et 
al. 2014).  
There are a range of factors that have been shown to improve postal survey response rates such 
as reminder mailings, assurances of confidentiality, incentives (monetary and non-monetary), 
pre-notification and follow-up telephone calls. However, some of these strategies can 
significantly increase the cost of the research study (e.g. incentives) or are time-consuming (e.g. 
follow-up telephone calls). In relation to the length of the questionnaire, shorter questionnaires 
have been shown to improve response rates (Edwards et al. 2009). There is a delicate balance 
between collecting sufficient information to explore the research questions and avoiding 
respondent fatigue and subsequent non-response. Despite this, there is a lack of evidence to 
indicate the optimal or maximum length of postal questionnaires (Nakash et al. 2006).  
It is commonly suggested that low survey response rates lead to non-response bias, whereby 
there are potential differences in responses to survey items between responders and non-
responders (Halbesleben and Whitman, 2013). Non-response bias can impact on the quality of 
the study and external validity (i.e. generalisability of findings beyond the study sample). 
Although response rates are often used as a proxy measure for non-response bias, Davern 
(2013) argues that this proxy measure lacks both strong reliability and validity. Instead of 
focusing solely on response rates, it is recommended that researchers take additional steps, 
where possible, to assess potential non-response bias (Davern, 2013; Halbesleben and 
Whitman, 2013). One suggested method of doing so is through the comparison of key 
characteristics (e.g. gender, age) of the study sample with those of the population of interest 
(MacDonald et al. 2009; Halbesleben and Whitman, 2013).  
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It is also important to recognise that the impact of a low response rate is likely to be of greatest 
significance when a random (probability) sampling strategy has been adopted. It has been 
argued that where non-random sampling strategies have been used, a low response rate is of 
less significance because even with a 100% response rate, the sample would still not be truly 
representative as the selection process was non-random (Bryman, 2013). 
Question format and wording 
When developing questionnaires, the nature of included questions need to be carefully 
considered. Questions can be broadly divided into closed and open-style formats. For self-
administered surveys it is recommended that open-style questions should be kept to a minimum 
as these are both time-consuming for participants to answer and for the researcher to analyse 
(Bryman, 2013; Neuman, 2013). Although closed questions are easier to process, they can be 
restrictive in terms of the depth of information that can be obtained.  
When designing survey questions, researchers should avoid ambiguous, double-barrelled, 
leading or double-negative questions/statements where possible (Neuman, 2013; Bresee, 
2014). An example of a double-negative statement would be: ‘It is not true that those in senior 
positions do not support me with providing MAS to older people’. Prior to distributing the 
questionnaire, it should be piloted with a small sample of individuals who are deemed to be 
similar to the study population. The aim of this is to ensure that all items in the questionnaire 
are clear and unambiguous and to give an estimate of completion time (Bryman, 2013). Where 
possible, standardised rating scales should be adopted for example, the most common strategy 
for measuring attitudes is the use of Likert items and scales (Likert, 1932).  
Likert items and Likert sales 
The Likert Scale was originally developed in 1932 by Rensis Likert (Likert, 1932). Individual 
questionnaire items are termed ‘Likert items’ whereas the combination of multiple Likert items 
are referred to as ‘Likert scales’ (Clason and Dormody, 1994; Uebersax, 2006; Boone and Boone, 
2012). A Likert item consists of a statement with multiple-response options (e.g. five to seven 
responses). The most commonly used format is the five response option (strongly agree, agree, 
neither agree nor disagree, disagree and strongly disagree) (Bryman, 2013). Likert items usually 
include a middle neutral response (e.g. neither agree nor disagree) to avoid forcing respondents 
to select a response that they do not truly believe. Responders who choose the neutral response 
may not hold an opinion or simply do not wish to think about the statement in-depth. Multiple 
Likert items are often used in questionnaires for consistency in responses. For data analysis 
purposes, each response to a Likert item can be assigned an integer as a score (e.g. 1 for strongly 
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agree up to 5 for strongly disagree or vice versa). In some cases, Likert item scores can be 
combined to produce a summative scale score (e.g. items around a particular trait or personality 
may be combined into a scale) (Clason and Dormody, 1994). 
When combining Likert items into a scale it is important to ensure the items are similar and that 
the scale has internal consistency; this concept is commonly measured using Cronbach’s alpha 
(α) on a scale of 0 to 1. Internal consistency has been defined as ‘the extent to which items on 
the test or instrument are measuring the same thing’ with higher α scores (closer to 1) indicating 
greater similarities between items (Bolarinwa, 2015). An α value above 0.7 is generally deemed 
sufficient for scaling multiple Likert items, although some researchers argue that lower values 
such as 0.6 are sufficient (Bryman, 2013). If a scale has an α value below the ideal cut-off point, 
it indicates that the items are potentially measuring different concepts (e.g. different theoretical 
constructs) and it would therefore be inappropriate to combine the items into the proposed 
scale. Alternatively, the Likert items can be analysed individually as ordinal-type questions 
(Clason and Dormody, 1994; Boone and Boone, 2012; Sullivan and Artino, 2013).  
Reliability and validity  
The reliability and validity of a questionnaire are commonly considered in survey research. The 
reliability (also termed stability) of a questionnaire, is the extent to which the results would be 
replicated if the study were to be repeated (i.e. whether the questions would be answered in 
the same way by participants on multiple occasions) (de Vaus, 2014). The most common method 
for measuring the reliability of a questionnaire is the test-re-test approach, however, due to 
time restrictions, this was deemed beyond the scope of the current project (Bryman, 2013). 
Validity is another important concept in survey research (i.e. whether the questionnaire has 
truly measured the concept that it was designed to measure). Bryman (2013) indicates that 
when developing a new questionnaire, as a minimum, face validity should be determined. Face 
validity is an assessment that the measure appears, albeit on the surface, to reflect the key 
concepts that it aims to measure. Other more complex methods are available to measure validity 
(e.g. concurrent validity) but these were deemed to be beyond the scope of this project and are 
therefore not discussed (Bolarinwa, 2015).  
Analysis of survey findings 
Researchers most commonly use surveys to describe the phenomenon or behaviour of interest 
based on data collected at a single point in time (Smith, 1997). Consequently, descriptive 
analysis is most frequently employed to analyse and present the findings of surveys (e.g. cross-
tabulations, measures of central tendencies such as means and medians). In some cases, 
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collected survey data can be analysed through the use of inferential statistics (e.g. parametric 
or non-parametric tests, regression analyses—a type of statistical test used to look for 
associations between dependent and independent variable) (Field, 2013). For instance, 
responses to Likert items between groups of respondents (e.g. males and females) could be 
compared or associations between attitudes and self-reported behaviour could be explored 
using inferential statistics (e.g. regression analysis) (Aparasu, 2011). It is important to note that 
although cross-sectional research can help to identify possible associations, it cannot prove 
causality (i.e. it cannot prove that a certain characteristic or attitude causes a behaviour) 
(Bryman, 2013). In the context of the current study, the target behaviour (provision of MAS by 
CPs to older adults prescribed polypharmacy) could not be measured discreetly due to its 
complexity as discussed previously in Section 5.1. Accordingly, it was not possible to perform 
regression analysis to look for associations between CPs’ attitudes (independent variable) and 
their current MAS behaviour (dependent variable).  
5.3.3. Overview of the mixed methods research design  
The mixed methods study outlined in this chapter was separated into two sequential phases: in-
depth qualitative interviews with CPs (Phase 1), followed by a quantitative survey (Phase 2) to 
gain a broader overview of the experiences and attitudes of CPs from across the region of NI. 
Ethical approval for the study was granted by the School of Pharmacy (Queen’s University 
Belfast) research ethics committee (Appendix 5.1). The qualitative aspect of this mixed methods 
study has been reported in line with the COREQ checklist (see Section 5.5.6) which aims to 
ensure comprehensive reporting of qualitative methods including interviews (Tong et al. 2007).   
TDF1 (12 domains) was selected as the theoretical framework of choice for this mixed methods 
study (Michie et al. 2005). The decision was made on the basis that this was the theoretical 
framework used in the development of the previous patient-targeted adherence intervention 
(ID-MAP intervention; see Chapters 3 and 4). In addition, Huijq et al. (2014b) assessed the 
distinctiveness of theoretical domains in TDF using a discriminant content validity exercise with 
19 experts in behaviour change to assess whether items were assigned to one or multiple 
domains. Their findings supported ‘keeping to the 12 original domains as a basis for the 
development of TDF questionnaires’. The specific methods employed for Phase 1 (qualitative) 
and Phase 2 (quantitative) of the study are outlined in more detail below. 
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5.3.4 Phase 1: Qualitative methods (interviews) 
Rationale for the use of semi-structured interviews 
TDF-based semi-structured qualitative interviews were selected to gain an initial in-depth 
understanding of the target behaviour (provision of MAS to older adults prescribed 
polypharmacy). Interviews were selected over focus groups as they were deemed a more cost-
effective approach for the target audience (CPs) in this study. Focus groups would have been 
more difficult to schedule and more expensive (in comparison with interviews) as it would be 
necessary to compensate CPs for their time, locum cover and travel expenses to attend. 
Sampling and recruitment strategy 
To be eligible for inclusion in this study, CPs had to be currently working in a registered 
community pharmacy in NI. CPs who had previously taken part in the feasibility study (Chapter 
4) were not eligible to participate. A purposive (non-probability) sampling strategy was selected 
to allow for a wide variety of locations and types of pharmacies (independently owned 
pharmacies and chains). The sampling frame initially included CPs who were part of the School 
of Pharmacy undergraduate community pharmacy placement Network (QUB). This network 
included CPs from 164 pharmacies including independently owned pharmacies (n=24), 
small/medium chains (2-9 pharmacies) (n=64) and large chains (10+ pharmacies) (n=76) from 
across both urban and rural areas in NI. A ‘snowball sampling’ approach was also used, whereby 
recruited participants identified other potentially ‘information-rich’ individuals (Atkinson and 
Flint, 2001). Due to the nature of qualitative research, the sample size was determined by data 
saturation (i.e. the point at which no new themes were emerging) (Fusch and Ness, 2015). 
Preliminary data analysis ran concurrently with data collection to aid the identification of this 
point.  
Upon identification of CPs using the sampling strategy detailed above, the researcher (DP) made 
initial contact via telephone to inform them of the research study and invite them to take part. 
At this stage, CPs who expressed an interest in taking part were e-mailed a formal letter of 
invitation (Appendix 5.2), along with a study information sheet (Appendix 5.3). CPs were given 
a minimum of 5 working days to decide if they would like to take part, after which point the 
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Interview topic guide 
A semi-structured interview topic guide was developed by the research team (Appendix 5.4). 
Key interview questions were developed based on the 12 theoretical domains in TDF1 (Michie 
et al. 2005). Examples of questions included: 
 What skills do you currently have as a community pharmacist that would enable you to 
provide medication adherence support to an older adult who is prescribed 
polypharmacy? [Skills domain] 
 To what extent is providing medication adherence support to older adults prescribed 
polypharmacy a priority for you? [Motivation and goals domain] 
Prompts were included in the topic guide to elicit additional information from participants 
where necessary. The interview topic guide was piloted with two researchers from the Clinical 
and Practice Research Group (QUB) who were both practising in the community pharmacy 
setting (on a part-time basis) at the time of the study and had experience of providing MAS to 
older adults. Minor refinements were made to the topic guide based on feedback from pilot 
participants, for example, the wording of a small number of questions were slightly altered to 
improve clarity. 
Conduct of interviews 
Each interview took place via face-to-face at a time and location that was convenient for both 
the CP and the researcher (e.g. pharmacy site, CP’s own home). The researcher (DP, MPharm, 
PhD Research Student/practising community pharmacist) had previous experience with 
qualitative research (focus groups) and had attended relevant training on qualitative research 
methodologies. Interviews were held between August and November 2016. Prior to the start of 
the interview, informed consent was collected in-person by the researcher (Appendix 5.5). 
Demographic details (e.g. job title, years qualified) were obtained at each interview to provide 
an overview of demographics of study participants. Each participant was offered an honorarium 
of £50 to account for the time dedicated to this study (funding was provided by the Harold and 
Marjorie Moss Charitable Trust Fund). Each interviewee was provided a certificate of 
participation on completion of the interview (Appendix 5.6). 
With participants’ permission, the interviews were audio-recorded and transcribed verbatim by 
the researcher. To ensure confidentiality, each participant was allocated a unique identification 
number (e.g. CP01, CP02 etc.). Transcripts were checked for accuracy prior to importing into a 
software package (NVivo® QSR 11) for organisation and analysis by the researcher (see Section 
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5.3.6 for further information on data analysis). All recordings, consent forms and personal 
contact details were stored either in a locked fire-resistant filing cabinet or on a password 
protected laptop, to which only the research team had access.  
5.3.5 Phase 2: Quantitative methods (survey) 
Rationale for the use of self-administered postal survey 
Following on from Phase 1 which involved in-depth qualitative interviews with a sample of CPs, 
Phase 2 aimed to gain a broader overview of the experiences and attitudes of CPs from across 
NI using a self-administered postal survey. This approach was selected as it allowed information 
to be obtained from a larger sample of participants within a short period of time and with 
relatively little cost. A self-administered approach was selected as this helps to avoid the 
‘interviewer effect’ which can otherwise lead to social desirability bias (Bryman, 2013). A postal 
survey was selected over an electronic survey due to the poor response rates often associated 
with the latter (Neuman, 2013; Hardigan et al. 2016). In addition, individual email addresses 
were not available to the researcher, making electronic distribution unfeasible. 
Content of questionnaire 
The questionnaire (Appendix 5.7) contained three sections as outlined in Figure 5.1 below. The 
structure and content of the questionnaire was developed based on similar literature (Bright et 
al. 2009; Mansoor et al. 2014; Mansoor et al. 2015; Clyne et al. 2016), findings from the 
qualitative interviews (Phase 1), and with respect to the theoretical domains in TDF1 (Michie et 







Figure 5.1: An overview of the content of the three sections within the questionnaire  
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Section 1 of the questionnaire contained demographic questions (n=16) including questions 
about gender, number of years practising as a CP, type of community pharmacy store they 
worked in, training undertaken on medication adherence and current service provision (i.e. MUR 
and MYM provision). 
Section 2 of the questionnaire focused on CPs’ experience of providing MAS. At the start of this 
section, a brief overview of the 2009 NICE guidance on MAS provision was provided (National 
Institute for Health and Clinical Excellence, 2009). This outlined exactly what MAS entailed (i.e. 
identifying/assessing non-adherence and delivering tailored interventions to improve 
adherence) and included illustrative examples. It was deemed necessary to include this 
information for the benefit of those who were unfamiliar with the term ‘medication adherence 
support’. The qualitative aspect of this study (Phase 1) highlighted that some CPs associate the 
term solely with the provision of MDS (plastic containers which segregate medications into days 
and times of the week to aid administration), as opposed to the full range of activities that 
medication adherence can encompass.  
Following the overview of NICE guidance, CPs were asked to report how frequently they 
identified/assessed non-adherence in older patients (e.g. through pharmacy-held records) and 
how frequently they delivered tailored adherence interventions (e.g. recommended the use of 
self-monitoring strategies). In total there were 24 items in this section, each based on a five 
point Likert-type ordinal scale (very frequently, frequently, occasionally, rarely, never/not at all). 
An open-style question was presented at the end of this section to identify any additional 
adherence support activities that were not previously covered.  
Section 3 of the questionnaire focused on CPs’ attitudes (barriers, facilitators) towards the 
provision of MAS. TDF1 was used as the theoretical framework for this section and 11 out of the 
12 domains were assessed. As highlighted previously, the ‘Nature of behaviours’ domain has 
been described as slightly different from the other domains in TDF1 in that it represents 
‘essential characteristics of the behaviour’ (dependent variable), rather than a predictor of the 
behaviour (independent variable) (Cane et al. 2012). The nature of behaviours was assessed as 
part of Section 2 of the questionnaire which examined CPs’ experiences of providing MAS and 
so was excluded from Section 3.  
TDF1 is a comprehensive framework with 12 theoretical domains, each of which includes a range 
of theoretical constructs, ranging from 4 to 24 constructs per domain (Michie et al. 2005). As it 
was deemed impractical to measure each individual construct sufficiently as part of the 
questionnaire, barriers and facilitators to the target behaviour were assessed at the domain 
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level. Between two to five Likert items (on a 5 point scale; strongly agree to strongly disagree) 
were assigned to each TDF domain (n=11) using a group consensus approach (37 items in total). 
This method followed the approaches used in the development of previous TDF-based 
questionnaires (Amemori et al. 2011; Beenstock et al. 2012; Manikam et al. 2015; McParlin et 
al. 2016). For example, the item ‘I know how to provide medication adherence support to older 
patients in line with NICE guidance’ was assigned to the domain ‘Knowledge’ and the item ‘I am 
confident that I can address any medication adherence problems that I encounter with older 
patients’ was assigned to the domain ‘Beliefs about capabilities’. Likert items within each 
domain were developed based on barriers and facilitators that had been identified in the 
qualitative interviews (Phase 1). Where possible, Likert items (n=21) were adapted from 
previous TDF-based questionnaires (Amemori et al. 2011; Beenstock et al. 2012; Taylor et al. 
2013; Huijg et al. 2014a; McParlin et al. 2016). To ensure relevance to the current context, it was 
necessary to devise a number of new items (n=16) based on the qualitative findings. At the end 
of this section, CPs were instructed to provide any further comments they felt were relevant to 
the provision of MAS. This open-style question aimed to identify any additional barriers or 
facilitators to providing MAS that had not been covered previously.  
The approach undertaken in developing the questionnaire aimed to ensure that its content 
covered the main research questions whilst being relevant to the target audience and as short 
as possible. This was deemed necessary to reduce ‘respondent fatigue’ and maximise the 
response rate (Bryman, 2013).  
Face validity and piloting of questionnaire 
Face validity of the questionnaire was assessed by three members of the research team (with 
experience of using the TDF) who assessed whether the items assigned to each theoretical 
domain, appeared on the surface to measure what they were intended to measure. The 
questionnaire was also piloted with five pharmacists from the Clinical and Practice Research 
Group at QUB who had current (n=4) or previous experience (n=1) of working in the community 
pharmacy setting and experience of providing MAS to older people. The aim of this was to 
ensure the readability and acceptability of the questionnaire. Following pilot testing, minor 
amendments were made to questions (e.g. ambiguous items were reworded) prior to the first 
mailing to CPs. Pilot responses were not included in the final sample.  
Sampling and recruitment strategy 
The target population for the questionnaire was CPs working in the region of NI, excluding those 
who had participated in Phase 1 of the current study (qualitative interviews) or in the previous 
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feasibility study (Chapter 4). The Pharmaceutical Society of Northern Ireland (PSNI) is the 
regulatory body with which all CPs working in NI are required to register. The PSNI register 
contains over 2,400 pharmacists working across a range of sectors including community, 
hospital, industry, and academia. Although it was possible to search for the surnames of 
pharmacists who were registered with the PSNI, the contact details of individual CPs were 
confidential and unavailable for research purposes. The PSNI were able to provide addresses for 
all currently registered pharmacy premises in NI. The list provided by the Society included other 
types of pharmacy premises such as prison and hospital pharmacies. The list (generated by the 
PSNI) was hand-searched and pharmacies other than community pharmacies were removed (in 
addition to pharmacies that participated in Phase 1 and in the feasibility study as discussed 
above). The final list, which included 521 community pharmacies, was used as the sampling 
framework for this quantitative study. 
Distribution of questionnaires 
A short invitation letter (Appendix 5.8), paper copy of the questionnaire and freepost return 
envelope was posted to the 521 community pharmacies in the sampling framework. As the 
names of individual CPs working in each pharmacy were not available to the researcher, letters 
were addressed to the ‘pharmacist in charge’. It was anticipated that the questionnaire would 
most likely be answered by the store manager/proprietor, however, pharmacists in other roles 
(e.g. support pharmacists) were not prohibited from taking part. A specific date for completion 
was highlighted in the invitation letter and participants were informed that their anonymity 
would be guaranteed. The letter provided a brief overview of the research study and included 
contact details for the research team for those wishing to find out further information or ask 
any questions.  
As a reminder and to encourage completion, a complete re-mailing was carried out four weeks 
after the first postal mailing. This second mailing included a reminder letter (Appendix 5.9) in 
addition to another copy of the questionnaire. As the survey was anonymous, it was necessary 
to post reminder copies to all community pharmacies in the sampling frame (n=521). The 
reminder letter clearly indicated that those CPs who had already taken the time to complete the 
questionnaire did not need to complete it again. Participation in the study was voluntary and 
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Response rate and non-response bias  
As discussed above, to maximise the response rate, a reminder copy of the questionnaire was 
posted out after four weeks. Efforts were made to restrict the length of the questionnaire and 
e-signatures of the researchers were included on the cover letter to personalise it. Due to a lack 
of information about CPs working in each pharmacy, it was not possible to address letters to 
individual pharmacists. Incentives were not included due to the costs associated with these. 
Following a low initial response rate, the research protocol was amended and ethical approval 
was sought to promote the questionnaire via relevant social media outlets (e.g. Twitter) after 
the second mailing of the questionnaire. 
Demographic data were also collected from respondents to allow this to be compared to 
demographic data from all pharmacists on the PSNI register. The aim of this was to help identify 
any differences between responders and non-responders so that potential non-response bias 
could be detected.  
Questionnaire data management  
Each respondent was assigned a unique identifier number based on the order in which 
questionnaires were returned (e.g. R01, where R denoted respondent and 01 denoted the 
questionnaire number). Questionnaire responses were entered by the researcher into IBM’s 
SPSS Version 24.0. Any missing responses were coded according and were subsequently 
excluded from statistical analyses (see Section 5.3.6 for details of data analysis). To check for 
inaccuracies in coding, a random 10% sample was generated in SPSS and double-checked. Out 
of the 1,290 variables that were double-checked, only three inaccuracies were identified (and 
corrected) giving an inaccuracy rate of 0.23%; this low level was deemed to be acceptable. 
Qualitative responses from the two open-style questions were entered into Microsoft Word 
2016.  
5.3.6 Data analysis of interviews and questionnaires 
In a similar approach used to develop the patient-targeted intervention (see Chapter 3; 
qualitative methods only), data analysis for the current study consisted of three key stages. For 
the current mixed methods study, it was necessary to slightly modify data analysis Stages 1 and 
2 (from Figure 3.1 in Chapter 3) to incorporate the additional quantitative methods employed. 
The three stages have been summarised in Figure 5.2 with further details provided in the 
subsequent text.  
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Key TDF domains mapped to BCTs 
using primary reference source (Cane 
et al. 2015)
Key TDF domains mapped to BCTs in 
secondary reference source (Michie et 
al. 2008)2
Production of a combined list of BCTs 
(from primary and secondary sources) 
that could target each key domain
Consensus-based discussion to select 
BCTs to include in the intervention3
Triangulation of data from 
interviews and questionnaires 
(O'Cathain et al. 2010) 
Review of barriers and facilitators 
within each TDF domain by 
research team
Group-based discussion to assess 
each domain's 
relevance/importance to the 
target behaviour1
Discussion of the feasibility of 
overcoming identified barriers (or 
enhancing facilitators) within the 
community pharmacy setting
Consensus-based discussion to 
identify key domains to target 
with an intervention




-Framework analyis (TDF1 as 
theoretical framework)
-Content analysis (themes identified 
i.e. barriers and facilitators)
Stage 1b: Quantitative analysis 
(survey)
-Descriptive analysis of demographics 
and CPs' experience of providing MAS
- Identification of domains containing 
potential barriers/facilitators to 
providing MAS
Figure 5.2: An overview of the three stages involved in data analysis  
1 Domain was considered relevant/important if it was frequently coded as part of the qualitative analysis (interviews) and/or it contained items that reflected 
potential barriers/facilitators to the target behaviour based on the quantitative analysis (survey); 2 No BCTs mapped to ‘Memory, attention and decision processes’ 
and ‘Social/professional role and identity’ domains in the primary reference source hence the secondary reference source was consulted; 3 Selection of BCTs was based 
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Data analysis Stage 1a: Identification of determinants of medication adherence support 
provision by CPs from qualitative interviews 
In line with methods outlined previously (Chapter 3), qualitative data analysis consisted of: 
familiarisation, framework analysis (with TDF1 as the analytical framework) and inductive 
content analysis to identify emergent themes (i.e. barriers and facilitators) within each TDF 
domain. Data analysis was undertaken by three independent researchers (two researchers 
per transcript) and disagreements were resolved through discussion. Refer back to Chapter 
3 (Section 3.3.7) for further details of these methods.     
Data analysis Stage 1b: Identification of determinants of medication adherence support 
provision by CPs from the quantitative survey 
Descriptive statistical analyses (e.g. frequencies, means, ranges) were conducted for 
demographic data collected in Section 1 of the questionnaire (e.g. gender, years practising 
as a CP). Descriptive statistical analyses (frequencies) were also employed for Section 2 of 
the questionnaire which explored CPs’ experience of providing MAS to older adults 
prescribed pharmacy (e.g. frequency of providing MDS, frequency of recommending the use 
of reminder strategies). Responses from the open-style questions (n=2) in the questionnaire 
were qualitatively analysed for emergent themes.  
Section 3 of the questionnaire explored CPs’ attitudes (i.e. determinants) towards the 
provision of MAS to older adults prescribed polypharmacy. Descriptive statistical analyses 
were employed to explore the proportion of CPs in agreement or disagreement with each 
Likert item in this section (n=37; each Likert item was assigned to one of 11 domains in TDF1). 
Each individual response to Likert items was assigned an integer (strongly agree=1, agree=2, 
neither agree nor disagree=3, disagree=4, strongly disagree=5).   
The median value for each individual Likert item was then calculated as a measure of central 
tendency. For ordinal data (e.g. individual Likert items), calculating the median is more 
appropriate than calculating the mean as the difference between responses cannot be 
deemed equivalent (Jamieson, 2004). The median is also more appropriate where data are 
skewed as this measure is not as strongly affected by outliers (Laerd, 2013). Lower median 
scores for a Likert item (score of 1 or 2) indicated mainly agreement with the Likert statement 
highlighting that respondents did not deem this to be a barrier to the target behaviour. 
Higher scores for a Likert item (score of 4 or 5) indicated more disagreement with the Likert 
statement, highlighting a potential barrier to the target behaviour. For ease of data 
interpretation some items were reverse-phrased from their original phrasing in the 
questionnaire so that all items could be analysed in the way described above to identify 
  Chapter 5  
173 
 
potential barriers (see Section 5.4.2) For example, if CPs mainly disagreed with the Likert item 
‘I know how to provide medication adherence support in line with NICE guidance’ (domain: 
knowledge) then this would produce a high median indicating a potential barrier (i.e. a lack 
of knowledge). Therefore, when interpreting the quantitative findings, although the term 
barrier is mainly used, it is recognised that some items are potentially facilitators when 
reverse worded. TDF domains that contained at least one Likert-item with a high median 
score of 4 or 5 were identified as possible targets for behaviour change as these contained 
potential barriers to the target behaviour. For example, if a median score of 4 was calculated 
for the Likert-item ‘I receive sufficient reimbursement for providing MAS to older patients’ 
(domain: ‘Motivation and goals’), this would have indicated that pharmacists mainly 
disagreed with the attitude statement and felt they received insufficient reimbursement, 
highlighting a potential barrier. Subsequently, the TDF domain ‘Motivation and goals’ would 
have been considered as a potential target for behaviour change. One item [‘Others (e.g. GPs, 
carers) decide which adherence support strategies are required by older patients] had the 
potential to be either a barrier or facilitator depending on the appropriateness of the 
recommendations made and was therefore excluded from this analysis. 
Data collected from Likert items were considered to be ordinal data and therefore not 
normally distributed (evident from skewed frequency distribution graphs). Consequently, 
non-parametric tests were deemed more appropriate and used to explore associations 
between different groups of CPs (e.g. males and females) and their responses to individual 
Likert items within each TDF domain (n=36). Mann-Whitney U (MWU) was selected for two 
independent groups (e.g. gender) and Kruskal-Wallis (KW) was selected for three 
independent groups (type of pharmacy). Where significant differences were identified using 
KW, post-hoc pairwise comparisons were explored (Dunn’s multiple comparisons test) and 
significance values adjusted using the Bonferroni correction for multiple tests. This 
adjustment was necessary because the performance of multiple tests on a data set can lead 
to an increased risk of Type 1 error (i.e. determining that there is a significant difference 
when one does not truly exist) (Field, 2013). MWU and KW were selected over the Chi (X2) 
squared test as the latter does not take into account the ordered nature of the response 
categories seen with Likert items (Pallant, 2013). A 95% level of probability was set a priori 
with probability (p) values less than 0.05 deemed to be significant.  
Previous researchers who have designed TDF-based questionnaires have calculated 
Cronbach’s alpha (α) values for each TDF domain as an indication of how closely items 
assigned to a domain were related (Amemori et al. 2011; McParlin et al. 2016). As discussed 
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in Section 5.3.2, a minimum α value of 0.6 has been deemed sufficient for combining 
individual Likert items into a scale (Bryman, 2013). For the current study, Cronbach alpha 
values were less than 0.6 for six out of the 11 TDF domains assessed. It was therefore deemed 
inappropriate to combine median scores from individual Likert-items within each domain to 
calculate total median domain scores.  
To explore alternative underlying structures, researchers have undertaken factor analysis 
techniques such as Exploratory Factor Analysis (Amemori et al. 2011; Manikam et al. 2015) 
or Principal Components Analysis (PCA) (Beenstock et al. 2012; Alqubaisi et al. 2016; McParlin 
et al. 2016). For factor analysis, both Field (2013) and Pallant (2013) recommend that a 
sample size of 300 is ideally recommended in order to produce a stable factor solution. 
Others have argued that a minimum sample size of 150 respondents is required (Hutcheson 
and Sofroniou, 1999). In addition to an adequate sample size, it is recommended that the 
ratio of respondents to items is ideally 10:1 but again others have argued that a ratio as low 
as 5:1 is sufficient (Nunnally, 1978; Hutcheson and Sofroniou, 1999; Osborne and Costello, 
2004). Factor analysis was not deemed appropriate for the current study as the sample size 
was below the recommended limit [n=135 when respondents with missing responses for any 
TDF item were excluded (listwise exclusion) and n=139-142 when respondents were only 
removed if there was a missing response to a particular item (pairwise exclusion) (Field, 
2013)]. In addition, the respondent to item ratio (3.9:1) was also below the lower 
recommended limit. This decision was made because inappropriate use of factor analysis 
could result in the incorrect extraction of factors/components and incorrect assignment of 
items to factors/components which could potentially lead to erroneous conclusions. 
Accordingly, it was deemed more appropriate to analyse individual Likert items that were 
assigned to each domain a priori using group consensus.  
Data analysis Stage 2: Triangulation of findings and identification of key TDF domains 
Data from qualitative and quantitative methods were integrated at the point of data 
interpretation (O’Cathain et al. 2010). Key findings from both methods were listed together 
to allow the research team to explore similarities and differences (Farmer et al. 2006). The 
research team discussed potential barriers identified within each domain and used the 
frequency of interview coding as a crude measure of the domains relevance/importance. The 
findings from the quantitative analysis (i.e. domains containing items with high medians and 
therefore potential barriers) were also considered when assessing the relevance/importance 
of each TDF domain in the context of the target behaviour. A domain was subsequently 
deemed relevant/important in the context of the target behaviour if it was frequently coded 
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in the qualitative analysis and/or the findings from the quantitative analysis indicated that 
there was a potential barrier (or multiple barriers) within the domain (highlighted by the 
presence of TDF Likert items with high medians of either 4 or 5).  
As discussed previously (Chapter 3), a domain can be deemed relevant/important to the 
behaviour but it may not be feasible to target the barriers (or enhance the facilitators further) 
with an intervention. The research team therefore used a group consensus approach to 
select domains containing barriers that could feasibly be overcome (or facilitators that could 
be enhanced) using strategies delivered either as part of a CP training package and/or as part 
of a future research study (e.g. incentives, reminders). Domains that could be feasibly 
targeted were termed ‘key domains’.  
Data analysis Stage 3: Mapping of Key TDF domains to BCTs 
Key domains were then mapped across to BCTs using methods developed by Michie et al. 
(2008) and updated by Cane et al. (2015). The methods for this mapping approach have 
previously been discussed at length in Chapter 3 (Section 3.3.7). BCTs were selected using a 
group consensus approach and decisions were informed by the triangulated findings from 
the qualitative (Phase 1) and quantitative analyses (Phase 2). The research team considered 
the applicability of each BCT to the target behaviour (provision of MAS to older adults 
prescribed polypharmacy) and the target audience (CPs). Potential difficulties with delivering 
BCTs, as part of a training workshop and/or in a future research study, were taken into 
consideration at this stage. For example, delivery of the BCT ‘Motivational interviewing’ 
would require specialised training for research staff which may not be feasible. This approach 
follows recommendations made by WIDER that recommends reporting on the ‘…change 
techniques used in the intervention’ (e.g. the CP training package) and ‘the causal processes 
targeted by these change techniques’ (Albrecht et al. 2013).  
  
  Chapter 5  
176 
 
5.4 Results  
5.4.1 Summary of findings from qualitative interviews (Phase 1) 
Interview participant characteristics 
Fifteen CPs took part in qualitative interviews between August and November 2016. More 
than half of CPs (56.6%) who were contacted by the researcher (total n=27) agreed to take 
part. The most common reasons stated for refusal were a lack of time or previous 
participation in research. Participants had been registered with the PSNI for an average of 
14.1 years (range 1-31 years). A small minority of CPs (20%; n=3) had additional pharmacy 
qualifications including a Clinical Diploma/Masters in Community Pharmacy (n=2) or a PhD 
(n=1). Less than half of CPs (40%; n=6) had received training on medication adherence and 
only a minority of CPs (13.3%; n=2) had participated in previous research on medication 
adherence (including service evaluations). Further demographic details are provided in Table 
5.1. Interviews ranged in duration from 30 to 72 minutes (average 46 minutes). Data 
saturation was reached by the fifteenth interview as no new themes were emerging.  
Table 5.1: Demographics of CP interview participants 
Demographic  Number of respondents in each category (%) 
Gender Female: 7 (46.7) 
Male: 8 (53.3) 
Type of pharmacy Independently owned: 7 (46.7) 
Small/medium chain (2-9 stores): 3 (20) 
Large chain (10+ stores): 5 (33.3) 
Location of pharmacy Rural area: 7 (46.7)  
Urban area: 8 (53.3) 
Current job title Proprietor (i.e. owner): 3 (20) 
Managerial role (but not owner): 8 (53.3) 
Non-managerial role (e.g. support pharmacist): 4 (26.7) 
 
Identification of determinants of medication adherence support provision (data analysis 
stage 1a findings: interviews) 
CPs reported a wide range of determinants (i.e. barriers and facilitators) that influenced the 
provision of MAS to older adults prescribed polypharmacy. The barriers and facilitators 
identified within each TDF domain are summarised in Table 5.2 together with illustrative 
quotes.  
 





Table 5.2: Determinants (barriers, facilitators) of CPs’ provision of MAS identified within each TDF domain and illustrative quotes (interviews) 
Domain Determinants (barriers, facilitator) of CPs’ provision of MAS to 
older adults prescribed polypharmacy 
Illustrative quotes 
Knowledge  Knowledge of medications/products/medical conditions 
(facilitator) 
 Lack of in-depth knowledge about 
medications/products/medical conditions/ (e.g. insulin 
products, diabetes) (barrier) 
 Knowledge of importance of adherence and consequences 
of non-adherence (facilitator) 
 Knowledge of patients (e.g. social background, medical 
history) (facilitator) 
 Knowledge of adherence problems/solutions (facilitator)  
 Lack of up-to-date knowledge on adherence problems and 
solutions (barrier) 
“So there’s the pharmaceutical knowledge and then I think just the community 
knowledge and background knowledge of knowing the patients and knowing 
their family set-up and, em, knowing their level of education…” (CP13)  
“I think we’re, we’re fairly aware of the… issues that are out there in terms of 
adherence.” (CP03) 
“…And giving them (CPs), sort of, even ideas that, that they could use within the 
pharmacy to help, help with the patients. And not just the simple Mediboxes… 
which are so time-consuming.” (CP07) 
“…you’re not going to give someone medication adherence sup– advice if you 
don’t really know— if, you know, that you don’t have obviously that, like, em, 
knowledge.” (CP05) 
Skills  Communication skills (e.g. listening, empathy, questioning 
skills) (facilitator) 
 Skills required to motivate/persuade older patients to 
adhere (facilitator)   
 Lack of skills required to motivate/persuade older patients 
to adhere (barrier) 
 Interpersonal skills (relationship-building, team-working) 
(facilitator) 
 Time management and problem solving skills (delegation, 
organisational skills) (facilitator) 
 Computer/technology skills (facilitator) 
 Lack of consultation skills (e.g. reviews, follow-ups) (barrier) 
“…communication skills is one of the most important ones to be able to converse 
with the patient. Em, and, eh, ask, sorry questions, so questioning skills, listening 
skills, everything within communication.” (CP13) 
“…any type of training where you’re, sort of, giving people ideas of how, how to 
approach people and just what way to speak with them, it’s– I think it would be 
good.” (CP07) 
“There’s a skill that would be needed, is how to actually instigate a review, how 
to, you know, get something happening, but then to actually come back and 
review it…” (CP09) 
Aw we try… are my persuasion skills that good? Sometimes yes but it can–… you 
do in ways with different people, and it’s back to the some of the people some of 















Table 5.2 (cont’d): Determinants (barriers, facilitators) of CPs’ provision of MAS identified within each TDF domain and illustrative quotes (interviews) 
Domain Determinants (barriers, facilitator) of CPs’ provision of MAS to 




role and identity 
 Important role to play in providing MAS including referral, 
liaison and social care roles (facilitator) 
 Not seen as major part of current role (barrier) 
 Unable to prescribe as part of current role (barrier) 
 Professional responsibility to support adherence (facilitator) 
 Isolated role/not integrated into primary care team (barrier) 
 Role unrecognised by others (e.g. patients, commissioners, 
GPs) (barrier) 
 Roles of pharmacy support staff (e.g. preparing MDS, 
identifying non-adherent patients) (facilitator) 
“In terms of their adherence with medication you are the last person in that 
chain before the medicine arrives with the patient. Em, so you— I suppose you 
have ultimate responsibility for understanding why they’re taking their medicines 
and how they should be taken.” (CP15)  
“…if there was something that I thought it wasn’t— it was beyond my 
responsibility I would still try and refer them to whoever… it was. Em, obviously 
like I can’t change their tablets over to something else but I, I can refer them on 
to the GP who can…” (CP01) 
“…the only potential problem I see is one, perception… of the public that this is 
our role.” (CP09) 
Beliefs about 
capabilities 
 Professional confidence (facilitator) 
 Lack of confidence in certain circumstances (e.g. 
unfamiliarity with medical conditions/medications) (barrier) 
 Lack of control over situations/difficult to change older 
patients’ adherence behaviours (barrier) 
 
“..when you say confident you, you, yeah you’d be confident to carry out the 
role…” (CP01) 
“…perhaps if it is some— you would even, medication itself, if you’re not overly 
familiar with it, maybe could make you feel maybe a bit less confident about, em, 
dealing with any issues.” (CP03) 
“I would like more training in, in engaging patients, you know, em, but I think a 
lot of it is down to confidence, you know, and em, but the MURs [Medicine Use 
Review Service] have definitely helped with that…” (CP15) 
 “Trying to break their determination down (laughs) ‘cause once they have an 
idea in their head, it’s very difficult to get them to move.” (CP04) 
Beliefs about 
consequences 
 Beliefs about potential positive outcomes (e.g. improved 
clinical outcomes, cost savings, fewer GP visits and hospital 
admissions) (facilitator) 
 Beliefs about personal gain (e.g. job satisfaction, increased 
respect) (facilitator) 
“I think there could be a financial benefit but also I think just a health benefit for 
















Table 5.2 (cont’d): Determinants (barriers, facilitators) of CPs’ provision of MAS identified within each TDF domain and illustrative quotes (interviews) 
Domain Determinants (barriers, facilitator) of CPs’ provision of MAS to 





 Beliefs that providing MAS improves the profile of 
community pharmacy (e.g. increased patient satisfaction, 
confidence) (facilitator) 
 Beliefs about potential costs and impact on time (i.e. 
negative impact on other services) (barrier) 
 Concerns about potential adverse events (e.g. side effects) 
when adherence improves (barrier) 
“…just personal gain in, like, eh, more— increased respect and maybe, like, that 
would come probably with more opportunities…” (CP05) 
“…You’d definitely— if you get a positive outcome it makes you feel good about 
your job.” (CP10) 
“ ‘cause once someone is non-adherent and then becomes adherent, potential is 
there that they could actually get really unwell. Because they’re not taking them 





 High intrinsic motivation (i.e. high personal priority) 
(facilitator) 
 Motivated by potential benefits to patients (e.g. improved 
clinical outcomes) (facilitator) 
 Lower priority than other pharmacy activities (e.g. 
dispensing, other paid services) (barrier) 
 Conflicting priorities (professional responsibility verses 
commercial priorities) (barrier) 
 Proprietors/owners largely motivated by financial rewards 
(barrier) 
 Employees less motivated by financial rewards (facilitator) 
 Prioritising high risk patients/medications (e.g. those with 
limited social support, patients taking warfarin) 
(facilitator)/(barrier) 
“Very high priority yeah, very important, very important.” (CP08) 
“Em, no I think it comes down to more than money. I think it’s a service we have 
to provide, whether we get paid for it or not…” (CP04)  
“I wouldn’t say it’s a priority at the minute… the priority would be patients who 
you look at and you see them going downhill or they’re not coping with their 
medication…” (CP02) 
“…we’ve a delicate balance between the commercial realities of having to keep 
customers happy and telling people this is what’s good for you, you have to do it, 
you don’t want to alienate people.” (CP06) 
“…the contractors, you would probably want some sort of a remuneration for it.” 
(CP14) 
 “…directly I’m not a contractor so I don’t get paid per MUR [Medicine Use 
Review]… I get paid to go in and do a day’s work, what that– a day’s work 














Table 5.2 (cont’d): Determinants (barriers, facilitators) of CPs’ provision of MAS identified within each TDF domain and illustrative quotes (interviews) 
Domain Determinants (barriers, facilitator) of CPs’ provision of MAS to 






 Difficult to remember (barrier) 
 Decisions tailored to individual patients (facilitator) 
 Involvement of patients, carers and other HCPs in decisions 
(facilitator) 
 Lack of structured approach to aid decisions (barrier) 
 
 “…without a formal assessment tool at the minute, em, it’s done very much on 
an individual basis…” (CP06) 
“Well the patient’s response to the questions or to the proposed interventions, 
em… so whether they would– whether a change would make any difference. Em, 
whether the GP buys into the change as well or the prescriber…” (CP15) 
“I think, you need some system that will highlight it, otherwise you see so many 
people, so many things that yeah some you might remember but no you 
wouldn’t consistently remember.” (CP02) 
“…we can put like notes on PMRs [Patient medication records] but sometimes 




 Time constraints due to heavy workload (barrier) 
 Currently funded services (MUR, MYM) (facilitator) 
 No service focusing specifically on adherence (barrier) 
 Accessibility of community pharmacy (facilitator) 
 Presence of multiple pharmacists (facilitator) 
 Inadequate pharmacist staff levels (barrier) 
 Adequate pharmacy support staff (levels, competency) 
(facilitator) 
 Technology (PMR, internet access, websites such as 
patient.co.uk) (facilitator) 
 Physical resources (e.g. reminder charts) (facilitator) 
 Inadequate space (barrier) 
 Lack of integration in primary healthcare team (barrier)  
 Lack of access to full medication history (ECR) (barrier) 
“But pharmacies like to say time is a problem–we don’t have time to do 
anything. (Laughs) No I think time is the only one but you would just fit it in– just 
one of those things.” (CP04) 
“….the only thing that puts me off is time, you know, pharmacy’s got busier and 
busier…” (CP15) 
 “…well I suppose just MURs [Medicine Use Review Service] and medicines 
management [Managing Your Medicines Service] would help, you know, would 
help identify the problems.” (CP01) 
“So if I’m not integrated within a team, then there’s, there’s only so much I can 
actually do...” (CP09) 
 “So I think, em, even having access to maybe the ECR [Electronic Care Record] or 
something like that where we could see exactly what sort of prescriptions have 
been… processed and, and that kind of thing would help to sort of establish if 













Table 5.2 (cont’d): Determinants (barriers, facilitators) of CPs’ provision of MAS identified within each TDF domain and illustrative quotes (interviews) 
Domain Determinants (barriers, facilitator) of CPs’ provision of MAS to 
older adults prescribed polypharmacy 
Illustrative quotes 
Social influences  Positive influences from patients, relatives, pharmacy 
support staff and other HCPS (e.g. GP, nurse, formal carers) 
(facilitator) 
 Resistance from patients (barrier) 
 Resistance/lack of support from GPs and surgery staff 
(barrier) 
 Pressure from others to provide solutions (e.g. pressure 
from formal carers, hospital staff to provide MDS) (barrier) 
 Others make decisions about solutions (barrier/facilitator) 
 Influence from colleagues in senior positions to focus on 
business priorities (e.g. proprietor, management) (barrier) 
“All of our patients have either been referred by doctors, by carers, by relatives.” 
(CP11) 
“Some patients, no matter what you say to them or how much you try and you 
try to talk to them about something, just don’t want to know.” (CP01)  
“…for whatever reason the powers that be, be it the family, the doctors, the 
carers– ‘cause the carers completely refuse to deal with medication if it’s not in a 
blister pack [Monitored Dosage System]” (CP04) 
“Sometimes you can, you can, reach a bit of a, not loggerheads but you’re kind 
of having problems with maybe getting onto a surgery, trying to get stuff sorted 
and you’re getting resistance there.” (CP12) 
“…obviously, like, you’re working for a company— would be, like, patients but 
your other, like, staff obviously, like, my, like, manager would have like a huge 
say in that and, em, like, what… we need to focus on, like in any kind of 
business…” (CP05) 
Emotion  Positive affect (i.e. encouraged)(facilitator) 
 Worried about providing incorrect advice (barrier) 
 Stress due to time constraints (barrier) 
 
“You feel like you’re helping somebody so you feel like you’re, you’re doing good 
so yeah it does make you feel good, if it, if it works out.” (CP01) 
 “It makes you feel good, that you’re actually doing something of benefit… and 
that they’re getting the best… that they can get.” (CP04)  
“I suppose a bit of a fear thing isn’t it like? Where, you’re afraid of saying the 
















Table 5.2 (cont’d): Determinants (barriers, facilitators) of CPs’ provision of MAS identified within each TDF domain and illustrative quotes (interviews) 
Domain Determinants (barriers, facilitator) of CPs’ provision of MAS to 




 Reactive behaviour (i.e. not proactive in identifying and 
supporting patients) (barrier) 
 Lack of formalised procedures (i.e. no standard operating 
procedures or framework currently in use) (barrier) 
 Record keeping (e.g. on PMR) (facilitator) 
 Positive feedback from patients  (facilitator) 
 Reminder systems as moderators of intention- behaviour 
gap (e.g. diary, notes on PMR) (facilitator) 
 Monitoring patients’ adherence behaviour (e.g. frequency of 
dispensing using PMR) 
“Speaking to the patient would probably be one of the main ones, seeing are 
they happier, you know. Do they feel like things have improved?” (CP01) 
“I suppose with their PMRs [Patient Medication Records] we’ve an opportunity 
to highlight sort of things on it… and throw up messages that maybe, you know, 
you can check back with them the next time…” (CP02) 
“…you’d like to assume that people’s following the directions and taking their 
medication as is, until that problem is identified. So maybe, potentially it might 
be something more proactive that we could do.” (CP12) 
Nature of the 
behaviours 
 Direct experience through provision of funded services (e.g. 
MUR, MYM services) (facilitator) 
 Identification of non-adherent patients is not routine 
(barrier) 
 Most routine activity is the supply of MDS (barrier) 
“Em… there’s nothing that I’d routinely do I suppose it would be coming from, 
like, the patient themselves.” (CP05) 
 “I think the current trend would be medidose boxes [Monitored Dosage 
System]… you know, if somebody’s having difficulty taking their tablets, put it in 
a medidose box but I’ve seen people do strange things with medidose boxes 
once they get them (Laughs).” (CP15) 
“… we’re kind of already doing it with our smoking cessation and our MURs 
[Medicine Use Review service], you know, Medicines Management [Managing 
Your Medicines Service], things like that.” (CP12)  
Key: ECR= Electronic summary of care record; HCP= Healthcare professional; MDS= Monitored Dosage System; MUR= Medicine Use Review; MYM= Managing Your Medicines service; PMR= 
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5.4.2 Summary of findings from the quantitative survey (Phase 2) 
Survey participant characteristics 
Seventy seven responses were received after the first mailing of the paper-based 
questionnaire and a further 66 responses were received after the second mailing. In total, 
143 questionnaires were returned giving a response rate of 27.4% (143/521). 
Demographic data for CPs who responded have been summarised in Table 5.3. Where 
available, data collected from survey participants were compared with demographic details 
of all pharmacists who are currently listed on the pharmaceutical register in NI (Fay, personal 
communication, 2017). As noted previously, demographics provided by the PSNI were not 
restricted to community pharmacists (i.e. data provided included pharmacists employed in 
other settings such as hospital, industry, academia). Information that was not made available 
to the researcher from the PSNI is marked with an asterisk in Table 5.3.  
Eighty-two respondents were female (57.3%), which, when compared to the PSNI register 
was marginally under-representative of females (68.1%). In relation to age categories, the 
PSNI provided a breakdown in different age groups to those that were used in the 
questionnaire, making direct comparison somewhat difficult. However, it appears that the 
age distribution of respondents is somewhat similar to those registered with the PSNI. 
Ninety-one (63.7%) survey respondents were aged 44 years or under, whereas in 2016, 68.1% 
of all PSNI pharmacist registrants were aged 40 years or under. Forty-nine survey 
respondents (34.3%) were aged 45 years or older, whereas in 2016, 31.9% of PSNI registrants 
were aged 41 years or older.    
CP respondents had been practising an average of 15.3 (SD: +11.2) years. Nineteen 
respondents (13.3%) had a postgraduate qualification (e.g. Independent Prescriber, Clinical 
Diploma). The PSNI was able to provide details of those with supplementary or independent 
prescribing qualifications (13.1%) and so this compared favourably with survey respondents 
who had a postgraduate qualification. Fifty-nine respondents (41.3%) worked for a large 
chain (10+ stores), 40 respondents (28.0%) worked for a small/medium chain (2-9 stores) and 
41 respondents (28.7%) worked at an independently-owned pharmacy. CPs also reported 
working across a range of locations: rural (n=43; 30.1%), suburban (n=32; 22.4%) and urban 
(n=65; 45.5%). Comparable data were not available from the PSNI on types of pharmacies 
and locations but the survey provided a wide range of views from across the spectrum of 
pharmacy types and locations in NI.  
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The majority of respondents reported working in a managerial role (n=114; 79.7%) such as 
superintendent pharmacist, proprietor or store manager. Less than a fifth of respondents 
reported working in non-managerial roles (n=25; 17.5%) such as a support pharmacist. Sixty-
four respondents (44.8%) reported being the only pharmacist during the working week, 
whereas 75 respondents (52.4%) reported having multiple pharmacists working in the store, 
ranging from additional part-time pharmacist staff (e.g. working only one day per week) up 
to four additional pharmacists daily. CPs reported having a mean of 3.84 (+1.83) non-
pharmacist support staff employed in their store (range: 1 to 10).  
The number of prescription items dispensed in pharmacies on an average weekday varied 
with the largest frequencies reported in the 200-299 items range (n=34; 23.8%) and 100-199 
items range (n=31; 21.7%). Twenty-two respondents (15.4%) worked in pharmacies that 
dispensed 500 items or more on an average weekday. A large proportion of respondents 
(n=90; 62.9%) estimated that over half of all patients who attended their community 
pharmacy were older adults. A large majority of respondents (n=113; 79.1%) estimated that 
at least half of all older patients who attended their pharmacy were prescribed four or more 
medications (i.e. polypharmacy). 
Most respondents (n=133; 93.0%) reported providing the MUR service in their clinical 
practice, whereas less than half of all respondents (n=61; 42.7%) reported providing the more 
comprehensive MYM review service. From those who provided the MUR service (n=133), 
75.2% of respondents documented the number of patients for whom they provided this 
service to in the last year [range: 0 to 120; mean: 70.2 (+42.7) patients]. From those who 
provided the MYM service (n=66), 72.7% documented the number of patients for whom they 
provided this service to in the last year [range: 0 to 30; mean: 8.08 (+ 8.35) patients]. The 
majority of respondents (n=139; 97.3%) provided MDS to older patients with 11.9% (n=17) 
reporting that they supplied MDS to more than 100 older patients every month.  
Just over half of all respondents (n=75; 52.4%) reported that they had received some form of 
training on medication adherence in the previous five years, but only a small minority (n=13; 
9.1%) had participated in research, audits  or service evaluations specifically related to 
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Table 5.3: Demographic profile of community pharmacist survey respondents 
 Number of survey 
respondents (%) 
Number of registrants on PSNI 
register (%) 
Gender 
Male 58 (40.6) 768 (31.9) 
Female 82 (57.3) 1637 (68.1) 
Missing 3 (2.1) N/A 
Age (years) 
<25  11 (7.7) 20-301  773 (32.1) 
25-34 56 (39.2) 31-40  835 (34.7) 
35-44  24 (16.8) 41-50  474 (19.7) 
45-54  37 (25.9) 51-60  256 (10.6) 
55-64  11 (7.7) 61-70  59 (2.5) 
65+  1 (0.7) 70+  8 (0.3) 
Missing 3 (2.1) N/A N/A 
Years practising as a community pharmacist 
< 5 35 (24.5) * 
6-11 35 (24.5) * 
12-17 11 (7.7) * 
18-23 14 (9.8) * 
24-29 29 (20.3) * 
30-35 12 (8.4) * 
> 36 4 (2.8) * 
Missing  3 (2.1) * 
Postgraduate qualification (e.g. Independent Prescriber) 
Yes 19 (13.3) 315 (13.1)2 
No 121 (84.6) 2090 (86.9) 
Missing 3 (2.1) N/A 
Type of community pharmacy 
Large chain (10+ stores) 59 (41.3) * 
Small/medium chain (2-9 stores) 40 (28.0) * 
Independently-owned  41 (28.7) * 
Missing 3 (2.1) * 
Location of community pharmacy 
Rural 43 (30.1) * 
Suburban 32 (22.4) * 
Urban 65 (45.5) * 
Missing 3 (2.1) * 
Current job role in community pharmacy 
Managerial 114 (79.7) * 
Non-managerial 25 (17.5) * 
Missing 4 (2.8) * 
Number of additional pharmacists working in store 
None 64 (44.8) * 
Part-time basis (e.g. 1 day per week) 5 (3.5) * 
One to two every week day 60 (42) * 
Three to four every week day 9 (6.3) * 
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Table 5.3 (cont’d): Demographic profile of community pharmacist survey respondents 
 Number of survey 
respondents (%) 
Number of registrants on 
PSNI register (%) 
Number of support staff working in store 
1-2 37 (25.9) * 
3-4 54 (37.8) * 
5-6 38 (26.6) * 
7+ 11 (7.7) * 
Missing 3 (2.1) * 
Average number of prescription items dispensed on weekdays 
< 100 7 (4.9) * 
100-199 31 (21.7) * 
200-299 34 (23.8) * 
300-399 27 (18.9) * 
400-499 19 (13.3) * 
500-599 13 (9.1) * 
600+ 9 (6.3) * 
Missing 3 (2.1) * 
Percentage3 of patients aged 65 years+ who attend their pharmacy 
< 25% 2 (1.4) * 
25-49% 47 (32.9) * 
50-74% 84 (58.7) * 
75%+ 6 (4.2) * 
Missing 4 (2.8) * 
Percentage3 of older patients prescribed polypharmacy who attend their pharmacy  
< 25% 2 (1.4) * 
25-49% 25 (17.5) * 
50-74% 69 (48.3) * 
75%+ 44 (30.8) * 
Missing 3 (2.1) * 
Number of older patients supplied with a MDS in previous month 
None 1 (0.7) * 
1-25 17 (11.9) * 
26-50 38 (26.6) * 
51-75 35 (24.5) * 
76-100 32 (22.4) * 
>100 17 (11.9) * 
Missing 3 (2.1) * 
Provision of Managing Your Medicines service 
Yes 61 (42.7) * 
No 74 (51.7) * 
Missing 8 (5.6) * 
Provision of Medicine Use Review service 
Yes 133 (93.0) * 
No 7 (4.9) * 
Missing 3 (2.1) * 
Training on adherence in previous 5 years 
Yes 75 (52.4) * 
No 64 (44.8) * 
Missing 4 (2.8) * 
Participation in research, audits or service evaluations on adherence in previous 5 years 
Yes 13 (9.1) * 
No 126 (88.1) * 
Missing 4 (2.8) * 
 
 
Key: MDS= Monitored dosage system; N/A= Not applicable; PSNI= Pharmaceutical Society of Northern Ireland  
1 Different age range to the survey; 2Only included Supplementary and Independent Prescribers; 3Estimated 
percentage  
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Survey participants’ experiences of providing medication adherence support 
In Section 2 of the questionnaire, CPs were asked about their experiences of providing MAS 
to older patients prescribed polypharmacy. Less than half of CPs reported very frequent or 
frequent use of pharmacy held-records (n=64; 44.8%) or return of unused medications (n= 
59; 41.3%) as methods for identifying non-adherent older patients. Only a third of CPs (n=48; 
33.6%) reported very frequently or frequently asking older patients (in a non-judgemental 
manor) about missed doses of medications. Less than a third of CPs (n=43; 30.1%) reported 
very frequently or frequently exploring the underlying reasons for older patients’ non-
adherence (see Figure 5.3). 
 
Figure 5.3: Identification and assessment of non-adherence in older adults prescribed polypharmacy 




















I ask older patients in a
non-judgemental way if
they have missed any
doses of medications
I explore older patients’ 
























Strategies for identifying/assessing non-adherence in older patients
Very frequently Frequently Occasionally Rarely Never/not at all Missing
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Just over half of the respondents (n=79; 55.3%) reported that they very frequently or 
frequently considered options to improve adherence in discussion with older patients. Just 
over a third of CPs (n=55; 38.5%) reported very frequently or frequently tailoring adherence 
support strategies to the underlying reasons for non-adherence.   
Adherence solutions that were most frequently employed (i.e. more than 70% of CPs 
reported very frequent or frequent provision) included: prescription collection services (n= 
134; 93.7%), supply of MDS at the request of others (n=126; 88.1%), 
support/reassurance/encouragement (n=114; 79.7%), prescription ordering services (n=109; 
76.2%) and deliveries to patients’ homes (n=101; 70.6%). Adherence solutions that were 
delivered least frequently (i.e. less than 30% of CPs reported very frequent or frequent 
provision) included: techniques to increase motivation such as goal-setting or action plans 
(n=18; 12.6%), requesting changes to medications/regimens (n=30; 21%), provision of 
alternative packaging (n=39; 27.3%), recommendations to purchase adherence aids (n=39; 
27.3%) and recommendation of self-monitoring strategies (e.g. diary, calendar) (n=42; 





































































  Chapter 5 
190 
 
Only a few additional adherence strategies were reported by respondents in the open-style 
question at the end of Section 2. These included: synchronising medications so that they 
could all be ordered at one time (n=3), home visits (n=1), colour coding time slots on MDS 
(n=1) and asking patients to return MDS packaging before providing a new supply (n=1).  
Identification of determinants of medication adherence support provision (data analysis 
stage 1b findings: questionnaire) 
Section 3 of the questionnaire included 37 Likert items that were assigned to 11 of the 12 
domains of TDF1 (2-5 items per domain). The proportion of CPs that agreed or disagreed with 
each Likert item is displayed in Table 5.4. As discussed previously in Section 5.3.5, for ease of 
data interpretation, some of the items in the table have been reverse-phrased (from their 
original phrasing in the questionnaire). The reason for this was to allow a median of either 4 
(mainly disagreement) or 5 (mainly strong disagreement) to signify a potential barrier to the 
target behaviour. As noted earlier, one item was excluded from this analysis as it could be 
either a barrier or a facilitator depending on individual circumstances (see Section 5.3.5). Six 
out of the 36 items analysed had high medians (of 4 or 5) highlighting potential barriers and 
therefore targets for behaviour change. These items had been assigned a priori to four TDF 
domains: ‘Skills’, ‘Environmental context and resources’, ‘Memory, attention and decision 
processes’ and ‘Motivation and goals’. High medians for Likert items are highlighted in bold 
text in Table 5.4. 
Within the ‘Skills’ domain, only 10.6% (n=15) of CPs expressed agreement with the item, ‘I 
do not require additional training on techniques that can be used to increase older patients' 
motivation to adherence’ (item reverse-phrased in the questionnaire). Within the 
‘Environmental context and resources’ domain: only 14% (n=20) of CPs expressed agreement 
with the item, ‘I have enough time to provide MAS to older patients’ (item reverse phrased 
in questionnaire), just under one third of CPs (n=45; 31.5%) expressed agreement with the 
item, ‘I have sufficient pharmacist staff levels to allow me to provide MAS to older patients’ 
and a minority of CPs (n=13; 9.1%) expressed agreement with the item, ‘Lack of access to 
patients’ medical notes is not a barrier to providing MAS’ (reverse phrased in questionnaire). 
Within the ‘Motivation and goals’ domain, only a very small minority of CPs (n=8; 5.6%) 
expressed agreement with the item, ‘I receive sufficient reimbursement for providing MAS 
to older patients’. In the ‘Memory, attention and decision processes’ domain, less than one 
tenth of CPs (n=13; 9.1%) reported agreement with the item, ‘Deciding on the best adherence 
support strategy for older patients is easy’ (reverse-phrased in questionnaire). 





Table 5.4: Community pharmacists’ responses to Likert items within each TDF domain 
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(score:2) 
Neither agree 

















Knowledge I know how to provide MAS  to older patients in line with 
NICE guidance 





I know the appropriate questions to ask older patients to 
determine underlying reasons for non-adherence 
16 (11.2) 87 (60.8) 26 (18.2) 12 (8.4) 1 (0.7) 1 (0.7) 2.0 (2.0-3.0) 
I have sufficient knowledge of the range of adherence 
strategies that are available to support older patients 
14 (9.8) 67 (46.9) 32 (22.4) 27 (18.9) 2 (1.4) 1 (0.7) 2.0 (2.0-3.0) 
Skills I have been trained to provide MAS to older patients in line 
with NICE guidance 
11 (7.7) 33 (23.1) 45 (31.5) 44 (30.8) 9 (6.3) 1 (0.7) 3.0 (2.0-4.0) Yes (domain 
contains an 
item with 
high median) I have the communication skills required to provide MAS to 
older patients 
38 (26.6) 89 (62.2) 13 (9.1) 1 (0.7) 0 (0) 2 (1.4) 2.0 (1.0-2.0) 
I do not require additional training on techniques that can 
be used to increase older patients' motivation to 
adherence2 
3 (2.1) 12 (8.5) 31 (21.7) 71 (49.7) 24 (16.8) 2 (1.4) 4.0 (3.0-4.0)1 
Social, 
professional 
role and identity  
Providing MAS to older patients is part of my current role 
as a community pharmacist 





It is my responsibility to provide MAS to older patients 22 (15.4) 83 (58.0) 29 (20.3) 7 (4.9) 1 (0.7) 1 (0.7) 2.0 (2.0-3.0) 
Older patients consider the provision of MAS to be part of 
my role as a community pharmacist 
10 (7.0) 52 (36.4) 56 (39.2) 22 (15.4) 1 (0.7) 2 (1.4) 3.0 (2.0-3.0) 
Beliefs about 
capabilities 
I find it easy to discuss medication adherence with older 
patients2 





I am confident that I can address any medication 
adherence problems that I encounter with older patients 
20 (14.0) 96 (67.1) 20 (14.0) 6 (4.2) 0 (0) 1 (0.7) 2.0 (2.0-2.0) 
I am confident that I can provide MAS to older patients 
even when they are not motivated 
13 (9.1) 82 (57.3) 28 (19.6) 19 (13.3) 0 (0) 1 (0.7) 2.0 (2.0-3.0) 
I am confident that I can provide MAS to older patients 
even when I am unfamiliar with their medical conditions 
 













Table 5.4 (cont’d): Community pharmacists’ responses to Likert items within each TDF domain 




























Providing MAS to older patients improves the profile of 
community pharmacy 





Providing MAS to older patients leads to health benefits 
for patients and cost-savings for the NHS 
65 (45.5) 67 (46.9) 6 (4.2) 0 (0) 1 (0.7) 4 (2.8) 2.0 (1.0-2.0) 
Providing MAS to older patients gives me job satisfaction 51 (35.7) 80 (55.9) 10 (7.0) 1 (0.7) 0 (0) 1 (0.7) 2.0 (1.0-2.0) 
Motivation and 
goals 
Seeing the benefits of providing MAS to older patients 
helps me to overcome barriers such as lack of time and 
reimbursement 
16 (11.2) 46 (32.2) 53 (37.1) 20 (14.0) 7 (4.9) 1 (0.7) 3.0 (2-3.0) Yes (domain 
contains an 
item with a  
high median) Providing MAS to older patients is a high priority for me in 
my daily practice1 
13 (9.1) 66 (46.2) 43 (30.1) 18 (12.6) 2 (1.4) 1 (0.7) 2.0 (2.0-3.0) 
I want to support more older patients with medication 
adherence in the future 
41 (28.7) 90 (62.9) 8 (1.4) 2 (1.4) 1 (0.7) 1 (0.7) 2.0 (1.0-2.0) 
It is important to always offer MAS to older patients 39 (27.3) 85 (59.4) 17 (11.9) 1 (0.7) 0 (0) 1 (0.7) 2.0 (1.0-2.0) 
I receive sufficient reimbursement for providing MAS to 
older patients 









Deciding on the best adherence support strategy for 
older patients is easy2 




I have sufficient pharmacist staff levels to allow me to 
provide MAS to older patients 





I have sufficient non-pharmacist staff levels to allow me 
to provide MAS to older patients 
8 (5.6) 47 (32.9) 26 (18.2) 40 (28.0) 21 (14.7) 1 (0.7) 3.0 (2.0-4.0) 
I have sufficient space in the pharmacy to allow me to 
provide MAS to older patients 
29 (20.3) 57 (39.9) 22 (15.4) 20 (14.0) 14 (9.8) 1 (0.7) 2.0 (2.0-3.0) 
I have enough time to provide MAS to older patients2 5 (3.5) 15 (10.5) 36 (25.2) 59 (41.3) 26 (18.2) 2 (1.4) 4.01 (3.0-4.0) 
Lack of access to patients medical notes is not a barrier 
to providing MAS2 















Table 5.4 (cont’d): Community pharmacists’ responses to Likert items within each TDF domain 




Agree N (%) 
(score:2) 
Neither agree 

















Social influences Colleagues in senior positions support me in providing 
adherence support to older patients 





I do not face resistance from GPs when trying to provide 
MAS2 
9 (6.3) 54 (37.8) 33 (23.1) 35 (24.5) 11 (7.7) 1 (0.7) 3.0 (2.0-3.0) 
I do not face resistance from patients when trying to 
provide MAS2 
8 (5.6) 60 (42.0) 43 (30.1) 31 (21.7) 0 (0) 1 (0.7) 3.0 (2.0-3.0 
Others (e.g. GPs, carers) decide which adherence support 
strategies are required by older patients3 
19 (13.3) 63 (44.1) 38 (26.6) 19 (13.3) 2 (1.4) 2 (1.4) 2.0 (2.0-3.0)2 
Emotion 
 
I do not worry about giving the wrong advice to older 
patients when providing MAS2 





I am comfortable talking to older patients about 
medication adherence2 
 
32 (22.4) 88 (61.5) 18 (12.6) 3 (2.1) 1 (0.7) 1 (0.7) 2.0 (2.0-2.0) 
Behavioural 
regulation 
I try to be proactive by planning how I can identify and 
support older patients with medication adherence 




this domain)  
I monitor and record the type of MAS that I provide to 
older patients 
6 (4.2) 43 (30.1) 34 (23.8) 52 (36.4) 6 (4.2) 2 (1.4) 3.0 (2.0-4.0) 
Receiving negative feedback from a patient regarding 
adherence support advice would not prevent me from 
offering this advice to others2 
15 (10.5) 82 (57.3) 25 (17.5) 18 (12.6) 1 (0.7) 2 (1.4) 2.0 (2.0-3.0) 
Key:  IQR= Interquartile range; MAS= Medication adherence support; MDS= Monitored dosage system; NICE= National Institute for Health and Care Excellence; N= Number of survey respondents; TDF= Theoretical 
Domains Framework 
1A high median of 4 or 5 signified a potential barrier to the provision of MAS;  2 Item reverse worded in questionnaire and rephrased/recoded for data analysis purposes; 3 This item could be either a barrier or facilitator 
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MWU and KW tests identified some significant differences between different groups of 
pharmacists. Differences in responses to Likert items were explored across gender, number 
of years practising (<10 years verses > 10 years), previous training (on medication adherence 
in last five years verses no training), number of pharmacists working in the store (only 
pharmacist verses two or more pharmacists) and the type of pharmacy (independently 
owned, small/medium chain, large chain). The results are presented in Table 5.5, Table 5.6, 
Table 5.7, Table 5.8 and Table 5.9, respectively. High medians are highlighted in bold text as 
these indicated potential barriers that could be targeted for behaviour change. Items with 
high medians (highlighted in bold) were identified in five domains in the subgroup analysis: 
‘Motivation and goals’, ‘Environmental context and resources’, ‘Skills’, ‘Behavioural 
regulation’ and ‘Social influences’.   
 





1 Includes those who strongly agreed or agreed; 2 Includes those who strongly disagreed or disagreed; 3 A high median of 4 or 5 signified a potential barrier to the provision of MAS; 4 Mann-
Whitney U test; 5 Item was reverse worded in questionnaire (reverse phrased and recoded for data analysis purposes)   
 
Table 5.5: Statistically significant differences in responses to TDF Likert items between male and female pharmacists 
TDF Likert Item (domain) Males Females Probability (p) value4 
Total N  N (%) who  
agreed1  




Total N N (%) who  
agreed1  




Providing MAS to older 
patients is part of my current 
role as a community 
pharmacist (social professional 
role and identity) 
58 53 (91.4) 1 (1.7) 2.0 (60.7) 82 65 (79.3) 3 (3.6) 2.0 (76.7) p=0.008*  
*Females expressed significantly less 
agreement than males 
Older patients consider the 
provision of MAS to be part of 
my role as a community 
pharmacist (social professional 
role and identity) 
57 31 (53.4) 6 (10.3) 2.0 (60.9) 82 29 (35.4) 17 (20.7) 3.0 (75.6) p= 0.024* 
*Females expressed significantly less 
agreement than males 
I find it easy to discuss 
medication adherence  with 
older patients5 (Beliefs about 
capabilities) 
58 46 (79.3) 3 (5.1) 2.0 (62.0) 82 56 (68.3) 9 (11.0) 2.0 (75.8) p=0.022*  
*Females expressed significantly less 
agreement than males 
Providing MAS to older 
patients is a high priority for 
me in my daily practice5 
(Motivation and goals) 
58 39 (67.2) 7 (12.0) 2.0 (61.3) 82 38 (46.3) 13 (15.8) 3.0 (76.2) p=0.02* 
*Females expressed significantly less 
agreement than males 
I receive sufficient 
reimbursement for providing 
MAS to older patients 
(Motivation and goals) 
58 2 (3.4) 51 (87.9) 5.03 (84.0) 82 6 (7.3) 55 (67.0) 4.03 (60.0) p<0.001* 
*Males expressed less significantly 
agreement than females 
I do not face resistance from 
GPs when trying to provide 
MAS4 (Social influences)  
58 31 (53.4) 11 (18.9) 2.0 (60.9) 82 31 (37.8) 33 (40.3) 3.0 (76.9) p=0.013*  
*Females expressed significantly less 
agreement than males 
I do not face resistance from 
patients when trying to 
provide MAS5 (Social 
influences) 
58 34 (58.6) 7 (12.1) 2.0 (60.0) 82 32 (39.1) 23 (28) 3.0 (77.2) p=0.008*  
*Females expressed significantly less 














Table 5.6: Statistically significant differences in responses to TDF Likert items between pharmacists practising 10 years or less and pharmacists practising more than 10 
years 
TDF Likert Item (domain) Practising 10 years or less Practising more than 10 years Probability (p) value4 
Total N  N (%) who  
agreed1  





Total N N (%) who  
agreed1  





I know how to provide MAS  
to older patients in line 
with NICE guidance 
(Knowledge) 
68 48 (70.6) 5 (7.4) 2.0 (63.7) 71 40 (55.5) 10 (13.9) 2.0 (76.0) p=0.049*  
*CPs practising >10 years 
expressed significantly less 
agreement 
It is my responsibility to 
provide MAS to older 
patients (Social, 
professional role and 
identity) 
68 59 (86.7) 0 (0) 3.0 (60.7) 71 45 (62.5) 8 (11.1) 2.0 (78.8) p=0.003* 
*CPs practising >10 years 
expressed significantly less 
agreement 
Lack of access to patients 
medical notes is not a 
barrier to providing MAS5 
(Environmental context 
and resources) 
68 3 (4.4) 61 (89.7) 4.03 (78.2) 71 10 (13.9) 45 (62.5) 4.0 (62.2) p=0.012* 
*CPs practising < 10 years  
expressed significantly less 
agreement 
I do not face resistance 
from GPs when trying to 
provide MAS5 (Social 
influences)  
68 27 (39.7) 29 (39.7) 4.03 (76.8) 70 35 (48.6) 15 (20.9) 3.0 (63.5) p=0.043*  
*CPs practising < 10 years  
expressed significantly less 
agreement 
I do not face resistance 
from patients when trying 
to provide MAS5 (Social 
influences) 
68 27 (39.7) 20 (29.4) 2.0 (76.7) 70 39 (54.2) 10 (13.9) 2.0 (63.5) p=0.040* 
*CPs practising < 10 years  
expressed significantly less 
agreement 
1 Includes those who strongly agreed or agreed; 2 Includes those who strongly disagreed or disagreed; 3 A high median of 4 or 5 signified a potential barrier to the provision of MAS; 4 Mann-












Table 5.7: Statistically significant differences in responses to TDF Likert items between CPs who had undertaken training on medication adherence in the past five years 
and those who had not 
TDF Likert Item (domain) Pharmacists with training on MAS in past five years Pharmacists with no training on MAS in past five years Probability (p) value4 
Total N N (%) who  
agreed1  
N (%) who 
disagreed2 
Median3 
(mean rank)  
Total N  N (%) who  
agreed1  
N (%) who 
disagreed2 
Median3 
(mean rank)  
I know how to provide MAS  to 
older patients in line with NICE 
guidance (knowledge) 
75 55 (73.3) 3 (4.0) 2.0 (61.3) 64 33 (51.6) 12 (18.8) 2.0 (80.2) p=0.002*  
*Those who had no training in 
previous 5 years expressed 
significantly less agreement 
I know the appropriate 
questions to ask older patients 
to determine underlying reasons 
for non-adherence 
(knowledge) 
75 62 (82.7) 2 (2.7) 2.0 (61.0) 64 39 (61.0) 10 (15.7) 2.0 (80.5) p=0.001*  
*Those who had no training in 
previous 5 years expressed 
significantly less agreement 
I have sufficient knowledge of 
the range of adherence 
strategies that are available to 
support older patients 
(knowledge) 
75 52 (69.4) 11 (14.7) 2.0 (60.2) 64 27 (42.2) 18 (28.1) 3.0 (81.5) p=0.001* 
*Those who had no training in 
previous 5 years expressed 
significantly less agreement 
I have been trained to provide 
MAS to older patients in line 
with NICE guidance (skills) 
75 32 (42.7) 17 (22.7) 3.0 (55.4) 64 10 (15.6) 36 (56.2) 4.03 (87.1) p<0.001* 
*Those who had no training in 
previous 5 years expressed 
significantly less agreement 
It is my responsibility to provide 
MAS to older patients (Social, 
professional role and identity) 
75 61 (81.4) 3 (4) 2.0 (64.4) 64 42 (65.6) 4 (6.3) 2.0 (76.6) p=0.046*  
*Those who had no training in 
previous 5 years expressed  
significantly less agreement 
It is important to always offer 
MAS to older patients 
(Motivation and goals) 
75 70 (93.4) 0 (0) 2.0 (60.4) 64 51 (79.7) 1 (1.6) 2.0 (81.2) p=0.001*  
*Those who had no training in 
previous 5 years expressed  
significantly less agreement 
I monitor and record the type 
of MAS that I provide to older 
patients (Behavioural 
regulation) 
75 33 (44.0) 24 (32.0) 3.0 (61.7) 64 15 (23.5) 32 (50.1) 4.03 (79.4) p=0.05* 
*Those who had no training in 
previous 5 years expressed 
significantly less agreement 
1 Includes those who strongly agreed or agreed; 2 Includes those who strongly disagreed or disagreed; 3 A high median of 4 or 5 signified a potential barrier to the provision of MAS; 4 














 Table 5.8: Statistically significant differences in responses to TDF Likert items between stores with an individual pharmacist and stores with multiple pharmacists1 
TDF Likert Item (domain) Individual pharmacist Multiple pharmacists1 Probability (p) value5 
Total N N (%) who  
agreed2  




Total N  N (%) who  
agreed2 




I have sufficient pharmacist 
staff levels to allow me to 
provide MAS to older 
patients (Environmental 
context and resources) 
64 10 (15.6) 47 (73.5) 4.04 (82.4) 
 
74 32 (42.6) 32 (42.7) 3.0 (58.4) P<0.001*  
*individual pharmacists expressed 
significantly less agreement 
I have sufficient non-
pharmacist staff levels to 
allow me to provide MAS 
to older patients 
(Environmental context and 
resources) 
64 19 (29.7) 35 (54.7) 4.04 (76.9) 74 34 (45.4) 25 (33.3) 3.0 (63.0) p=0.033*  
*individual pharmacists expressed 
significantly less agreement 
Colleagues in senior 
positions support me in 
providing adherence 
support to older patients 
(Social influences) 
64 7(10.9) 38 (59.4) 4.04 (84.2) 74 29 (38.7) 20 (26.7) 3.0 (65.8) p<0.001* 
*individual pharmacists expressed 
significantly less agreement 
1 Stores which had two or more CPs working on at least one day of the week; 2 Includes those who strongly agreed or agreed; 3 Includes those who strongly disagreed or disagreed; 4 A high 














Table 5.9: Statistically significant differences in responses to TDF Likert items between pharmacists working at independently owned pharmacies, small/medium chains and 
large chains  
TDF Likert Item 
(domain) 
Independently owned pharmacy 
(IND) 
Small/medium chain (S/M= 2-9 
stores) 
Large chain (LG= 10+ stores) Overall 
Probability 
(p) value4 
Post hoc pair wise comparison: 
probability (p) values5 
 
 




















Total N  N (%)  
who  
agreed1  








I have been trained 
to provide MAS to 
older patients in 


















p=0.022 IND verses S/M: p=0.919 
S/M verses LG: p=0.021*  
IND verses LG: p=0.316 
*CPs in large chains expressed  
significantly less agreement than 
CPs in small/medium chains 
Providing MAS to 
older patients is a 
high priority for me 















p=0.024 IND verses S/M: p= 0.286 
S/M verses LG: p=0.019* 
IND verses LG: p=  1.000 
*CPs in large chains expressed  
significantly less agreement than 
CPs in small/medium chains 
I have sufficient 
pharmacist staff 
levels to allow me 











39 15  
(37.5) 








p=0.17 IND verses S/M: p= 1.000 
S/M verses LG: p= 0.057 
IND verses LG: p= 0.046* 
*CPs in large chains expressed 
significantly less agreement than 
CPs in independent pharmacies 
Colleagues in senior 
positions support 
me in providing 
adherence support 




















p=0.002 IND verses S/M: p=1.000 
S/M verses LG: p=0.020* 
IND verses LG: p=0.004* 
*CPs in large chains expressed  
significantly less agreement than 
CPs in both independent 








1Includes those who strongly agreed or agreed; 2Includes those who strongly disagreed or disagreed; 3A high median of 4 or 5 signified a potential barrier to the provision of MAS; 4Kruskal-
wallis test; 5Post-hoc pairwise comparisons (Dunn’s multiple comparisons test) were adjusted using the Bonferroni correction for multiple tests; 6Item was reverse worded in questionnaire 
(reverse phrased and recoded for data analysis purposes) 
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A quarter of CPs (n=35; 24.5%) took the opportunity to comment at the end of the 
questionnaire, with comments re-emphasising barriers and facilitators that had previously 
been addressed within Section 3 of the questionnaire. Although MAS provision was seen as 
a valuable service, the majority of comments focused on insufficient levels of reimbursement 
(n=17), followed by the lack of time in current practice to provide such support (n=7). 
“MAS [Medication Adherence Support] is an important service but remuneration 
warrants it unfeasible. We do it when it is required but do not offer it freely—the 
payment— what payment!” (R95) 
“Much, much work has to be carried out to convince GPs and HSCB [Health and Social 
Care Board] how vital this service is. At present the service is not sustainable without 
a fair contract and appropriate remuneration.” (R115) 
“The service must be appropriately remunerated to allow a quality service— unlike 
the current provision of blister packs– grossly underfunded and supported. This 
service has grown as an ad-hoc [sticking] plaster service.” (R141) 
 “Although an important service and part of my practice I feel that time constraints 
sometimes make it difficult to provide comprehensive support for all patients.” (R03) 
A large number of participants’ (n=17) comments focused specifically on the provision of 
MDS as an adherence enhancing strategy (e.g. rising demand, safety issues/adverse events, 
mixed benefits, pressure from other HCPs to supply MDS, inadequate reimbursement, time 
constraints). 
“I feel we are pressured by social care and GPs to provide ‘mediboxes’ [Monitored 
Dosage System] which in my experience have mixed results in terms of adherence…” 
(R57) 
“Safety is priority so we have to limit the number of patients we supply dossette boxes 
[Monitored Dosage System] to make sure there is sufficient time/staff to make them 
safely. Unfortunately demand for dossette boxes is higher than what we can 
physically cope with.” (R101) 
A few CPs emphasised the potential benefits of having access to the ECR (n=3) and access to 
additional training (n=2). 
“More integrated software solutions with PMR [Patient medication record], ECR 
[Electronic Care Record summary] would be extremely beneficial.” (R86) 
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“Any further training would be welcomed. Delivery of medication adherence support 
is currently only touching the tip of the iceberg. Lack of funding and a limit of MUR 
[Medicine Use Review Service] and MYM [Managing Your Medicines Service] 
thresholds is a limiting factor.” (R07)  
Other CPs emphasised that they would need additional pharmacist staffing levels to allow 
this type of support to be provided more routinely (n=2). 
“There needs to be an adherence support service with training, goals, guidelines, 
remuneration. When I get sufficient proper services then I can consider employing a 
second pharmacist leaving me uninterrupted time to discuss medication issues.” 
(R01) 
“The main factor which determines how much time I can spend on adherence issues 
depends on the availability of a second pharmacist.” (R131) 
Some CPs emphasised a perceived lack of support from GP colleagues (n=4). 
“Very little support from GPs regarding issues.” (R38) 
“Time is a massive factor—I don’t have it and GPs are unwilling to help.” (R73) 
Other comments highlighted that the provision of MAS was opportunistic (n=1), conflicting 
demands, such as remunerated services, took priority (n=1) and that MAS should be 
prioritised to those with a lack of family support (n=1). 
5.4.3 Triangulation of findings and identification of key TDF domains (data analysis 
stage 2 findings) 
Following comparison of the summary of findings from the qualitative data analysis (Phase 
1) and quantitative data analysis (Phase 2), and discussion among members of the research 
team, eight out of 12 domains were identified as relevant/important in the context of the 
target behaviour: ‘Knowledge’, ‘Skills’, ‘Social, professional role and identity’, ‘Motivation 
and goals’, ‘Memory, attention and decision processes’, ‘Environmental context and 
resources’, Social influences’ and ‘Behavioural regulation’. Four domains were not seen 
relevant/important in the context of the target behaviour: ‘Beliefs about capabilities’, ‘Beliefs 
about consequences’, ‘Emotion’, ‘Nature of the behaviours‘. The reasons for this are 
discussed later in Section 5.5.3.  
Out of the eight domains deemed relevant/important in the context of the target behaviour, 
seven of these were considered to be key domains for targeting for behaviour change with a 
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training package for CPs and/or as part of a future research study. The domain ‘Social, 
professional role and identity’ was not selected for targeting; the reason for this is discussed 
later in Section 5.5.3. 
5.4.4 Mapping of key TDF domains to BCTs (data analysis Stage 3 findings) 
The seven key domains identified in Stage 2 were mapped across to BCTs using the two 
reference sources discussed previously in Chapter 3 (Section 3.3.7) (Michie et al. 2008; Cane 
et al. 2015). Thirty nine potential BCTs were identified using this mapping approach and were 
subsequently considered by the research team for inclusion in a CP training package to 
accompany the ID-MAP intervention and/or to be delivered as part of a future research 
study. Using group consensus, 18 BCTs were selected: ‘Information about health 
consequences (and behaviour)’, ‘Antecedents’, ‘Feedback on behaviour’, ‘Graded tasks’, 
‘Behavioural rehearsal/practice’, ‘Self-monitoring’, ‘Rewards/incentives’, ‘Increasing skills 
(e.g. decision making, problem solving)’, ‘Modelling or demonstrating the behaviour’, 
‘Homework’, ‘Behavioural contract’, ‘Action planning’, ‘Social support (unspecified)’, 
‘Credible source’, ‘Prompts/cues’, ‘Restructuring the social environment’, ‘Social reward’ and 
‘Use of imagery’. Table 5.10 outlines the BCTs that mapped to each key domain as well as 
reasons for selection (or non-selection). Table 5.11 provides definitions for each selected BCT 
(n=18) and an indication of whether the BCT could be delivered as part of a training package 
and/or as part of a future research study to improve the implementation of the patient-
targeted (ID-MAP) intervention.   





Table 5.10: Mapping of key domains to behaviour change techniques (BCTs) for inclusion in a future training package for community pharmacists and/or to deliver as 




a=Primary reference source (Cane et al. 2015)  
b=Secondary reference source (Michie et al. 2008)  
BCT 
selected 
 = YES 
X = NO 
Rationale for selection (or non-selection) of BCT(s) to include in a training package and/or 
to deliver as part of a future research study 
Knowledge  Information about health 
consequencesa /Information regarding 
behaviour, outcomeb  
 Information about the behaviour and potential positive outcomes for patients could be 
presented to CPs at a training workshop. This BCT also mapped to the ‘Motivation and goals’ 
domain—see below. Note: The BCT ‘information regarding behaviour, outcome’ encapsulates 
the BCT ‘information about health consequences’. 
 Feedback on behavioura  CPs could be given verbal feedback on their performance of providing MAS during a training 
workshop, after having the opportunity to practice the behaviour. Feedback on behavioural 
performance could also be given as part of a future research study.  
 Antecedentsa (i.e. preceding factors)  CPs could be provided information about the factors that can positively or negatively affect 
the performance of the behaviour such as time, skills training etc.  
 Biofeedbacka X This BCT was not deemed relevant in the context of the target behaviour (provision of MAS). 
Skills 
 
 Graded tasksa/Graded tasks, starting 
with easy tasksb 
 CPs could be set tasks to perform in a training workshop, ranging in complexity from easy to 
difficult. This BCT also mapped to the ‘Motivation and goals’ domain—see below. Note: 




 CPs could practice performing the behaviour with patient actors as part of a training 
workshop using role play scenarios. Note: These BCTs were deemed to be equivalent. 
 Habit reversala 
 Body changesa 
 Habit formationa 
 Perform behaviour in different 
settingsb 
X These BCTs were not deemed relevant in the context of the target behaviour (provision of 
MAS). 
 Goal/target specified: behaviour or 
outcomeb 
X This BCT was not deemed appropriate to deliver in the context of a future study as 












Table 5.10 (cont’d): Mapping of key domains to behaviour change techniques (BCTs) for inclusion in a future training package for community pharmacists and/or to 




a=Primary reference source (Cane et al. 2015)  
b=Secondary reference source (Michie et al. 2008)   
BCT 
selected 
 = YES 
X = NO 
Rationale for selection (or non-selection) of BCT(s) to include in a training package and/or 
to deliver as part of a future research study 
Skills (cont’d)  Self-monitoringb  CPs could record the number of patients they provided MAS to during future research studies 
in a daily pharmacy tasks diary. This BCT also mapped to ‘Memory, attention and decision 
processes’ domain—see below.  
 Monitoring (i.e. feedback on 
behaviour)b 
 Equivalent to ‘Feedback on behaviour’ from BCTTv1. This BCT also mapped to the 
‘Knowledge’ domain—see above.  
 Rewards; incentivesb   Small monetary incentives could be provided to encourage CPs to perform the target 
behaviour as part of future research studies. This BCT also mapped to the ‘Motivation and 
goals’ domain—see below.  
 Increasing skills e.g. decision making, 
problem solvingb 
 CPs could be trained on how to decide on the best adherence solutions for older patients 
during a training workshop. This could be facilitated by a decision-making tool (e.g. a mobile 
application on a hand-held tablet device) that maps adherence problems across to potential 
adherence solutions.  
 Modelling/demonstration of 
behaviour by othersb 
 The target behaviour (provision of MAS) could be demonstrated as part of the training 
workshop. This could be video-recorded in advance with a patient actor.  
 Homeworkb  CPs could be given reading material on the target behaviour to review at home in advance of 
the workshop or given additional example patient scenarios following the training workshop. 
Motivation and 
goals  
 Behavioural contracta/contractb  CPs could be asked to sign a written contract, agreeing to carry out the target behaviour in 
their own clinical practice as instructed in the training workshop.  Note: These BCTs were 
deemed to be equivalent. 
 Commitmenta X This BCT was not deemed relevant in the context of the target audience (CPs). 
 Goal setting (outcome)a 
 Goal setting (behaviour)a 
 Review of outcome goal(s)a 
 Review behaviour goal(s)a 
 Goal/target specified: behaviour or 
outcomeb   
X Goal/target specified: behaviour/outcome also mapped to ‘Skills’ domain— see reason for 
non-selection above. Note: The BCT ‘Goal/target specified: behaviour/outcome’ encompasses 














Table 5.10 (cont’d): Mapping of key domains to behaviour change techniques (BCTs) for inclusion in a future training package for community pharmacists and/or to 




a=Primary reference source (Cane et al. 2015)  
b=Secondary reference source (Michie et al. 2008)   
BCT 
selected 
 = YES 
X = NO 
Rationale for selection (or non-selection) of BCT(s) to include in a training package and/or 
to deliver as part of a future research study 
Motivation and 
goals (cont’d) 
 Action planning (including 
implementation intentions)a 
 As part of a training workshop, CPs could be instructed to develop advance plans for how 
they will identify and provide MAS to older patients in their clinical practice. 
 Rewards; incentives   These BCTs also mapped to the ‘Skills’ domain—see above. 
 Graded tasks, starting with easy taskb  
 Increasing skills e.g. decision making, 
problem solving b 
 
 Social processes of encouragement, 
pressure, supportb 
 The research team could provide encouragement/support as part of a future research study. 
Group support could also be encouraged as part of the training workshops. This BCT also 
mapped to ‘Social influences’— see below.  
 Persuasive communication i.e. 
credible sourceb 
 A credible source (defined as an expert or leader in the field) could present arguments in 
favour of performing the behaviour to CPs at a training workshop. 
 Information regarding 
behaviour/outcome b 
 This BCT also maps to the domain ‘Knowledge’—see above.  
 Motivational interviewingb X This BCT would not be feasible to deliver as part of a future study as it would likely require 





 Self-monitoring b  This BCT also mapped to the ‘Skills’ domain— see above.  
 Planning, implementation  Equivalent to ‘Action planning’ in BCTTv1. This BCT also mapped to the ‘Motivation and goals’ 
and ‘Behavioural regulation’ domains— see reason for selection above.  
 Prompts, triggers, cuesb  Prompts could be included as part of the decision-making tool on a mobile application using a 
hand-held tablet device. In addition, pharmacy support staff could help prompt CPs to 
provide MAS to older people. This BCT also mapped to the domains ‘Environmental context 















Table 5.10 (cont’d): Mapping of key domains to behaviour change techniques (BCTs) for inclusion in a future training package for community pharmacists and/or to 




a=Primary reference source (Cane et al. 2015)  
b=Secondary reference source (Michie et al. 2008) 
BCT 
selected 
 = YES 
X = NO 
Rationale for selection (or non-selection) of BCT(s) to include in a training package and/or 




 Restructuring the social environment  CPs could be advised to restructure their social working environment by involving pharmacy 
support staff in the process of identifying potentially non-adherent older patients. 
 Avoidance/ changing exposure to cues 
for the behavioura  
 Discriminative (learned) cuea  
 Restructuring the physical 
environmenta/environmental changesb 
X These BCTs were not deemed relevant to the target behaviour (provision of MAS). 
 Prompts/cuesa  This BCT also mapped to ‘Memory, attention and decision processes’ and ‘Behavioural 
regulation’ domains—see reason for selection above.  
Social 
influences 
 Social comparisona 
 Information about others’ approvala 
X These BCTs would not be feasible to deliver as part of a training package or in the context of 
future research studies.  
 Social support (unspecified)a/Social 
processes of encouragement, 
pressure, supportb 
 This BCT mapped to the ‘Motivation and goals’ domain—see above. Note: These BCTs were 
deemed to be equivalent. 
 Social support (practical)a  
 Social support (emotional)a  
X These BCTs are encompassed by the BCT ‘Social support (unspecified)’—see above.  
 Vicarious reinforcementa 
 Identification of self as role modela 
X These BCTs were not deemed relevant in the context of the target behaviour (provision of 
MAS).  
 Restructuring the social environmenta  This BCT also mapped to the domain ‘Environmental context and resources’—see above.   
 Modelling or demonstrating the 
behavioura/ 
modelling/demonstration of 
behaviour by othersb 
 This BCT also mapped to the domain ‘Skills’—see above. Note: These BCTs were deemed to be 
equivalent. 
 Social reward  CPs could be given verbal rewards if there has been sufficient effort/progress in performing 












Table 5.10 (cont’d): Mapping of key domains to behaviour change techniques (BCTs) for inclusion in a future training package for community pharmacists and/or to 




a=Primary reference source (Cane et al. 2015)  
b=Secondary reference source (Michie et al. 2008) 
BCT 
selected 
 = YES 
X = NO 
Rationale for selection (or non-selection) of BCT(s) to include in a training package and/or 
to deliver as part of a future research study 
Behavioural 
regulation 
Goal/target specified: behaviour or 
outcome 
X This BCT also mapped to the ‘Motivation and goals’ domain—see reason for non-selection 
above.  
Contract  This BCT also mapped to the ‘Motivation and goals’ domain—see reason for selection above.  
Planning, implementation  This BCT also mapped to ‘Motivation and goals’ and ‘Memory, attention and decision 
processes’ domains— see reason for selection above. 
Prompts, triggers, cues  This BCT also mapped to ‘Memory, attention and decision processes’ and ‘Environmental 
context and resources’ domains—see reason for selection above. 














Table 5.11: Proposed delivery of BCTs as part of a training package for CPs and/or as part of a future research study to support the delivery of the ID-MAP intervention 
Behaviour change technique 
(BCT) 
Definition from BCTTv1 (Michie et al. 2013) How might the BCT be delivered? 
As part of a 
training package 
for CPs (e.g. a one 
day group-based 
workshop) 
As part of a future 
research study 
(e.g. pilot study) 
Information on health 
consequences (and 
behaviour) 
‘Provide information (e.g. written, verbal, visual) about health consequences of 
performing the behaviour.’ Also includes provision of information about the 
behaviour (Michie et al. 2008) 
  
Antecedents ‘Provide information about antecedents (e.g. social and environmental situations and 
events, emotions, cognitions) that reliably predict performance of the behaviour.’ 
  
Feedback on behaviour ‘Monitor and provide informative or evaluative feedback on performance of the 
behaviour (e.g. form, frequency, duration, intensity).’ 
  
Graded tasks ‘Set easy-to-perform tasks, making them increasingly difficult, but achievable, until 




‘Prompt practice or rehearsal of the performance of the behaviour one or more times 
in a context or at a time when the performance may not be necessary, in order to 
increase habit and skill.’ 
  
Self-monitoring ‘Establish a method for the person to monitor and record their behaviour(s) as part of 
a behaviour change strategy’ 
  
Rewards; incentives ‘Arrange for the delivery of money, vouchers or other valued objects if and only if 
there has been effort and/or progress in performing the behavior’ 
  
Increasing skills (e.g. decision 
making, problem solving) 
Not included in BCTTv1: no definition provided in either Cane et al. (2015) or Michie 
et al. (2008) 
  
Modelling or demonstrating 
the behaviour 
‘Provide an observable sample of the performance of the behaviour, directly in 
person or indirectly e.g. via film, pictures, for the person to aspire to or imitate…’ 
  
Homework Not included in BCTTv1: no definition provided in either Cane et al. (2015) or Michie 














Table 5.11 (cont’d):  Proposed delivery of BCTs as part of a training package for CPs and/or as part of a future research study to support the delivery of the ID-MAP 
intervention 
Behaviour change technique 
(BCT) 
Definition from BCTTv1 (Michie et al. 2013) How might the BCT be delivered? 
As part of a 
training package 
for CPs (e.g. one 
day group 
workshop) 
As part of a future 
research study 
(e.g. pilot study) 
Behavioural contract ‘Create a written specification of the behaviour to be performed, agreed on by the 
person, and witnessed by another.’ 
  
Action planning ‘Prompt detailed planning of performance of the behaviour (must include at least one 
of context, frequency, duration and intensity). Context may be environmental 
(physical or social) or internal (physical, emotional or cognitive).’ 
  
Social support (unspecified) ‘Advise on, arrange or provide social support (e.g. from friends, relatives, colleagues,’ 
buddies’ or staff) or non-contingent praise or reward for performance of the 






‘Present verbal or visual communication from a credible source (e.g. celebrities or 
words used to indicate expertise or leader in field) in favour of or against the 
behavior.’ 
  
Prompts/cues ‘Introduce or define environmental or social stimulus with the purpose of prompting 
or cueing the behaviour. The prompt or cue would normally occur at the time or place 
of performance.’ 
  
Restructuring the social 
environment 
‘Change, or advise to change the social environment in order to facilitate 
performance of the wanted behaviour or create barriers to the unwanted behaviour 
(other than prompts/cues, rewards and punishments).’ 
  
Social reward ‘Arrange verbal or non-verbal reward if and only if there has been effort and/or 
progress in performing the behaviour.’ 
  
Use of imagery  Not included in BCTTv1. Defined in Michie et al. (2008) as ‘Use planned images (visual, 












The current chapter has outlined key findings from a mixed methods study that sought to 
identify key determinants influencing the provision of MAS by CPs to older adults prescribed 
polypharmacy. In a similar approach used to develop the content of the patient-targeted 
intervention (outlined in Chapter 3), the TDF was used as a ‘theoretical lens’ in the current 
study to explore the clinical behaviour of CPs. This study has extended the methods used 
previously in this thesis by incorporating a quantitative phase and triangulating findings with 
findings from the qualitative phase. Following identification of key TDF domains to target for 
behaviour change (using the triangulated data), these domains (n=7) were mapped across to 
BCTs (n=18) using established methods (Michie et al. 2008; Cane et al. 2015). As part of future 
research the identified BCTs will be delivered to CPs as part of a theory-based training 
package (e.g. ‘Demonstration of the behaviour’) that will accompany the patient-targeted 
intervention and/or as part of a future research study (e.g. ‘Rewards; incentives’) to improve 
the provision of MAS by CPs and subsequent implementation of the patient intervention.  
5.5.1 Current provision of medication adherence support by community 
pharmacists in Northern Ireland 
As part of this mixed methods study it was also deemed important to explore what CPs in NI 
were doing in their daily practice to support older patients prescribed polypharmacy with 
medication adherence. The quantitative phase of this study (Phase 2) highlighted that less 
than half of surveyed CPs reported frequent use of methods (e.g. PMR computer systems) to 
identify non-adherent older patients who may require adherence support. For example, only 
a third of surveyed CPs (33.6%) reported frequently asking older patients if they had missed 
any doses of medication. This reflects findings from an EU-wide survey of 3,196 HCPs 
(pharmacists, doctors and nurses) that found only half of HCPs regularly asked patients about 
missed doses (Clyne et al. 2016). Pharmacists in the EU-wide survey were five times less likely 
to ask patients about missed doses (OR: 0.2; 95% CI: 0.17-0.27) in comparison with doctors. 
Given the scale of the problem of non-adherence, this represents a missed opportunity in 
the community pharmacy setting, as CPs have frequent contact with these patients when 
they collect prescriptions for repeat medications. CPs have a significant role to play in 
identifying non-adherent patients and delivering strategies to improve this, but to do this 
effectively CPs require access to specific training on managing medication adherence and 
systems (e.g. adequate reimbursement levels) that support this (Sabate, 2003). Despite the 
provision of services such as MURs and MYM, the current study has shown that only half of 
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surveyed CPs in NI have undertaken training on medication adherence in the previous five 
years, highlighting that more widespread training is necessary. 
The provision of MURs in recent years in NI has provided the opportunity for CPs to identify 
non-adherent patients. The majority of surveyed pharmacists offered this service (93.0%) to 
an average of 70 (+42.7) patients each year. In comparison, the MYM service, which is a more 
comprehensive medication review service available in NI, was only offered by less than half 
of surveyed CPs (42.7%) and to a very small minority of patients [8.08 (+ 8.35)] each year. As 
indicated previously, neither service incorporates a structured adherence support 
component which could be limiting their usefulness in the context of improving adherence. 
In addition, their effectiveness and cost-effectiveness remains unknown (Wright, 2016) 
Despite research emphasising the importance of tailored approaches to addressing 
medication non-adherence, under two fifths of CPs (38.5%) reported frequently tailoring 
adherence solutions to the underlying reasons for older patients’ non-adherence. One of the 
most frequently offered adherence solutions was the provision of MDS which was most 
commonly supplied at the request of others (e.g. carers). This finding is similar to findings 
reported by Mansoor et al. (2014), whereby 95% of Australian CPs who were surveyed 
reported that MDS was the most common adherence strategy they offered. Some CPs who 
were interviewed in Phase 1 of the current study emphasised purposefully avoiding offering 
this solution to patients due to pressures they faced in terms of capacity (i.e. limited staff 
members to prepare MDS), safety concerns (potential increased risk of dispensing errors) 
and a lack of funding for the provision of this adherence solution.  
The UK Royal Pharmaceutical Society has recently published guidance on the best use of 
MDS, indicating that this solution is commonly selected without giving full consideration to 
the range of alternative adherence solutions (Royal Pharmaceutical Society, 2013). The 
reason for this may be due to the convenience this solution offers for patients on complex 
regimens. The RPS guidance indicates that MDS should be selected out a range of solutions 
taking into consideration any risks and potential benefits. It has been recognised both in this 
study and similar research that focused specially on MDS provision in the community 
pharmacy setting (Stewart et al. 2017) that CPs do not consider MDS to be the most suitable 
solution for all non-adherent patients. The decision to supply MDS is often influenced by 
others (e.g. other HCPs, carers) and research has shown that they are commonly issued 
without first discussing the best option with patients (Nunney et al. 2011; Stewart et al. 
2017). This approach does not align with patient-centred care that has been advocated by 
NICE (National Institute for Health and Clinical Excellence, 2009). 
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Although MDS are widely used, there is limited evidence to support this, with systematic 
reviews that have explored their effectiveness reporting mixed findings (Mahtani et al. 2011; 
Boeni et al. 2014; Watson et al. 2016). The evidence in relation to the effectiveness of MDS 
is also limited by high risk of bias and poor quality studies and so more research in this area 
is urgently needed. In the UK, research is underway to explore the effectiveness/cost-
effectiveness of MDS, although a definitive RCT has yet to be completed (Bhattacharya et al. 
2016). There are a number of problems associated with MDS such as the stability of 
medications, potential to cause adverse events if medications are inappropriately prescribed 
and safety considerations (e.g. dispensing errors) (Royal Pharmaceutical Society, 2013). 
Although MDS are potentially beneficial for those who are unintentionally non-adherent (e.g. 
due to forgetfulness), this adherence solution does not address intentional non-adherence. 
Alternative solutions relevant for all patients or packages of solutions that can be individually 
tailored to each patient’s need require investigation. Self-monitoring of the behaviour 
through the use of a medication diary is an example of a solution that could be relevant for 
a wide range of non-adherent patients, by acting both as a reminder for unintentionally non-
adherent patients and forcing intentionally non-adherent patients to reflect on their 
behaviour (Snyder, 1979). Self-monitoring also offers the opportunity for HCPs to provide 
feedback to patients (based on a review of the patients’ diary) and a platform for discussing 
the potential health consequences of non-adherence.  
5.5.2 Determinants of providing medication adherence support to older adults 
prescribed polypharmacy 
This study has highlighted multiple determinants potentially influencing CPs’ behaviour in 
terms of providing MAS to older adults who are prescribed polypharmacy. Although the vast 
majority of surveyed CPs in Phase 2 of this study agreed that the provision of MAS was their 
responsibility (73.4%) and part of their current role as a community pharmacist (83.9%), it 
appears that this has not been translated into action in clinical practice. It was unsurprising 
that a lack of time, insufficient pharmacist staff levels (domain: ‘Environmental context and 
resources’) and insufficient reimbursement (domain: ‘Motivation and goals’) were identified 
as potential barriers to the target behaviour. These findings reflect the most commonly 
identified barriers to the provision of clinical services in the community setting (Dunlop and 
Shaw, 2002; Roberts et al. 2008; Lounsbery et al. 2009; Osborne et al. 2011) and are also 
consistent with findings from similar research on the provision on MAS that was recently 
conducted in Australia (Mansoor et al. 2014).  
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A lack of time was the most frequently mentioned barrier in the qualitative phase of this 
study (Phase 1) but this was not the greatest potential barrier in the quantitative phase 
(Phase 2). Just over half of CPs (59.5%) in the quantitative survey indicated they did not have 
enough time to provide MAS to older people, whereas a lack of reimbursement appeared to 
be the greatest potential barrier with just over three-quarters of CPs (76.3%) indicating they 
did not receive sufficient reimbursement for this clinical activity. A qualitative study 
conducted in Scotland (Bacci et al. 2014) has also reported that a lack of time was not seen 
as the greatest barrier to implementing an adherence intervention, which was in contrast 
with previously conducted research (Osborne et al. 2011). A lack of reimbursement has also 
been cited as the most important facilitator of practice change from the viewpoint of CPs in 
a study conducted in Spain (Gastelurrutia et al. 2009).  
The use of a comprehensive theoretical model of behaviour change in this study has 
however, helped go beyond identifying the barriers most commonly considered in the 
delivery of any new community pharmacy service, such as a lack of time, insufficient staff 
resources or reimbursement (Dunlop and Shaw, 2002; Roberts et al. 2008; Lounsbery et al. 
2009; Osborne et al. 2011; Huston, 2015). This theory-based approach has allowed for an 
exploration of other important areas such as CPs’ knowledge, skills and confidence in relation 
to the target behaviour. Although CPs were mainly confident in this area and reported having 
good communication skills, two thirds of CPs (66.5%) indicated that they required additional 
training on techniques that can be used to increase older patients' motivation to adhere, 
such as goal-setting techniques and action planning (domain: ‘Skills’). This is an important 
finding as these types of skills would be essential for the future implementation of the patient 
(ID-MAP) intervention. 
The qualitative component of this study (Phase 1) also highlighted that there may be 
differences in perceived barriers across different groups of CPs, for example, between those 
working at independently-owned pharmacies versus those working for pharmacy chains. To 
explore this further, subgroup analysis was undertaken as part of Phase 2 (quantitative 
component) of this study which revealed some interesting findings. Interestingly, more CPs 
working at independently-owned pharmacies (41.5%) and small/medium chains (2-9 
pharmacies) (35.0%) felt supported by colleagues working in senior positions in comparison 
with CPs working at larger chains (10+ pharmacies) (8.5%; p=0.002). In addition, only 17% of 
CPs working at large chains agreed they had sufficient pharmacist staff levels in comparison 
with 41.4% of CPs at independently-owned pharmacies (p=0.046) (domain: Environmental 
context and resources). Another interesting finding was that CPs who had undertaken 
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training on medication adherence in the previous five years were more likely to monitor and 
record their behaviour (44%) in comparison with those who had not undertaken training 
(23.5%; p=0.05) (domain: ‘Behavioural regulation’). Self-monitoring of behaviour could help 
CPs to reflect on what they are currently doing in practice and encourage them to improve 
on this in the future.  
5.5.3 Selection of key TDF domains to target for behaviour change 
Following triangulation of data from Phases 1 and 2 and discussions between members of 
the research group (DP, CH, CR), consensus was reached and eight domains were identified 
as relevant/important in the context of the target behaviour. Six of these domains were 
selected because they were frequently coded in the qualitative analysis (listed in order of 
frequency): ‘Environmental context and resources’, ‘Motivation and goals’, ‘Social, 
professional role and identity’, ‘Social influences’ ‘Skills’ and ‘Knowledge’. All but two of these 
domains (‘Knowledge’, ‘Social, professional role and identity’) also had had potential barriers 
identified in the quantitative analysis (Phase 2). The following two domains, although not as 
frequently coded in Phase 1, were selected because the quantitative analysis (Phase 2) 
revealed potential barriers to the target behaviour within these domains: ‘Memory, attention 
and decision processes’ and ‘Behavioural regulation’. For example, under the ‘Memory, 
attention and decision processes’ domain, over two-thirds of CPs (68.5%) reported that they 
found it difficult to decide on the best adherence solutions to offer older patients. The 2003 
WHO report recognised this difficulty and highlighted that clinical decision-making process 
needs to be covered as part of training alongside the development of ‘behavioural tools’ for 
HCPs (Sabate, 2003). A decision making tool, such as that developed for the feasibility study 
outlined in Chapter 4 (ID-MAP Tool), may assist CPs in this complex decision process.  
Four domains (‘Beliefs about capabilities’, ‘Beliefs about consequences’, ‘Emotion’, ‘Nature 
of the behaviours’) were not selected as relevant/important in the context of the target 
behaviour. This was because they were not frequently coded in the qualitative analysis 
(Phase 1) and the quantitative analysis (Phase 2) did not highlight potential 
barriers/facilitators to the target behaviour within these domains. In relation to CPs’ 
confidence (domain: ‘Beliefs about capabilities’), the qualitative findings suggest that this 
stems from their level of skills training and so focusing on the latter is of greater importance. 
The quantitative component of this study confirmed that the majority of CPs were confident 
in providing adherence support to older patients but lacked the skills required to motivate 
older patients to change their behaviour. Emotions were rarely discussed in the context of 
the target behaviour and no barriers were identified under the ‘Emotion’ domain in the 
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quantitative analysis which confirmed this finding. In relation to CPs’ ‘Beliefs about the 
consequences’, these were discussed less frequently than other domains in the qualitative 
analysis and CPs reported having awareness of the positive consequences of providing MAS 
to older adults prescribed polypharmacy. In addition, no barriers were identified under this 
domain in the quantitative analysis. Although it was noted that certain adherence support 
activities were already routine (e.g. provision of MDS) or could become more routine (e.g. 
asking patients about missed doses), the overall behaviour was not seen as automatic and 
instead requires planning and consideration. Consequently, the ‘Nature of the behaviours’ 
domain was not deemed relevant/important in this context.  
The current study has highlighted the usefulness of a mixed methods approach in selecting 
domains that are relevant/important in the context of the target behaviour. The majority of 
studies that have previously employed the TDF have relied on qualitative data from 
interviews and used frequency counts as a crude measure of a domain’s 
relevance/importance (Atkins et al. 2017). This study takes this a step further by providing 
quantitative data to support the qualitative findings and also identify domains which are 
likely to be important but are infrequently coded in qualitative research (e.g. ‘Behavioural 
regulation’ in the current study).  
Although the domain ‘Social, professional role and identity’ was identified as 
important/relevant in this context, it was not selected as a key target domain for behaviour 
change. CPs largely considered the target behaviour to be part of their role, although they 
recognised that an inability to prescribe and lack of integration in the primary healthcare 
team were potential barriers to the provision of MAS. Changing the role of CPs in the primary 
care setting would require major policy and organisational changes which was deemed to be 
beyond the scope of a future research study (e.g. pilot study).  
5.5.4 Selection of BCTs to bring about behaviour change 
Out of the 39 BCTs identified using the mapping approaches developed by Michie et al. (2008) 
and updated by Cane et al. (2015), 18 BCTs were selected. These were selected because it 
was agreed that these would be feasible to deliver either as part of a training package for CPs 
to accompany the ID-MAP intervention or in a future research study. As discussed previously 
in Chapter 3, some BCTs in the two reference sources have overlapping characteristics and 
similar names. The research team opted for the most up-to-date terminology, as reported by 
Cane et al. (2015), as these are consistent with the BCTTv1 (Michie et al. 2013).  
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It was proposed that 10 BCTs could be delivered during a training workshop (e.g. 
‘Demonstration of the behaviour’), four BCTs could be solely delivered as part of a future 
research study (e.g. ‘Reminders; incentives’) and four BCTs could be delivered as part of both. 
For example, the BCT 'Social support (unspecified)’ could be delivered both at a training 
workshop through group activities and also as part of a future research study through 
encouragement from the research team or by creating opportunities for CPs to communicate 
with each other for support (e.g. using social messaging platforms).  
Ten out of the 18 BCTs that were selected in this mapping process mapped to multiple key 
target TDF domains and collectively covered all seven key domains. For example, the BCT 
‘Prompts and cues’ mapped to three domains (‘Memory, attention and decision processes’, 
‘Environmental context and resources’ and ‘Behavioural regulation’). For the patient-
targeted intervention (Chapter 3), the time constraints in the community pharmacy setting 
dictated the selection of BCTs as CPs would have only limited time to spend with individual 
patients in which to deliver BCTs. Therefore, BCTs that targeted multiple domains were 
selected over those that did not in the patient-targeted intervention. For the current study, 
the issue of time was not deemed a major consideration as a larger number of BCTs could be 
delivered to CPs during a one day workshop (e.g. ‘Demonstration of the behaviour’, ‘Graded 
tasks’) or as part of a future study (e.g. ‘Rewards; incentives’). 
5.5.5 Methodological advancements  
The current study involved a mixed methods approach using both qualitative and 
quantitative methods to guide the selection of key domains to target for behaviour change. 
To the best of our knowledge, this is the first study to outline, in detail, the processes 
undertaken to select key TDF domains to target by triangulating findings from both 
qualitative and quantitative approaches. Guidance on the use of the TDF was published 
shortly after the completion of this study (Atkins et al. 2017). This guidance focuses on 
qualitative approaches, although the authors recognised that TDF-based methodology is 
evolving to include quantitative approaches. The current study contributes to the growing 
literature on the use of mixed methods TDF-based approaches. The qualitative methods 
employed in both the current study and in Chapter 3 (patient focus groups) reflect the 
methods advocated in this recently published guidance on how to use the TDF.  
5.5.6 Study strengths and limitations 
To the author’s best knowledge, this is the first study to make use of the TDF as a theoretical 
lens to explore the provision of MAS by CPs to older adults prescribed polypharmacy. A key 
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strength of this study was the triangulation of data from both qualitative and quantitative 
approaches which helps to increase the generalisability of findings. The study followed 
guidance from the MRC which recommends incorporating a theoretical base when 
developing interventions designed to change behaviours, such as training packages for HCPs 
(Medical Research Council, 2008). By explicitly outlining the techniques that will be used to 
change CPs’ behaviours (and the hypothesised causal processes), the current study follows 
recommendations in WIDER guidelines (Albrecht et al. 2013). The qualitative component of 
this study has also been reported in line with the COREQ checklist (see completed checklist 
in Appendix 5.10). 
As a limitation of this study, the low response rate (27.4%) achieved for the survey (Phase 2) 
should be noted. This response rate was comparable to the response rate (27.6%) obtained 
in a survey on MAS that was mailed to 500 CPs in New South Wales, Australia (Mansoor et 
al. 2014). Both surveys focused on CPs’ experiences of, and barriers to, providing MAS, 
although only the current study was informed by a theoretical framework (TDF). Despite two 
reminders in the study by Mansoor et al. (2014) and one reminder in the current study, 
response rates remained low. This may be due to a number of factors such as a lack of time 
to complete the survey, the time of mailing (which in the current study coincided with public 
holidays), a lack of interest in the topic or a current lack of provision of MAS.  
Nonetheless, as discussed in Section 5.3.2, the response rate alone is not indicative of a poor 
quality study and instead researchers should seek to identify non-response bias (Davern, 
2013; Halbesleben and Whitman, 2013). Attempts were therefore made to compare the 
survey sample characteristics with those of the entire population of CPs in NI. Despite 
challenges in doing so due to a lack of data focusing solely on CPs, similarities in terms of 
gender, age groups and post-graduate qualifications were observed between the sample of 
survey respondents and all pharmacists who were registered with the PSNI at the time of the 
study. However, it is important to note that there was a slight underrepresentation of 
females in the survey sample of CPs and over-representation of those in managerial positions 
which may impact on the generalisability of findings. Nonetheless, the findings reported in 
this study included the views and opinions of CPs from across different areas (rural, 
suburban, urban) and working in different types of pharmacies (independently-owned 
pharmacies, small/medium chains and large chains). This variation helps to increase the 
generalisability of findings, to a certain extent, to the population of CPs practising in NI. The 
potential for social desirability bias must also be noted, as CPs (in both the interviews and 
the survey) were made aware of the latest guidance on supporting patients with medication 
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adherence that had been published by NICE (National Institute for Health and Clinical 
Excellence, 2009). By using an anonymous self-administered questionnaire which included 
both positive and negatively phrased items it is hoped that the level of social desirability bias 
in the survey was minimal.  
As indicated in Section 5.3.2, due to the complexity of the target behaviour (i.e. provision of 
MAS), it was not possible to discreetly measure this using a cross-sectional survey. Other 
studies of HCPs’ behaviour have been able to measure their target behaviour. For example, 
a study by McParlin et al (2016) measured how frequently midwives advised pregnant 
women to undertake exercise and used this in regression analysis to explore which attitudes 
had the most significant influence on midwives’ behaviour. In the current study, it was not 
feasible to carry out regression analysis which requires a specific target behaviour (i.e. 
dependent variable) and so statistical analyses were limited to descriptive statistics and non-
parametric group comparison tests (MWU, KW).  
As discussed in Section 5.3.6, it was not possible to combine scores for individual Likert items 
in each TDF domain due to low Cronbach’s alpha values. As stated by Tavakol and Dennick 
(2011), ‘A low value of alpha could be due to a low number of questions, poor 
interrelatedness between items or heterogeneous constructs’. Items for the current 
questionnaire were developed at the domain level which may help to explain the low α values 
(Huijg et al. 2014a). This findings is consistent with other TDF-based questionnaires that have 
sought to explore HCPs’ behaviours and also reported low α values for domains (Amemori et 
al. 2011; Beenstock et al. 2012; Manikam et al. 2015). It was also not possible to carry out 
factor analysis (e.g. principle components analysis), to explore alternative underlying 
structures as has been done in previous TDF-based survey research, for the reasons stated 
previously (see Section 5.3.6). Alternatively, to aid the selection of TDF-domains to target for 
behaviour change, Likert items were individually assessed to identify potential barriers to the 
target behaviour within each domain. Triangulated qualitative and quantitative data aided 
decisions about the barriers that were most likely to influence the target behaviour. This 
represents a novel approach to selecting important/relevant domains that can be targeted 
for behaviour change.  
 




This study involved a mixed methods approach to explore CPs’ clinical behaviour, in terms of 
providing MAS to older adults prescribed polypharmacy. A range of determinants (barriers, 
facilitators) were perceived to influence the target behaviour including insufficient 
reimbursement, lack of relevant skills, and social support from colleagues and other HCPs. 
Triangulation of qualitative and quantitative findings facilitated the selection of seven key 
theoretical domains that could be targeted for behaviour change. Established methods were 
employed to map key TDF domains to BCTs, and using group consensus methods, multiple 
BCTs (n=18) were identified as applicable to the target audience and behaviour. As part of 
future research these BCTs will be delivered as part of a training package for CPs that will 
accompany the ID-MAP intervention and/or as part of a research study to improve the 
provision of MAS by CPs.
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6.1 General discussion 
The research presented in this thesis has focused on improving medication adherence in 
older adults prescribed polypharmacy. Older patients commonly suffer from multimorbidity 
and it is widely accepted that polypharmacy is unavoidable and in many cases can be of 
therapeutic benefit. As stated by Duerden et al. (2013), ‘Polypharmacy is likely to be futile if 
medicines are not taken as the prescriber intends’. Although a plethora of interventions have 
been tested over the last four decades to improve patients’ medication adherence 
behaviours, there is a lack of strong evidence to support any particular strategy to bring about 
behaviour change. As a result, the problem of non-adherence continues to be a significant 
global challenge (Bosworth et al. 2011; Nieuwlaat et al. 2014).  
It has been recognised that complex interventions containing multiple interacting 
components are likely to be the only possible answer to a multi-faceted problem such as 
adherence, although there are major challenges associated with developing and evaluating 
such interventions (Medical Research Council, 2008; Nieuwlaat et al. 2014). The role of 
theory in developing and evaluating complex adherence interventions has become a major 
topic in recent years, due to its potential to advance the field by going beyond simply 
identifying what works, and what does not, and more importantly, helping to explain the 
reasons why (Ruppar, 2010b).  
The research presented in this thesis has therefore focused on the development and 
feasibility testing of a novel complex theory-based intervention (ID-MAP intervention) to 
improve medication adherence in older adults prescribed polypharmacy and managed in 
primary care. This intervention was designed for delivery by CPs in the community pharmacy 
setting for reasons stated previously (Nieuwlaat et al. 2014; Ryan et al. 2014). The methods 
adopted throughout the thesis have followed recommendations from the UK MRC with a 
focus on development and feasibility testing, as well as future implementation and training 
of intervention providers (Medical Research Council, 2008). 
Chapter 2 of this thesis outlined findings from a systematic review that aimed to address a 
gap in the literature by exploring exactly how theory had been used previously to develop 
adherence interventions delivered to older adults prescribed polypharmacy. Chapter 3 
involved the use of a comprehensive theoretical framework of behaviour change (TDF1), to 
guide the selection of components of a novel complex intervention aimed at improving older 
patients’ adherence to multiple medications (i.e. polypharmacy). The work presented in 
Chapter 4 combined components identified in Chapter 3 into a complex intervention package 
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(ID-MAP intervention) and tested whether it was feasible to deliver this in the community 
pharmacy setting. Finally, Chapter 5 involved further development work to explore how the 
CP training package that accompanied the patient-targeted intervention could be enhanced 
by incorporating a theoretical basis (also using TDF1). This final study also identified 
strategies that could be used to enhance the future implementation of the intervention by 
exploring CPs’ clinical behaviour in terms of providing MAS to older patients. The key findings 
from the work presented in this thesis are discussed below in more detail in the context of 
the wider literature, along with recommendations for future research, practice and policy 
considerations in this area.   
6.1.1 Theory-based adherence interventions for older adults prescribed 
polypharmacy: an evidence gap 
Previous systematic reviews of adherence interventions for older patients have not focused 
on how psychological theory has informed intervention development and evaluation 
(Banning, 2008; George et al. 2008; Ruppar et al. 2008). The research presented in Chapter 2 
of this thesis addressed this gap in the literature by examining the effectiveness of theory-
based adherence interventions that had been delivered to older adults prescribed 
polypharmacy and through an exploration of exactly how theory was used. The conduct of 
this review was in line with the development phase of the MRC framework, which 
recommends that researchers explore existing evidence in relation to the topic of interest 
and address any noted gaps in the literature.  
An important finding from the review was that all of the studies focused on patients with a 
single long-term medical condition (or comorbidity) instead of including older patients with 
a range of LTCs (i.e. multimorbidity). This finding was not surprising given that the structure 
of healthcare provision globally focuses on a single-disease framework (Barnett et al. 2012). 
With an ageing population and growing number of older patients with multi-morbidity, 
adherence research needs to focus on developing interventions that can be tailored to 
multimorbid older patients irrespective of their underlying LTCs. This approach is necessary 
to meet the needs of both current and future populations of older people and is consistent 
with guidance published by NICE in 2016 on multimorbidity, which advocates for a tailored 
approach to healthcare (National Institute for Health and Care Excellence, 2016). The findings 
from the systematic review supported the need for further research in this area and the 
subsequent need for the remainder of the work presented in this thesis. 
The findings from the review have also added to the literature by highlighting that only a 
limited number of interventions in this area have reported using psychological theory in their 
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development. As a result, there is a lack of robust evidence on their effectiveness and 
therefore more research is needed. Although authors from studies in the review cited theory, 
it was evident that the selection of intervention components was not always guided by 
theory, or at least was not reported as such. This may help to explain findings recently 
reported in a large meta-analysis of adherence interventions (delivered to all types of 
patients) that found effect sizes were greater for theory-based interventions (0.302) than 
non-theory based interventions (0.289), but this difference was not statistically significant 
(p=0.727) (Conn and Ruppar, 2017). The authors of this meta-analysis did not explore theory 
use in great detail as has been done in the review presented in this thesis. It is, therefore, 
hypothesised that this non-significant finding could be due to insufficient use of theory in 
intervention development. 
Authors of studies included in our review rarely reported using theory to explore the 
underlying mechanism of action of the intervention (e.g. in a process evaluation). This is an 
important aspect of theory that could be better utilised to advance the field of adherence 
research by exploring not just ‘if’ interventions are effective but also ‘how’. Furthermore, 
there was insufficient evidence available to support the use of any individual psychological 
theory in future intervention development. This reinforced the decision to use a 
comprehensive theoretical framework as a lens to explore the target behaviour in detail. 
Hence, the next chapter of the thesis presented how TDF1 was used as a theoretical lens to 
explore older patients’ adherence behaviours, in the context of polypharmacy.  
6.1.2 Selection of components for a complex intervention to improve medication 
adherence in older adults prescribed polypharmacy 
In line with the development stage of the MRC framework, the work presented in Chapter 3 
of this thesis described how TDF1 was used as part of a qualitative focus group study to 
explore the target behaviour of medication adherence in the target audience of older adults 
prescribed polypharmacy. Although determinants of adherence have been studied in 
previous research, to the best of our knowledge, determinants most relevant to older 
patients prescribed polypharmacy had not yet been explored using the TDF (Sabate, 2003; 
Clifford et al. 2008; Demonceau et al. 2013).  
The findings from this TDF-based focus group study led to the identification of a wide range 
of determinants (barriers, facilitators) that were perceived to be influencing older patients’ 
adherence behaviour. Examples of determinants included prioritising medications, social 
support from family, beliefs that medications are unnecessary, forgetfulness and difficulty 
opening medication packaging. The habitual nature of the behaviour was also emphasised as 
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important by participants. Identified determinants were assigned to domains within TDF1 (12 
domains) and all 12 domains were deemed to be relevant in the context of older patients’ 
adherence behaviours based on group consensus. Some of the determinants reported in this 
qualitative study (such as physical difficulties, forgetfulness, concerns about side effects), and 
also the importance of routines, reflect findings from previous qualitative research 
conducted with older people (Thompson and Stewart, 2001; Granås and Bates, 2005; Tordoff 
et al. 2010a; Sanders and Van Oss, 2013; Notenboom et al. 2014) and also quantitative 
research (Barat et al. 2001; Tordoff et al. 2010b; Ben-Natan and Noselozich, 2011). However, 
the qualitative research presented in Chapter 3 of this thesis has added to the literature by 
using a comprehensive theoretical framework of behaviour change to better understand and 
categorise determinants. 
The study outlined in Chapter 3 also aimed to identify which theoretical domains could 
feasibly be targeted for behaviour change as part of a community pharmacy-based 
intervention. This was because, although all 12 domains were deemed relevant to the target 
behaviour, it was recognised that determinants assigned to some theoretical domains could 
not be easily modified (e.g. ability to open medication packaging identified under the ‘Skills’ 
domain). Eight domains (e.g. ‘Beliefs about consequences, ‘Motivation and goals’, ‘Social 
influences’) were therefore identified as key domains that could feasibly be targeted. These 
domains were then mapped to 11 intervention components (BCTs such as ‘Information about 
health consequences’ ‘Self-monitoring of behaviour’, ‘Social support-unspecified’) using 
established mapping methods (Michie et al. 2008; Cane et al. 2015).  
This theory-based approach also facilitated the identification of intervention components 
(BCTs) that have been infrequently used in adherence interventions directed at older patients 
prescribed multiple medications. This included the BCTs ‘Goal-setting-behaviour’ and 
‘Feedback on behaviour’ which may otherwise have been overlooked (George et al. 2008; 
Nieuwlaat et al. 2014; Allemann et al. 2016). Focusing on patients’ goals and priorities adopts 
a similar approach to that recommended for prescribing physicians when managing patients 
with multimorbidity, known as the Ariadne principles (Muth et al. 2014). These principles 
have been suggested to aid decision-making for multimorbid patients and centre on selecting 
treatment goals that are relevant and realistic for patients. Focusing on what is important to 
patients may help to improve motivation and willingness to change their adherence 
behaviours.  
Although the key target domain ‘Nature of the behaviours’ did not map to any specific 
intervention components (BCTs) in the mapping exercise, the routine nature of medication-
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taking was deemed essential to take into consideration. Recent evidence from a meta-
analysis has found that habit-based interventions are more effective than other types of 
interventions and so this further supports our decision to consider this (Conn and Ruppar, 
2017). The BCTs ‘Self-monitoring of the behaviour’ (medication diary) and ‘Prompts and cues’ 
(e.g. situational cues such as meals) were selected to include in the intervention, as they 
could also serve to help patients establish effective medication-taking routines.  
Another study (Allemann et al. 2016) published after the conduct of the study that has been 
presented in Chapter 3, has linked determinants of adherence and also intervention 
components to domains in TDF2 (Version 2: 14 domains) (Cane et al. 2012). This study by 
Alleman et al. (2016) did not focus specifically on any patient group and it adopted a different 
approach by undertaking a review of the literature to identify determinants and intervention 
components. The determinants and components linked to each TDF domain by Alleman et 
al. (2016) largely corresponded with the findings of our study but there were some 
differences noted including perceptual differences (i.e. differences in the way information 
was interpreted or understood). For example, in our study the relationship between patients 
and HCPs was assigned to the ‘Social influences’ domain, whereas this was assigned to ‘Social, 
professional role and identity’ domain by Alleman et al. (2016). The TDF guide recently 
published by Atkins et al. (2017) has recognised that assigning behavioural determinants to 
TDF domains requires a level of interpretation of theoretical constructs. Hence, they 
recommend that an expert (with experience in the application of the TDF) should be 
consulted to clarify any uncertainties, where possible. For the current study, one of the 
original developers of the TDF (Prof. Jill Francis) provided advice and guidance where there 
were uncertainties.  
By explicitly stating the key target theoretical domains and links to intervention components 
(i.e. BCTs) in published reports, this will aid replication of the intervention by others and 
future process evaluations to explore the underlying mechanism of action. The next stage of 
this research, in line with the MRC approach, involved testing the feasibility of delivering the 
identified components (BCTs) as part of a complex intervention in the proposed setting of 
community pharmacies. Therefore the next chapter of the thesis outlined the design process 
and findings from a small-scale feasibility study.  
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6.1.3 Design and feasibility testing of a theory-based complex patient-targeted 
intervention  
Design of a complex intervention package 
The first phase of the study outlined in Chapter 4 reported on how the ID-MAP intervention 
was designed for delivery by CPs to older patients prescribed polypharmacy. This involved 
combining the 11 BCTs identified in Chapter 3 into a complex package and required 
development of intervention materials (e.g. leaflets, medication diary to aid delivery of BCTs) 
and a brief training package for CPs. At this early stage of testing, a brief training session was 
deemed sufficient as a starting point for exploring the intensity and type of training required 
by CPs.  
A key consideration when designing the intervention was how the intervention could be 
tailored to each older patient’s needs. Previous research (Chapter 3) indicated that older 
patients prescribed polypharmacy are often non-adherent for a range of different reasons 
and these can vary both between and within patients (i.e. different reasons for different 
medications). However, to the best of the author’s knowledge there is no guidance available 
in the literature that outlines exactly how complex interventions should be tailored. In order 
for a tailored intervention to be replicable, it was agreed that the process needed to be 
systematic and outlined in detail in any published reports. Thus, the study presented in 
Chapter 4 sought to explicitly outline exactly how the intervention was designed to be 
tailored based on an adherence assessment using a novel assessment tool (ID-MAP tool). This 
assessment tool was developed using findings from the previous qualitative research with 
older patients (Chapter 3) and it included a range of open style questions to help CPs explore 
the underlying nature of adherence problems faced. Each type of adherence problem was 
then linked to at least one intervention component (BCT) and this aimed to guide CPs in 
consistently tailoring the intervention content to older patients’ needs.  
Research undertaken by Easthall et al. (2014) which explored medication adherence in adults 
(18 years+) with CVD, led to the development of a 30-item questionnaire for patients to 
complete to help identify barriers to adherence. This was subsequently refined to a 10-item 
version as the previous version was deemed to be too lengthy for practice (Unpublished work 
available at: http://www.uea.ac.uk/pharmacy/research/imab-q). For older patients, who 
were the focus of the current project, a more informal conversational style approach to 
barrier (and potential facilitator) identification was deemed most suitable. This decision was 
made based on findings from the previous qualitative research (Chapter 3) in which patients 
emphasised the importance of conversations with HCPs in establishing/maintaining 
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relationships and addressing any issues they faced. In our study, a short validated 
questionnaire (MMAS-8) was deemed appropriate for measuring adherence and as a 
screening tool to identify non-adherent patients who required support. However, this 
method was not considered the best approach for exploring, in-depth, factors (barriers, 
facilitators) influencing older people’s adherence behaviours and mapping these across to 
potential adherence solutions (i.e. BCTs). 
Tailoring of adherence interventions in the literature is uncommon. This has been illustrated 
in a meta-analysis of 771 adherence interventions delivered to adult patients (18 years+) 
which found only nine studies that reported individual-level tailoring (Conn and Ruppar, 
2017). Therefore, this part of the study will add to the literature by outlining exactly how a 
complex adherence intervention was designed so that it could be tailored at an individual-
level. Following design of the intervention package, the next phase of this study was to test 
the feasibility of delivering this in the community pharmacy setting. 
Feasibility testing in the community pharmacy setting 
The second phase of the study outlined in Chapter 4, reported findings from a small-scale 
feasibility study which took place in two community pharmacy sites and included three CPs 
and 10 older patients who were prescribed polypharmacy. The decision to select CPs as the 
intervention provider in the primary care setting has been further supported by findings from 
a large meta-analysis that found that interventions delivered by pharmacists produced 
significantly (p=0.031) larger effect sizes (0.337) in comparison with those delivered by other 
HCPs such as nurses and physicians (0.279) (Conn and Ruppar, 2017).  
The feasibility study findings presented in Chapter 4 demonstrated the usability and 
acceptability of the ID-MAP intervention from the viewpoint of both intervention recipients 
(older adults) and providers (CPs) with a patient retention rate of 90%. Although many of the 
findings from the feasibility study were positive, this research demonstrated that 
modifications are required to optimise both the intervention content and future study 
procedures. This highlights the benefits of conducting feasibility studies prior to pilot testing 
and larger evaluation studies (e.g. RCTs). Qualitative feedback from CPs and patients in this 
study has helped to identify where such modifications could be beneficial. This includes 
minor changes to the patient medication diary, changes to how intervention components are 
tailored and changes to key study procedures (e.g. screening and data collection). This 
feasibility study has also indicated that a strict appointment system may not be optimal for 
this group of patients as adherence problems can range in severity and therefore patients 
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require varying levels of support and contact with HCPs. This finding reflects guidance from 
NICE discussed previously that advocates a tailored approach to healthcare for individuals 
with multimorbidity (National Institute for Health and Care Excellence, 2016). Due to the high 
acceptability and usability levels reported, the ID-MAP intervention warrants further testing 
in a larger sample of community pharmacies and patients. 
Another key finding from this study was the need for additional training for CPs to enhance 
delivery of the intervention in accordance with the intervention manual (i.e. intervention 
fidelity). For example, CPs did not always deliver goal-based BCTs with high fidelity which was 
thought to be due to a lack of experience and only limited training provided in these 
techniques. Consequently, the research presented in the next chapter of the thesis sought to 
examine CPs’ behaviour (provision of MAS) in more detail. The aim of this was to identify 
how the training package could be modified and identify any additional strategies needed to 
improve the future implementation of the patient-targeted intervention. 
6.1.4 Selection of components to include in a theory-based community pharmacist 
training package and strategies to improve the provision of medication adherence 
support 
It has been recognised that in order to elicit behaviour change in one group of individuals, 
the behaviours of another group of individuals may need to be targeted (Huston, 2015). In 
the feasibility study (Chapter 4), CPs were selected as the intervention provider and therefore 
the study outlined in Chapter 5 sought to explore CPs’ clinical behaviour, in terms of providing 
MAS to older adults prescribed polypharmacy. The overall aim of this study was to help select 
components to include in an enhanced CP training package and also explore strategies to 
improve the future implementation of the patient-targeted intervention (e.g. in future 
research studies).  
In line with methods used previously in this thesis for exploring older patients’ adherence 
behaviours (Chapter 3), the TDF was selected as a theoretical lens to explore CPs’ clinical 
behaviour. The use of such a framework can help researchers explore a wide range of 
potential influences on behaviour that may otherwise be overlooked and help integrate a 
theoretical basis into the design of complex interventions such as training packages. At the 
time of this study, the research team noted that TDF-based methods were rapidly evolving 
with more researchers using quantitative methods as an alternative to, or alongside, 
qualitative methods. Therefore, this chapter used a mixed methods approach to explore CPs’ 
behaviour and extended the methods used previously in this package of research. 
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Despite the low response rate for the quantitative aspect of the study (survey), the mixed 
methods approach undertaken allowed this information to be triangulated with qualitative 
research. Findings from this study highlighted a range of behavioural determinants that were 
perceived to be influencing the provision of MAS to older patients in current practice. For 
example, some CPs appeared to lack knowledge of the full range of adherence solutions that 
were available to address adherence problems. MDS were one of the most frequently offered 
adherence solutions, despite evidence indicating that these are not always the most 
appropriate solution (Raynor and Nunney, 2002; Royal Pharmaceutical Society, 2013; 
Stewart et al. 2017). An Australian study also found that MDS were the most commonly 
provided adherence support strategy, indicating that this issue is not isolated to the UK 
(Mansoor et al. 2015). Our mixed methods study also found that CPs could benefit from 
additional skills training on techniques that can be used to increase older patients’ motivation 
to adhere to prescribed regimens. This mirrored findings from the feasibility study (Chapter 
4) whereby CPs experienced difficulties with delivering motivational-based techniques such 
as the BCT ‘Goal-setting (outcome)’. Other key determinants (barriers) to providing MAS to 
older adults included a lack of reimbursement and time. Although it was noted that these 
barriers cannot be addressed as part of a training package, these are important behavioural 
influences to consider for future implementation.  
Triangulation of findings from the qualitative and quantitative aspects of this study aided the 
selection of seven theoretical domains (e.g. ‘Knowledge’, ‘Skills’, ‘Motivation and goals’) that 
could be targeted to change CPs’ behaviour. These domains were then mapped across to 18 
BCTs that could be incorporated as components of a future training package (e.g. 
‘Demonstration of the behaviour’, ‘Behaviour rehearsal/practice’) and/or delivered as part 
of future research studies (e.g. ‘Rewards/incentives’, ‘Prompts/cues’) to improve the 
implementation of the ID-MAP intervention by CPs.  
Although the TDF provided a useful framework for the current study, other frameworks have 
been developed for use in implementation research and developing behaviour change 
interventions (May et al. 2009; Stewart and Klein, 2016; Kok et al. 2016). One example is the 
Normalization Process Theory which can help researchers explain ‘…how new technologies, 
ways of acting, and ways of working become routinely embedded in everyday practice…’ 
(May et al. 2009). Nonetheless, the TDF was selected for the study presented in Chapter 5 
for consistency as it was used as the theoretical framework for developing the patient-
targeted intervention (Chapter 3). 
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6.1.5 Recommendations for future research, practice and policy 
Effectiveness of theory-based interventions 
Further research needs to be conducted to establish whether or not this theory-based 
approach to developing complex interventions using the TDF is effective. To the best of the 
author’s knowledge, only two TDF-based studies have reached the evaluation stage of 
intervention testing in a RCT (French et al. 2013; Nathan et al. 2016). A study by Nathan et al 
(2016) which focused on the implementation of a healthy school canteen policy showed 
statistically significant effects, whereas a study by French et al. (2013), which aimed to 
improve GPs’ management of low back pain, despite showing improvements, did not 
produce statistically significant effects. These findings highlight that whilst using this 
systematic theory-based approach has potential benefits, it does not automatically 
guarantee effectiveness. Instead, this type of approach is useful in that it can aid 
understanding of why an intervention has worked or failed to work through the use of theory 
testing and process evaluations. A process evaluation of the ID-MAP intervention should 
therefore be undertaken in future research to explore the proposed mechanism of action.   
Identifying non-adherent patients 
The feasibility study (Chapter 4) provided the opportunity to test whether a short validated 
questionnaire (MMAS-8) could be used to identify older patients who were non-adherent, as 
previous research has shown that including all patients who are willing to take part often 
results in high baseline adherence levels (Ruppar, 2010a). The MMAS-8 questionnaire was 
largely acceptable to participants as a screening tool, however it is recognised that self-report 
methods are limited by social desirability bias and therefore a combination of methods for 
identifying non-adherent patients may be more useful (Lam and Fresco, 2015). In Australia, 
electronic pharmacy-held record systems have been used to flag non-adherent patients who 
could benefit from an adherence assessment using an algorithm developed by MIRIXA® 
(https://www.mirixa.com/payers/mirixa-solutions). Future research could explore whether 
it is possible for this type of system to be developed for use in the UK and for patients taking 
multiple medications.  
Tailoring adherence interventions 
The qualitative findings presented in Chapter 3 have illustrated that knowledge is just one of 
many potential determinants of older patients’ adherence behaviours. This supports claims 
made by other researchers that patient education alone is insufficient in changing patients’ 
adherence behaviour (Nieuwlaat et al. 2014; Allemann et al. 2016; Kahwati et al. 2016). 
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Consequently, CPs should move away from focusing solely on patient education strategies to 
improve knowledge and instead should try to explore the underlying reasons for each older 
patients’ non-adherence. Until more evidence on the most effective combination of 
adherence solutions becomes available, it seems reasonable to recommend that CPs should 
adopt a tailored approach in practice when deciding on the best adherence solutions.  
In addition to tailoring adherence solutions, future research should focus on how best to 
tailor the number of intervention appointments to each older patient’s needs. To be 
replicable by others, this tailoring process needs be systematic and involve decision rules to 
guide CPs. As an alternative to face-to-face appointments, short telephone calls could be 
made at pre-specified intervals where adherence could be reassessed (e.g. using validated 
self-report measures). If adherence has not been maintained, patients could then be re-
invited to attend additional face-to-face appointments in the pharmacy to identify ongoing 
challenges. It is likely that ongoing contact with HCPs is necessary to maintain the effects of 
the intervention and therefore future research should explore how this type of ongoing 
support can be best achieved. 
Important outcomes to measure in future studies 
The feasibility study outlined in Chapter 4 only assessed adherence as an outcome measure 
at baseline and three months post-intervention (i.e. medium-term) due to time restrictions. 
Future research should attempt to assess changes in adherence after at least six months to 
measure longer-term effects of the intervention (Cross et al. 2016). Although adverse drug 
events (ADEs) were not recorded as part of our feasibility study, ADEs were reported in a 
feasibility study conducted by Bhattacharya et al. (2016) that aimed to explore the 
effectiveness of MDS on unintentional medication adherence. This emphasises the 
importance of follow-up appointments/telephone calls for all patients as these provide 
opportunities to detect unwanted side effects which may result from improved adherence. 
It will be prudent to collect outcome data on ADEs and hospitalisations as part of future 
testing of the ID-MAP intervention. In addition, Wright (2016) recommends that a risk 
assessment should be carried out prior to the adherence assessment. This could include 
checking whether the patient’s medical conditions are already controlled on the prescribed 
regimen despite non-adherence (e.g. BP already at optimal level), as improving adherence 
could result in ADEs (e.g. hypotension). However, conducting such risk assessments poses a 
challenge for CPs in current practice as this may require direct contact with GPs to access this 
information. Having access to this type of information as part of the Electronic Care Record 
would help with this process but this is not currently available to CPs in NI.  
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Enhancing the reach of the intervention 
The feasibility study presented in this thesis only explored delivery of the ID-MAP 
intervention at the community pharmacy site which may restrict the reach of the 
intervention. Additional research is required to explore how this type of intervention could 
be adapted for delivery in the domiciliary setting to support older patients who are 
housebound. One of the key purposes of the Responsible Pharmacist Regulations (introduced 
in 2008) was to allow CPs to be absent from the pharmacy to carry out these types of roles 
(Pharmaceutical Society of Northern Ireland, 2016). However, the qualitative research 
conducted with CPs in this thesis (Chapter 5) suggests that this has not translated into 
practice, with some CPs, particularly those working as the sole pharmacist, reporting that it 
is not feasible for them to leave the pharmacy to conduct these type of domiciliary reviews. 
In 2016, significant funding was announced by the Department of Health (NI) in an attempt 
to relieve the pressure currently faced by GPs in the primary care setting. Funding was 
allocated to allow for the development of 300 (full-time equivalent) GP practice-based 
pharmacist posts in NI by 2020 (Strategic Leadership Group for Pharmacy, 2016). GP practice-
based pharmacists may have a future role to play in improving medication adherence, 
particularly in the context of frail housebound older patients through the provision of 
domiciliary adherence support.  
Future integration into community pharmacy practice  
The patient-targeted intervention outlined in this thesis was developed as a stand-alone 
intervention for ease of development and testing but future research could focus on how this 
type of intervention could be integrated with services already in place in community 
pharmacies (e.g. as an extension to MURs) or as a replacement for these. In NI, a new 
adherence service (Medication Adherence Support Service) has recently undergone a service 
evaluation in two administrative (HSCT) areas, although the findings of this have yet to be 
reported (http://www.hscbusiness.hscni.net/pdf/Service_Guidance_Version_2.pdf). It is 
unclear how the components of this service were selected and without a link to theory, it will 
be difficult to explore its mechanism of action. In addition, without undertaking 
comprehensive intervention development, feasibility and pilot testing followed by a robust 
evaluation (e.g. RCT along with a process and economic evaluation), it will be unclear 
whether this service is effective or cost-effective. As recommended by Wright (2016) ‘New 
[community pharmacy] services should always be feasibility tested and piloted first with a 
focus at this stage on training, implementation and delivery rather than outcomes.’ 
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Funding models in community pharmacy  
As a first step to providing MAS, CPs need to be more pro-active in identifying non-adherent 
older patients in their daily practice. The research findings in Chapter 5 have highlighted that 
less than half of surveyed CPs frequently reported using strategies to identify non-adherent 
older patients. The qualitative findings indicated that a lack of reimbursement and time 
constraints are major barriers to this. The current funding model in community pharmacies 
in the UK focuses on volume of activity (i.e. ‘volume-based’ services contract) whereby CPs 
are paid based on the number of patients to whom they provide services (Wright, 2016). This 
is a potential barrier to implementation of the ID-MAP intervention in future practice as this 
could lead to suboptimal delivery in an attempt to increase efficiency and maximise profits, 
as has been reported with other volume-based services (Smith et al. 2017).  Suggestions have 
been made to move towards a ‘value-based’ services community pharmacy contract by 
focusing more on outcomes in relation to payment, for example, CPs could be paid a higher 
fee if improvements in adherence are evidenced (e.g. through a post-service questionnaire) 
(Wright, 2016). Until such a policy change is made, it is likely that CPs will need to be 
incentivised to deliver this type of adherence intervention in practice. 
The role of improving adherence as part of medicines optimisation  
Although improving medication adherence is vital to improving clinical outcomes, it is 
recognised that this is only one aspect of ‘medicines optimisation’ (‘…a person-centred 
approach to safe and effective medicines use, to ensure people obtain the best possible 
outcomes from their medicines’) (National Institute for Health and Care Excellence, 2015). 
Evidence suggests that around 30 to 34% of older adults in the UK and NI are prescribed at 
least one unnecessary/inappropriate medication (e.g. duplication of therapies) (Bradley et 
al. 2012; Bradley et al. 2014). As outlined previously, the current adherence project outlined 
in this thesis was part of a larger project on polypharmacy that sought to improve the use of 
multiple medications in older patients. In this larger project, a complex intervention has been 
developed (Cadogan et al. 2015; Cadogan et al. 2016a) to improve the appropriateness of 
polypharmacy by targeting GPs’ prescribing behaviours and this has undergone feasibility 
testing (Cadogan et al. 2017).  
A comprehensive medication review was not undertaken by CPs as part of the feasibility 
study (Chapter 4) in this thesis as this was not the focus of the current project. Nonetheless, 
CPs in the feasibility study were instructed to prepare a list of each patient’s medications in 
advance of delivering the ID-MAP adherence intervention. CPs were advised to contact the 
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prescriber (GP) if they had any concerns regarding prescribed regimens (e.g. duplication of 
therapy, interactions) and were instructed to ask patients about side effects during the 
adherence assessment. The latter also provided an opportunity to explore how each patient 
managed their medication regimen and the opportunity to refer patients onto the prescriber 
(GP) if the pill burden or regimen complexity was affecting adherence. These activities were 
included in the feasibility study to help identify medications/regimens that required 
modifications prior to attempting to improve adherence. Despite this, it is recognised that 
CPs could likely benefit from further training on recognising and dealing with inappropriate 
polypharmacy. Future research could focus on integrating a comprehensive medication 
review, conducted by a prescriber (e.g. GP, GP practice-based pharmacist), with the ID-MAP 
adherence intervention, in a sequential manner. This stepwise approach has been advocated 
by other researchers to ensure the regimen is the most appropriate one prior to addressing 
problems of non-adherence (George et al. 2008; Marcum and Gellad, 2012). Nevertheless, 
due to the complexity of these interventions (prescriber-targeted and patient/CP-targeted), 
in terms of the number and types of behaviours being targeted, individually optimising each 
intervention first is warranted prior to combining these into a step-wise approach.  
To reduce medication waste and harm to patients and improve clinical outcomes, healthcare 
systems need to be re-organised in a way that facilitates the optimal use of medicines, 
particularly in the context of polypharmacy and older multi-morbid patients (Duerden et al. 
2013). A large EU-funded research project (Stimulating Innovation Management of 
Oolypharmacy and Adherence In The Elderly; SIMPATHY) has placed emphasis on working 
together to address key challenges faced in relation to polypharmacy. SIMPATHY’s vision is 
that by ‘…2030 European healthcare will be widely characterised by effective policies for the 
management of polypharmacy implemented through multi-disciplinary teams.’ (Mair et al. 
2017). The research presented in this thesis has added to the literature on polypharmacy and 
medication adherence in older people. In line with the MRC approach adopted in this 
package of research, the next stage will involve testing the patient-targeted intervention and 
enhanced CP training package in a pilot study with a larger sample of patients and pharmacies 
and across another region in the UK to explore if the findings are transferable.  
6.2 General conclusion 
The work presented in this thesis has addressed an identified gap in the literature by 
developing a complex theory-based intervention to improve medication adherence in older 
adults prescribed polypharmacy. In line with guidance from the MRC, the patient-targeted 
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intervention was developed based on a theoretical exploration of older patients’ adherence 
behaviour using a TDF-based qualitative study. Multiple determinants (barriers, facilitators) 
were identified and assigned to theoretical domains in TDF1. Key domains for targeting were 
selected and mapped across to intervention components (BCTs) that could be included in a 
complex intervention package. The feasibility of tailoring the components of this complex 
intervention package to older patients’ needs in the community pharmacy setting was then 
explored in a small-scale feasibility study. Although findings demonstrated that this 
intervention was highly acceptable and useful for both older patients and CPs, some 
recommendations were made to further enhance this, including more comprehensive 
training for CPs. As a result, a TDF-based mixed methods (qualitative, quantitative) study was 
used to explore CPs’ behaviour in terms of supporting older patients with adherence to help 
enhance the training package. A range of determinants (barriers, facilitators) were identified 
and assigned to domains in TDF1 in a similar approach used to develop the patient-targeted 
intervention. Key target domains were selected and linked to multiple strategies (BCTs) that 
could be delivered as part of an enhanced CP training package and/or in future research 
studies to facilitate the implementation of the patient-targeted intervention. Future research 
will involve the conduct of a pilot study to test a modified version of the patient-targeted 
intervention and CP training package in a larger sample of participants.  
This research adds to the broader literature on medication adherence, a field that has 
attracted significant attention in the last few decades. It is widely accepted that medications 
will only be effective if taken as prescribed and finding an effective solution to non-adherence 
could bring greater health outcomes than any individual advances in therapeutics (Sabate, 
2003). With an ageing population and predicted rise in the number of patients with 
multimorbidity, the issue of non-adherence will continue to be of concern in the coming 
years. Therefore, it of vital importance that research into finding effective adherence 
interventions continues and most importantly, identifies strategies to address this behaviour.  
Before providing a new drug to patients, an in-depth systematic exploration of both how and 
if the drug works is undertaken (Jacobsen and Wertheimer, 2010). To advance the field of 
adherence research, a similar systematic approach to intervention development is essential. 
Future research should dedicate sufficient time to developing and optimising adherence 
interventions before embarking on sufficiently powered evaluation studies (e.g. RCTs) to 
explore their effectiveness.
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# Checklist item  Page in 
thesis 
TITLE   
Title  1 Identify the report as a systematic review, 
meta-analysis, or both.  
30 
ABSTRACT   
Structured 
summary  
2 Provide a structured summary including, as 
applicable: background; objectives; data 
sources; study eligibility criteria, participants, 
and interventions; study appraisal and 
synthesis methods; results; limitations; 
conclusions and implications of key findings; 
systematic review registration number.  
Not 
relevant 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the 
context of what is already known.  
31-33 
Objectives  4 Provide an explicit statement of questions 
being addressed with reference to 
participants, interventions, comparisons, 
outcomes, and study design (PICOS).  
34-35 




5 Indicate if a review protocol exists, if and 
where it can be accessed (e.g., Web address), 
and, if available, provide registration 




6 Specify study characteristics (e.g., PICOS, 
length of follow-up) and report characteristics 
(e.g., years considered, language, publication 









7 Describe all information sources (e.g., 
databases with dates of coverage, contact with 
study authors to identify additional studies) in 
the search and date last searched.  
35-36 
Search  8 Present full electronic search strategy for at 
least one database, including any limits used, 




9 State the process for selecting studies (i.e., 
screening, eligibility, included in systematic 






10 Describe method of data extraction from 
reports (e.g., piloted forms, independently, in 
duplicate) and any processes for obtaining and 
confirming data from investigators.  
36 
Data items  11 List and define all variables for which data 
were sought (e.g., PICOS, funding sources) and 
any assumptions and simplifications made.  
266-267 




12 Describe methods used for assessing risk of 
bias of individual studies (including 
specification of whether this was done at the 
study or outcome level), and how this 




13 State the principal summary measures (e.g., 








of results  
14 Describe the methods of handling data and 
combining results of studies, if done, including 













Appendix 2.2: MEDLINE search string  
 
1. Medication adherence (MeSH)  
2. ‘Patient adherence’ (keyword) 
3. ‘Medication compliance’ (keyword) 
4. ‘Patient compliance’ (MeSH)  
5. ‘Non complian$’ (keyword) 
6. ‘Non-complian$’ (keyword) 
7. ‘Concordan$’ (keyword) 
8. ‘Treatment adj3 persistence’ (keyword) 
9. ‘Treatment adj3 refusal’ (keyword) 
10. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9  
11. Polypharmacy (MeSH)  
12. Drug therapy (MeSH)  
13. Drug therapy, combination (MeSH)  
14. ‘Multiple adj3 medicat$’ (keyword) 
15. ‘Multidrug$’ (keyword) 
16. ‘Drug polytherapy’ (keyword) 
17. ‘Polymedicine’ (keyword) 
18. ‘Multiple drug regimen’ (keyword) 
19. ‘Combination therapy’ (keyword) 
20. 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 
21. ‘Theor$’ (keyword) 
22. ‘Theoretical’ (keyword) 
23. ‘Model$’ (keyword) 
24. ‘Principle’ (keyword) 
25. ‘Behavio$r$’ (keyword) 
26. ‘Psycho$social’ (keyword) 
27. Psychological theory (MeSH) 
28. ‘Construct$’ (keyword) 
29. ‘Framework’ (keyword) 
30. ‘Cognitive’ (keyword) 
31. Concept formation (MeSH) 
32. 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 
33. ‘Older adj3 adult$’ (keyword) 
34. ‘Older adj3 patient$’ (keyword) 
35. Aged (MeSH)  
36. ‘Senior’ (keyword) 
37. Geriatrics (MeSH)  
38. Veterans (MeSH)  
39. ‘Elderly’ (keyword) 
40. 33 or 34 or 35 or 36 or 37 or 38 or 39 









































































Appendix 3.1: TDF to BCT mapping table taken from  




















NB: Four independent experts were asked ‘Which techniques would you use as part of 
an intervention to change each construct domain?’ and responded within each cell of 
table with one of four options (possibly=1; probably=2; definitely=3; No=blank). The 
key indicates the combined responses for the four experts who took part (agreed use, 











Appendix 3.2: TDF to BCT mapping table adapted from Cane 
et al. (2015)  
Domain BCT BCT Definition from BCTTV1 (Michie et al. 2013) 
Knowledge Information about 
health consequences1 
‘Provide information (e.g. written, verbal, visual) about 
health consequences of performing the behaviour.’ 
Biofeedback  
 
‘Provide feedback about the body (e.g. physiological or 
biochemical state) using an external monitoring device 
as part of a behaviour change strategy.’ 
Antecedents  
 
‘Provide information about antecedents (e.g. social and 
environmental situations and events, emotions, 




‘Monitor and provide informative or evaluative 
feedback on performance of the behaviour (e.g. form, 
frequency, duration, intensity).’ 
Skills Graded tasks  
 
‘Set easy-to-perform tasks, making them increasingly 




‘Prompt practice or rehearsal of the performance of the 
behaviour one or more times in a context or at a time 
when the performance may not be necessary, in order 
to increase habit and skill.’ 
Habit reversal  
 
‘Prompt rehearsal and repetition of an alternative 
behaviour to replace an unwanted habitual behaviour.’ 
Body changes  
 
‘Alter body structure, functioning or support directly to 
facilitate behaviour change.’ 
Habit formation ‘Prompt rehearsal and repetition of the behaviour in 
the same context repeatedly so that the context elicits 
the behaviour’ 
Social/ 
professional role and 
identity  
No BCTs mapped to 





Verbal persuasion to 
boost self-efficacy 
‘Tell the person that they can successfully perform the 
wanted behaviour, arguing against self-doubts and 
asserting that they can and will succeed’ 
Focus on past success ‘Advise to think about or list previous successes in 
performing the behaviour (or parts of it).’ 
Optimism Verbal persuasion to 
boost self-efficacy 











‘Provide information (e.g. written, verbal, visual) about 




‘Use methods specifically designed to emphasise the 
consequences of performing the behaviour with the 
aim of making them more memorable (goes beyond 
informing about consequences).’ 
Covert sensitization Part of the BCT ‘Imaginary punishment’ which is 
defined as: ‘Advise to imagine performing the 
unwanted behaviour in a real-life situation followed by 
imagining an unpleasant consequence…’ 
Anticipated regret 
 
‘Induce or raise awareness of expectations of future 




‘Provide information (e.g. written, verbal, visual) about 
social and environmental consequences of performing 
the behaviour.’ 
Comparative 
imagining of future 
outcomes 
‘Prompt or advise the imagining and comparing of 




‘Prompt observation of the consequences 
(including rewards and punishments) for others when 
they perform the behaviour.’ 
Threat  
 
Part of the BCT ‘Future punishment’ which is defined 
as: ‘Inform that future punishment or removal of 
reward will be a consequence of 
performance of an unwanted behaviour 
(may include fear arousal)…’ 
Pros and cons 
 
‘Advise the person to identify and compare reasons for 
wanting (pros) and not wanting to (cons) change the 
behaviour.’ 
Covert conditioning Part of ‘Imaginary reward’ which is defined as: ‘Advise 
to imagine performing the wanted behaviour in a real-












Appendix 3.2 (cont’d): TDF to BCT mapping table adapted from 
Cane et al. (2015)  
 
Domain BCT BCT Definition from BCTTV1 (Michie et al. 2013) 
Reinforcement 
 
Threat See above under ‘Beliefs about consequences’ domain.  
Self-reward  
 
‘Prompt self-praise or self-reward if and only if there 





Part of BCT: ‘Reward alternative behaviour’ which is 
defined as: ‘Arrange reward for performance of an 
alternative to the unwanted behaviour.’ 
Shaping  Part of BCT ‘Reward approximation’ which is defined 
as: ‘Arrange for reward following any approximation to 
the target behaviour, gradually rewarding only 
performance closer to the wanted behaviour…’ 
Thinning  
 
Part of BCT ‘Reduce reward frequency’ which is 
defined as: ‘Arrange for rewards to be made contingent 
on increasing duration or frequency of the behaviour…’ 
Negative 
reinforcement 
Part of BCT ‘Remove punishment’ which is defined as: 
‘Arrange for removal of an unpleasant consequence 
contingent on performance of the wanted behaviour…’ 
Incentive1 
 
‘Inform that money, vouchers or other valued objects 
will be delivered if and only if there has been effort 
and/or progress in performing the behaviour.’ 
Counter conditioning  Part of BCT ‘Reward incompatible behaviour’ which is 
defined as: ‘Arrange reward for responding in a 
manner that is incompatible with a previous response 
to that situation…’ 
Discrimination 
training  
Part of BCT ‘Situation-specific reward’ which is defined 
as: ‘Arrange for reward following the behaviour in one 
situation but not in another.’ 
Material reward1 ‘Arrange for the delivery of money, vouchers or other 
valued objects if and only if there has been effort 
and/or progress in performing the behaviour.’ 
Social reward  ‘Arrange verbal or non-verbal reward if and only if 
there has been effort and/or progress in performing the 
behaviour.’ 
Non-specific reward  ‘Inform that a reward will be delivered if and only if 
there has been effort and/or progress in performing the 
behaviour.’ 
Response cost Part of BCT ’Behaviour cost’ which is defined as: 
‘Arrange for withdrawal of something valued if and 
only if an unwanted behaviour is performed…’ 
Anticipation of future 
rewards or removal of 
punishment 
No definition provided in BCTTV1. 
 
 
Punishment  ‘Arrange for aversive consequence contingent on the 
performance of the unwanted behaviour.’ 
 
 
Domain BCT BCT Definition from BCTTV1 (Michie et al. 2013) 
Reinforcement (cont’d) 
 
Extinction  Part of ‘Remove reward’ which is defined as:  ‘Arrange 
for discontinuation of contingent reward following 
performance of the unwanted behaviour.’ 
Classical conditioning Part of BCT ‘Associative learning’ which is defined as: 
‘Present a neutral stimulus jointly with a stimulus that 
already elicits the behaviour  






‘Ask the person to affirm or reaffirm statements 
indicating commitment to change the behaviour.’ 
Behavioural contract ‘Create a written specification of the behaviour to be 
performed, agreed on by the person, and witnessed by 
another.’ 
Goals Goal setting 
(outcome)1 
‘Set or agree on a goal defined in terms of a positive 
outcome of wanted behaviour.’ 
Goal setting 
(behaviour)1 
‘Set or agree on a goal defined in terms of the 
behaviour to be achieved.’ 
Review of outcome 
goal(s)1 
 
‘Review outcome goal(s) jointly with the person and 
consider modifying goal(s) in light of achievement. This 
may lead to resetting the same goal, a small change in 
that goal or setting a new goal instead of, or in 




‘Review behaviour goal(s) jointly with the person and 
consider modifying goal(s) or behaviour change 
strategy in light of achievement. This may lead to re-
setting the same goal, a small change in that goal or 
setting a new goal instead of (or in addition to) the 





‘Prompt detailed planning of performance of the 
behaviour (must include at least one of context, 
frequency, duration and intensity). Context may be 
environmental (physical or social) or internal (physical, 
emotional or cognitive).’ 
Memory, Attention, 
and Decision Processes 
No BCTs mapped to 






















Appendix 3.2 (cont’d): TDF to BCT mapping table adapted from 
Cane et al. (2015)  






‘Change, or advise to change the physical environment 
in order to facilitate performance of the wanted 
behaviour or create barriers to the unwanted 
behaviour…’ 
Discriminative 
(learned) cue  
 
Part of BCT ‘Cue signalling reward’ which is defined as: 
‘Identify an environmental stimulus that reliably 
predicts that reward will follow the behaviour.’ 
Prompts/cues1 ‘Introduce or define environmental or social stimulus 
with the purpose of prompting or cueing the behaviour. 
The prompt or cue would normally occur at the time or 
place of performance.’ 
Restructuring the 
social environment  
 
‘Change, or advise to change the social environment in 
order to facilitate performance of the wanted 
behaviour or create barriers to the unwanted 
behaviour (other than prompts/cues, rewards and 
punishments).’ 
Avoidance/ changing 
exposure to cues for 
the behaviour 
‘Advise on how to avoid exposure to specific social and 
contextual/physical cues for the behaviour, including 
changing daily or weekly routines.’ 
 
Social Influences Social comparison1 
 
‘Draw attention to others’ performance to 




‘Advise on, arrange or provide social support (e.g. from 
friends, relatives, colleagues,’ buddies’ or staff) or non-
contingent praise or reward for performance of the 
behaviour. It includes encouragement and counselling, 
but only when it is directed at the behaviour.’ 
Information about 
others’ approval  
 
‘Provide information about what other people think 
about the behaviour. The information clarifies whether 
others will like, approve or disapprove of what the 




‘Advise on, arrange, or provide emotional social 
support (e.g. from friends, relatives, colleagues, 
‘buddies’ or staff) for performance of the behaviour.’ 
 






‘Advise on, arrange, or provide practical help (e.g. from 
friends, relatives, colleagues, ‘buddies’ or staff) for 
performance of the behaviour.’ 
Vicarious 
reinforcement  
See above under ‘Beliefs about consequences’ domain.  
Restructuring the 
social environment 






‘Provide an observable sample of the performance of 
the behaviour, directly in person or indirectly e.g. via 
film, pictures, for the person to aspire to or imitate…’ 
Identification of self as 
role model  
‘Inform that one's own behaviour may be an example 
to others.’ 






‘Advise on ways of reducing negative emotions to 












See above under ‘Social influences’ domain.  
Behavioural Regulation Self-monitoring of 
behaviour1 
‘Establish a method for the person to monitor and 
record their behaviour(s) as part of a behaviour change 
strategy’ 
  



































































Appendix 3.4 (cont’d): Patient information sheet (focus groups) 
 
























































































Appendix 3.8: Completed COREQ checklist (focus groups) (Tong et 
al. 2007) 




Which author/s conducted the interview or 
focus group? 
Two researchers carried out the focus 
groups. CC acted as the moderator and DP 
took notes and provided a brief summary 
at the end of each session. 
2. Credentials  What were the researcher’s credentials? 
E.g. PhD, MD 
CC had a PhD and BSc in pharmacy. DP 
had an MPharm degree and was a PhD 
candidate. CC and DP were both qualified 
pharmacists.  
3. Occupation  What was their occupation at the time of 
the study? 
CC was working as a Post-doctoral 
Research Fellow and DP was a PhD 
student at the time of the research study. 
DP continued to practise in the 
community pharmacy setting on a part 
time basis. 
4. Gender  Was the researcher male or female? CC-male, DP-female. 
5. Experience and 
training 
What experience or training did the 
researcher have? 
CC and DP had both undertaken training 
in qualitative research methodologies and 
CC had previous experience.  
Relationship with participants 
6. Relationship 
established  
Was a relationship established prior to 
study commencement? 
No prior relationship was established 
between the interviewers and focus group 
participants, other than contact with CC 
to arrange the sessions. 
7. Participant 
knowledge of the 
interviewer  
What did the participants know about the 
researcher? e.g. personal goals, reasons for 
doing the research 
Participants were aware that both 
researchers worked at the School of 
Pharmacy (QUB) and that the research 
was funded by the Dunhill Medical Trust. 
8. Interviewer 
characteristics  
What characteristics were reported about 
the interviewer/facilitator? e.g. Bias, 
assumptions, reasons and interests in the 
research topic 
Both facilitators had an interest in the 
research topic of polypharmacy. DP had a 















Appendix 3.8 (cont’d): Completed COREQ checklist (focus 
groups) (Tong et al. 2007) 





What methodological orientation was stated 
to underpin the study? e.g. grounded 
theory, discourse analysis, ethnography, 
phenomenology, content analysis 
The focus group topic guide was 
underpinned by the TDF. Framework 
analysis was conducted, followed by 
inductive qualitative content analysis.  
Participant selection 
10. Sampling  How were participants selected? e.g. 
purposive, convenience, consecutive, 
snowball 
General practices that had participated in 
a previous linked study were approached 
and asked if they would facilitate patient 
recruitment for the focus groups. This 
included general practices from across the 
five HSC Trusts in NI (two per Trust area). 
A purposive sampling strategy was 
adopted for this study to identify 
‘information-rich’ participants. 
11. Method of 
approach 
How were participants approached? e.g. 
face-to-face, telephone, mail, email 
Participants were mailed letters of 
invitation (from their general practice). 
12. Sample size  How many participants were in the study? Fifty participants took part in the study 




How many people refused to participate or 
dropped out? Reasons? 
Numbers of refusals were not recorded by 
nurses from the Northern Ireland Clinical 
Research Network who were responsible 
for issuing invitations.  
Setting 
14. Setting of data 
collection  
Where was the data collected? e.g. home, 
clinic, workplace 
Data was collected either at the patients’ 
general practice or other convenient 
location (e.g. local leisure centre) 
15. Presence of 
non-participants  
Was anyone else present besides the 
participants and researchers? 
Only CC, DP and focus group participants 
were present. 
16. Description of 
sample  
What are the important characteristics of 
the sample? e.g. demographic data, date 
All participants were aged over 65 years 





Domain 2 (cont’d): study design 
Data collection  
17. Interview guide  Were questions, prompts, guides provided 
by the authors? Was it pilot tested? 
A topic guide with prompts was 
developed and used during the sessions. 
This was tested and refined prior to use.  
18. Repeat 
interviews  
Were repeat interviews carried out? If yes, 
how many? 




Did the research use audio or visual 
recording to collect the data? 
Focus group sessions were audio-
recorded. 
20. Field notes  Were field notes made during and/or after 
the interview or focus group? 
Field notes were made by DP during the 
focus group sessions. 
21. Duration  What was the duration of the interviews or 
focus group? 
Each focus group ranged from 65-123 
minutes (618 minutes in total). 
22. Data saturation  Was data saturation discussed? Data saturation was reached by the 




Were transcripts returned to participants 
for comment and/or correction? 
Transcripts were not returned to focus 
group participants. 
Domain 3: analysis and findings 
Data analysis 
24. Number of 
data coders  
How many data coders coded the data? Three researchers (DP, CR, CH) 
independently coded the data (two 
researchers per transcript). 
25. Description of 
the coding tree  
Did authors provide a description of the 
coding tree? 
Codes represented barriers and 
facilitators expressed by participants that 
were assigned to each domain of the TDF.  
26. Derivation of 
themes  
Were themes identified in advance or 
derived from the data? 
Themes in each domain were informed by 
the content of the focus groups.  
27. Software  What software, if applicable, was used to 
manage the data? 
NVivo® QSR 10. 
28. Participant 
checking  
Did participants provide feedback on the 
findings? 
At the end of each focus group DP 
provided a summary of the issues 












Appendix 3.8 (cont’d): Completed COREQ checklist (focus 
groups) (Tong et al. 2007) 




Were participant quotations presented to 
illustrate the themes / findings? Was each 
quotation identified? e.g. participant 
number 
Quotations have been presented in 
Section 3.4.2 of this thesis with identifiers 
removed. Each participant was given an 
anonymous code (e.g. FG01PT01).  
30. Data and 
findings consistent  
Was there consistency between the data 
presented and the findings? 
See Section 3.4.2 of this thesis. We 
endeavoured to report the study findings 
in a clear, consistent manner in order to 
accurately reflect the data that has been 
collected. 
31. Clarity of major 
themes  
Were major themes clearly presented in 
the findings? 
32. Clarity of minor 
themes  
Is there a description of diverse cases or 
discussion of minor themes? 
 
 











































































































Appendix 4.2: Medication diary 










































Appendix 4.3: Voicing concerns about your medicines leaflet 
  



















Appendix 4.4: Generic medicines leaflet      Appendix 4.5: Goal setting exercise sheets 



































































































































































































































































































































































Appendix 4.16: Standard Operating Procedure for handling the    Appendix 4.17: Standard Operating Procedure for handling 
situation where dementia is suspected or where a patient    patients who become distressed during the study 
is diagnosed with dementia during the course of the study 
 







































































Appendix 4.22: Patient study consent form 2 (feasibility study) 
 




































































Appendix 4.26 (cont’d): Permission for use of EQ-5D-5L     Appendix 4.27: Semi-structured interview topic guide for  













Appendix 4.27 (cont’d): Semi-structured interview topic guide for                        



















Appendix 4.27 (cont’d): Semi-structured interview topic  












Appendix 4.28: Semi-structured interview topic guides for  





















Appendix 4.28 (cont’d): Semi-structured interview topic guide for  

















Appendix 4.28 (cont’d): Semi-structured interview topic guide for  











Appendix 4.28 (cont’d): Semi-structured interview topic guide for  

































can be found 
 
1. 





WHY: Describe any rationale, theory, or goal of the 
















Materials: Describe any physical or informational materials 
used in the intervention, including those provided to 
participants or used in intervention delivery or in training 
of intervention providers. Provide information on where 
the materials can be accessed (e.g. online appendix, URL). 
Procedures: Describe each of the procedures, activities, 
and/or processes used in the intervention, including any 














WHO PROVIDED: For each category of intervention 
provider (e.g. psychologist, nursing assistant), describe 








HOW: Describe the modes of delivery (e.g. face-to-face or 
by some other mechanism, such as internet or telephone) 
of the intervention and whether it was provided 











can be found 
 
7. 
WHERE: Describe the type(s) of location(s) where the 
intervention occurred, including any necessary 





WHEN and HOW MUCH: Describe the number of times the 
intervention was delivered and over what period of time 
including the number of sessions, their schedule, and their 






TAILORING: If the intervention was planned to be 
personalised, titrated or adapted, then describe what, 





MODIFICATIONS: If the intervention was modified during 
the course of the study, describe the changes (what, why, 
when, and how). 
 
















Planned: If intervention adherence or fidelity was 
assessed, describe how and by whom, and if any strategies 
were used to maintain or improve fidelity, describe them. 
Actual: If intervention adherence or fidelity was assessed, 
describe the extent to which the intervention was 



















Appendix 5.1: Approval letter from School of Pharmacy ethics     Appendix 5.2: Study invitation letter for community 












Appendix 5.3: Study information sheet for community  












Appendix 5.3 (cont’d): Study information sheet for  


























Appendix 5.4 (cont’d): Semi-structured topic guide  




























Appendix 5.4 (cont’d): Semi-structured topic guide  



















Appendix 5.4 (cont’d): Semi-structured topic guide  












Appendix 5.4 (cont’d): Semi-structured topic guide     Appendix 5.5: Community pharmacist consent form (Phase 1:  














































































































Appendix 5.8: Invitation letter to community pharmacists     Appendix 5.9: Reminder letter for community pharmacists 













Appendix 5.10: Completed COREQ checklist (interviews) 
 (Tong et al. 2007) 




Which author/s conducted the 
interview or focus group? 
DP carried out all 15 interviews. 
2. Credentials  What were the researcher’s 
credentials? E.g. PhD, MD 
DP had an MPharm degree and was a PhD 
candidate. 
3. Occupation  What was their occupation at the 
time of the study? 
DP was a PhD research student and registered 
pharmacist working in the community setting 
on a part-time basis (MPSNI). 
4. Gender  Was the researcher male or female? Female. 
5. Experience and 
training 
What experience or training did the 
researcher have? 
DP had attended training in qualitative research 
methodologies and had previous involvement in 
conducting focus groups. 
Relationship with participants 
6. Relationship 
established  
Was a relationship established prior 
to study commencement? 
Pharmacists were contacted via telephone prior 
to participation to discuss taking part in the 
study. All community pharmacists were part of 
the QUB School of Pharmacy Undergraduate 
Placement Network and had links with QUB. 
Some participants were known to the 
researcher through personal pharmacy 
networks/contacts. 
7. Participant 
knowledge of the 
interviewer  
What did the participants know 
about the researcher? e.g. personal 
goals, reasons for doing the research 
Participants were aware that the researcher 
was a PhD student at QUB with an interest in 
medication adherence. Participants were aware 
that the research was ethically approved and 
funded by the Harold and Marjorie Moss 
Charitable Trust Fund and by the Department of 
Employment and Learning. 
8. Interviewer 
characteristics  
What characteristics were reported 
about the interviewer/facilitator? e.g. 
Bias, assumptions, reasons and 
interests in the research topic 





What methodological orientation was 
stated to underpin the study? e.g. 




The interview topic guide was underpinned by 
the TDF. Framework analysis was conducted, 
followed by inductive content analysis. 
Participant selection 
10. Sampling  How were participants selected? e.g. 
purposive, convenience, consecutive, 
snowball 
Purposive and snowball sampling strategies 
were employed to identify pharmacists working 
in both urban and rural areas and different 
types of community pharmacies (e.g. 
independently owned and chains). 
11. Method of 
approach 
How were participants approached? 
e.g. face-to-face, telephone, mail, 
email 
Participants were initially contacted via 
telephone and if interested at this stage they 
were emailed a letter of invitation and study 
information sheet.  
12. Sample size  How many participants were in the 
study? 
Fifteen participants took part in the study. 
13. Non-
participation 
How many people refused to 
participate or dropped out? Reasons? 
Eleven pharmacists refused to participate, one 
pharmacist cancelled a scheduled interview due 
to time constraints.  
Setting 
14. Setting of data 
collection  
Where was the data collected? e.g. 
home, clinic, workplace 
Data was collected at the participant’s place of 
work (e.g. consultation room) or other 
convenient location (local café, pharmacist’s 
own home, School of Pharmacy QUB). 
15. Presence of 
non-participants  
Was anyone else present besides the 
participants and researchers? 
No others were present at the time of each 
interview. 
16. Description of 
sample  
What are the important 
characteristics of the sample? e.g. 
demographic data, date 
Information about the participant’s professional 
background (e.g. years qualified, job title, 
training on medication adherence) was 
collected (see Table 5.1 in thesis). 
Data collection  
17. Interview guide  Were questions, prompts, guides 
provided by the authors? Was it pilot 
tested? 
A topic guide with prompts guided interview 
sessions. The topic guide was piloted before use 
with two practising community pharmacists. 
18. Repeat 
interviews  
Were repeat interviews carried out? 
If yes, how many? 
No repeat interviews were required. 
19. Audio/visual 
recording  
Did the research use audio or visual 
recording to collect the data? 
All interviews were audio-recorded. 
20. Field notes  Were field notes made during and/or 
after the interview or focus group? 
No notes were made during interviews. All 
audio recordings were checked after interviews 













Data collection (cont’d) 
21. Duration  What was the duration of the 
interviews or focus group? 
Interviews ranged in duration from 30 minutes 
to 72 minutes (total duration 698 minutes). 
22. Data saturation  Was data saturation discussed? Data saturation was reached by the fifteenth 
interview as no new themes were emerging. 
23. Transcripts 
returned  
Were transcripts returned to 
participants for comment and/or 
correction? 
Transcripts were not returned to interview 
participants. 
Domain 3: analysis and findings 
Data analysis 
24. Number of 
data coders  
How many data coders coded the 
data? 
Three researchers (DP, CR, CH) independently 
coded the data (two researchers per transcript). 
25. Description of 
the coding tree  
Did authors provide a description of 
the coding tree? 
Codes represented barriers and facilitators 
expressed by participants that were assigned to 
each domain of the TDF. 
26. Derivation of 
themes  
Were themes identified in advance or 
derived from the data? 
Themes arising from each of the TDF domains 
were informed by the content of the focus 
groups. 
27. Software  What software, if applicable, was 
used to manage the data? 
NVivo® QSR 11. 
28. Participant 
checking  
Did participants provide feedback on 
the findings? 





Were participant quotations 
presented to illustrate the themes / 
findings? Was each quotation 
identified? e.g. participant number 
Quotations have been presented in Section 
5.4.1 of this thesis with identifiers removed. 
Each participant was given an anonymous code 
(e.g. CP01). 
30. Data and 
findings consistent  
Was there consistency between the 
data presented and the findings? 
See Section 5.4.1 of this thesis. We have 
endeavoured to report the study findings in a 
clear, consistent manner in order to accurately 
reflect the data that has been collected. 
31. Clarity of major 
themes  
Were major themes clearly 
presented in the findings? 
32. Clarity of minor 
themes  
Is there a description of diverse cases 
or discussion of minor themes? 
 
Appendix 5.10 (cont’d): Completed COREQ checklist (interviews) 
(Tong et al. 2007) 
 
A
p
p
en
d
ices 
